
<html lang="en"     class="pb-page"  data-request-id="4dd50e9e-1089-4a1b-862b-9e43293d85b6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01312;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics" /></meta><meta name="dc.Creator" content="Hao  Chen" /></meta><meta name="dc.Creator" content="Jeff B.  Smaill" /></meta><meta name="dc.Creator" content="Tongzheng  Liu" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Creator" content="Xiaoyun  Lu" /></meta><meta name="dc.Description" content="KRAS, the most frequently mutated oncogene, plays a predominant role in driving initiation and progression of cancers. Decades of effort to target KRAS using small molecules has been unsuccessful, ..." /></meta><meta name="Description" content="KRAS, the most frequently mutated oncogene, plays a predominant role in driving initiation and progression of cancers. Decades of effort to target KRAS using small molecules has been unsuccessful, ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 23, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01312" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01312" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01312" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01312" /></link>
        
    
    

<title>Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01312" /></meta><meta property="og:title" content="Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0033.jpeg" /></meta><meta property="og:description" content="KRAS, the most frequently mutated oncogene, plays a predominant role in driving initiation and progression of cancers. Decades of effort to target KRAS using small molecules has been unsuccessful, causing KRAS to be considered an “undruggable” cancer target. However, this view began to change recently, as drug discovery techniques have developed several KRAS G12C allosteric inhibitors that are currently being evaluated in clinical trials. Herein we provide an in-depth analysis of the structure and binding pockets of KRAS, medicinal chemistry optimization processes, and the biological characterization of small-molecule inhibitors that directly target KRAS, including covalent allosteric inhibitors specific for the G12C mutant, GTP-competitive inhibitors targeting the nucleotide-binding site, and protein–protein interaction inhibitors that bind in the switch I/II pocket or the A59 site. Additionally, we propose potential challenges faced by these new classes of KRAS inhibitors under clinical evaluation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01312"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01312">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01312&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01312&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01312&amp;href=/doi/10.1021/acs.jmedchem.0c01312" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14404-14424</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01248" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01332" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Hao Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Chen">Hao Chen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeff B. Smaill</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeff B. Smaill</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeff+B.++Smaill">Jeff B. Smaill</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tongzheng Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tongzheng Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tongzheng++Liu">Tongzheng Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ke Ding</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ke Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#5034393e373b35103a3e257e3534257e333e"><span class="__cf_email__" data-cfemail="9df9f4f3faf6f8ddf7f3e8b3f8f9e8b3fef3">[email protected]</span></a>. Phone: +86-20-85223259.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Xiaoyun Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyun Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#bcd0c9c4c58e8c8d8afcd6d2c992d9d8c992dfd2"><span class="__cf_email__" data-cfemail="fc90898485cecccdcabc969289d2999889d29f92">[email protected]</span></a>. Phone: +86-20-85223259.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyun++Lu">Xiaoyun Lu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7931-6873" title="Orcid link">http://orcid.org/0000-0001-7931-6873</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01312&amp;href=/doi/10.1021%2Facs.jmedchem.0c01312" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14404–14424</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 23, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 July 2020</li><li><span class="item_label"><b>Published</b> online</span>23 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01312" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01312</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14404%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHao%2BChen%252C%2BJeff%2BB.%2BSmaill%252C%2BTongzheng%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01312%26title%3DSmall-Molecule%2BInhibitors%2BDirectly%2BTargeting%2BKRAS%2Bas%2BAnticancer%2BTherapeutics%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14424%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01312"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4558</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01312" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;B. Smaill&quot;},{&quot;first_name&quot;:&quot;Tongzheng&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Xiaoyun&quot;,&quot;last_name&quot;:&quot;Lu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14404-14424&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01312&quot;},&quot;abstract&quot;:&quot;KRAS, the most frequently mutated oncogene, plays a predominant role in driving initiation and progression of cancers. Decades of effort to target KRAS using small molecules has been unsuccessful, causing KRAS to be considered an “undruggable” cancer target. However, this view began to change recently, as drug discovery techniques have developed several KRAS G12C allosteric inhibitors that are currently being evaluated in clinical trials. Herein we provide an in-depth analysis of the structure and binding pockets of KRAS, medicinal chemistry optimization processes, and the biological characterization of small-molecule inhibitors that directly target KRAS, including covalent allosteric inhibitors specific for the G12C mutant, GTP-competitive inhibitors targeting the nucleotide-binding site, and protein–protein interaction inhibitors that bind in the switch I/II pocket or the A59 site. Additionally, we propose potential challenges faced by these new classes of KRAS inhibitors under clinical evaluation.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01312&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01312" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01312&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01312" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01312&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01312" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01312&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01312&amp;href=/doi/10.1021/acs.jmedchem.0c01312" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01312" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01312" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (11 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01312%26sid%3Dliteratum%253Aachs%26pmid%3D33225706%26genre%3Darticle%26aulast%3DChen%26date%3D2020%26atitle%3DSmall-Molecule%2BInhibitors%2BDirectly%2BTargeting%2BKRAS%2Bas%2BAnticancer%2BTherapeutics%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14404%26epage%3D14424%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0033.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">KRAS, the most frequently mutated oncogene, plays a predominant role in driving initiation and progression of cancers. Decades of effort to target KRAS using small molecules has been unsuccessful, causing KRAS to be considered an “undruggable” cancer target. However, this view began to change recently, as drug discovery techniques have developed several KRAS G12C allosteric inhibitors that are currently being evaluated in clinical trials. Herein we provide an in-depth analysis of the structure and binding pockets of KRAS, medicinal chemistry optimization processes, and the biological characterization of small-molecule inhibitors that directly target KRAS, including covalent allosteric inhibitors specific for the G12C mutant, GTP-competitive inhibitors targeting the nucleotide-binding site, and protein–protein interaction inhibitors that bind in the switch I/II pocket or the A59 site. Additionally, we propose potential challenges faced by these new classes of KRAS inhibitors under clinical evaluation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Rat sarcoma viral oncogene homologue (RAS), encoded by <i>HRAS</i>, <i>NRAS</i>, and <i>KRAS</i>, are small GTPase enzymes that function as cellular signal transducers cycling between an active GTP-bound and inactive GDP-bound state.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Oncogenic mutation of KRAS is closely linked to tumorigenesis,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> being found in 22% of cancer patients, including lung (17%), colon (33%), and pancreatic cancers (61%). Indeed, KRAS has become regarded as the most frequently mutated oncogene in cancers.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Patients with KRAS mutations are typically resistant to standard-of-care chemotherapy and have a poor prognosis,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> representing an extraordinary unmet clinical need requiring new therapies to directly target KRAS. However, unlike other frequently mutated oncoproteins such as EGFR and VEGFR,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> the lack of an ideal small-molecule binding pocket and high affinity toward an abundance of cellular guanosine triphosphate (GTP) renders the development of specific small-molecule drugs that directly target KRAS challenging.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">KRAS is “switched on” by binding GTP,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> which results in conformational changes in the effector protein binding regions, namely, the switch regions, followed by the activation of downstream signaling such as that through the RAS–RAF–MEK–ERK and RAS–PI3K–AKT pathways.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Targeting upstream and downstream proteins in the KRAS pathway and directly targeting KRAS itself are important strategies to inhibit KRAS function.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Generally, three approaches could theoretically be explored to directly inhibit KRAS with small molecules: (i) impeding GTP binding through the use of a competitive ligand; (ii) locking KRAS G12C in an inactive state through allosteric modulation; and (iii) disrupting the interaction of KRAS with its effector proteins and guanine nucleotide exchange factors (GEFs) (e.g., the proteins son of sevenless (SOS) (a GEF), RAF, and PI3K) through the use of protein–protein interaction (PPI) inhibitors. However, the high binding affinity of the intrinsic ligand GTP for KRAS renders the development of competitive inhibitors of GTP binding particularly challenging. Additionally, the relatively small size and smooth surface of KRAS as well as the high flexibility of the KRAS switch regions have also made it difficult to develop allosteric or PPI inhibitors.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><div class="NLM_p last">Despite these difficulties, the recent development of novel allosteric inhibitors that directly target KRAS G12C provides a promising opportunity to selectively target mutant KRAS in patients. Four novel KRAS G12C inhibitors with similar allosteric mechanisms are now in clinical trials: AMG 510, MRTX849, JNJ-74699157 (no structure disclosure), and GDC-6036 (no structure disclosure).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These inhibitors covalently bind to KRAS G12C at the key mutant residue cysteine 12, locking the GTPase in an inactive state and inhibiting KRAS signaling. More excitingly, recent data from clinical trials reveal that AMG 510 and MRTX849 demonstrate substantial clinical activity in KRAS G12C-mutated nonsmall cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Herein we provide an in-depth analysis of the structure and binding pockets of KRAS, medicinal chemistry optimization processes, and the biological characterization of small-molecule inhibitors that directly target mutant KRAS, including covalent allosteric inhibitors specific for the G12C mutant, GTP-competitive inhibitors targeting the nucleotide-binding site, and PPI inhibitors that bind in the switch I/II pocket or the A59 site. Additionally, we also propose potential challenges faced by these new classes of KRAS inhibitors under clinical evaluation.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  KRAS Structure</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13125" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13125" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">KRAS is a protein composed of 188 amino acids with three functionally distinct domains: the effector lobe (residues 1–86), the allosteric lobe (residues 87–166), and the hypervariable region (HVR) (residues 167–188) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> The effector lobe acts as a substrate-binding motif containing three regions for nucleotide and effector protein binding: the phosphate-binding loop (P-loop) (residues 10–17), the switch I region (residues 30–38), and the switch II region (residues 60–76). The activation of KRAS proceeds from the inactive GDP-bound state to the active GTP-bound state, where the γ-phosphate of GTP forms two hydrogen bonds with Thr35 in the switch I region and Gly60 in the switch II region simultaneously. This anchors GTP in place and holds the two switch regions in an active conformation, which then allows the binding of effector proteins.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The interactions between the switch I/switch II regions and GTP are maintained until a deactivation process occurs where the hydrogen bonds are disturbed following GTP hydrolysis, which releases the switch regions and allows the conformation to revert back to the inactive GDP-bound state (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of GDP-bound KRAS (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OBE">4OBE</a>). The effector lobe, allosteric lobe, and hypervariable region are shown in blue, pink, and cyan, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Comparison of the KRAS GppNHp-bound active conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GOD">6GOD</a>) and the KRAS GDP-bound inactive conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OBE">4OBE</a>). (A) KRAS active conformation. The switch I region, the switch II region, and the P-loop are shown in blue, pink, and yellow, respectively. Hydrogen bonds are shown in dashed yellow lines. Guanosine 5′-[β,γ-imido]triphosphate (GppNHp) is a nonhydrolyzable analogue of GTP where one oxygen atom is replaced by an amine. (B) Alignment of KRAS active and inactive conformations. The major difference lies in the conformation of the switch II region, which moves away from the guanine binding pocket as the γ-phosphate is dissociated (as indicated by the pink arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Unlike the effector lobe, which is 100% conserved across the three isoforms (HRAS, NRAS, and KRAS), the allosteric lobe and the HVR diverge between isoforms, with 86% and 15% amino acid sequence homology, respectively.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The allosteric lobe is implicated in KRAS membrane interactions and dimerization,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> while the HVR is involved in recognition and association with the membrane, a process that is necessary for KRAS to interact with its effectors. The membrane binding process is initiated by the cysteine of the HVR’s CAAX box (a four amino acid motif comprising cysteine, aliphatic amino acid, aliphatic amino acid, and any residue), which undergoes prenylation by farnesyltransferase (FTase).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Following this lipidation process, the AAX amino acids are cleaved by RAS-converting enzyme 1 (RCE1), while the remaining farnesylcysteine is methyl-esterified by isoprenylcysteine carboxyl methyltransferase (ICMT), leading to KRAS protein that is rich in hydrophobic tails with high membrane binding affinity.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  KRAS Mutations and Signaling Pathways</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">KRAS is the predominant mutated subtype in the RAS family (comprising about 85% of total RAS mutations) and is associated with 22% of human cancers. KRAS mutations are frequently observed in lung (17%), colon (33%), and pancreatic cancers (61%)<a onclick="showRef(event, 'ref4 ref26'); return false;" href="javascript:void(0);" class="ref ref4 ref26">(4,26)</a> and are considered the most common mutated drivers in human cancer.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Besides some rare mutation observed at codons 13 and 61 (e.g., G13D and Q61H), 80% of KRAS mutations occur at amino acid position 12, from glycine to other residues such as cysteine (G12C, 14%), aspartic acid (G12D, 36%), and valine (G12V, 23%). Of importance, as shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, the profile of KRAS mutations can vary distinctly across different cancer types. For example, the KRAS G12C mutation is more frequent in lung cancer (44%), while KRAS G12D is the predominant mutation in pancreatic and colorectal cancer.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The mutations at codon 12 alter glycine to other residues with a larger steric footprint, impeding binding of KRAS with GTPase-activating proteins (GAPs) and interfering with GTP hydrolysis (discussed below).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> This locks KRAS in its constitutively GTP-bound active state, supporting activation of KRAS effector pathways.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Profiles of KRAS codon 12 mutations in three types of cancer.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">KRAS cycles between an active GTP-bound state and an inactive GDP-bound state. The conversion between these two states is regulated by GEFs,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> which produce the exchange from GDP to GTP, and GAPs,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> which promote hydrolysis of GTP (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> As KRAS acts as a signal transducer in cells, the biological effects of KRAS activation are highly related to its three downstream signaling pathways, including the rapidly accelerated fibrosarcoma–mitogen-activated protein kinase kinase–extracellular signal-regulated kinase (RAF–MEK–ERK),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> phosphoinositide 3-kinase–protein kinase B–mammalian target of rapamycin (PI3K–AKT–mTOR),<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> and RAL guanine nucleotide dissociation stimulator–RAL (RALGDS–RAL) pathways.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In response to growth factors and other stimuli, KRAS and its downstream pathways control various cellular functions such as survival, proliferation, differentiation, adhesion, apoptosis, and migration. This process can be corrupted to become an oncogenic driver of cancer when KRAS is mutated and overactivated.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mutated KRAS signaling pathways and current therapeutic strategies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Besides direct KRAS inhibitors, tremendous effort has been focused on indirect approaches to inhibit KRAS signaling. Upstream inhibition, including receptor tyrosine kinase inhibitors such as sorafenib (NCT01715441) and regorafenib (NCT03520842), GEF (SOS) inhibitors such as BI 1701963 (NCT04111458), and SHP2 inhibitors such as TNO155 (NCT03114319) and JAB-3312 (NCT04045496), provides promising treatment for KRAS-mutated cancer patients, and their recent developments have been reviewed elsewhere.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> Besides, inhibition of downstream pathways such as the MAPK and PI3K pathways<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> and post-translational modification of KRAS could also be possible therapeutics for KRAS-mutated cancer. Several early clinical trials were undertaken to evaluate the combination of PI3K inhibitors and MEK inhibitors in different cancer subtypes bearing KRAS mutations,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> but to date none have proven to be effective in this setting. Notably, phase II evaluation of the MEK inhibitor selumetinib in combination with docetaxel in KRAS-mutant NSCLC patients demonstrated some benefit in terms of progression-free survival, but this combination did not significantly improve overall survival, possibly because of increased adverse events.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In addition, several post-translational modifications are essential to locate KRAS on the plasma membrane, where it is activated (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> Thus, enzymes such as FTase, RCE1, and ICMT,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> each of which plays pivotal roles in the post-translational modification of KRAS, are considered as potential targets for inhibition of KRAS signaling.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Lonafarnib and tipifarnib were identified as two successful FTase inhibitors that unfortunately failed to show efficacy against KRAS-driven cancers in clinical trials.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> One major reason for this lack of efficacy is that the KRAS protein is able to escape the inhibition of FTase through alternative prenylation mediated by geranylgeranyl transferase I (GGTase I).<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Inhibitors targeting RCE1 and ICMT are in the early stages of development,<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> but no inhibitor to date has shown promising mechanism-based activity.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">4.  Direct Inhibitors of KRAS</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21270" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21270" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The challenges in achieving mutant selectivity and antitumor efficacy through the aforementioned indirect methods of targeting KRAS signaling prompted medicinal chemists to reinvestigate the possibility of directly targeting KRAS. Poor conformational stability and the notable lack of suitable binding pockets (other than the nucleotide-binding site of KRAS) make this task extremely challenging. Recently, enabled by the crystal structure of KRAS and structure-based drug design approaches, several new KRAS binding pockets have been identified. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, the representative binding pockets include the switch II pocket, the switch I/II pocket, and the A59 site. All of these pockets are located near the switch I and switch II regions of the effector lobe. As these regions play a pivotal role in KRAS activation and substrate protein recognition,<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> small molecules targeting these pockets have the potential to impede KRAS function by either decreasing active KRAS GTP-bound levels or disrupting the interaction of KRAS with its downstream effectors. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> shows the recently developed small-molecule inhibitors that directly target KRAS.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Reported binding pockets for direct KRAS inhibitors. The switch I and switch II regions of KRAS are colored in blue and red ribbons, respectively. The nucleotide-binding pocket is colored in pink (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LDJ">4LDJ</a>). The A59 site is colored in ocher (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DSN">4DSN</a>). The switch I/II pocket is colored in blue (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPY">4EPY</a>). The switch II pocket is colored in green (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F2E">5F2E</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of Small-Molecule Inhibitors Directly Targeting KRAS</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0031.gif" alt="" id="gr32" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0032.gif" alt="" id="gr33" /></img><div></div></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">4.1.  Inhibitors That Bind at the Nucleotide Binding Site</h3><div class="NLM_p">GTP (<b>1</b>) is the intrinsic ligand required for KRAS to adopt an activated conformation, and its binding pocket is well-defined.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Therefore, impeding the binding of <b>1</b> by the use of GTP mimics has been considered as a potential strategy to inhibit oncogenic KRAS. However, unlike ATP mimics that successfully target a wide range of protein kinases, the development of competitive GTP mimics as inhibitors of KRAS has been speculated to be a nearly impossible challenge because of the remarkably high affinity of <b>1</b> for KRAS (picomolar range) and the abundance of <b>1</b> in cells (submillimolar concentration).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">Given the fact that covalent inhibitors can bind with a target protein irreversibly and therefore prevent further exchange,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Lim et al. developed an analogue of <b>1</b> named SML-8-73-1 (<b>2</b>) to covalently bind with Cys12 of the KRAS G12C mutant.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The G12C mutation places a reactive cysteine near the usual binding position of the γ-phosphate of the native GTP ligand, making it possible to design a covalent binding inhibitor that occupies the GTP binding pocket and targets this cysteine to induce an inactive conformation of the KRAS G12C protein. To achieve high affinity for KRAS while integrating covalent binding, they utilized the guanine nucleotide GDP scaffold and targeted Cys12 by incorporating various linkers bearing electrophilic groups at the β-phosphate. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, X-ray crystallography and mass spectrometry demonstrated that SML-8-73-1 binds with the KRAS inactive conformation in a similar manner as GDP, except for the 2-chloroacetamide moiety, which extends into the solvent-exposed area and forms a covalent bond with Cys12.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. GDP binding pocket of the KRAS G12C mutant. (A) GDP in complex with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LDJ">4LDJ</a>). The β-phosphate of GDP is proximal to KRAS Cys12. (B) SML-8-73-1 in complex with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NMM">4NMM</a>). A covalent bond has been formed between Cys12 and the 2-chloroacetamide moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Covalent binding of <b>2</b> to Cys12 results in strong and persistent occupation of the GTP-binding pocket, thus impeding binding of GTP and the formation of the KRAS G12C active form. The complex of <b>2</b> and KRAS G12C has a significantly lower affinity for the Raf-RAS-binding domain (Raf-RBD) downstream effector than active KRAS G12C as determined by the AlphaScreen biochemical assay,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> suggesting a potential ability to inhibit the KRAS signaling pathway. However, further biological assays were hindered by the poor cellular permeability of <b>2</b>, attributed to its two negatively charged phosphate groups (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Therefore, an alanine ester phosphoramidate prodrug derivative, SML-10-70-1 (<b>3</b>), was designed to regenerate <b>2</b> in cells through intracellular hydrolysis. Although ester compound <b>3</b> was cell-permeable, it showed only a marginal and unspecific effect on both inhibition of KRAS signaling and antiproliferative activity against KRAS G12C-dependent H358 NSCLC cells, with an EC<sub>50</sub> of 26.6 μM, similar to the efficacy toward KRAS-independent A549 cells (EC<sub>50</sub> = 43.8 μM).</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0021.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Structural Modifications of the Covalent GDP Mimics as KRAS G12C Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To further improve the cell permeability and potency, efforts were made to replace the β-phosphate group of <b>2</b> with bioisosteres such as sulfonates, sulfonamides, and amides (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). While the sulfonamide compound XY-02-075 (<b>4</b>) demonstrated the best potency of the phosphate bioisostere series investigated, it was still significantly less potent than the parent phosphate compound <b>2</b> because of disruption of magnesium ion coordination observed for the diphosphate motif of <b>2</b> in the nucleotide-binding site.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In addition, kinetic simulations conducted by Müller and co-workers suggested that the parent compound <b>2</b>, which had been modified only at the GDP β-phosphate, had approximately 10<sup>4</sup>-fold lower reversible binding affinity to KRAS compared with GDP itself.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> This loss of affinity results in significant ligand dissociation before covalent reaction of the chloroacetamide can take place. Collectively, to date, inhibitors targeting the nucleotide-binding site of KRAS G12C though covalent binding cannot sufficiently compete with GTP in a cellular context, suggesting that (1) other modifications and anchor points other than the β-phosphate must be identified and (2) the discovery of other allosteric binding sites may be a more practical way to target KRAS G12C.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">4.2.  Inhibitors That Bind at the Switch II Pocket</h3><div class="NLM_p">While covalent modification of Cys12 of KRAS G12C has yet to yield an effective inhibitor that binds in the nucleotide-binding site, the proximity of this cysteine to the switch regions of the protein that are involved in effector binding suggested that it may be an “anchoring point” to investigate potential allosteric sites. Ostrem et al. used a “tethering” approach to screen a library of 480 fragments bearing disulfide groups against KRAS G12C in the GDP-bound inactive state.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> These disulfide fragments were allowed to react with cysteine residues of the protein, where the stability of the fragment complex formed was highly related to the fragments’ intrinsic affinity. When the unstable fragment was reduced, high-affinity fragments could then be captured by mass spectrometry.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> This approach led to the discovery of compounds that bind at a novel allosteric pocket near the switch II region, called the switch II pocket (S-IIP).</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">4.2.1.  Anilines</h4><div class="NLM_p">The first group of fragments identified by Ostrem et al. were phenyl thioether derivatives with pendent reactive disulfide groups.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> One representative compound, 6H05 (<b>5</b>), was demonstrated to be an allosteric site binder, whose binding (by definition) does not compete with that of GDP. Further optimization of the tethering linker and phenyl substituents of 6H05 yielded compound <b>6</b> with quadrupled potency (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The cocrystal structure of compound <b>6</b>, KRAS G12C, and GDP revealed a distinct binding pocket, the S-IIP, that is hardly visible in the absence of the ligand. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, through covalent anchoring of Cys12, <b>6</b> creates an extra groove surrounded by the switch II region and the central β-sheet adjacent to the nucleotide-binding site. The binding of <b>6</b> reorders the conformation of the switch II region, moving some residues that are important for GTP binding away from the nucleotide-binding site, including Gly60, a key residue that under normal circumstances forms a hydrogen bond with the γ-phosphate of GTP in the KRAS G12C active state.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In addition, compound <b>6</b> also makes steric hindrance with the γ-phosphate of GTP by the linker and bond to Cys12. Altogether, these observations led to the hypothesis that the affinity of KRAS G12C for GTP may decrease upon allosteric inhibitor binding.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding of <b>6</b> induces a conformational change in KRAS G12C. The switch I region, the switch II region, Gly60, and Cys12 are shown in blue, pink, cyan, and yellow, respectively. (A) KRAS GppNHp-bound active conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P21">5P21</a>). A hydrogen bond is formed between Gly60 and the GppNHp terminal phosphoramidate group. (B) KRAS G12C GDP in complex with <b>6</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LUC">4LUC</a>). Compound <b>6</b> penetrates into the switch II region and pushes Gly60 away from the nucleotide binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0022.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Optimization Process for ARS-853</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the disulfide group of <b>6</b> has potential reaction promiscuity, the researchers further replaced the covalent binding warhead with several carbon-based electrophiles, resulting in the identification of acrylamide <b>7</b>. As expected, KRAS G12C shifts its preference from GTP to GDP when <b>7</b> occupies the S-IIP, and as a consequence, the KRAS G12C GTP-bound active form is downregulated. This translates into inhibition of KRAS signaling and moderate antiproliferative activity in KRAS G12C-dependent cell lines (EC<sub>50</sub> for H1792 NSCLC cells = 0.32 μM).</div><div class="NLM_p">The search for an irreversible KRAS G12C inhibitor with improved cellular potency, carried out by Wellspring Biosciences, led to the discovery of ARS-853 (<b>8</b>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> ARS-853 possesses the same chemical scaffold as compound <b>7</b>, with the electrophilic acrylamide warhead redirected to provide better interaction with the Cys12 residue and the hydrophobic pocket binding fragment modified for better potency. Biochemical analysis indicates that ARS-853 acquires a 600-fold increase in potency compared with compound <b>7</b>, with a rate constant of 76 M<sup>–1</sup> s <sup>–1</sup> for covalent binding to KRAS G12C. The cocrystal structure of ARS-853 with KRAS G12C indicates that the benzene ring and the methylcyclopropane group insert into a hydrophobic pocket that is sandwiched by Tyr64 and Met72, allowing the phenol group to form a hydrogen bond with Asp69 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). In addition, the aniline nitrogen and the carbonyl group of the piperazine carboxamide participate in a hydrogen-bonding network that includes Glu63, Gln61, Arg68, and Ala59 and is mediated by two ordered water molecules. On the right-hand side of the molecule, the piperazine nitrogen forms a water-mediated hydrogen-bonding network with Thr58 and Gly10, and the acrylamide carbonyl interacts directly with Lys16 and via an ordered water molecule that is close to the GTP γ-phosphate binding site, bridging to Pro34. The hydrogen bond between Lys16 and the acrylamide carbonyl has been found to be particularly important to the covalent reaction with the proximal Cys12, as the basic lysine side chain is able to stabilize the transition state of the Michael addition reaction.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Binding mode of ARS-853 with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F2E">5F2E</a>). The key residues are represented as stick structures. Hydrogen bonds are shown as yellow dashes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Mechanistic studies have revealed that ARS-853 specifically binds with KRAS G12C in the GDP-bound inactive form and that nucleotide exchange is prevented upon ARS-853 binding.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> However, GTP-bound KRAS is the dominant form observed for the KRAS G12C mutant.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Therefore, whether ARS-853 could reach high levels of inhibition was the key concern for the development of S-IIP inhibitors. Surprisingly, further studies revealed a relatively rapid interconversion between GTP-bound and GDP-bound KRAS G12C,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> suggesting that ARS-853 would be able to lock KRAS G12C in the GDP-bound inactive state as the nucleotide hydrolyzes (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Consistent with this, complete inhibition of KRAS signaling was maintained for 72 h with ∼5 μM ARS-853 in H358 NSCLC cells.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> In summary, ARS-853 is not only the first reported direct KRAS inhibitor that was potent enough to completely suppress p-ERK signaling in a cellular setting but also provided a proof of concept for the use of S-IIP inhibitors as a potential strategy for the treatment of cancers harboring the KRAS G12C mutation.</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Rationale for ARS-853 KRAS G12C inhibition. The inhibitor targets the KRAS G12C GDP-bound inactive state to prevent nucleotide exchange. Therefore, the level of the KRAS G12C GTP-bound active form decreases as nucleotide hydrolysis takes place.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">4.2.2.  Quinazolines</h4><div class="NLM_p">To improve the metabolic stability of the glycine linker portion of ARS-853, a series of rigid quinazoline-based compounds were designed and synthesized (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> However, an early starting point (<b>12</b>) employing a similar Asp69-interacting phenol moiety on a rigidified core did not show any improvement in potency compared with ARS-853, as assessed by the measured <i>k</i><sub>obs</sub>/[I] value (a rate constant that is generally considered to be the best measure of covalent inhibitor potency).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> A strategy to further increase conformational restriction, particularly around the flexible quinazoline–benzene σ bond, was utilized to improve the compound potency. With the introduction of two fluorine atoms, the biaryl bond of ARS-1620 (<b>13</b>) is conformationally fixed, directing the hydroxy group to the solvated region surrounded by a group of polar amino acid residues. ARS-1620 is significantly more potent than ARS-853 in the biochemical enzyme binding assay (<i>k</i><sub>obs</sub>/[I] = 1100 M<sup>–1</sup> s<sup>–1</sup> compared with 140 M<sup>–1</sup> s<sup>–1</sup>) and exhibits improved oral bioavailability (<i>F</i> > 60%) and murine plasma stability. An X-ray cocrystal structure of ARS-1620 with KRAS G12C revealed that the binding mode of ARS-1620 is similar to that of the parent compound ARS-853, maintaining polar interactions with Asp69, Arg68, and Lys16 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). One additional hydrogen bond was observed between the quinazoline N1 nitrogen and His95, which may in part explain its improved potency over ARS-853.</div><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0023.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Optimization Process for ARS-1620</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Binding mode of ARS-1620 with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U">5V9U</a>). The key residues are represented as stick structures. Hydrogen bonds are shown as yellow dashes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the improvement in pharmacokinetic properties achieved through the discovery of ARS-1620, the researchers then moved to characterize the efficacy of S-IIP inhibitors in vivo using a subcutaneous xenograft model bearing the KRAS G12C mutation.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In the study, ARS-1620 showed both on-target effects (dose- and time-dependent inhibition of KRAS GTP-bound levels and downstream pathway signaling) and antitumor activity (significant regression of the tumor xenograft at a dose of 200 mg kg<sup>–1</sup> day<sup>–1</sup>). ARS-1620 also displayed good in vivo antitumor activity in patient-derived tumor xenograft (PDX) models, demonstrating preferential activity in models that harbor KRAS G12C over those that lack the mutant allele (harboring KRAS G12D or WT). Collectively, these results indicate that ARS-1620 inhibits the growth of KRAS G12C tumor models effectively and specifically, offering strong evidence that the development of S-IIP-binding inhibitors may be a promising therapeutic strategy for the treatment of patients harboring KRAS G12C mutations. This molecule has been subsequently modified, resulting in the identification of ARS-3248 (JNJ-74699157; structure undisclosed), which is currently being evaluated in a Phase I trial (NCT04006301) for patients with molecularly identified KRAS G12C-positive advanced solid tumors under the sponsorship of Janssen Research and Development.</div><div class="NLM_p">Zeng et al. also reported a series of quinazoline-based KRAS G12C irreversible inhibitors with improved cellular potency compared with ARS-853.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Differing from the strategy that led to ARS-1620, the researchers incorporated various amine substituents at the quinazoline C2 position of lead compound <b>9</b> in order to make additional interactions with His95 (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The amide group of 1-AM (<b>10</b>) interacts with His95 through a π–π-stacking interaction, and this analogue stood out among the series as having the best activity against KRAS G12C. Subsequent modifications included the introduction of a fluorine substituent at the 8-position of the quinazoline ring and replacement of the phenyl ring by a hydroxynaphthyl group, resulting in compound 4-AM (<b>11</b>), which inhibits KRAS G12C-dependent H358 cell proliferation in the low micromolar range.</div><figure id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0024.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Optimization Process for 4-AM</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">4.2.3.  Tetrahydropyridopyrimidines</h4><div class="NLM_p">In collaboration with Array Biopharma, Mirati Therapeutics has also utilized a “tethering” method similar to that used by Ostrem et al.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> to identify novel S-IIP inhibitors, leading to the discovery of tetrahydropyridopyrimidine <b>14</b>.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The tetrahydropyridopyrimidine core is closely related to a quinazoline core (both are [6 + 6] fused ring systems), and therefore, the binding mode of <b>14</b> closely resembles that of ARS-1620, with the tetrahydropyridopyrimidine core forming a hydrogen bond between the pyrimidine N1 nitrogen and His95 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><figure id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Binding modes of KRAS G12C with <b>14</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N2J">6N2J</a>) and MRTX849 (<b>19</b>) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UT0">6UT0</a>). The key residues are represented as stick structures. Hydrogen bonds are shown as yellow dashes. The bound water molecule between Gly10 and Thr58 is highlighted in yellow. The cyanomethyl substituent that displaces the bound water is highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The medicinal chemistry optimization of <b>14</b> to improve the cellular potency followed an approach similar to that for 4-AM,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> focusing on both the aryl group connected to the piperidine nitrogen and the pyrimidine C2 position (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). The incorporation of a hydroxy group at the 2-position of the naphthalene ring was designed to interact with Asp69, yielding the substantially more potent compound <b>15</b>. The introduction of a basic side chain at the pyrimidine C2 position favored polar interactions with Glu62, leading to compound <b>16</b>, which demonstrated an antiproliferative IC<sub>50</sub> of 0.07 μM against KRAS G12C-dependent H358 NSCLC cells. Nonetheless, the metabolically labile naphthol hydroxy group of <b>16</b> resulted in high clearance (CL = 46 mL min<sup>–1</sup> kg<sup>–1</sup>) of this compound in mice. Elimination of the hydroxy group led to an over 30-fold loss of potency, suggesting that additional S-IIP interactions would be required to maintain potency. As the water molecule bound between Thr58 and Gly10 (highlighted in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) was predicted to possess high energy, a cyanomethyl group was incorporated on the piperazine ring of the series in order to displace this key water molecule. The resulting compound <b>17</b> recovered potency lost through elimination of the hydroxy group, showing a 6-fold improvement in potency compared with hydroxy compound <b>16</b>, with an H358 cellular antiproliferative IC<sub>50</sub> of 10 nM.</div><figure id="sch5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0025.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Optimization Process for MRTX849</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequent modification was focused on the 8-position of the naphthalene ring, which extends into an open lipophilic pocket under the tetrahydropyridopyrimidine core.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Several compounds bearing small hydrophobic substituents, such as chloride, cyanide, methoxy, and methyl, were designed and evaluated. The chloro derivative <b>18</b> possessed the best potency against the H358 cell line, with an IC<sub>50</sub> value of 1 nM. However, further studies demonstrated that compound <b>18</b> was readily metabolized by direct chemical reaction with glutathione (GSH) or by glutathione S-transferase (GST)-mediated GSH conjugation, leading to its low in vitro stability in whole-blood isolate (WB) (WB stability <i>t</i><sub>1/2</sub> = 5, 12, and 14 h in mouse, dog, and human, respectively). To reduce GST/GSH conjugation, the 2-fluoroacrylamide derivative MRTX849 (<b>19</b>) was prepared that showed a concomitant improvement in WB stability (<i>t</i><sub>1/2</sub> > 50 h in mouse/dog/human), albeit with a slight reduction in H358 cellular potency (IC<sub>50</sub> = 14 nM). As a result, the in vivo stability of MRTX849 (CL in mice = 19.9 mL min<sup>–1</sup> kg<sup>–1</sup>) was improved compared with <b>18</b> (37.3 mL min<sup>–1</sup> kg<sup>–1</sup>). This enabled further characterization of the MRTX849 antitumor activity in vivo against the MIA PaCa-2 pancreatic cancer xenograft model. MRTX849 achieved tumor regression at doses as low as 10 mg/kg while remaining well-tolerated at doses of up to 100 mg/kg.</div><div class="NLM_p">The cocrystal structure of MRTX849 and KRAS G12C verifies the above ideas of structural modification (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Compared with the binding mode of <b>14</b>, the extra pyrrolidine side chain at the C2 position forms a salt bridge with Glu62, while the cyanomethyl substituent on the piperazine ring interacts with the backbone of Thr58 by a hydrogen bond and replaces the bound water between Gly10 and Thr58.</div><div class="NLM_p">While MRTX849 inhibited cell mobility and KRAS G12C-dependent signaling in the H358 NSCLC cell line in the low nanomolar range, the degree of sensitivity to the inhibitor varied significantly across KRAS G12C mutant cell lines. Hallin et al. suggested that this variability may be related to co-occurring genetic alterations in KRAS-mutated cancers.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> To identify sensitizers of the response to MRTX849, Hallin et al. studied a wide range of combination treatments with upstream or downstream inhibitors of KRAS both in vitro and in vivo. A substantial synergistic effect was observed when MRTX849 was used in combination with EGFR, SHP2, CDK4, CDK6, or mTOR inhibitors, suggesting that these combinational treatments may be potential strategies when the sensitivity to single-agent KRAS G12C inhibition is limited.</div><div class="NLM_p last">Given its excellent antitumor efficacy and low toxicity in mice, MRTX849 was identified for further development and is currently being evaluated in Phase I/II clinical trials as a single agent (NCT03785249) or in combination with the experimental SHP2 inhibitor TNO155 (NCT04330664) for the treatment of patients with advanced solid tumors harboring a KRAS G12C mutation. Reports to date indicate that MRTX849 demonstrates antitumor activity with low toxicity in patients. At the dose of 600 mg/kg, 50% of NSCLC patients (three of six) demonstrated a partial response (PR), with the other 50% showing stable disease (SD). Notable side effects include diarrhea, nausea, and aspartate aminotransferase elevations, which are considered mild and controllable.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">4.2.4.  Quinazolinones</h4><div class="NLM_p">In collaboration with Carmot Therapeutics, Amgen Inc. has utilized a “Chemotype Evolution” screening method<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> to identify chemically unique irreversible covalent inhibitors of KRAS G12C.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In the screening method, a large library of compounds comprising cysteine reactive warheads (baits) linked to diverse fragments were designed and evaluated. Indole compound <b>20</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>) was identified as the most active hit using a mass-spectrometry-based assay that estimated the average rate of covalent adduct formation at Cys12 of KRAS G12C (compound <b>20</b><i>k</i><sub>obs</sub>/[I] = 230 M<sup>–1</sup> s<sup>–1</sup>). It displayed moderate cellular activity against MIA PaCa-2 pancreatic cancer cells with a p-ERK inhibition IC<sub>50</sub> of 11.4 μM. A cocrystal structure of <b>20</b> and KRAS G12C demonstrated that <b>20</b> occupies the switch II pocket covalently targeting Cys12 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The acrylamide carbonyl forms a hydrogen bond with Lys16, while the “central amide” forms a hydrogen bond with Tyr96. The indole scaffold makes van der Waals interactions with the protein. Notably, the 5-methoxytetrahydroisoquinoline moiety extends into a so-called “cryptic pocket” bounded by His95, Tyr96, and Gln99 and forms a π–π interaction with His95 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A). Further modifications of this candidate at the 2-, 5-, and 7-positions of the indole ring resulted in a substantial improvement in MIA PaCa-2 cellular potency and downstream p-ERK inhibition. The resulting compound <b>21</b> bearing a 5-chloro-2-cyclopropyl-7-methylindole core exhibited the best activity, with a p-ERK inhibition IC<sub>50</sub> of 0.219 μM. However, <b>21</b> demonstrated a high rate of clearance and poor oral bioavailability in rodent model systems.</div><figure id="fig12" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0012.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Binding mode of <b>20</b> with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6P8Y">6P8Y</a>). (B) Superimposition of the binding modes of ARS-1620 (pink, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U">5V9U</a>) and <b>20</b> (green). Hydrogen bonds are shown as yellow dashes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch6" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0026.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Optimization Process for AMG 510</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compared with the binding mode of ARS-1620, <b>20</b> approximately occupies the binding site of the quinazoline core with the indole core, with an additional interaction to the aforementioned cryptic pocket (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B). Therefore, a molecular hybridization strategy that incorporated a cryptic pocket binding fragment into the quinazoline core of ARS-1620 was applied and afforded a novel series of quinazolinone KRAS G12C inhibitors.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Representative compound <b>22</b> with an isopropylphenyl substituent at the N1 position of the quinazolinone ring demonstrated a substantial improvement in p-ERK inhibition (IC<sub>50</sub> = 0.13 μM). An X-ray crystal structure of <b>22</b> and GDP-bound KRAS G12C confirmed that <b>22</b> possesses a binding mode similar to that of ARS-1620 in which the isopropylphenyl group (with an <i>R</i> atropisomer conformation) inserts into the cryptic pocket. However, compound <b>22</b> displayed poor aqueous solubility and low oral bioavailability (<i>F</i> < 0.5%). Subsequent optimization at the quinazolinone 7-position and the piperazine 2-position led to azaquinazolinone <b>23</b> that possessed significant improvements in oral bioavailability and cellular activity (<i>F</i> = 33% and p-ERK IC<sub>50</sub> = 44 nM). Nonetheless, <b>23</b> exhibited poor stability due to slow rotation between the two possible atropisomers at room temperature. An additional methyl group was introduced to impede the rotation of the C–N bond, resulting in compound <b>24</b>, with a racemization <i>t</i><sub>1/2</sub> of greater than 2000 years. The more stable conformation of compound <b>24</b> also resulted in an improvement in cellular potency compared with compound <b>23</b> (p-ERK IC<sub>50</sub> = 28 nM). Further modification through the introduction of a polar nitrogen atom into the methyl–isopropyl phenyl ring and replacement of a chloride atom by fluorine improved the pharmacokinetic properties of the class, affording AMG 510 (<b>25</b>), which inhibits KRAS G12C cellular signaling with low nanomolar activity (p-ERK IC<sub>50</sub> = 68 nM) and displays acceptable oral bioavailability (<i>F</i> = 22–40%). Human tumor xenograft studies in nude mice confirmed that AMG 510 significantly inhibits tumor growth and ERK phosphorylation at a dose of 10 mg/kg. In addition, the efficacy of AMG 510 was further improved through combination with MEK (PD-0325901) or anti PD-L1 therapy.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">An X-ray crystal structure of AMG 510 and KRAS G12C demonstrates that it binds to the allosteric S-IIP by covalently targeting Cys12, employing a binding mode similar to that of ARS-1620 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). The carboxyl group of the quinazolinone forms additional water-mediated hydrogen bonds with Asp92 and Tyr96. Significantly, the substituted pyridyl ring extends into the cryptic pocket, with the pyridine nitrogen forming a hydrogen bond with a rotated His95 mediated by a bridging water molecule. The methylpiperazine ring binds in a twist-boat conformation so that the methyl group can form some favorable contacts with Cys12 and Gln61. All together, these critical contacts contribute to the exceptional potency of AMG 510.</div><figure id="fig13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0013.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Superimposition of the binding modes of AMG 510 (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OIM">6OIM</a>) and ARS-1620 (pink, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U">5V9U</a>). The two molecules have highly similar binding conformations, except for the substituted pyridine moiety of AMG 510, which penetrates into the “cryptic pocket” surrounded by His95, Tyr96, and Gln99.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In 2019, Amgen announced the first clinical results from a Phase 1 study evaluating AMG 510 (NCT03600883).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The study enrolled 35 patients with a KRAS G12C mutation in various solid tumors (14 NSCLC, 19 colorectal cancer, and two others) across four dosing cohorts (180, 360, 720, and 960 mg). When taken orally once daily as a monotherapy, AMG 510 showed significant antitumor efficacy. Among 14 NSCLC patients, 10 experienced a partial response (PR), while the remaining four demonstrated stable disease (SD). Additionally, 13 of 18 evaluable patients with colorectal cancer achieved SD. AMG 510 also displayed an acceptable safety profile, as only two severe treatment-related adverse events (anemia and diarrhea) were reported. The report that AMG 510 demonstrated antitumor activity in a clinical trial represents a significant milestone for the development of KRAS inhibitors. This exciting clinical study continues to define the maximum tolerated dose and recommended Phase 2 dose of AMG 510, with patient enrollment ongoing.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Besides, AMG 510 is also being tested in a Phase I study combined with anti-PD-1 immune checkpoint inhibition (NCT04185883).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">4.2.5.  Tetracyclic Derivatives</h4><div class="NLM_p">Conformational restriction is becoming a promising strategy in drug design.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Inspired by the quinazoline-based KRAS G12C inhibitor <b>26</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>), AstraZeneca developed a series of tetracyclic compounds aiming to rigidify the torsion angle between the quinazoline and piperazine ring systems.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> On the basis of relative energy predictions, it was determined that there are significant differences in the 4-piperazinoquinazoline torsion angle for the low-energy conformations (60°, 150–210°, and 300°) compared with the bioactive conformation (312°). It was therefore suggested that connecting the piperazine and quinazoline cores by the formation of an additional ring might restrict the rotation and lock the molecule in a bioactive conformation. Development of this approach led to the identification of tetracyclic compound <b>27</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). The activity of <b>27</b> was evaluated through measurement of KRAS G12C GTP-bound levels after treatment of the KRAS G12C/GDP/inhibitor complex with the SOS nucleotide exchange factor. This demonstrated that <b>27</b> inhibits KRAS G12C with an IC<sub>50</sub> value of 81 nM. While the formation of the tetracycle led to a 4-fold increase in inhibitory potency, the consequential increase in log <i>D</i> also provoked a high rate of clearance in human and rat in vitro ADME models.</div><figure id="sch7" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0027.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Optimization Process for Compound <b>30</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequent optimization led to the more potent compound <b>28</b>. Switching the aryl substituent from methylindazole to fluorophenol, as employed by ARS-1620, lowered the lipophilicity. Furthermore, the introduction of an additional fluorine substituent at the 8-position of the quinolone ring locked the fluorophenol ring into position as the active atropoisomer. Additional optimization of the six-membered tether ring led to <i>N</i>-methyllactam <b>29</b> with improved potency and a significantly lower log <i>D</i> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Furthermore, a “magic methyl” was added at the 5-position of the piperazine ring to give compound <b>30</b>, which displayed an increase in potency (KRAS G12C IC<sub>50</sub> < 5 nM) as well as exceptionally high oral bioavailability in rats (94%). As illustrated in the cocrystal structure of <b>30</b> in complex with KRAS G12C (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), the improved potency might be due to the magic methyl group, which displaces a bound water molecule (in a similar manner to the acetonitrile group of MRTX849), and the cyclic constraint of the lactam tether, which induces a bioactive diaxial conformation. Moreover, compound <b>30</b> demonstrated antiproliferative activity selectively in KRAS G12C cancer cell lines and dose-dependent regression of MIA PaCa-2 human pancreatic cancer xenografts bearing KRAS G12C mutation in nude mice when administrated daily at 100, 50, or 20 mg/kg.</div><figure id="fig14" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0014.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Superimposition of the binding modes of <b>30</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T5B">6T5B</a>) and a typical quinazoline inhibitor, ARS-1620 (pink, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U">5V9U</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.3.  Inhibitors That Bind at the Switch I/II Pocket</h3><div class="NLM_p">Despite the success of switch II pocket inhibitors, the covalent nature of these compounds provides minimal efficacy against other KRAS mutants such as the G12D, G12V, and Q61H variants, which are found in the vast majority of patients and lack the reactive cysteine required for covalent binding.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> To address this shortcoming, other screening methods (beyond screens for covalent inhibitors) were explored in the development of KRAS inhibitors with the aim of identifying and exploring other suitable binding pockets.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">4.3.1.  Indoles</h4><div class="NLM_p">In 2012, Maurer et al.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> reported a series of fragments that are able to bind with KRAS and disrupt the interaction between KRAS and the GEF SOS, which converts KRAS to the active GTP-bound state.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Inhibition of the KRAS–SOS interaction leads to a shift in KRAS from the active form to the inactive GDP-bound form.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> To discover potential fragments for KRAS, a 3300-compound library was screened against KRAS G12D using an NMR saturation transfer difference (STD) assay. A novel binding site situated between the switch I and switch II regions, called the switch I/II pocket, was identified (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). The pocket is bounded by Thr74 of helix α2 and Lys5, Arg41, Asp54, and Leu56 of the core β-sheet of KRAS and is relatively shallow, being only 7 Å × 7 Å wide and 5 Å deep.</div><figure id="fig15" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0015.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Binding mode of DCAI with KRAS G12D. (A) Overview of the switch I/II binding pocket. The switch I and II regions of KRAS are shown in blue and pink, respectively. The side chain of Asp54 (shown in cyan, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DSN">4DSN</a>) rotates outward upon ligand binding (shown in light gray, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DST">4DST</a>). (B) Alignment of the KRAS–DCAI complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DST">4DST</a>) with the KRAS–SOS complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BKD">1BKD</a>). The ethylamine side chain of DCAI penetrates into the surface between KRAS and SOS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The most potent compound identified from the NMR-STD screen, DCAI (<b>31</b>), binds to the switch I/II pocket through hydrophobic interactions of the indole ring and the two chloride atoms with KRAS. In addition, residue Asp54, which typically forms a salt bridge with Arg41 of SOS to stabilize the KRAS–SOS complex, rotates outward upon binding of DCAI (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A). In addition, the ethylamine side chain at the indole 3-position penetrates into the surface between KRAS and SOS, impeding protein–protein binding by inducing steric hindrance (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B). This observation is supported by the finding that an indole analogue without the ethylamine side chain had no effect on the KRAS–SOS interaction. Further nucleotide exchange and release assays demonstrated that DCAI inhibits SOS-mediated KRAS nucleotide exchange. DCAI showed moderate inhibition of RAS activation in HEK-293T cells with an EC<sub>50</sub> of 15.8 μM. The study provides a new direction in the search for therapeutically effective inhibitors of KRAS mutants other than G12C by disruption of the interactions of KRAS with its effectors.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">4.3.2.  2-((1<i>H</i>-Indol-3-yl)methyl)-1<i>H</i>-benzo[<i>d</i>]imidazoles</h4><div class="NLM_p">Sun et al. performed an NMR-spectroscopy-based screen of 11 000 fragments to identify a series of 2-((1<i>H</i>-indol-3-yl)methyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-based compounds that bind to the switch I/II pocket of KRAS G12D.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Interestingly, compound <b>32</b> binds to KRAS quite differently from the aforementioned DCAI. Rather than expelling Asp54 through a hydrophobic interaction, the indole NH group of <b>32</b> forms a hydrogen bond with Asp54. In addition, the imidazo[4,5-<i>c</i>]pyridine moiety forms a hydrogen bond with Ser39 mediated by a bridging water molecule (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A).</div><figure id="fig16" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0016.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Binding modes of (A) <b>32</b> with KRAS (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPV">4EPV</a>) and (B) <b>34</b> with KRAS G12V (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPY">4EPY</a>). The key residues are represented as stick structures. Hydrogen bonds are shown as yellow dashes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, compound <b>32</b> binds to KRAS with an affinity in the millimolar range. Subsequent modifications to improve the potency focused on a nearby negatively charged pocket with two acidic amino acid residues, Glu37 and Asp38, which offered opportunities to incorporate new polar interactions. Thus, the introduction of amide-linked amino acid groups yielded the Ile and Pro derivatives <b>33</b> and <b>34</b>, respectively (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>), which showed significant improvements in potency. The most potent compound, <b>33</b>, showed inhibitory activity in the SOS-catalyzed nucleotide exchange assay (78% inhibition at 1 mM). An X-ray crystal structure of the compound <b>34</b>–KRAS G12V complex indicated that the improved binding affinity could be explained by penetration of the proline moiety into the KRAS–SOS binding surface forming an extra hydrogen bond with Asp38 and Glu37 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B).</div><figure id="sch8" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0028.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Optimization Process for Compounds <b>33</b> and <b>34</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Most recently, Boehringer Ingelheim utilized structure-based design principles to optimize <b>32</b> by introducing a basic amine group at the 2-position of the indole ring to interact with Asp54.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Moreover, the imidazo[4,5-<i>c</i>]pyridine ring of <b>32</b> was replaced by a 2-hydroxyindolinone scaffold designed to make contact with Glu37. The resulting compound <b>35</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>) inhibited the interaction of GTP-bound KRAS G12D with SOS with an EC<sub>50</sub> of 33 μM. Further incorporation of a bulky <i>N</i>-benzylindole group on the amine side chain at the indole 2-position resulted in compound <b>36</b>. This derivative displayed a significant improvement in potency (EC<sub>50</sub> = 0.87 μM) that was attributed to its ability to displace three ordered water molecules. However, the introduction of this large lipophilic group also led to poor aqueous solubility, which was addressed through <i>N</i>-methylimidazole derivative <b>37</b> (BI-2852).</div><figure id="sch9" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0029.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Optimization Process for Compound <b>37</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Mechanistic studies on BI-2852 revealed that switch I/II pocket inhibitors not only inhibit the protein–protein interaction between GDP-bound KRAS and SOS but also potently disrupt the interaction between GTP-bound KRAS and GAP as well as other downstream effectors (CRAF, PI3K) since a common binding site on KRAS is shared (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref81 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref81 ref84 ref85">(81,84,85)</a> However, opposite biological outcomes result from disrupting the interactions of GAP and SOS with KRAS (hydrolyzing GTP as opposed to replacing GDP with GTP). As a result, GTP-bound KRAS levels remained unchanged in cells upon treatment with BI-2852.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Therefore, the inhibition of KRAS signaling observed in cells treated with switch I/II pocket inhibitors is attributed to the blockade of downstream effectors of KRAS, resulting in reduced pERK and pAKT levels (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). BI-2852 showed moderate antiproliferative activity in H358 NSCLC cells (IC<sub>50</sub> = 6.7 μM), providing a starting point for the design of more potent switch I/II pocket KRAS inhibitors in the future.</div><figure id="fig17" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0017.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Binding mode of BI-2852 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GJ7">6GJ7</a>) and alignment of the interaction interfaces between KRAS and its effector proteins SOS, GAP, and RAF (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BKD">1BKD</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0N">4G0N</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1WQ1">1WQ1</a>, respectively).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0018.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Rationale for KRAS inhibition by S-I/IIP inhibitors. The inhibitor targets both the KRAS GDP-bound inactive state and the KRAS GTP-bound active state at the same level by mutually impeding nucleotide exchange and GTP hydrolysis. Although KRAS GTP-bound levels remain unchanged, binding of the inhibitor with the KRAS GTP-bound form disrupts the interaction between KRAS and its effectors to block KRAS signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">4.3.3.  1,1′-Biaryls</h4><div class="NLM_p">Quevedo et al. developed an antibody fragment competition assay to identify RAS inhibitors through surface plasmon resonance (SPR).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The benzodioxane compound Abd-2 (<b>38</b>) was identified as a hit from among 656 compounds, demonstrating a preference for binding to the GppNHp-bound active form of KRAS rather than the inactive GDP-bound form. An X-ray crystal structure of Abd-2 with KRAS Q61H revealed the compound binds at the switch I/II pocket with the benzodioxane moiety anchoring the molecule in a hydrophobic pocket formed by Lys5, Leu6, Val7, and Glu37 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). Further medicinal chemistry modification focused on the 8-position of Abd-2, where an extended aromatic system could be incorporated to obtain additional interactions with the switch I region (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>). The advanced compound Abd-7 (<b>39</b>) showed improved binding affinity toward the KRAS G12V GppNHp-bound active form (<i>K</i><sub>d</sub> = 51 nM). Additionally, Abd-7 inhibited protein–protein interactions of KRAS G12D with PI3K, RAF, and RALGDS as well as the phosphorylation of AKT in a dose-dependent manner. These on-target effects were further validated in a DLD1 colorectal cancer cell (KRAS G13D) viability assay, in which Abd-7 displayed an IC<sub>50</sub> value of 8 μM. The potency of this series of biaryl compounds was further improved when a hybrid molecule based on Abd-7 and another SPR screening hit, biphenyl <b>40</b>, was prepared. The resulting compound Ch-3 (<b>41</b>) inhibited DLD1 cell proliferation with an IC<sub>50</sub> value of 4.5 μM.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><figure id="fig19" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0019.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Binding modes of Abd-2 (<b>38</b>) and Abd-7 (<b>39</b>) with KRAS Q61H (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OCO">5OCO</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FA4">6FA4</a>, respectively). The key residues are represented as stick structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch10" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0030.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Structural Modification of the 1,1′-Biaryl Switch I/II Pocket Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">4.4.  Inhibitors That Bind at the A59 Site</h3><div class="NLM_p">To discover KRAS G12D inhibitors that disrupt the interactions of KRAS with its effector proteins, Welsch et al. focused on identifying binding sites near the switch I region.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> A virtual library of designed small molecules were docked into the switch I region binding site in silico. One of the molecules, termed 3144 (<b>42</b>), was identified on the basis of its docking score and ideal clogP. Modeling studies and site-directed point mutation studies led to the hypothesis that 3144 binds in a distinct pocket named the A59 site, located between the KRAS switch I and switch II regions near Ala59. The A59 site is also close to the previously identified switch I/II pocket (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). Compound 3144 binds to GTP-bound KRAS G12D with a binding dissociation constant (<i>K</i><sub>d</sub>) of 9–20 μM, and a similar degree of binding to HRAS and NRAS was also observed. Further, 3144 exhibits selective lethality and signaling blockade in RAS-dependent cells while demonstrating inhibition of tumor growth and p-ERK levels in KRAS mutant xenograft models in nude mice. However, high toxicity was observed at a dose of 30 mg/kg in mice bearing the engineered murine KP<sup>f/f</sup>C pancreatic cancer model<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> harboring a KRAS G12D mutation. This toxicity is attributed to a lack of selectivity of this agent toward the RAS family of proteins, such as KRAS WT, NRAS, and HRAS.</div><figure id="fig20" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0020.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Proposed binding mode of 3144 (wheat) with KRAS G12D. The switch I region and the switch II region are shown in blue and pink, respectively. The proximal switch I/II binding pocket is indicated by the bound inhibitor DCAI (pink sticks).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">5.  Conclusions and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25625" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25625" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A significant amount of effort has been invested in the search for KRAS inhibitors. Despite the picomolar affinity of KRAS for GTP/GDP in cells, the recent success of covalent inhibitors of KRAS G12C provides a promising approach for addressing cancers harboring a KRAS mutation. Among them, both MRTX849 and AMG 510 have shown good therapeutic efficacy in initial clinical trials.<a onclick="showRef(event, 'ref17 ref71'); return false;" href="javascript:void(0);" class="ref ref17 ref71">(17,71)</a></div><div class="NLM_p last">However, despite the success of KRAS G12C inhibitors, several problems are still worth discussing. First, G12C inhibitors rely on covalent modification of Cys12 unique to the KRAS G12C mutation, limiting their efficacy against other oncogenic KRAS mutations, such as G12V, G12D, and Q61H. These mutations are even more frequently identified in cancer mutation profiling and are responsible for cancer growth and development in a great number of patients.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Nonetheless, efforts to target these mutations, either through the discovery of non-covalent inhibitors (e.g., the switch I/II pocket inhibitors and the A59 site inhibitors described above) or through the design of inhibitors with alternate covalent-bond-forming electrophiles,<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> have to date failed to produce selective molecules with sufficient in vitro activity. Second, the sensitivity toward covalent KRAS G12C inhibitors varies significantly across KRAS G12C mutated tumor types.<a onclick="showRef(event, 'ref18 ref91'); return false;" href="javascript:void(0);" class="ref ref18 ref91">(18,91)</a> This may in part depend on co-occurring genetic alterations in genes such as <i>TP53</i>, <i>CDKN2A</i>, and <i>PIK3CA.</i><a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Accordingly, the available evidence indicates that the sensitivity and efficacy of covalent KRAS G12C inhibitors could be enhanced through combination with inhibitors of several other signaling pathways, such as HER, CDK4, and SHP2, but the correlation between the co-occurring mutations and sensitivity to KRAS target therapy is not well-established, and there is a potential concern about the overlapping toxicity profiles of these inhibitor classes.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The sensitivity toward KRAS inhibitors may also be related to the immune system, considering the important role of mutant KRAS in promoting an immunosuppressive tumor microenvironment.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> Indeed, the improved antitumor activity of AMG 510 in combination with immune-checkpoint inhibition has been demonstrated in preclinical studies.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, there are many lines of evidence, particularly in lung cancer patients, indicating that when small molecules are combined with immunotherapy, life-threatening side effects can occur.<a onclick="showRef(event, 'ref91 ref93'); return false;" href="javascript:void(0);" class="ref ref91 ref93">(91,93)</a> Finally, acquired resistance is a major challenge in target therapy, and KRAS inhibitors are by no means an exception. Recent studies by Xue et al. revealed that ARS-1620-treated KRAS G12C mutant cells acquire resistance through the synthesis of a new KRAS G12C protein that is maintained in an active GTP-bound state through EGFR and SHP2 signaling.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> This has the effect of rendering the cells insensitive to covalent KRAS G12C inhibitors because they selectively bind the GDP-bound inactive state.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Additionally, similar to previous efforts to inhibit the RAS–RAF–MEK pathway,<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> acquired resistance mediated by adaptive feedback reactivation of pathway signaling has also been observed following KRAS G12C inhibition.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> In short, the encouraging clinical data reported for AMG 510 and MRTX849 signal the start of a new era of KRAS-targeted cancer therapy. We sincerely hope that these breakthroughs will be translated into an improvement in the treatment outcomes of KRAS-mutated patients in the near future, making the dream of “drugging” KRAS come true.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01312" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#395d50575e525c7953574c175c5d4c175a57"><span class="__cf_email__" data-cfemail="94f0fdfaf3fff1d4fefae1baf1f0e1baf7fa">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyun Lu</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7931-6873" title="Orcid link">http://orcid.org/0000-0001-7931-6873</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fa968f8283c8cacbccba90948fd49f9e8fd49994"><span class="__cf_email__" data-cfemail="f09c858889c2c0c1c6b09a9e85de959485de939e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Chen</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff B. Smaill</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tongzheng Liu</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Hao Chen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=BIO-d7e1697-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hao Chen</b> received his Bachelor’s degree at Shenyang Pharmaceutical University in China. He is currently study for his Ph.D. degree at Jinan University in Guangzhou, China. His recent academic work is focused on the synthesis of kinase inhibitors as anticancer drugs.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Jeff B. Smaill</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=BIO-d7e1702-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jeff B. Smaill</b> is an associate professor at the University of Auckland and an Associate Investigator of the Maurice Wilkins Centre (a New Zealand CoRE). He received his Ph.D. degree in Organic Chemistry at the University of Otago in 1992 and conducted his postdoctoral training at the University of Cambridge. His research interests include the discovery of novel small-molecule covalent kinase inhibitors and hypoxia-activated prodrugs. He has been involved in the design and development of canertinib, dacomitinib, and tarloxotinib.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Tongzheng Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=BIO-d7e1707-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tongzheng Liu</b> is a professor of pharmacology at Jinan University. He studied pharmacology at The Ohio State University and received his Ph.D. degree in 2009. During his postdoctoral period, he was rigorously trained at Mayo Clinic in the United States. In 2017, he joined the College of Pharmacy at Jinan University. His research interests are mainly focused on understanding how aberrant signaling pathways cause cancer development. He has published more than 20 articles in highly ranked journals, including <i>Nature</i>, <i>Cell</i>, <i>Molecular Cell</i>, and <i>Nature Communications</i>.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Ke Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=BIO-d7e1724-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ke Ding</b> is a professor of medicinal chemistry at Jinan University. He studied organic chemistry at Fudan University and received his Ph.D. degree in 2001. He worked as a postdoctoral fellow at the University of Michigan, Ann Arbor. After working for 5 years, he joined GIBH. In 2016, he moved to the School of Pharmacy at Jinan University. His research focuses on the design and synthesis of bioactive inhibitors of kinase for novel drug discovery. He has successfully developed two drug-like inhibitors of kinase into the clinic.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Xiaoyun Lu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=BIO-d7e1729-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiaoyun Lu</b> is a professor of medicinal chemistry at Jinan University. She studied medicinal chemistry at China Pharmaceutical University and received her Ph.D. degree in 2010. After working for 6 years at GIBH, she moved to the School of Pharmacy at Jinan University in 2016. Her research interests include the design of novel inhibitors of protein kinase involved in targeting lung disease. She has been involved in the design and development of Bcr-Abl, EGFR, and DDR inhibitors.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors appreciate the financial support from the National Natural Science Foundation of China (81922062), the National Key Research and Development Program of China (2018YFE0105800), the Guangdong Provincial Science and Technology Program (2018A050506043), Jinan University, the Health Research Council of New Zealand (18/1016), and Cancer Society Auckland Northland.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">FTase</td><td class="NLM_def"><p class="first last">farnesyltransferase</p></td></tr><tr><td class="NLM_term">GAP</td><td class="NLM_def"><p class="first last">GTPase-activating protein</p></td></tr><tr><td class="NLM_term">GDP</td><td class="NLM_def"><p class="first last">guanosine diphosphate</p></td></tr><tr><td class="NLM_term">GEF</td><td class="NLM_def"><p class="first last">guanine nucleotide exchange factor</p></td></tr><tr><td class="NLM_term">GGTaseI</td><td class="NLM_def"><p class="first last">geranylgeranyl transferase I</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">glutathione S-transferase</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine triphosphate</p></td></tr><tr><td class="NLM_term">HVR</td><td class="NLM_def"><p class="first last">hypervariable region</p></td></tr><tr><td class="NLM_term">ICMT</td><td class="NLM_def"><p class="first last">isoprenyl cysteine carboxyl methyltransferase</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">P-loop</td><td class="NLM_def"><p class="first last">phosphate-binding loop</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">partial response</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">RALGDS</td><td class="NLM_def"><p class="first last">RAL guanine nucleotide-dissociation stimulator</p></td></tr><tr><td class="NLM_term">RBD</td><td class="NLM_def"><p class="first last">RAS-binding domain</p></td></tr><tr><td class="NLM_term">RCE1</td><td class="NLM_def"><p class="first last">RAS-converting enzyme 1</p></td></tr><tr><td class="NLM_term">S-IIP</td><td class="NLM_def"><p class="first last">switch II pocket</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">stable disease</p></td></tr><tr><td class="NLM_term">SHP2</td><td class="NLM_def"><p class="first last">Src homology phosphatase 2</p></td></tr><tr><td class="NLM_term">SOS</td><td class="NLM_def"><p class="first last">son of sevenless</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">STD</td><td class="NLM_def"><p class="first last">saturation transfer difference</p></td></tr><tr><td class="NLM_term">WB</td><td class="NLM_def"><p class="first last">whole-blood isolate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 97 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Ras history</span>. <i>Small GTPases</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.4161/sgtp.1.1.12178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.4161%2Fsgtp.1.1.12178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=21686117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BC2srisVWnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=2-27&issue=1&author=A.+D.+Coxauthor=C.+J.+Der&title=Ras+history&doi=10.4161%2Fsgtp.1.1.12178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Ras history: The saga continues</span></div><div class="casAuthors">Cox Adrienne D; Der Channing J</div><div class="citationInfo"><span class="NLM_cas:title">Small GTPases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although the roots of Ras sprouted from the rich history of retrovirus research, it was the discovery of mutationally activated RAS genes in human cancer in 1982 that stimulated an intensive research effort to understand Ras protein structure, biochemistry and biology.  While the ultimate goal has been developing anti-Ras drugs for cancer treatment, discoveries from Ras have laid the foundation for three broad areas of science.  First, they focused studies on the origins of cancer to the molecular level, with the subsequent discovery of genes mutated in cancer that now number in the thousands.  Second, elucidation of the biochemical mechanisms by which Ras facilitates signal transduction established many of our fundamental concepts of how a normal cell orchestrates responses to extracellular cues.  Third, Ras proteins are also founding members of a large superfamily of small GTPases that regulate all key cellular processes and established the versatile role of small GTP-binding proteins in biology.  We highlight some of the key findings of the last 28 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJN8gMSAebef9pSBfyDvp7fW6udTcc2eZZ0uW6Pp0Qwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srisVWnsA%253D%253D&md5=69fba6e1e1203a0f35fad4d1c89258ae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.4161%2Fsgtp.1.1.12178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fsgtp.1.1.12178%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DRas%2520history%26jtitle%3DSmall%2520GTPases%26date%3D2010%26volume%3D1%26issue%3D1%26spage%3D2%26epage%3D27%26doi%3D10.4161%2Fsgtp.1.1.12178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancias, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">KRAS: feeding pancreatic cancer proliferation</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2013.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.tibs.2013.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=24388967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=91-100&issue=2&author=K.+L.+Bryantauthor=J.+D.+Manciasauthor=A.+C.+Kimmelmanauthor=C.+J.+Der&title=KRAS%3A+feeding+pancreatic+cancer+proliferation&doi=10.1016%2Fj.tibs.2013.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS: feeding pancreatic cancer proliferation</span></div><div class="casAuthors">Bryant, Kirsten L.; Mancias, Joseph D.; Kimmelman, Alec C.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Oncogenic KRAS mutation is the signature genetic event in the progression and growth of pancreatic ductal adenocarcinoma (PDAC), an almost universally fatal disease.  Although it has been appreciated for some time that nearly 95% of PDAC harbor mutationally activated KRAS, to date no effective treatments that target this mutant protein have reached the clinic.  A no. of studies have shown that oncogenic KRAS plays a central role in controlling tumor metab. by orchestrating multiple metabolic changes including stimulation of glucose uptake, differential channeling of glucose intermediates, reprogrammed glutamine metab., increased autophagy, and macropinocytosis.  We review these recent findings and address how they may be applied to develop new PDAC treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrziZgcJvGfpbVg90H21EOLACvtfcHk0ljBVbpH_H4UUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVCjug%253D%253D&md5=e027cbe3a26649002154765249cfef93</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2013.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2013.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DK.%2BL.%26aulast%3DMancias%26aufirst%3DJ.%2BD.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DKRAS%253A%2520feeding%2520pancreatic%2520cancer%2520proliferation%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2014%26volume%3D39%26issue%3D2%26spage%3D91%26epage%3D100%26doi%3D10.1016%2Fj.tibs.2013.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pylayeva-Gupta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabocka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span> <span> </span><span class="NLM_article-title">RAS oncogenes: weaving a tumorigenic web</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1038/nrc3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrc3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=21993244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=761-774&issue=11&author=Y.+Pylayeva-Guptaauthor=E.+Grabockaauthor=D.+Bar-Sagi&title=RAS+oncogenes%3A+weaving+a+tumorigenic+web&doi=10.1038%2Fnrc3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">RAS oncogenes: weaving a tumorigenic web</span></div><div class="casAuthors">Pylayeva-Gupta, Yuliya; Grabocka, Elda; Bar-Sagi, Dafna</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">761-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAS proteins are essential components of signalling pathways that emanate from cell surface receptors.  Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer.  A wealth of biochem. and genetic studies indicates that RAS proteins control a complex mol. circuitry that consists of a wide array of interconnecting pathways.  In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdHRt0jsiXtLVg90H21EOLACvtfcHk0ljBVbpH_H4UUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K&md5=d1be47023ab43a30cb81e71cb92bc0aa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3106%26sid%3Dliteratum%253Aachs%26aulast%3DPylayeva-Gupta%26aufirst%3DY.%26aulast%3DGrabocka%26aufirst%3DE.%26aulast%3DBar-Sagi%26aufirst%3DD.%26atitle%3DRAS%2520oncogenes%253A%2520weaving%2520a%2520tumorigenic%2520web%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26issue%3D11%26spage%3D761%26epage%3D774%26doi%3D10.1038%2Fnrc3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prior, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">A comprehensive survey of Ras mutations in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2467</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-2612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F0008-5472.CAN-11-2612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=22589270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2457-2467&issue=10&author=I.+A.+Priorauthor=P.+D.+Lewisauthor=C.+Mattos&title=A+comprehensive+survey+of+Ras+mutations+in+cancer&doi=10.1158%2F0008-5472.CAN-11-2612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Survey of Ras Mutations in Cancer</span></div><div class="casAuthors">Prior, Ian A.; Lewis, Paul D.; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2457-2467</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  All mammalian cells express 3 closely related Ras proteins, termed H-Ras, K-Ras, and N-Ras, that promote oncogenesis when they are mutationally activated at codon 12, 13, or 61.  Although there is a high degree of similarity among the isoforms, K-Ras mutations are far more frequently obsd. in cancer, and each isoform displays preferential coupling to particular cancer types.  We examd. the mutational spectra of Ras isoforms curated from large-scale tumor profiling and found that each isoform exhibits surprisingly distinctive codon mutation and amino-acid substitution biases.  These findings were unexpected given that these mutations occur in regions that share 100% amino-acid sequence identity among the 3 isoforms.  Of importance, many of these mutational biases were not due to differences in exposure to mutagens, because the patterns were still evident when compared within specific cancer types.  We discuss potential genetic and epigenetic mechanisms, as well as isoform-specific differences in protein structure and signaling, that may promote these distinct mutation patterns and differential coupling to specific cancers.  Cancer Res; 72(10); 2457-67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2lqiicosOLVg90H21EOLACvtfcHk0ljBVbpH_H4UUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D&md5=6d1894847015468f77c8b08b57c6d62a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-2612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-2612%26sid%3Dliteratum%253Aachs%26aulast%3DPrior%26aufirst%3DI.%2BA.%26aulast%3DLewis%26aufirst%3DP.%2BD.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DA%2520comprehensive%2520survey%2520of%2520Ras%2520mutations%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3D10%26spage%3D2457%26epage%3D2467%26doi%3D10.1158%2F0008-5472.CAN-11-2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marabese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganzinelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garassino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caiola, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macerelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauricella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floriani, I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">34014</span>– <span class="NLM_lpage">34022</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.18632%2Foncotarget.5607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26416458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BC283ms1eruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=34014-34022&issue=32&author=M.+Marabeseauthor=M.+Ganzinelliauthor=M.+C.+Garassinoauthor=F.+A.+Shepherdauthor=S.+Pivaauthor=E.+Caiolaauthor=M.+Macerelliauthor=A.+Bettiniauthor=C.+Lauricellaauthor=I.+Floriani&title=KRAS+mutations+affect+prognosis+of+non-small-cell+lung+cancer+patients+treated+with+first-line+platinum+containing+chemotherapy&doi=10.18632%2Foncotarget.5607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy</span></div><div class="casAuthors">Marabese Mirko; Caiola Elisa; Floriani Irene; Broggini Massimo; Rulli Eliana; Ganzinelli Monica; Garassino Marina C; Macerelli Marianna; Shepherd Frances A; Piva Sheila; Farina Gabriella; Bettini Anna; Bonomi Lucia; Lauricella Calogero; Veronese Silvio; Longo Flavia; Fabbri M Agnese; Marsoni Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">34014-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  KRAS mutations seem to indicate a poor outcome in Non-Small-Cell Lung Cancer (NSCLC) but such evidence is still debated.  The aim of this planned ancillary study within the TAILOR trial was to assess the prognostic value of KRAS mutations in advanced NSCLC patients treated with platinum-based first-line chemotherapy.  Patients (N = 540), enrolled in the study in 52 Italian hospitals, were centrally genotyped twice in two independent laboratories for EGFR and KRAS mutational status.Of these, 247 patients were eligible and included in the present study.  The primary endpoint was overall survival (OS) according to KRAS mutational status in patients harboring EGFR wild-type.Sixty (24.3%) out of 247 patients harbored KRAS mutations.  Median OS was 14.3 months and 10.6 months in wild-type and mutated KRAS patients, respectively (unadjusted Hazard Ratio [HR]=1.41, 95%Confidence Interval [CI]: 1.03-1.94 P = 0.032; adjusted HR=1.39, 95%CI: 1.00-1.94 P = 0.050).  This study, with all consecutive patients genotyped, indicates that the presence of KRAS mutations has a mild negative impact on OS in advanced NSCLC patient treated with a first-line platinum-containing regimen.  TRIAL REGISTRATION:  clinicaltrials.gov identifierNCT00637910.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyoFn7ddEXhxFwe7cAcrfPfW6udTcc2eam_WXJ67B3ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ms1eruw%253D%253D&md5=8405e9fa5762ce0fd27a414662626763</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5607%26sid%3Dliteratum%253Aachs%26aulast%3DMarabese%26aufirst%3DM.%26aulast%3DGanzinelli%26aufirst%3DM.%26aulast%3DGarassino%26aufirst%3DM.%2BC.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DPiva%26aufirst%3DS.%26aulast%3DCaiola%26aufirst%3DE.%26aulast%3DMacerelli%26aufirst%3DM.%26aulast%3DBettini%26aufirst%3DA.%26aulast%3DLauricella%26aufirst%3DC.%26aulast%3DFloriani%26aufirst%3DI.%26atitle%3DKRAS%2520mutations%2520affect%2520prognosis%2520of%2520non-small-cell%2520lung%2520cancer%2520patients%2520treated%2520with%2520first-line%2520platinum%2520containing%2520chemotherapy%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D32%26spage%3D34014%26epage%3D34022%26doi%3D10.18632%2Foncotarget.5607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lohinai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klikovits, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldvay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostoros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalszky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenessey, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aigner, C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39721</span>, <span class="refDoi"> DOI: 10.1038/srep39721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fsrep39721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=28051122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=39721&issue=1&author=Z.+Lohinaiauthor=T.+Klikovitsauthor=J.+Moldvayauthor=G.+Ostorosauthor=E.+Rasoauthor=J.+Timarauthor=K.+Fabianauthor=I.+Kovalszkyauthor=I.+Kenesseyauthor=C.+Aigner&title=KRAS-mutation+incidence+and+prognostic+value+are+metastatic+site-specific+in+lung+adenocarcinoma%3A+poor+prognosis+in+patients+with+KRAS+mutation+and+bone+metastasis&doi=10.1038%2Fsrep39721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis</span></div><div class="casAuthors">Lohinai, Zoltan; Klikovits, Thomas; Moldvay, Judit; Ostoros, Gyula; Raso, Erzsebet; Timar, Jozsef; Fabian, Katalin; Kovalszky, Ilona; Kenessey, Istvan; Aigner, Clemens; Renyi-Vamos, Ferenc; Klepetko, Walter; Dome, Balazs; Hegedus, Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39721</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS mutation in lung adenocarcinoma (LADC).  We investigated the effect of KRAS mutation on overall survival (OS) in this setting.  In our retrospective study, 500 consecutive Caucasian metastatic LADC patients with known KRAS mutational status were analyzed after excluding 32 patients with EGFR mutations.  KRAS mutation incidence was 28.6%.  The most frequent metastatic sites were lung (45.6%), bone (26.2%), adrenal gland (17.4%), brain (16.8%), pleura (15.6%) and liver (11%).  Patients with intrapulmonary metastasis had significantly increased KRAS mutation frequency compared to those with extrapulmonary metastases (35% vs 26.5%, p = 0.0125).  In contrast, pleural dissemination and liver involvement were assocd. with significantly decreased KRAS mutation incidence (vs all other metastatic sites; 17% (p < 0.001) and 16% (p = 0.02) vs 33%, resp.).  Strikingly, we found a significant prognostic effect of KRAS status only in the bone metastatic subcohort (KRAS-wild-type vs KRAS-mutant; median OS 9.7 v 3.7 mo; HR, 0.49; 95% CI, 0.31 to 0.79; p = 0.003).  Our study suggests that KRAS mutation frequency in LADC patients shows a metastatic site dependent variation and, moreover, that the presence of KRAS mutation is assocd. with significantly worse outcome in bone metastatic cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZSgE4MURwRLVg90H21EOLACvtfcHk0lgphy0HRDK6Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslOjsw%253D%253D&md5=00a2dc3c1d6273f4975bd3c34a008bfb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fsrep39721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep39721%26sid%3Dliteratum%253Aachs%26aulast%3DLohinai%26aufirst%3DZ.%26aulast%3DKlikovits%26aufirst%3DT.%26aulast%3DMoldvay%26aufirst%3DJ.%26aulast%3DOstoros%26aufirst%3DG.%26aulast%3DRaso%26aufirst%3DE.%26aulast%3DTimar%26aufirst%3DJ.%26aulast%3DFabian%26aufirst%3DK.%26aulast%3DKovalszky%26aufirst%3DI.%26aulast%3DKenessey%26aufirst%3DI.%26aulast%3DAigner%26aufirst%3DC.%26atitle%3DKRAS-mutation%2520incidence%2520and%2520prognostic%2520value%2520are%2520metastatic%2520site-specific%2520in%2520lung%2520adenocarcinoma%253A%2520poor%2520prognosis%2520in%2520patients%2520with%2520KRAS%2520mutation%2520and%2520bone%2520metastasis%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D39721%26doi%3D10.1038%2Fsrep39721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gounder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Tine, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhem, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conry, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movva, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Sorafenib for advanced and refractory desmoid tumors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">2417</span>– <span class="NLM_lpage">2428</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1805052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1056%2FNEJMoa1805052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30575484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlt1SjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=2417-2428&issue=25&author=M.+M.+Gounderauthor=M.+R.+Mahoneyauthor=B.+A.+Van+Tineauthor=V.+Raviauthor=S.+Attiaauthor=H.+A.+Deshpandeauthor=A.+A.+Guptaauthor=M.+M.+Milhemauthor=R.+M.+Conryauthor=S.+Movva&title=Sorafenib+for+advanced+and+refractory+desmoid+tumors&doi=10.1056%2FNEJMoa1805052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib for advanced and refractory desmoid tumors</span></div><div class="casAuthors">Gounder, Mrinal M.; Mahoney, Michelle R.; Van Tine, Brian A.; Ravi, Vinod; Attia, Steven; Deshpande, Hari A.; Gupta, Abha A.; Milhem, Mohammed M.; Conry, Robert M.; Movva, Sujana; Pishvaian, Michael J.; Riedel, Richard F.; Sabagh, Tarek; Tap, William D.; Horvat, Natally; Basch, Ethan; Schwartz, Lawrence H.; Maki, Robert G.; Agaram, Narasimhan P.; Lefkowitz, Robert A.; Mazaheri, Yousef; Yamashita, Rikiya; Wright, John J.; Dueck, Amylou C.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2417-2427</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs.  There is no std. of care. methods In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.  Crossover to the sorafenib group was permitted for patients in the placebo group who had disease progression.  The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated. results With a median follow-up of 27.2 mo, the 2-yr progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001).  Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.  The median time to an objective response among patients who had a response was 9.6 mo (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 mo (interquartile range, 11.2 to 31.1) in the placebo group.  The objective responses are ongoing.  Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%). conclusions Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged progression-free survival and induced durable responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1f78z_60ZrVg90H21EOLACvtfcHk0lgphy0HRDK6Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlt1SjtQ%253D%253D&md5=1ea0d38a8e70ca3552886654a7efc7a2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1805052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1805052%26sid%3Dliteratum%253Aachs%26aulast%3DGounder%26aufirst%3DM.%2BM.%26aulast%3DMahoney%26aufirst%3DM.%2BR.%26aulast%3DVan%2BTine%26aufirst%3DB.%2BA.%26aulast%3DRavi%26aufirst%3DV.%26aulast%3DAttia%26aufirst%3DS.%26aulast%3DDeshpande%26aufirst%3DH.%2BA.%26aulast%3DGupta%26aufirst%3DA.%2BA.%26aulast%3DMilhem%26aufirst%3DM.%2BM.%26aulast%3DConry%26aufirst%3DR.%2BM.%26aulast%3DMovva%26aufirst%3DS.%26atitle%3DSorafenib%2520for%2520advanced%2520and%2520refractory%2520desmoid%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D25%26spage%3D2417%26epage%3D2428%26doi%3D10.1056%2FNEJMoa1805052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.+C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurata&title=Osimertinib+in+untreated+EGFR-mutated+advanced+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0lh6ZMlzL2fBkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26atitle%3DOsimertinib%2520in%2520untreated%2520EGFR-mutated%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashiguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iinuma, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer</span>. <i>Int. J. Colorectal Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1007/s00384-019-03344-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1007%2Fs00384-019-03344-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31309326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BB3Mznslejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=1491-1496&issue=8&author=T.+Hayamaauthor=Y.+Hashiguchiauthor=K.+Okamotoauthor=Y.+Okadaauthor=K.+Onoauthor=R.+Shimadaauthor=T.+Ozawaauthor=T.+Toyodaauthor=T.+Tsuchiyaauthor=H.+Iinuma&title=G12V+and+G12C+mutations+in+the+gene+KRAS+are+associated+with+a+poorer+prognosis+in+primary+colorectal+cancer&doi=10.1007%2Fs00384-019-03344-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer</span></div><div class="casAuthors">Hayama Tamuro; Hashiguchi Yojiro; Okada Yuka; Ono Kohei; Shimada Ryu; Ozawa Tsuyoshi; Tsuchiya Takeshi; Iinuma Hisae; Nozawa Keijiro; Matsuda Keiji; Okamoto Koichi; Toyoda Tetsutaka</div><div class="citationInfo"><span class="NLM_cas:title">International journal of colorectal disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1491-1496</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The increased incidence of colorectal cancer (CRC) has necessitated the development of novel prognostic and predictive factors from which new diagnostic tests could evolve.  Evidence suggests the KRAS gene represents such a factor; its mutations are considered to be early indicators of CRC progression.  This study assessed the prognostic impact of specific known KRAS codon 12/13 mutations on survival in patients with CRC.  METHODS:  Formalin-fixed paraffin-embedded tissue blocks or sections from primary were obtained from patients registered between 2014 and 2016 for genomic DNA extraction.  KRAS gene was analyzed by direct sequencing or Luminex assay.  The primary endpoint was the frequency of KRAS gene mutations and the secondary endpoints were differences in KRAS mutation rates by various stratification factors.  Univariate and multivariate analyses were performed to investigate relationships between KRAS mutation rates and patient background factors.  RESULTS:  Sequencing of 200 CRC primary tumor samples demonstrated 74 (37.5%) with KRAS mutations in codons 12 (77%; 57/74) and 13 (23%; 17/74), all of which were TNM stages I-III.  Tumors with KRAS mutations were more frequently located in the right side of the colon.  Multivariate analysis indicated that G12V or G12C mutations were associated with poor prognosis [hazard ratio (HR) = 3.77, 95% confidence interval (CI), 1.54-8.39 and HR = 6.57; 95% CI, 1.90-17.7, respectively] in terms of recurrence-free survival.  CONCLUSION:  KRAS codon 12G-to-V or G-to-C mutations are independent prognostic factors in patients with stage I-III CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRc23_CSyS508ULxIEhxUjPfW6udTcc2eYBKipy4NLlPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mznslejug%253D%253D&md5=895688f5e8c9e70683851435a9039ea1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00384-019-03344-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00384-019-03344-9%26sid%3Dliteratum%253Aachs%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DHashiguchi%26aufirst%3DY.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DR.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DToyoda%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DT.%26aulast%3DIinuma%26aufirst%3DH.%26atitle%3DG12V%2520and%2520G12C%2520mutations%2520in%2520the%2520gene%2520KRAS%2520are%2520associated%2520with%2520a%2520poorer%2520prognosis%2520in%2520primary%2520colorectal%2520cancer%26jtitle%3DInt.%2520J.%2520Colorectal%2520Dis.%26date%3D2019%26volume%3D34%26issue%3D8%26spage%3D1491%26epage%3D1496%26doi%3D10.1007%2Fs00384-019-03344-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, E. F.</span></span> <span> </span><span class="NLM_article-title">The structure of Ras protein: a model for a universal molecular switch</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1016/0968-0004(91)90156-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2F0968-0004%2891%2990156-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1785141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3MXmslemsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1991&pages=382-387&author=A.+Wittinghoferauthor=E.+F.+Pal&title=The+structure+of+Ras+protein%3A+a+model+for+a+universal+molecular+switch&doi=10.1016%2F0968-0004%2891%2990156-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of Ras protein:  a model for a universal molecular switch</span></div><div class="casAuthors">Wittinghofer, Alfred; Pai, Emil F.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">382-7</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    </div><div class="casAbstract">A review and discussion with 33 refs.  X-ray crystallog. has revealed the mol. architecture of the cellular and oncogenic forms of p21Ha-ras, the protein encoded by the human Ha-ras gene, in both its active (GTP-bound) and in its inactive (GDP-bound) forms.  From comparison of these 2 structures, a mechanism is suggested for the GTPase hydrolysis reaction that triggers the conformational change necessary for signal transduction.  The structures have also allowed identification of the structural consequences of point mutations and the way in which they interfere with the intrinsic GTPase activity of p21ras.  The p21ras structure is similar to that of the G-domain of elongation factor Tu (EF-Tu) from Escherichia coli, suggesting that p21ras can serve as a good model for other guanine nucleotide-binding proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolH9XO3ovsfLVg90H21EOLACvtfcHk0lh6ZMlzL2fBkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmslemsb4%253D&md5=85e2227d6ca0c097d3b5efc8fdbb3156</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2F0968-0004%2891%2990156-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0968-0004%252891%252990156-P%26sid%3Dliteratum%253Aachs%26aulast%3DWittinghofer%26aufirst%3DA.%26aulast%3DPal%26aufirst%3DE.%2BF.%26atitle%3DThe%2520structure%2520of%2520Ras%2520protein%253A%2520a%2520model%2520for%2520a%2520universal%2520molecular%2520switch%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1991%26volume%3D16%26spage%3D382%26epage%3D387%26doi%3D10.1016%2F0968-0004%2891%2990156-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downward, J.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrc969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&issue=1&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy&doi=10.1038%2Fnrc969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0licNlJCGWyWPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26issue%3D1%26spage%3D11%26epage%3D22%26doi%3D10.1038%2Fnrc969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">The GTPase superfamily: conserved structure and molecular mechanism</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>349</i></span> (<span class="NLM_issue">6305</span>),  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1038/349117a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2F349117a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1898771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3MXlslygsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=1991&pages=117-127&issue=6305&author=H.+R.+Bourneauthor=D.+A.+Sandersauthor=F.+McCormick&title=The+GTPase+superfamily%3A+conserved+structure+and+molecular+mechanism&doi=10.1038%2F349117a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The GTPase superfamily:  conserved structure and molecular mechanism</span></div><div class="casAuthors">Bourne, Henry R.; Sanders, David A.; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">6305</span>),
    <span class="NLM_cas:pages">117-27</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A review with 150 refs.  GTPases are conserved mol. switches, built according to a common structural design.  Rapidly accruing knowledge of individual GTPases, crystal structures, biochem. properties, or results of mol. genetic expts., support and generate hypotheses relating structure to function in other members of the diverse family of GTPases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoitAaJH96dMrVg90H21EOLACvtfcHk0licNlJCGWyWPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlslygsA%253D%253D&md5=38aeab01721108f6e6827033830ed6bf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2F349117a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F349117a0%26sid%3Dliteratum%253Aachs%26aulast%3DBourne%26aufirst%3DH.%2BR.%26aulast%3DSanders%26aufirst%3DD.%2BA.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DThe%2520GTPase%2520superfamily%253A%2520conserved%2520structure%2520and%2520molecular%2520mechanism%26jtitle%3DNature%26date%3D1991%26volume%3D349%26issue%3D6305%26spage%3D117%26epage%3D127%26doi%3D10.1038%2F349117a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span> <span> </span><span class="NLM_article-title">Therapeutic strategies to target RAS-mutant cancers</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">720</span>, <span class="refDoi"> DOI: 10.1038/s41571-018-0105-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41571-018-0105-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30275515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVeqs7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=709-720&issue=11&author=M.+B.+Ryanauthor=R.+B.+Corcoran&title=Therapeutic+strategies+to+target+RAS-mutant+cancers&doi=10.1038%2Fs41571-018-0105-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to target RAS-mutant cancers</span></div><div class="casAuthors">Ryan, Meagan B.; Corcoran, Ryan B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">709-720</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive.  A key aspect of this challenge is the fact that direct inhibition of RAS proteins has proved difficult, leading researchers to test numerous alternative strategies aimed at exploiting RAS-related vulnerabilities or targeting RAS effectors.  In the past few years, we have witnessed renewed efforts to target RAS directly, with several promising strategies being tested in clin. trials at different stages of completion.  Important advances have also been made in approaches designed to indirectly target RAS by improving inhibition of RAS effectors, exploiting synthetic lethal interactions or metabolic dependencies, using therapeutic combination strategies or harnessing the immune system.  In this Review, we describe historical and ongoing efforts to target RAS-mutant cancers and outline the current therapeutic landscape in the collective quest to overcome the effects of this crucial oncogene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojQcBt2xwv47Vg90H21EOLACvtfcHk0licNlJCGWyWPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVeqs7bM&md5=44839eb1482998d710b74e9362f4e0ea</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41571-018-0105-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41571-018-0105-0%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DM.%2BB.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26atitle%3DTherapeutic%2520strategies%2520to%2520target%2520RAS-mutant%2520cancers%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26issue%3D11%26spage%3D709%26epage%3D720%26doi%3D10.1038%2Fs41571-018-0105-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Drugging the undruggable RAS: mission possible?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">828</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1038/nrd4389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrd4389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=25323927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=828-851&issue=11&author=A.+D.+Coxauthor=S.+W.+Fesikauthor=A.+C.+Kimmelmanauthor=J.+Luoauthor=C.+J.+Der&title=Drugging+the+undruggable+RAS%3A+mission+possible%3F&doi=10.1038%2Fnrd4389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the undruggable RAS: Mission Possible?</span></div><div class="casAuthors">Cox, Adrienne D.; Fesik, Stephen W.; Kimmelman, Alec C.; Luo, Ji; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">828-851</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite more than three decades of intensive effort, no effective pharmacol. inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'.  However, recent data from the lab. and the clinic have renewed our hope for the development of RAS-inhibitory mols.  In this Review, we summarize the progress and the promise of five key approaches.  Firstly, we focus on the prospects of using direct inhibitors of RAS.  Secondly, we address the issue of whether blocking RAS membrane assocn. is a viable approach.  Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favorable current approach.  Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise.  Finally, RAS-mediated changes in cell metab. have recently been described and we discuss whether these changes could be exploited for new therapeutic directions.  We conclude with perspectives on how addnl. complexities, which are not yet fully understood, may affect each of these approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvWzW1JqxN4LVg90H21EOLACvtfcHk0licNlJCGWyWPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE&md5=6c8645293b079023de7d31011ae1a192</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd4389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4389%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DDrugging%2520the%2520undruggable%2520RAS%253A%2520mission%2520possible%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D11%26spage%3D828%26epage%3D851%26doi%3D10.1038%2Fnrd4389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span> <span> </span><span class="NLM_article-title">Crystal structures at 2.2 A resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP.</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>217</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1016/0022-2836(91)90753-S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2F0022-2836%2891%2990753-S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1899707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3MXhtFOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=1991&pages=503-516&issue=3&author=L.+A.+Tongauthor=A.+M.+de+Vosauthor=M.+V.+Milburnauthor=S.+H.+Kim&title=Crystal+structures+at+2.2+A+resolution+of+the+catalytic+domains+of+normal+ras+protein+and+an+oncogenic+mutant+complexed+with+GDP.&doi=10.1016%2F0022-2836%2891%2990753-S"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures at 2.2 Å resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP</span></div><div class="casAuthors">Tong, Liang; De Vos, Abraham M.; Milburn, Michael V.; Kim, Sung Hou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">503-16</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">The biol. functions of ras proteins are controlled by the bound guanine nucleotides, GDP or GTP.  The GTP-bound conformation was biol. active, and was rapidly deactivated to the GDP-bound conformation through interaction with GAP (GTPase-activating protein).  Most transforming mutants of ras proteins have drastically reduced GTP hydrolysis rates even in the presence of GAP.  The crystal structures of the GDP complexes of ras proteins at 2.2 Å resoln. revealed the detailed interaction between the ras proteins and the GDP mol.  All of the currently known transforming mutation positions are clustered around the bound guanine nucleotide mol.  The presumed effector region and the GAP recognition region are both highly exposed.  No significant structural differences were found between the GDP complexes of normal ras protein and the oncogenic mutant with valine at position 12, except the side-chain of the valine residue.  However, comparison with GTP-analog complexes of ras proteins suggests that the valine side-chain may inhibit GTP hydrolysis in 2 possible ways: (1) interacting directly with the γ-phosphate and altering its orientation or the conformation of protein residues around the phosphates; and/or (2) preventing either the departure of γ-phosphate on GTP hydrolysis or the entrance of a nucleophilic group to attack the γ-phosphate.  The structural similarity between ras protein and bacterial elongation factor Tu suggests that their common structural motif might be conserved for other guanine nucleotide-binding proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6GojCi4jrr7Vg90H21EOLACvtfcHk0lh417nPm2U8CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtFOhsb8%253D&md5=8995773660b0e6ba4a7982c25fcc19fd</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2F0022-2836%2891%2990753-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-2836%252891%252990753-S%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%2BA.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26atitle%3DCrystal%2520structures%2520at%25202.2%2520A%2520resolution%2520of%2520the%2520catalytic%2520domains%2520of%2520normal%2520ras%2520protein%2520and%2520an%2520oncogenic%2520mutant%2520complexed%2520with%2520GDP.%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1991%26volume%3D217%26issue%3D3%26spage%3D503%26epage%3D516%26doi%3D10.1016%2F0022-2836%2891%2990753-S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hallak, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azmi, A. S.</span></span> <span> </span><span class="NLM_article-title">KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">101974</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2020.101974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.ctrv.2020.101974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=32014824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFKqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2020&pages=101974&author=M.+Nagasakaauthor=Y.+Liauthor=A.+Sukariauthor=S.+I.+Ouauthor=M.+N.+Al-Hallakauthor=A.+S.+Azmi&title=KRAS+G12C+Game+of+Thrones%2C+which+direct+KRAS+inhibitor+will+claim+the+iron+throne%3F&doi=10.1016%2Fj.ctrv.2020.101974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?</span></div><div class="casAuthors">Nagasaka, Misako; Li, Yiwei; Sukari, Ammar; Ou, Sai-Hong Ignatius; Al-Hallak, Mohammed Najeeb; Azmi, Asfar S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101974</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) are among the most common aberrations in cancer, including non-small cell lung cancer (NSCLC).  The lack of an ideal small mol. binding pocket in the KRAS protein and its high affinity towards the abundance of cellular guanosine triphosphate (GTP) renders the design of specific small mol. drugs challenging.  Despite efforts, KRAS remains a challenging therapeutic target.  Among the different known mutations; the KRASG12C (glycine 12 to cysteine) mutation has been considered potentially druggable.  Several novel covalent direct inhibitors targeting KRASG12C with similar covalent binding mechanisms are now in clin. trials.  Both AMG 510 from Amgen and MRTX849 from Mirati Therapeutics covalently binds to KRASG12C at the cysteine at residue 12, keeping KRASG12C in its inactive GDP-bound state and inhibiting KRAS-dependent signaling.  Both inhibitors are being studied as a single agent or as combination with other targets.  In addn., two novel KRAS G12C inhibitors JNJ-74699157 and LY3499446 will have entered phase 1 studies by the end of 2019.  Given the rapid clin. development of 4 direct covalent KRAS G12C inhibitors within a short period of time, understanding the similarities and differences among these will be important to det. the best treatment option based on tumor specific response (NSCLC vs. colorectal carcinoma), potential resistance mechanisms (i.e. anticipated acquired mutation at the cysteine 12 residue) and central nervous system (CNS) activity.  Addnl., further investigation evaluating the efficacy and safety of combination therapies with agents such as immune checkpoint inhibitors will be important next steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW_hHZl2d9TrVg90H21EOLACvtfcHk0lh417nPm2U8CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFKqur8%253D&md5=94a40ad262868c5ff7185da4aed0bf62</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2020.101974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2020.101974%26sid%3Dliteratum%253Aachs%26aulast%3DNagasaka%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSukari%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DAl-Hallak%26aufirst%3DM.%2BN.%26aulast%3DAzmi%26aufirst%3DA.%2BS.%26atitle%3DKRAS%2520G12C%2520Game%2520of%2520Thrones%252C%2520which%2520direct%2520KRAS%2520inhibitor%2520will%2520claim%2520the%2520iron%2520throne%253F%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2020%26volume%3D84%26spage%3D101974%26doi%3D10.1016%2Fj.ctrv.2020.101974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppada, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span> (<span class="NLM_issue">7781</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1694-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41586-019-1694-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31666701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=217-223&issue=7781&author=J.+Canonauthor=K.+Rexauthor=A.+Y.+Saikiauthor=C.+Mohrauthor=K.+Cookeauthor=D.+Bagalauthor=K.+Gaidaauthor=T.+Holtauthor=C.+G.+Knutsonauthor=N.+Koppada&title=The+clinical+KRAS%28G12C%29+inhibitor+AMG+510+drives+anti-tumour+immunity&doi=10.1038%2Fs41586-019-1694-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span></div><div class="casAuthors">Canon, Jude; Rex, Karen; Saiki, Anne Y.; Mohr, Christopher; Cooke, Keegan; Bagal, Dhanashri; Gaida, Kevin; Holt, Tyler; Knutson, Charles G.; Koppada, Neelima; Lanman, Brian A.; Werner, Jonathan; Rapaport, Aaron S.; San Miguel, Tisha; Ortiz, Roberto; Osgood, Tao; Sun, Ji-Rong; Zhu, Xiaochun; McCarter, John D.; Volak, Laurie P.; Houk, Brett E.; Fakih, Marwan G.; O'Neil, Bert H.; Price, Timothy J.; Falchook, Gerald S.; Desai, Jayesh; Kuo, James; Govindan, Ramaswamy; Hong, David S.; Ouyang, Wenjun; Henary, Haby; Arvedson, Tara; Cee, Victor J.; Lipford, J. Russell</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7781</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumors1,2.  The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclin. activity3-5.  Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity.  Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clin. development.  In preclin. analyses, treatment with AMG 510 led to the regression of KRASG12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents.  In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumor microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors.  Cured mice rejected the growth of isogenic KRASG12D tumors, which suggests adaptive immunity against shared antigens.  Furthermore, in clin. trials, AMG 510 demonstrated anti-tumor activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHdBftQfnhbVg90H21EOLACvtfcHk0lh417nPm2U8CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F&md5=3819175980905976ba87ff545b9506e1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1694-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1694-1%26sid%3Dliteratum%253Aachs%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DK.%26aulast%3DBagal%26aufirst%3DD.%26aulast%3DGaida%26aufirst%3DK.%26aulast%3DHolt%26aufirst%3DT.%26aulast%3DKnutson%26aufirst%3DC.%2BG.%26aulast%3DKoppada%26aufirst%3DN.%26atitle%3DThe%2520clinical%2520KRAS%2528G12C%2529%2520inhibitor%2520AMG%2520510%2520drives%2520anti-tumour%2520immunity%26jtitle%3DNature%26date%3D2019%26volume%3D575%26issue%3D7781%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fs41586-019-1694-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calinisan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowcut, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-19-1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F2159-8290.CD-19-1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31658955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtleitbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=54-71&issue=1&author=J.+Hallinauthor=L.+D.+Engstromauthor=L.+Hargisauthor=A.+Calinisanauthor=R.+Arandaauthor=D.+M.+Briereauthor=N.+Sudhakarauthor=V.+Bowcutauthor=B.+R.+Baerauthor=J.+A.+Ballard&title=The+KRASG12C+inhibitor+MRTX849+provides+insight+toward+therapeutic+susceptibility+of+KRAS-mutant+cancers+in+mouse+models+and+patients&doi=10.1158%2F2159-8290.CD-19-1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients</span></div><div class="casAuthors">Hallin, Jill; Engstrom, Lars D.; Hargis, Lauren; Calinisan, Andrew; Aranda, Ruth; Briere, David M.; Sudhakar, Niranjan; Bowcut, Vickie; Baer, Brian R.; Ballard, Joshua A.; Burkard, Michael R.; Fell, Jay B.; Fischer, John P.; Vigers, Guy P.; Xue, Yaohua; Gatto, Sole; Fernandez-Banet, Julio; Pavlicek, Adam; Velastagui, Karen; Chao, Richard C.; Barton, Jeremy; Pierobon, Mariaelena; Baldelli, Elisa; Patricoin, Emanuel F., III; Cassidy, Douglas P.; Marx, Matthew A.; Rybkin, Igor I.; Johnson, Melissa L.; Ou, Sai-Hong Ignatius; Lito, Piro; Papadopoulos, Kyriakos P.; Janne, Pasi A.; Olson, Peter; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-71</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite decades of research, efforts to directly target KRAS have been challenging.  MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits KRAS-dependent signaling.  MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRASG12C-pos. cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been obsd. in patients with KRASG12C-pos. lung and colon adenocarcinomas.  Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant nonclin. models identified mechanisms implicated in limiting antitumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence.  These factors included activation of receptor tyrosine kinases (RTK), bypass of KRAS dependence, and genetic dysregulation of cell cycle.  Combinations of MRTX849 with agents that target RTKs, mTOR, or cell cycle demonstrated enhanced response and marked tumor regression in several tumor models, including MRTX849-refractory models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxAUhi3n75ULVg90H21EOLACvtfcHk0lhONPd5mg-Trg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtleitbfL&md5=48f4c34e757385eed89b47f19cbb10db</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-1167%26sid%3Dliteratum%253Aachs%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHargis%26aufirst%3DL.%26aulast%3DCalinisan%26aufirst%3DA.%26aulast%3DAranda%26aufirst%3DR.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DSudhakar%26aufirst%3DN.%26aulast%3DBowcut%26aufirst%3DV.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520KRASG12C%2520inhibitor%2520MRTX849%2520provides%2520insight%2520toward%2520therapeutic%2520susceptibility%2520of%2520KRAS-mutant%2520cancers%2520in%2520mouse%2520models%2520and%2520patients%26jtitle%3DCancer%2520Discovery%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D54%26epage%3D71%26doi%3D10.1158%2F2159-8290.CD-19-1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassar, N.</span></span> <span> </span><span class="NLM_article-title">The structural basis for the transition from Ras-GTP to Ras-GDP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">12138</span>– <span class="NLM_lpage">12142</span>, <span class="refDoi"> DOI: 10.1073/pnas.192453199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.192453199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=12213964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD38XntlClu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=12138-12142&issue=19&author=B.+E.+Hallauthor=D.+Bar-Sagiauthor=N.+Nassar&title=The+structural+basis+for+the+transition+from+Ras-GTP+to+Ras-GDP&doi=10.1073%2Fpnas.192453199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for the transition from Ras-GTP to Ras-GDP</span></div><div class="casAuthors">Hall, Brian E.; Bar-Sagi, Dafna; Nassar, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12138-12142</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The conformational changes in Ras that accompany the hydrolysis of GTP are crit. to its function as a mol. switch in signaling pathways.  Understanding how GTP is hydrolyzed by revealing the sequence of intermediary structures in the reaction is essential for understanding Ras signaling.  Until now, no structure of an intermediate in GTP hydrolysis has been exptl. detd. for Ras alone.  We have solved the crystal structure of the Ala-59 to Gly mutant of Ras, (RasA59G), bound to guanosine 5'-imidotriphosphate or GDP to 1.7-Å resoln.  In the guanosine 5'-imidotriphosphate-bound form, this mutant adopts a conformation that is intermediate between the GTP- and GDP-bound forms of wild-type Ras and that is similar to what has been predicted by mol. dynamics simulation.  This conformation is stabilized by direct and water-mediated interactions between the switch 1 and switch 2 regions and is characterized by an increase in the binding affinity for GTP.  We propose that the structural changes promoted by the Ala-59 to Gly mutation exhibit a discrete conformational state assumed by wild-type Ras during GTP hydrolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc87uPfQFSWrVg90H21EOLACvtfcHk0lhONPd5mg-Trg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntlClu7o%253D&md5=e50240da002f78dd9db37a61cc211a2e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.192453199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.192453199%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DB.%2BE.%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DNassar%26aufirst%3DN.%26atitle%3DThe%2520structural%2520basis%2520for%2520the%2520transition%2520from%2520Ras-GTP%2520to%2520Ras-GDP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26issue%3D19%26spage%3D12138%26epage%3D12142%26doi%3D10.1073%2Fpnas.192453199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVos, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaizumi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span> <span> </span><span class="NLM_article-title">Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>247</i></span> (<span class="NLM_issue">4945</span>),  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">945</span>, <span class="refDoi"> DOI: 10.1126/science.2406906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1126%2Fscience.2406906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=2406906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3cXhslCgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1990&pages=939-945&issue=4945&author=M.+V.+Milburnauthor=L.+Tongauthor=A.+M.+DeVosauthor=A.+Brungerauthor=Z.+Yamaizumiauthor=S.+Nishimuraauthor=S.-H.+Kim&title=Molecular+switch+for+signal+transduction%3A+structural+differences+between+active+and+inactive+forms+of+protooncogenic+ras+proteins&doi=10.1126%2Fscience.2406906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular switch for signal transduction:  structural differences between active and inactive forms of protooncogenic ras proteins</span></div><div class="casAuthors">Milburn, Michael V.; Tong, Liang; DeVos, Abraham M.; Bruenger, Axel; Yamaizumi, Ziro; Nishimura, Susumu; Kim, Sung Hou</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">4945</span>),
    <span class="NLM_cas:pages">939-45</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Ras proteins participate as a mol. switch in the early steps of the signal transduction pathway that is assocd. with cell growth and differentiation.  When the protein is in its GTP complexed form it is active in signal transduction, whereas it is inactive in its GDP complexed form.  A comparison of 8 3-dimensional structures of ras proteins in 4 different crystal lattices, 5 with a nonhydrolyzable GTP analog and 3 with GDP, reveals that the on and off states of the switch are distinguished by conformational differences that span a length of >40 Å, and are induced by the γ-phosphate.  The most significant differences are localized in 2 regions: residues 30-38 (the switch I region) in the second loop and residues 60-76 (the switch II region) consisting of the fourth loop and the short α-helix that follows the loop.  Both regions are highly exposed and form a continuous strip on the mol. surface most likely to be the recognition sites for the effector and receptor mol. (or mols.).  The conformational differences also provide a structural basis for understanding the biol. and biochem. changes of the proteins due to oncogenic mutations, autophosphorylation, and GTP hydrolysis, and for understanding the interactions with other proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYvBH7oUudMLVg90H21EOLACvtfcHk0lhONPd5mg-Trg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslCgtrw%253D&md5=edc58a62f4a5ad734a7f6bcc1c84a333</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.2406906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2406906%26sid%3Dliteratum%253Aachs%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DDeVos%26aufirst%3DA.%2BM.%26aulast%3DBrunger%26aufirst%3DA.%26aulast%3DYamaizumi%26aufirst%3DZ.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.-H.%26atitle%3DMolecular%2520switch%2520for%2520signal%2520transduction%253A%2520structural%2520differences%2520between%2520active%2520and%2520inactive%2520forms%2520of%2520protooncogenic%2520ras%2520proteins%26jtitle%3DScience%26date%3D1990%26volume%3D247%26issue%3D4945%26spage%3D939%26epage%3D945%26doi%3D10.1126%2Fscience.2406906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratcioglu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keskin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Ras conformational ensembles, allostery, and signaling</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6607</span>– <span class="NLM_lpage">6665</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=6607-6665&issue=11&author=S.+Luauthor=H.+Jangauthor=S.+Muratciogluauthor=A.+Gursoyauthor=O.+Keskinauthor=R.+Nussinovauthor=J.+Zhang&title=Ras+conformational+ensembles%2C+allostery%2C+and+signaling&doi=10.1021%2Facs.chemrev.5b00542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ras Conformational Ensembles, Allostery, and Signaling</span></div><div class="casAuthors">Lu, Shaoyong; Jang, Hyunbum; Muratcioglu, Serena; Gursoy, Attila; Keskin, Ozlem; Nussinov, Ruth; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6607-6665</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ras proteins are classical members of small GTPases that function as mol. switches by alternating between inactive GDP-bound and active GTP-bound states.  Ras activation is regulated by guanine nucleotide exchange factors that catalyze the exchange of GDP by GTP, and inactivation is terminated by GTPase-activating proteins that accelerate the intrinsic GTP hydrolysis rate by orders of magnitude.  In this review, we focus on data that have accumulated over the past few years pertaining to the conformational ensembles and the allosteric regulation of Ras proteins and their interpretation from our conformational landscape standpoint.  The Ras ensemble embodies all states, including the ligand-bound conformations, the activated (or inactivated) allosteric modulated states, post-translationally modified states, mutational states, transition states, and nonfunctional states serving as a reservoir for emerging functions.  The ensemble is shifted by distinct mutational events, cofactors, post-translational modifications, and different membrane compns.  A better understanding of Ras biol. can contribute to therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY2oezVaRCvbVg90H21EOLACvtfcHk0lhONPd5mg-Trg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyhu74%253D&md5=7600b971015bd3cf635ca1b4299dc7d5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00542%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DMuratcioglu%26aufirst%3DS.%26aulast%3DGursoy%26aufirst%3DA.%26aulast%3DKeskin%26aufirst%3DO.%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DRas%2520conformational%2520ensembles%252C%2520allostery%252C%2520and%2520signaling%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26issue%3D11%26spage%3D6607%26epage%3D6665%26doi%3D10.1021%2Facs.chemrev.5b00542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krengel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span> <span> </span><span class="NLM_article-title">Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>341</i></span> (<span class="NLM_issue">6239</span>),  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/341209a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2F341209a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=2476675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaL1MXmtFSksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1989&pages=209-214&issue=6239&author=E.+F.+Paiauthor=W.+Kabschauthor=U.+Krengelauthor=K.+C.+Holmesauthor=J.+Johnauthor=A.+Wittinghofer&title=Structure+of+the+guanine-nucleotide-binding+domain+of+the+Ha-ras+oncogene+product+p21+in+the+triphosphate+conformation&doi=10.1038%2F341209a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation</span></div><div class="casAuthors">Pai, Emil F.; Kabsch, Wolfgang; Krengel, Ute; Holmes, Kenneth C.; John, Jacob; Wittinghofer, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6239</span>),
    <span class="NLM_cas:pages">209-14</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The crystal structure of the guanine nucleotide-binding domain of p21 (amino acids 1-166) complexed to the GTP analog guanosine-5'-(β,γ-imido)triphosphate (GppNp) has been detd. at a resoln. of 2.6 Å.  The topol. order of secondary structure elements is the same as that of the guanine nucleotide-binding domain of bacterial elongation factor EF-Tu.  Many interactions between nucleotide and protein have been identified.  The effects of point mutations and the conservation of amino acid sequence in the guanine-nucleotide-binding proteins are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphBg5LmSHO07Vg90H21EOLACvtfcHk0lj99d5PWppfsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtFSksLs%253D&md5=799c6cfbd2561db9c075fdccfebab93a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2F341209a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F341209a0%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DE.%2BF.%26aulast%3DKabsch%26aufirst%3DW.%26aulast%3DKrengel%26aufirst%3DU.%26aulast%3DHolmes%26aufirst%3DK.%2BC.%26aulast%3DJohn%26aufirst%3DJ.%26aulast%3DWittinghofer%26aufirst%3DA.%26atitle%3DStructure%2520of%2520the%2520guanine-nucleotide-binding%2520domain%2520of%2520the%2520Ha-ras%2520oncogene%2520product%2520p21%2520in%2520the%2520triphosphate%2520conformation%26jtitle%3DNature%26date%3D1989%26volume%3D341%26issue%3D6239%26spage%3D209%26epage%3D214%26doi%3D10.1038%2F341209a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spencer-Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Bryan, J. P.</span></span> <span> </span><span class="NLM_article-title">Direct inhibition of RAS: quest for the holy grail?</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2017.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.semcancer.2017.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29248537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWmu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=138-148&author=R.+Spencer-Smithauthor=J.+P.+O%E2%80%99Bryan&title=Direct+inhibition+of+RAS%3A+quest+for+the+holy+grail%3F&doi=10.1016%2Fj.semcancer.2017.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Direct inhibition of RAS: Quest for the Holy Grail?</span></div><div class="casAuthors">Spencer-Smith, Russell; O'Bryan, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-148</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  RAS GTPases (H-, K-, and N-RAS) are the most frequently mutated oncoprotein family in human cancer.  However, the relatively smooth surface architecture of RAS and its picomolar affinity for nucleotide have given rise to the assumption that RAS is an "undruggable" target.  Recent advancements in drug screening, mol. modeling, and a greater understanding of RAS function have led to a resurgence in efforts to pharmacol. target this challenging foe.  This review focuses on the state of the art of RAS inhibition, the approaches taken to achieve this goal, and the challenges of translating these discoveries into viable therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJGavQxEObQ7Vg90H21EOLACvtfcHk0lj99d5PWppfsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWmu7%252FN&md5=0286efe034301610071e6db9586433f4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2017.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2017.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSpencer-Smith%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Bryan%26aufirst%3DJ.%2BP.%26atitle%3DDirect%2520inhibition%2520of%2520RAS%253A%2520quest%2520for%2520the%2520holy%2520grail%253F%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2019%26volume%3D54%26spage%3D138%26epage%3D148%26doi%3D10.1016%2Fj.semcancer.2017.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">The Ras–membrane interface: isoform-specific differences in the catalytic domain</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-14-0535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F1541-7786.MCR-14-0535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=25566993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlChsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=595-603&issue=4&author=J.+A.+Parkerauthor=C.+Mattos&title=The+Ras%E2%80%93membrane+interface%3A+isoform-specific+differences+in+the+catalytic+domain&doi=10.1158%2F1541-7786.MCR-14-0535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras-Membrane Interface: Isoform-Specific Differences in the Catalytic Domain</span></div><div class="casAuthors">Parker, Jillian A.; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">595-603</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The small GTPase Ras is mutated in about 20% of human cancers, primarily at active site amino acid residues G12, G13, and Q61.  Thus, structural biol. research has focused on the active site, impairment of GTP hydrolysis by oncogenic mutants, and characterization of protein-protein interactions in the effector lobe half of the protein.  The C-terminal hypervariable region has increasingly gained attention due to its importance in H-Ras, N-Ras, and K-Ras differences in membrane assocn.  A high-resoln. mol. view of the Ras-membrane interaction involving the allosteric lobe of the catalytic domain has lagged behind, although evidence suggests that it contributes to isoform specificity.  The allosteric lobe has recently gained interest for harboring potential sites for more selective targeting of this elusive "undruggable" protein.  The present review reveals crit. insight that isoform-specific differences appear prominently at these potentially targetable sites and integrates these differences with knowledge of Ras plasma membrane localization, with the intent to better understand the structure-function relationships needed to design isoform-specific Ras inhibitors.  ©2015 AACR, Mol Cancer Res; 13(4); 595-603.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr68q_rIeYO07Vg90H21EOLACvtfcHk0lgyIfJVAq-jfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlChsb4%253D&md5=728b13cfc149ce878dd2bb7b60d76f35</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-14-0535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-14-0535%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DJ.%2BA.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DThe%2520Ras%25E2%2580%2593membrane%2520interface%253A%2520isoform-specific%2520differences%2520in%2520the%2520catalytic%2520domain%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26issue%3D4%26spage%3D595%26epage%3D603%26doi%3D10.1158%2F1541-7786.MCR-14-0535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahearn, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. R.</span></span> <span> </span><span class="NLM_article-title">Regulating the regulator: post-translational modification of RAS</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nrm3255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrm3255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GksLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=39-51&issue=1&author=I.+M.+Ahearnauthor=K.+Haigisauthor=D.+Bar-Sagiauthor=M.+R.+Philips&title=Regulating+the+regulator%3A+post-translational+modification+of+RAS&doi=10.1038%2Fnrm3255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Regulating the regulator: post-translational modification of RAS</span></div><div class="casAuthors">Ahearn, Ian M.; Haigis, Kevin; Bar-Sagi, Dafna; Philips, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAS proteins are monomeric GTPases that act as binary mol. switches to regulate a wide range of cellular processes.  The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), which regulate the activation state of RAS without covalently modifying it.  By contrast, post-translational modifications (PTMs) of RAS proteins direct them to various cellular membranes and, in some cases, modulate GTP-GDP exchange.  Important RAS PTMs include the constitutive and irreversible remodeling of its C-terminal CAAX motif by farnesylation, proteolysis, and methylation, reversible palmitoylation, and conditional modifications, including phosphorylation, peptidyl-prolyl isomerization, monoubiquitination, diubiquitination, nitrosylation, ADP-ribosylation, and glucosylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlGVFnsduedLVg90H21EOLACvtfcHk0lgyIfJVAq-jfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GksLnP&md5=5983466c8e758dabac8326710a44e64a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrm3255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3255%26sid%3Dliteratum%253Aachs%26aulast%3DAhearn%26aufirst%3DI.%2BM.%26aulast%3DHaigis%26aufirst%3DK.%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DRegulating%2520the%2520regulator%253A%2520post-translational%2520modification%2520of%2520RAS%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D13%26issue%3D1%26spage%3D39%26epage%3D51%26doi%3D10.1038%2Fnrm3255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beare, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">suppl_1</span>),  <span class="NLM_fpage">D945</span>– <span class="NLM_lpage">D950</span>, <span class="refDoi"> DOI: 10.1093/nar/gkq929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1093%2Fnar%2Fgkq929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=20952405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivF2msbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=D945-D950&issue=suppl_1&author=S.+A.+Forbesauthor=N.+Bindalauthor=S.+Bamfordauthor=C.+Coleauthor=C.+Y.+Kokauthor=D.+Beareauthor=M.+Jiaauthor=R.+Shepherdauthor=K.+Leungauthor=A.+Menzies&title=COSMIC%3A+mining+complete+cancer+genomes+in+the+catalogue+of+somatic+mutations+in+cancer&doi=10.1093%2Fnar%2Fgkq929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer</span></div><div class="casAuthors">Forbes, Simon A.; Bindal, Nidhi; Bamford, Sally; Cole, Charlotte; Kok, Chai Yin; Beare, David; Jia, Mingming; Shepherd, Rebecca; Leung, Kenric; Menzies, Andrew; Teague, Jon W.; Campbell, Peter J.; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">D945-D950</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">COSMIC (http://www.sanger.ac.uk/cosmic) curates comprehensive information on somatic mutations in human cancer.  Release v48 (July 2010) describes over 136 000 coding mutations in almost 542 000 tumor samples; of the 18 490 genes documented, 4803 (26%) have one or more mutations.  Full scientific literature curations are available on 83 major cancer genes and 49 fusion gene pairs (19 new cancer genes and 30 new fusion pairs this year) and this no. is continually increasing.  Key amongst these is TP53, now available through a collaboration with the IARC p53 database.  In addn. to data from the Cancer Genome Project (CGP) at the Sanger Institute, UK, and The Cancer Genome Atlas project (TCGA), large systematic screens are also now curated.  Major website upgrades now make these data much more mineable, with many new selection filters and graphics.  A Biomart is now available allowing more automated data mining and integration with other biol. databases.  Annotation of genomic features has become a significant focus; COSMIC has begun curating full-genome resequencing expts., developing new web pages, export formats and graphics styles.  With all genomic information recently updated to GRCh37, COSMIC integrates many diverse types of mutation information and is making much closer links with Ensembl and other data resources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpalgzfv6Y9s7Vg90H21EOLACvtfcHk0lgyIfJVAq-jfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivF2msbo%253D&md5=3456c7ae37b9f81da68a624a09d0d524</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkq929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkq929%26sid%3Dliteratum%253Aachs%26aulast%3DForbes%26aufirst%3DS.%2BA.%26aulast%3DBindal%26aufirst%3DN.%26aulast%3DBamford%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DC.%26aulast%3DKok%26aufirst%3DC.%2BY.%26aulast%3DBeare%26aufirst%3DD.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DShepherd%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DMenzies%26aufirst%3DA.%26atitle%3DCOSMIC%253A%2520mining%2520complete%2520cancer%2520genomes%2520in%2520the%2520catalogue%2520of%2520somatic%2520mutations%2520in%2520cancer%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2011%26volume%3D39%26issue%3Dsuppl_1%26spage%3DD945%26epage%3DD950%26doi%3D10.1093%2Fnar%2Fgkq929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manandhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span> <span> </span><span class="NLM_article-title">Biochemical and structural analysis of common cancer-associated KRAS mutations</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1335</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-15-0203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F1541-7786.MCR-15-0203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26037647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=1325-1335&issue=9&author=J.+C.+Hunterauthor=A.+Manandharauthor=M.+A.+Carrascoauthor=D.+Gurbaniauthor=S.+Gondiauthor=K.+D.+Westover&title=Biochemical+and+structural+analysis+of+common+cancer-associated+KRAS+mutations&doi=10.1158%2F1541-7786.MCR-15-0203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations</span></div><div class="casAuthors">Hunter, John C.; Manandhar, Anuj; Carrasco, Martin A.; Gurbani, Deepak; Gondi, Sudershan; Westover, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1325-1335</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS mutations are the most common genetic abnormalities in cancer, but the distribution of specific mutations across cancers and the differential responses of patients with specific KRAS mutations in therapeutic clin. trials suggest that different KRAS mutations have unique biochem. behaviors.  To further explain these high-level clin. differences and to explore potential therapeutic strategies for specific KRAS isoforms, we characterized the most common KRAS mutants biochem. for substrate binding kinetics, intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activities, and interactions with the RAS effector, RAF kinase.  Of note, KRAS G13D shows rapid nucleotide exchange kinetics compared with other mutants analyzed.  This property can be explained by changes in the electrostatic charge distribution of the active site induced by the G13D mutation as shown by X-ray crystallog.  High-resoln. X-ray structures are also provided for the GDP-bound forms of KRAS G12V, G12R, and Q61L and reveal addnl. insight.  Overall, the structural data and measurements, obtained herein, indicate that measurable biochem. properties provide clues for identifying KRAS-driven tumors that preferentially signal through RAF.  Implications: Biochem. profiling and subclassification of KRAS-driven cancers will enable the rational selection of therapies targeting specific KRAS isoforms or specific RAS effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh7ZuvQswanLVg90H21EOLACvtfcHk0lgyIfJVAq-jfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVykt7fK&md5=50c6126a383e79e46f35b4e7677d6543</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-15-0203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-15-0203%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DJ.%2BC.%26aulast%3DManandhar%26aufirst%3DA.%26aulast%3DCarrasco%26aufirst%3DM.%2BA.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DGondi%26aufirst%3DS.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26atitle%3DBiochemical%2520and%2520structural%2520analysis%2520of%2520common%2520cancer-associated%2520KRAS%2520mutations%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26issue%3D9%26spage%3D1325%26epage%3D1335%26doi%3D10.1158%2F1541-7786.MCR-15-0203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrd.2016.139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=27469033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=771-785&issue=11&author=J.+M.+L.+Ostremauthor=K.+M.+Shokat&title=Direct+small-molecule+inhibitors+of+KRAS%3A+from+structural+insights+to+mechanism-based+design&doi=10.1038%2Fnrd.2016.139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design</span></div><div class="casAuthors">Ostrem, Jonathan M. L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">771-785</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in human cancer.  In addn. to holding this distinction, unsuccessful attempts to target this protein have led to the characterization of RAS as 'undruggable'.  However, recent advances in technol. and novel approaches to drug discovery have renewed hope that a direct KRAS inhibitor may be on the horizon.  In this Review, we provide an in-depth anal. of the structure, dynamics, mutational activation and inactivation, and signalling mechanisms of RAS.  From this perspective, we then consider potential mechanisms of action for effective RAS inhibitors.  Finally, we examine each of the many recent reports of direct RAS inhibitors and discuss promising avenues for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBobrhZLF3V7Vg90H21EOLACvtfcHk0li5n424Ggvg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FK&md5=b0832c7ef45cc0555e11c59baccc5abd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.139%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DDirect%2520small-molecule%2520inhibitors%2520of%2520KRAS%253A%2520from%2520structural%2520insights%2520to%2520mechanism-based%2520design%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D771%26epage%3D785%26doi%3D10.1038%2Fnrd.2016.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherfils, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeghouf, M.</span></span> <span> </span><span class="NLM_article-title">Regulation of small gtpases by gefs, gaps, and gdis</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1152/physrev.00003.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1152%2Fphysrev.00003.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23303910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=269-309&issue=1&author=J.+Cherfilsauthor=M.+Zeghouf&title=Regulation+of+small+gtpases+by+gefs%2C+gaps%2C+and+gdis&doi=10.1152%2Fphysrev.00003.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of small GTPases by GEFs, GAPs, and GDIs</span></div><div class="casAuthors">Cherfils, Jacqueline; Zeghouf, Mahel</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">269-309</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Small GTPases use GDP/GTP alternation to actuate a variety of functional switches that are pivotal for cell dynamics.  The GTPase switch is turned on by GEFs, which stimulate dissocn. of the tightly bound GDP, and turned off by GAPs, which accelerate the intrinsically sluggish hydrolysis of GTP.  For Ras, Rho, and Rab GTPases, this switch incorporates a membrane/cytosol alternation regulated by GDIs and GDI-like proteins.  The structures and core mechanisms of representative members of small GTPase regulators from most families have now been elucidated, illuminating their general traits combined with scores of unique features.  Recent studies reveal that small GTPase regulators have themselves unexpectedly sophisticated regulatory mechanisms, by which they process cellular signals and build up specific cell responses.  These mechanisms include multilayered autoinhibition with stepwise release, feedback loops mediated by the activated GTPase, feed-forward signaling flow between regulators and effectors, and a phosphorylation code for RhoGDIs.  The flipside of these highly integrated functions is that they make small GTPase regulators susceptible to biochem. abnormalities that are directly correlated with diseases, notably a striking no. of missense mutations in congenital diseases, and susceptible to bacterial mimics of GEFs, GAPs, and GDIs that take command of small GTPases in infections.  This review presents an overview of the current knowledge of these many facets of small GTPase regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Tzda3wVs6LVg90H21EOLACvtfcHk0li5n424Ggvg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKns7s%253D&md5=e718a66f23b7040e1354e4990c8d15d8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00003.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00003.2012%26sid%3Dliteratum%253Aachs%26aulast%3DCherfils%26aufirst%3DJ.%26aulast%3DZeghouf%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520small%2520gtpases%2520by%2520gefs%252C%2520gaps%252C%2520and%2520gdis%26jtitle%3DPhysiol.%2520Rev.%26date%3D2013%26volume%3D93%26issue%3D1%26spage%3D269%26epage%3D309%26doi%3D10.1152%2Fphysrev.00003.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sprang, S. R.</span></span> <span> </span><span class="NLM_article-title">G proteins, effectors and GAPs: structure and mechanism</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.1016/S0959-440X(97)80157-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2FS0959-440X%2897%2980157-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9434906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK1cXjtl2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=849-856&issue=6&author=S.+R.+Sprang&title=G+proteins%2C+effectors+and+GAPs%3A+structure+and+mechanism&doi=10.1016%2FS0959-440X%2897%2980157-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">G proteins, effectors and GAPs: structure and mechanism</span></div><div class="casAuthors">Sprang, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">849-856</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review, with 62 refs.  G proteins form a diverse family of regulatory GTPases which, in the GTP-bound state, bind to and activate downstream effectors.  Structures of Ras homologs bound to effector domains have revealed mechanisms by which G proteins couple GTP binding to effector activation and achieve specificity.  Complexes between structurally unrelated GTPase-activating proteins with complementary G proteins suggest common mechanisms by which GTP hydrolysis is stimulated via direct interactions with conformationally labile switch regions of the G protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_mG_wz29YXrVg90H21EOLACvtfcHk0li5n424Ggvg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtl2lsw%253D%253D&md5=46d618e0cce0d01e384dd57c97ab0980</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0959-440X%2897%2980157-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-440X%252897%252980157-1%26sid%3Dliteratum%253Aachs%26aulast%3DSprang%26aufirst%3DS.%2BR.%26atitle%3DG%2520proteins%252C%2520effectors%2520and%2520GAPs%253A%2520structure%2520and%2520mechanism%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D7%26issue%3D6%26spage%3D849%26epage%3D856%26doi%3D10.1016%2FS0959-440X%2897%2980157-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willumsen, B. M.</span></span> <span> </span><span class="NLM_article-title">Function and regulation of ras</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">851</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1146/annurev.bi.62.070193.004223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1146%2Fannurev.bi.62.070193.004223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=8352603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFCjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1993&pages=851-891&issue=1&author=D.+R.+Lowyauthor=B.+M.+Willumsen&title=Function+and+regulation+of+ras&doi=10.1146%2Fannurev.bi.62.070193.004223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Function and regulation of ras</span></div><div class="casAuthors">Lowy, Douglas R.; Willumsen, Berthe M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">851-91</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    </div><div class="casAbstract">A review, with 315 refs., on the structure, regulation, properties and function of ras genes and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX9Nsuu0HOq7Vg90H21EOLACvtfcHk0li5n424Ggvg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFCjuro%253D&md5=bc95816f7b6e73c5222b684b240ee87a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.62.070193.004223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.62.070193.004223%26sid%3Dliteratum%253Aachs%26aulast%3DLowy%26aufirst%3DD.%2BR.%26aulast%3DWillumsen%26aufirst%3DB.%2BM.%26atitle%3DFunction%2520and%2520regulation%2520of%2520ras%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1993%26volume%3D62%26issue%3D1%26spage%3D851%26epage%3D891%26doi%3D10.1146%2Fannurev.bi.62.070193.004223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnecki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span> <span> </span><span class="NLM_article-title">Ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1041</span>– <span class="NLM_lpage">1050</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(92)90076-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2F0092-8674%2892%2990076-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1312393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK38XisV2gt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1992&pages=1041-1050&issue=6&author=K.+W.+Woodauthor=C.+Sarneckiauthor=T.+M.+Robertsauthor=J.+Blenis&title=Ras+mediates+nerve+growth+factor+receptor+modulation+of+three+signal-transducing+protein+kinases%3A+MAP+kinase%2C+Raf-1%2C+and+RSK&doi=10.1016%2F0092-8674%2892%2990076-O"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK</span></div><div class="casAuthors">Wood, Kenneth W.; Sarnecki, Charlyn; Roberts, Thomas M.; Blenis, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1041-50</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The authors report that in PC12 cells, expression of a dominant inhibitory mutant of ras, c-Ha-ras(Asn-17), antagonizes growth factor- and phorbol ester-induced activation of the erk-encoded family of mitogen-activated protein (MAP) kinases, the 85-92-kDa RSKs, and the kinase(s) responsible for hyperphosphorylation of the proto-oncogene product Raf-1.  In addn., the authors find that expression of the activated ras oncogene is sufficient to stimulate these events.  These data indicate that ras mediates nerve growth factor receptor and protein kinase C modulation of MAP kinases, RSKs, and Raf-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8yvMuYoOGvrVg90H21EOLACvtfcHk0lgEfFyuf6EVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisV2gt7g%253D&md5=15cdeebc5e970907a0d246e1aaf3527d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2892%2990076-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252892%252990076-O%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DK.%2BW.%26aulast%3DSarnecki%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DRas%2520mediates%2520nerve%2520growth%2520factor%2520receptor%2520modulation%2520of%2520three%2520signal-transducing%2520protein%2520kinases%253A%2520MAP%2520kinase%252C%2520Raf-1%252C%2520and%2520RSK%26jtitle%3DCell%26date%3D1992%26volume%3D68%26issue%3D6%26spage%3D1041%26epage%3D1050%26doi%3D10.1016%2F0092-8674%2892%2990076-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunn, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederrecht, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, J. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5256</span>– <span class="NLM_lpage">5267</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1996.tb00911.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fj.1460-2075.1996.tb00911.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=8895571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK28XmsVeiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=5256-5267&issue=19&author=G.+J.+Brunnauthor=J.+Williamsauthor=C.+Sabersauthor=G.+Wiederrechtauthor=J.+C.+Lawrenceauthor=R.+T.+Abraham&title=Direct+inhibition+of+the+signaling+functions+of+the+mammalian+target+of+rapamycin+by+the+phosphoinositide+3-kinase+inhibitors%2C+wortmannin+and+LY294002&doi=10.1002%2Fj.1460-2075.1996.tb00911.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002</span></div><div class="casAuthors">Brunn, Greogry J.; Williams, Josie; Sabers, Candace; Widerrecht, Gregory; Lawrence, John C., Jr.; Abraham, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5256-5267</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The immunosuppressant, rapamycin, inhibits cell growth by interfering with the function of a novel kinase, termed mammalian target of rapamycin (mTOR).  The putative catalytic domain of mTOR is similar to those of mammalian and yeast phosphatidylinositol (PI) 3-kinases.  This study demonstrates that mTOR is a component of a cytokine-triggered protein kinase cascade leading to the phosphorylation of the eukaryotic initiation factor-4E (eIF-4E)-binding protein, PHAS-1, in activated T lymphocytes.  This event promotes G1 phase progression by stimulating eIF-4E-dependent translation initiation.  A mutant YAC-1 T lymphoma cell line, which was selected for resistance to the growth-inhibitory action of rapamycin, was correspondingly resistant to the suppressive effect of this drug on PHAS-1 phosphorylation.  In contrast, the PI 3-kinase inhibitor, wortmannin, reduced the phosphorylation of PHAS-1 in both rapamycin-sensitive and -resistant T cells.  At similar drug concns. (0.1-1 μM), wortmannin irreversibly inhibited the serine-specific autokinase activity of mTOR.  The autokinase activity of mTOR was also sensitive to the structurally distinct PI 3-kinase inhibitor, LY294002, at concns. (1-30 μM) nearly identical to those required for inhibition of the lipid kinase activity of the mammalian p85-p110 heterodimer.  These studies indicate that the signaling functions of mTOR, and potentially those of other high mol. wt. PI 3-kinase homologs, are directly affected by cellular treatment with wortmannin or LY294002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ntqkdItCzLVg90H21EOLACvtfcHk0lgEfFyuf6EVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVeiu74%253D&md5=792b373486bb634c47ebc3d0d298f4d3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1996.tb00911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1996.tb00911.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrunn%26aufirst%3DG.%2BJ.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DSabers%26aufirst%3DC.%26aulast%3DWiederrecht%26aufirst%3DG.%26aulast%3DLawrence%26aufirst%3DJ.%2BC.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DDirect%2520inhibition%2520of%2520the%2520signaling%2520functions%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520by%2520the%2520phosphoinositide%25203-kinase%2520inhibitors%252C%2520wortmannin%2520and%2520LY294002%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26issue%3D19%26spage%3D5256%26epage%3D5267%26doi%3D10.1002%2Fj.1460-2075.1996.tb00911.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. S.</span></span> <span> </span><span class="NLM_article-title">Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">11089</span>– <span class="NLM_lpage">11093</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.23.11089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.91.23.11089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=7972015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2MXitV2rtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=11089-11093&issue=23&author=F.+Hoferauthor=S.+Fieldsauthor=C.+Schneiderauthor=G.+S.+Martin&title=Activated+Ras+interacts+with+the+Ral+guanine+nucleotide+dissociation+stimulator&doi=10.1073%2Fpnas.91.23.11089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator</span></div><div class="casAuthors">Hofer, Franz; Fields, Stanley; Schneider, Christopher; Martin, G. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11089-93</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The yeast two-hybrid system was used to identify proteins that interact with Ras.  H-Ras protein interacted with a guanine nucleotide dissocn. stimulator (GDS) that has been previously shown to regulate guanine nucleotide exchange on another member of the Ras protein family, Ral.  The interaction is mediated by the C-terminal, noncatalytic segment of the RalGDS and can be detected both in vivo, using the two-hybrid system, and in vitro, with purified recombinant proteins.  The interaction of the RalGDS C-terminal segment with Ras is specific, dependent on activation of Ras by GTP, and blocked by a mutation that affects Ras effector function.  These characteristics are similar to those previously demonstrated for the interaction between Ras and its putative effector, Raf, suggesting that the RalGDS may also be a Ras effector.  Consistent with this idea, the RalGDS inhibited the binding of Raf to Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ZEobZ7aA3bVg90H21EOLACvtfcHk0lgEfFyuf6EVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitV2rtr8%253D&md5=853ec836b570b5f2d423843f2fdf8328</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.23.11089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.23.11089%26sid%3Dliteratum%253Aachs%26aulast%3DHofer%26aufirst%3DF.%26aulast%3DFields%26aufirst%3DS.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DActivated%2520Ras%2520interacts%2520with%2520the%2520Ral%2520guanine%2520nucleotide%2520dissociation%2520stimulator%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26issue%3D23%26spage%3D11089%26epage%3D11093%26doi%3D10.1073%2Fpnas.91.23.11089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamarsheh, S.’a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groß, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiser, R.</span></span> <span> </span><span class="NLM_article-title">Immune modulatory effects of oncogenic KRAS in cancer.</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5439</span>, <span class="refDoi"> DOI: 10.1038/s41467-020-19288-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41467-020-19288-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=33116132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Ojur%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=5439&issue=1&author=S.%E2%80%99a+Hamarshehauthor=O.+Gro%C3%9Fauthor=T.+Brummerauthor=R.+Zeiser&title=Immune+modulatory+effects+of+oncogenic+KRAS+in+cancer.&doi=10.1038%2Fs41467-020-19288-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Immune modulatory effects of oncogenic KRAS in cancer</span></div><div class="casAuthors">Hamarsheh, Shaima'a; Gross, Olaf; Brummer, Tilman; Zeiser, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5439</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most difficult to target.  While sustained proliferation caused by oncogenic KRAS-downstream signalling is a main driver of carcinogenesis, there is increasing evidence that it also mediates autocrine effects and crosstalk with the tumor microenvironment (TME).  Here, we discuss recent reports connecting KRAS mutations with tumor-promoting inflammation and immune modulation caused by KRAS that leads to immune escape in the TME.  We discuss the preclin. work on KRAS-induced inflammation and immune modulation in the context of currently ongoing clin. trials targeting cancer entities that carry KRAS mutations and strategies to overcome the oncogene-induced effects on the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY2OLEfSnyQLVg90H21EOLACvtfcHk0lgEfFyuf6EVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Ojur%252FM&md5=6b3e28bd7b539bffd67471dbd8a63fca</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-19288-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-19288-6%26sid%3Dliteratum%253Aachs%26aulast%3DHamarsheh%26aufirst%3DS.%25E2%2580%2599a%26aulast%3DGro%25C3%259F%26aufirst%3DO.%26aulast%3DBrummer%26aufirst%3DT.%26aulast%3DZeiser%26aufirst%3DR.%26atitle%3DImmune%2520modulatory%2520effects%2520of%2520oncogenic%2520KRAS%2520in%2520cancer.%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D5439%26doi%3D10.1038%2Fs41467-020-19288-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Ras–SOS interactions</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">821</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fcmdc.201500481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26630662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=814-821&issue=8&author=S.+Luauthor=H.+Jangauthor=J.+Zhangauthor=R.+Nussinov&title=Inhibitors+of+Ras%E2%80%93SOS+interactions&doi=10.1002%2Fcmdc.201500481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Ras-SOS Interactions</span></div><div class="casAuthors">Lu, Shaoyong; Jang, Hyunbum; Zhang, Jian; Nussinov, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">814-821</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Activating Ras mutations are found in about 30 % of human cancers.  Ras activation is regulated by guanine nucleotide exchange factors, such as the son of sevenless (SOS), which form protein-protein interactions (PPIs) with Ras and catalyze the exchange of GDP by GTP.  This is the rate-limiting step in Ras activation.  However, Ras surfaces lack any evident suitable pockets where a mol. might bind tightly, rendering Ras proteins still 'undruggable' for over 30 years.  Among the alternative approaches is the design of inhibitors that target the Ras-SOS PPI interface, a strategy that is gaining increasing recognition for treating Ras mutant cancers.  Herein we focus on data that has accumulated over the past few years pertaining to the design of small-mol. modulators or peptide mimetics aimed at the interface of the Ras-SOS PPI.  We emphasize, however, that even if such Ras-SOS therapeutics are potent, drug resistance may emerge.  To counteract this development, we propose "pathway drug cocktails", i.e., drug combinations aimed at parallel (or compensatory) pathways.  A repertoire of classified cancer, cell/tissue, and pathway/protein combinations would be beneficial toward this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFdUllM-dcxLVg90H21EOLACvtfcHk0lhxDyh2moXWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsrvK&md5=697ec8726368e7b1b89f569c4a079750</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500481%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520Ras%25E2%2580%2593SOS%2520interactions%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D8%26spage%3D814%26epage%3D821%26doi%3D10.1002%2Fcmdc.201500481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span> <span> </span><span class="NLM_article-title">A treatment strategy for KRAS-driven tumors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">902</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0111-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41591-018-0111-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29988139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWjsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=902-904&issue=7&author=T.+T.+Maiauthor=P.+Lito&title=A+treatment+strategy+for+KRAS-driven+tumors&doi=10.1038%2Fs41591-018-0111-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A treatment strategy for KRAS-driven tumors</span></div><div class="casAuthors">Mai, Trang T.; Lito, Piro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">902-904</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgaFi5mnw3KrVg90H21EOLACvtfcHk0lhxDyh2moXWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWjsLvK&md5=03c6ec6d34bac76f8826e1f783dac0a7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0111-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0111-x%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DLito%26aufirst%3DP.%26atitle%3DA%2520treatment%2520strategy%2520for%2520KRAS-driven%2520tumors%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D7%26spage%3D902%26epage%3D904%26doi%3D10.1038%2Fs41591-018-0111-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.ejmech.2020.112117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=32061959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112117&author=D.+Shenauthor=W.+Chenauthor=J.+Zhuauthor=G.+Wuauthor=R.+Shenauthor=M.+Xiauthor=H.+Sun&title=Therapeutic+potential+of+targeting+SHP2+in+human+developmental+disorders+and+cancers&doi=10.1016%2Fj.ejmech.2020.112117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span></div><div class="casAuthors">Shen, Dadong; Chen, Wenxia; Zhu, Jinlin; Wu, Guofeng; Shen, Runpu; Xi, Meiyang; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Src homol. 2 (SH2)-contg. protein tyrosine phosphatase 2 (SHP2), encoded by PTPN11, regulates cell proliferation, differentiation, apoptosis and survival via releasing intramol. autoinhibition and modulating various signaling pathways, such as mitogen-activated protein kinase (MAPK) pathway.  Mutations and aberrant expression of SHP2 are implicated in human developmental disorders, leukemias and several solid tumors.  As an oncoprotein in some cancers, SHP2 represents a rational target for inhibitors to interfere.  Nevertheless, its tumor suppressive effect has also been uncovered, indicating the context-specificity.  Even so, two types of SHP2 inhibitors including targeting catalytic pocket and allosteric sites have been developed assocd. with resolved cocrystal complexes.  Herein, we describe its structure, biol. function, deregulation in human diseases and summarize recent advance in development of SHP2 inhibitors, trying to give an insight into the therapeutic potential in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkb-7jOXJ8DLVg90H21EOLACvtfcHk0lhxDyh2moXWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D&md5=9f40f6d2a560deac59c2b24616ac9f94</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112117%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DXi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520SHP2%2520in%2520human%2520developmental%2520disorders%2520and%2520cancers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112117%26doi%3D10.1016%2Fj.ejmech.2020.112117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunn, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederrecht, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5256</span>– <span class="NLM_lpage">5267</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1996.tb00911.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fj.1460-2075.1996.tb00911.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=8895571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK28XmsVeiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=5256-5267&issue=19&author=G.+J.+Brunnauthor=J.+Williamsauthor=C.+Sabersauthor=G.+Wiederrechtauthor=J.+Lawrenceauthor=R.+T.+Abraham&title=Direct+inhibition+of+the+signaling+functions+of+the+mammalian+target+of+rapamycin+by+the+phosphoinositide+3-kinase+inhibitors%2C+wortmannin+and+LY294002&doi=10.1002%2Fj.1460-2075.1996.tb00911.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002</span></div><div class="casAuthors">Brunn, Greogry J.; Williams, Josie; Sabers, Candace; Widerrecht, Gregory; Lawrence, John C., Jr.; Abraham, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5256-5267</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The immunosuppressant, rapamycin, inhibits cell growth by interfering with the function of a novel kinase, termed mammalian target of rapamycin (mTOR).  The putative catalytic domain of mTOR is similar to those of mammalian and yeast phosphatidylinositol (PI) 3-kinases.  This study demonstrates that mTOR is a component of a cytokine-triggered protein kinase cascade leading to the phosphorylation of the eukaryotic initiation factor-4E (eIF-4E)-binding protein, PHAS-1, in activated T lymphocytes.  This event promotes G1 phase progression by stimulating eIF-4E-dependent translation initiation.  A mutant YAC-1 T lymphoma cell line, which was selected for resistance to the growth-inhibitory action of rapamycin, was correspondingly resistant to the suppressive effect of this drug on PHAS-1 phosphorylation.  In contrast, the PI 3-kinase inhibitor, wortmannin, reduced the phosphorylation of PHAS-1 in both rapamycin-sensitive and -resistant T cells.  At similar drug concns. (0.1-1 μM), wortmannin irreversibly inhibited the serine-specific autokinase activity of mTOR.  The autokinase activity of mTOR was also sensitive to the structurally distinct PI 3-kinase inhibitor, LY294002, at concns. (1-30 μM) nearly identical to those required for inhibition of the lipid kinase activity of the mammalian p85-p110 heterodimer.  These studies indicate that the signaling functions of mTOR, and potentially those of other high mol. wt. PI 3-kinase homologs, are directly affected by cellular treatment with wortmannin or LY294002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ntqkdItCzLVg90H21EOLACvtfcHk0lhxDyh2moXWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVeiu74%253D&md5=792b373486bb634c47ebc3d0d298f4d3</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1996.tb00911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1996.tb00911.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrunn%26aufirst%3DG.%2BJ.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DSabers%26aufirst%3DC.%26aulast%3DWiederrecht%26aufirst%3DG.%26aulast%3DLawrence%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DDirect%2520inhibition%2520of%2520the%2520signaling%2520functions%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520by%2520the%2520phosphoinositide%25203-kinase%2520inhibitors%252C%2520wortmannin%2520and%2520LY294002%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26issue%3D19%26spage%3D5256%26epage%3D5267%26doi%3D10.1002%2Fj.1460-2075.1996.tb00911.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimaraes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1351</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1038/nm.1890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnm.1890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=19029981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1351-1356&issue=12&author=J.+A.+Engelmanauthor=L.+Chenauthor=X.+Tanauthor=K.+Crosbyauthor=A.+R.+Guimaraesauthor=R.+Upadhyayauthor=M.+Mairaauthor=K.+McNamaraauthor=S.+A.+Pereraauthor=Y.+Song&title=Effective+use+of+PI3K+and+MEK+inhibitors+to+treat+mutant+Kras+G12D+and+PIK3CA+H1047R+murine+lung+cancers&doi=10.1038%2Fnm.1890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers</span></div><div class="casAuthors">Engelman, Jeffrey A.; Chen, Liang; Tan, Xiaohong; Crosby, Katherine; Guimaraes, Alexander R.; Upadhyay, Rabi; Maira, Michel; McNamara, Kate; Perera, Samanthi A.; Song, Youngchul; Chirieac, Lucian R.; Kaur, Ramneet; Lightbown, Angela; Simendinger, Jessica; Li, Timothy; Padera, Robert F.; Garcia-Echeverria, Carlos; Weissleder, Ralph; Mahmood, Umar; Cantley, Lewis C.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1351-1356</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations that activate phosphoinositide 3-kinase (P13K) have been identified in the p1 10-x catalytic subunit (encoded by PIK3CA).  They are most frequently obsd. in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R).  Although the pl 10-o mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models.  Furthermore, clin. trials with P13K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies.  In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p-110-c H 1047R.  Treatment of these tumors - with NVP-BEZ235, a dual pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor in clin. development, led to labored breathing and MRI images consistent with lung tumors after marked tumor regression as shown by positron emission imaging and microscopic examn.  In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to CN single-agent NVP-BEZ235.  However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these kras-mutant cancers.  These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmFCNzeJpeErVg90H21EOLACvtfcHk0lji5Hw_uFMgVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rI&md5=3d9fd9c11132319c5e22807e15d592f3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnm.1890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1890%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DGuimaraes%26aufirst%3DA.%2BR.%26aulast%3DUpadhyay%26aufirst%3DR.%26aulast%3DMaira%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DSong%26aufirst%3DY.%26atitle%3DEffective%2520use%2520of%2520PI3K%2520and%2520MEK%2520inhibitors%2520to%2520treat%2520mutant%2520Kras%2520G12D%2520and%2520PIK3CA%2520H1047R%2520murine%2520lung%2520cancers%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26issue%3D12%26spage%3D1351%26epage%3D1356%26doi%3D10.1038%2Fnm.1890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C. D.</span></span> <span> </span><span class="NLM_article-title">PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2121-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1007%2Fs00280-013-2121-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23443307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVejsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=1395-1409&issue=6&author=C.+D.+Britten&title=PI3K+and+MEK+inhibitor+combinations%3A+examining+the+evidence+in+selected+tumor+types&doi=10.1007%2Fs00280-013-2121-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types</span></div><div class="casAuthors">Britten, Carolyn D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1395-1409</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most frequently dysregulated kinase cascades in human cancer.  Mol. alterations in these pathways are implicated in tumorigenesis and resistance to anticancer therapies.  The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are known to interact with each other at several nodes, and mounting evidence suggests that dual blockade of both pathways may be required to achieve anticancer effects in certain contexts.  This may include tumor types with a high frequency of RAS/RAF/MEK/ERK pathway activation, or situations in which dual pathway strategies may be required to overcome resistance to current targeted therapies.  Several clin. studies are currently evaluating the combination of PI3K and MEK inhibitors in a variety of different cancers with certain types of mol. alterations.  This review will summarize existing knowledge of the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways, the cross-talk between them, and the current generation of PI3K and MEK inhibitors that target them.  The preclin. rationale for dual pathway inhibition will be discussed within the context of the major tumor types currently being explored in ongoing clin. trials, namely malignant melanoma with BRAF or NRAS mutations, and colorectal, ovarian, pancreatic, and basal-like breast cancers.  The emerging clin. profile of PI3K and MEK inhibitor combinations, as reported in Phase I trials, will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop6Rpu4niStLVg90H21EOLACvtfcHk0lji5Hw_uFMgVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVejsLo%253D&md5=c746af8f20c34afa8542c27b1c7d89ce</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2121-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2121-1%26sid%3Dliteratum%253Aachs%26aulast%3DBritten%26aufirst%3DC.%2BD.%26atitle%3DPI3K%2520and%2520MEK%2520inhibitor%2520combinations%253A%2520examining%2520the%2520evidence%2520in%2520selected%2520tumor%2520types%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26issue%3D6%26spage%3D1395%26epage%3D1409%26doi%3D10.1007%2Fs00280-013-2121-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeannin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinsted, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zazulina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70489-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2FS1470-2045%2812%2970489-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23200175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BC3s7otVCnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=38-47&issue=1&author=P.+A.+J%C3%A4nneauthor=A.+T.+Shawauthor=J.+R.+Pereiraauthor=G.+Jeanninauthor=J.+Vansteenkisteauthor=C.+Barriosauthor=F.+A.+Frankeauthor=L.+Grinstedauthor=V.+Zazulinaauthor=P.+Smith&title=Selumetinib+plus+docetaxel+for+KRAS-mutant+advanced+non-small-cell+lung+cancer%3A+a+randomised%2C+multicentre%2C+placebo-controlled%2C+phase+2+study&doi=10.1016%2FS1470-2045%2812%2970489-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study</span></div><div class="casAuthors">Janne Pasi A; Shaw Alice T; Pereira Jose Rodrigues; Jeannin Gaelle; Vansteenkiste Johan; Barrios Carlos; Franke Fabio Andre; Grinsted Lynda; Zazulina Victoria; Smith Paul; Smith Ian; Crino Lucio</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  No targeted therapies are available for KRAS-mutant non-small-cell lung cancer (NSCLC).  Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers.  We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC.  METHODS:  Eligible patients were older than 18 years of age; had histologically or cytologically confirmed stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performance status of 0-1; had not received previous therapy with either a MEK inhibitor or docetaxel; and had adequate bone marrow, renal, and liver function.  Patients were randomly assigned (in a 1:1 ratio) to either oral selumetinib (75 mg twice daily in a 21 day cycle) or placebo; all patients received intravenous docetaxel (75 mg/m(2) on day 1 of a 21 day cycle).  Randomisation was done with an interactive voice response system and investigators, patients, data analysts, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival, analysed for all patients with confirmed KRAS mutations.  This study is registered with ClinicalTrials.gov, number NCT00890825.  FINDINGS:  Between April 20, 2009, and June 30, 2010, we randomly assigned 44 patients to receive selumetinib and docetaxel (selumetinib group) and 43 to receive placebo and docetaxel (placebo group).  Of these, one patient in the selumetinib group and three in the placebo group were excluded from efficacy analyses because their tumours were not confirmed to be KRAS-mutation positive.  Median overall survival was 9·4 months (6·8-13·6) in the selumetinib group and 5·2 months (95% CI 3·8-non-calculable) in the placebo group (hazard ratio [HR] for death 0·80, 80% CI 0·56-1·14; one-sided p=0·21).  Median progression-free survival was 5·3 months (4·6-6·4) in the selumetinib group and 2·1 months (95% CI 1·4-3·7) in the placebo group (HR for progression 0·58, 80% CI 0·42-0·79; one-sided p=0·014). 16 (37%) patients in the selumetinib group and none in the placebo group had an objective response (p<0·0001).  Adverse events of grade 3 or higher occurred in 36 (82%) patients in the selumetinib group and 28 (67%) patients in the placebo group.  The most common grade 3-4 adverse events were neutropenia (29 [67%] of 43 patients in the selumetinib group vs 23 [55%] of 42 patients in the placebo group), febrile neutropenia (eight [18%] of 44 patients in the selumetinib group vs none in the placebo group), dyspnoea (one [2%] of 44 patients in the selumetinib group vs five [12%] of 42 in the placebo group), and asthenia (four [9%] of 44 patients in the selumetinib group vs none in the placebo group).  INTERPRETATION:  Selumetinib plus docetaxel has promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC.  These findings warrant further clinical investigation of selumetinib plus docetaxel in KRAS-mutant NSCLC.  FUNDING:  AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_DnSQjq4ctlm8bhe6roZYfW6udTcc2ebVJHHknQCq3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7otVCnug%253D%253D&md5=3987f8d7cb411810eb05c507a0bc9a73</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970489-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970489-8%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DPereira%26aufirst%3DJ.%2BR.%26aulast%3DJeannin%26aufirst%3DG.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%26aulast%3DFranke%26aufirst%3DF.%2BA.%26aulast%3DGrinsted%26aufirst%3DL.%26aulast%3DZazulina%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DP.%26atitle%3DSelumetinib%2520plus%2520docetaxel%2520for%2520KRAS-mutant%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520randomised%252C%2520multicentre%252C%2520placebo-controlled%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26issue%3D1%26spage%3D38%26epage%3D47%26doi%3D10.1016%2FS1470-2045%2812%2970489-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, J.</span></span> <span> </span><span class="NLM_article-title">Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1989.tb03478.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fj.1460-2075.1989.tb03478.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=2663468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaL1MXitVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1989&pages=1093-1098&issue=4&author=L.+Gutierrezauthor=A.+Mageeauthor=C.+Marshallauthor=J.+Hancock&title=Post-translational+processing+of+p21ras+is+two-step+and+involves+carboxyl-methylation+and+carboxy-terminal+proteolysis&doi=10.1002%2Fj.1460-2075.1989.tb03478.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis</span></div><div class="casAuthors">Gutierrez, Lourdes; Magee, Anthony I.; Marshall, Christoper J.; Hancock, John F.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1093-8</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    </div><div class="casAbstract">The post-translational processing of p21ras proteins was studied.  The primary translation product pro-p21 is cytosolic and is rapidly converted to a cytosolic form (c-p21) of higher mobility on SDS-PAGE.  Protein c-p21 is converted in turn to the membrane-bound mature palmitoylated form (m-p21) of slightly higher mobility.  These processing steps are accompanied by increases in isoelec. point and in hydrophobicity as judged by Triton X-114 partitioning.  Although the increases in electrophoretic mobility and hydrophobicity precede acylation, mutation of Cys186, which has been shown to block acylation, also abolishes the pro-p21 to c-p21 conversion.  Thus the Cys186 residue is involved in the processing steps prior to acylation.  Two processing events were identified which contribute to the pro-p21 conversion.  Site-directed mutagenesis to insert tryptophan, which is not present in the wild type, followed by metabolic labeling with [3H]tryptophan made it possible to map a proteolytic processing event which removes the three C-terminal residues.  In addn., both the c-p21 and m-p21 forms are carboxyl-methylated.  Approx. one Me group is incorporated per mol. of p21 at steady state, which can partially account for the increase in isoelec. point.  Unlike palmitate, Me group turnover is not obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCviE0IiktLrVg90H21EOLACvtfcHk0ljV3jQUX82QfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXitVyjtbg%253D&md5=bd186a082edce40c5b00eb45ccd181d2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1989.tb03478.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1989.tb03478.x%26sid%3Dliteratum%253Aachs%26aulast%3DGutierrez%26aufirst%3DL.%26aulast%3DMagee%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DC.%26aulast%3DHancock%26aufirst%3DJ.%26atitle%3DPost-translational%2520processing%2520of%2520p21ras%2520is%2520two-step%2520and%2520involves%2520carboxyl-methylation%2520and%2520carboxy-terminal%2520proteolysis%26jtitle%3DEMBO%2520J.%26date%3D1989%26volume%3D8%26issue%3D4%26spage%3D1093%26epage%3D1098%26doi%3D10.1002%2Fj.1460-2075.1989.tb03478.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. R.</span></span> <span> </span><span class="NLM_article-title">Thematic review series: lipid posttranslational modifications CAAX modification and membrane targeting of Ras</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1194/jlr.R600004-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1194%2Fjlr.R600004-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=16543601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVChurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=883-891&issue=5&author=L.+P.+Wrightauthor=M.+R.+Philips&title=Thematic+review+series%3A+lipid+posttranslational+modifications+CAAX+modification+and+membrane+targeting+of+Ras&doi=10.1194%2Fjlr.R600004-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">CAAX modification and membrane targeting of Ras</span></div><div class="casAuthors">Wright, Latasha P.; Philips, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">883-891</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Proteins that terminate with a consensus sequence known as CAAX undergo a series of posttranslational modifications that include polyisoprenylation, endoproteolysis, and carboxyl methylation.  These modifications render otherwise hydrophilic proteins hydrophobic at their C termini such that they assoc. with membranes.  Whereas prenylation occurs in the cytosol, postprenylation processing is accomplished on the cytoplasmic surface of the endoplasmic reticulum and Golgi app.  Among the numerous CAAX proteins encoded in mammalian genomes are many signaling mols. such as monomeric GTPases, including the Ras proteins that play an important role in cancer.  In the course of their processing, nascent Ras proteins traffic from their site of synthesis in the cytosol to the endomembrane and then out to the plasma membrane (PM) by at least 2 pathways.  Recently, retrograde pathways were discovered that deliver mature Ras from the PM back to the Golgi.  The Golgi was identified as a platform upon which Ras can signal.  Thus, the subcellular trafficking of Ras proteins has the potential to increase the complexity of Ras signaling by adding a spatial dimension.  The complexity of Ras trafficking also affords a wider array of potential targets for the discovery of drugs that might inhibit tumors by interfering with Ras trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLRbofH7NgtrVg90H21EOLACvtfcHk0ljV3jQUX82QfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVChurs%253D&md5=fd6d0d6dd7a5c200e83241bb34229b1e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R600004-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R600004-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DL.%2BP.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DThematic%2520review%2520series%253A%2520lipid%2520posttranslational%2520modifications%2520CAAX%2520modification%2520and%2520membrane%2520targeting%2520of%2520Ras%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2006%26volume%3D47%26issue%3D5%26spage%3D883%26epage%3D891%26doi%3D10.1194%2Fjlr.R600004-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diver, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S. B.</span></span> <span> </span><span class="NLM_article-title">Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>553</i></span> (<span class="NLM_issue">7689</span>),  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">529</span>, <span class="refDoi"> DOI: 10.1038/nature25439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnature25439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29342140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=553&publication_year=2018&pages=526-529&issue=7689&author=M.+M.+Diverauthor=L.+Pediauthor=A.+Koideauthor=S.+Koideauthor=S.+B.+Long&title=Atomic+structure+of+the+eukaryotic+intramembrane+RAS+methyltransferase+ICMT&doi=10.1038%2Fnature25439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT</span></div><div class="casAuthors">Diver, Melinda M.; Pedi, Leanne; Koide, Akiko; Koide, Shohei; Long, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">553</span>
        (<span class="NLM_cas:issue">7689</span>),
    <span class="NLM_cas:pages">526-529</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The maturation of RAS GTPases and approx. 200 other cellular CAAX proteins involves three enzymic steps: addn. of a farnesyl or geranylgeranyl prenyl lipid to the cysteine (C) in the C-terminal CAAX motif, proteolytic cleavage of the AAX residues and methylation of the exposed prenylcysteine residue at its terminal carboxylate.  This final step is catalyzed by isoprenylcysteine carboxyl methyltransferase (ICMT), a eukaryote-specific integral membrane enzyme that resides in the endoplasmic reticulum.  ICMT is the only cellular enzyme that is known to methylate prenylcysteine substrates; methylation is important for the biol. functions of these substrates, such as the membrane localization and subsequent activity of RAS, prelamin A and RAB.  Inhibition of ICMT has potential for combating progeria and cancer.  Here we present an X-ray structure of ICMT, in complex with its cofactor, an ordered lipid mol. and a monobody inhibitor, at 2.3 Å resoln.  The active site spans cytosolic and membrane-exposed regions, indicating distinct entry routes for the cytosolic Me donor, S-adenosyl-L-methionine, and for prenylcysteine substrates, which are assocd. with the endoplasmic reticulum membrane.  The structure suggests how ICMT overcomes the topog. challenge and unfavorable energetics of bringing two reactants that have different cellular localizations together in a membrane environment-a relatively uncharacterized but defining feature of many integral membrane enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXFRW8xr3AZbVg90H21EOLACvtfcHk0ljV3jQUX82QfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOisb4%253D&md5=612327b61ef2d9448552fbf617e8d891</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnature25439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25439%26sid%3Dliteratum%253Aachs%26aulast%3DDiver%26aufirst%3DM.%2BM.%26aulast%3DPedi%26aufirst%3DL.%26aulast%3DKoide%26aufirst%3DA.%26aulast%3DKoide%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DS.%2BB.%26atitle%3DAtomic%2520structure%2520of%2520the%2520eukaryotic%2520intramembrane%2520RAS%2520methyltransferase%2520ICMT%26jtitle%3DNature%26date%3D2018%26volume%3D553%26issue%3D7689%26spage%3D526%26epage%3D529%26doi%3D10.1038%2Fnature25439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. R.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS membrane association: back to the future for anti-RAS drug discovery?</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">8127</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F1078-0432.CCR-14-3214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=25878363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2gt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1819-8127&author=A.+D.+Coxauthor=C.+J.+Derauthor=M.+R.+Philips&title=Targeting+RAS+membrane+association%3A+back+to+the+future+for+anti-RAS+drug+discovery%3F&doi=10.1158%2F1078-0432.CCR-14-3214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?</span></div><div class="casAuthors">Cox, Adrienne D.; Der, Channing J.; Philips, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1819-1827</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">RAS proteins require membrane assocn. for their biol. activity, making this assocn. a logical target for anti-RAS therapeutics.  Lipid modification of RAS proteins by a farnesyl isoprenoid is an obligate step in that assocn., and is an enzymic process.  Accordingly, farnesyltransferase inhibitors (FTI) were developed as potential anti-RAS drugs.  The lack of efficacy of FTIs as anticancer drugs was widely seen as indicating that blocking RAS membrane assocn. was a flawed approach to cancer treatment.  However, a deeper understanding of RAS modification and trafficking has revealed that this was an erroneous conclusion.  In the presence of FTIs, KRAS and NRAS, which are the RAS isoforms most frequently mutated in cancer, become substrates for alternative modification, can still assoc. with membranes, and can still function.  Thus, FTIs failed not because blocking RAS membrane assocn. is an ineffective approach, but because FTIs failed to accomplish that task.  Recent findings regarding RAS isoform trafficking and the regulation of RAS subcellular localization have rekindled interest in efforts to target these processes.  In particular, improved understanding of the palmitoylation/depalmitoylation cycle that regulates RAS interaction with the plasma membrane, endomembranes, and cytosol, and of the potential importance of RAS chaperones, have led to new approaches.  Efforts to validate and target other enzymically regulated posttranslational modifications are also ongoing.  In this review, we revisit lessons learned, describe the current state of the art, and highlight challenging but promising directions to achieve the goal of disrupting RAS membrane assocn. and subcellular localization for anti-RAS drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCImUyZbuCKrVg90H21EOLACvtfcHk0ljV3jQUX82QfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2gt74%253D&md5=6f41ac23a7d14b90633755e374b6ffea</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3214%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DTargeting%2520RAS%2520membrane%2520association%253A%2520back%2520to%2520the%2520future%2520for%2520anti-RAS%2520drug%2520discovery%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1819%26epage%3D8127%26doi%3D10.1158%2F1078-0432.CCR-14-3214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marín-Ramos, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Gutiérrez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Rodríguez, M. L.</span></span> <span> </span><span class="NLM_article-title">Blocking Ras inhibition as an antitumor strategy</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2018.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.semcancer.2018.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29409706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=91-100&author=N.+I.+Mar%C3%ADn-Ramosauthor=S.+Ortega-Guti%C3%A9rrezauthor=M.+L.+L%C3%B3pez-Rodr%C3%ADguez&title=Blocking+Ras+inhibition+as+an+antitumor+strategy&doi=10.1016%2Fj.semcancer.2018.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking Ras inhibition as an antitumor strategy</span></div><div class="casAuthors">Marin-Ramos, Nagore I.; Ortega-Gutierrez, Silvia; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ras proteins are among the most frequently mutated drivers in human cancer and remain an elusive pharmaceutical targeting.  Previous studies have improved the understanding of Ras structure, processing, and signaling pathways in cancer cells and have opened new possibilities for inhibiting Ras function.  In this review we discuss the most recent advances towards inhibiting Ras activity with small mols., highlighting the two approaches: (i) compds. that bind directly to Ras protein and (ii) inhibitors of the enzymes involved in the post-translational modifications of Ras.  In the former, we analyze the most recent contributions in each of the main classes of Ras direct binders, including the different types of nucleotide exchange inhibitors, allosteric compds., and mols. that interfere with the interaction between Ras and its effectors.  In the latter, we examine the compds. that inhibit Ras activation by blocking any of its post-translational modifications.  Also, a special focus is made on those mols. that have progressed the farthest from medicinal chem. and drug development points of view.  Finally, the current scene regarding the clin. trials of Ras inhibitors, together with the future promising avenues for further development of the challenging Ras field are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWw2RqFhpnErVg90H21EOLACvtfcHk0liOm5oTNC6Tjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKjs74%253D&md5=721a62e21dddff7fc9d25732ec30040f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2018.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2018.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DMar%25C3%25ADn-Ramos%26aufirst%3DN.%2BI.%26aulast%3DOrtega-Guti%25C3%25A9rrez%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez-Rodr%25C3%25ADguez%26aufirst%3DM.%2BL.%26atitle%3DBlocking%2520Ras%2520inhibition%2520as%2520an%2520antitumor%2520strategy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2019%26volume%3D54%26spage%3D91%26epage%3D100%26doi%3D10.1016%2Fj.semcancer.2018.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowell, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczyk, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. M.</span></span> <span> </span><span class="NLM_article-title">Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">14093</span>– <span class="NLM_lpage">14097</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.22.14093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1074%2Fjbc.272.22.14093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9162034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=14093-14097&issue=22&author=C.+A.+Rowellauthor=J.+J.+Kowalczykauthor=M.+D.+Lewisauthor=A.+M.+Garcia&title=Direct+demonstration+of+geranylgeranylation+and+farnesylation+of+Ki-Ras+in+vivo&doi=10.1074%2Fjbc.272.22.14093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo</span></div><div class="casAuthors">Rowell, Cheryl A.; Kowalczyk, James J.; Lewis, Michael D.; Garcia, Ana Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">14093-14097</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">It has recently been reported that Ki-Ras protein can be modified in vitro by farnesylation or geranylgeranylation.  However, a previous anal. of Ki-Ras prenylation in vivo found only farnesylated Ki-Ras.  In this report it is shown that under normal conditions, Ki-Ras is farnesylated in vivo and when cells are treated with the farnesyl transferase inhibitors B956 or B957, farnesylation is inhibited and Ki-Ras becomes geranylgeranylated in a dose dependent manner.  These results have strong implications in the design of anticancer drugs based on inhibition of prenylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolB-vVx7wo-bVg90H21EOLACvtfcHk0liOm5oTNC6Tjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOjtro%253D&md5=7cee7201fa0062bd1e62fc28de19f829</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.22.14093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.22.14093%26sid%3Dliteratum%253Aachs%26aulast%3DRowell%26aufirst%3DC.%2BA.%26aulast%3DKowalczyk%26aufirst%3DJ.%2BJ.%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DGarcia%26aufirst%3DA.%2BM.%26atitle%3DDirect%2520demonstration%2520of%2520geranylgeranylation%2520and%2520farnesylation%2520of%2520Ki-Ras%2520in%2520vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26issue%3D22%26spage%3D14093%26epage%3D14097%26doi%3D10.1074%2Fjbc.272.22.14093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockenberry, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez-Oliva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catino, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, J.-K.</span></span> <span> </span><span class="NLM_article-title">K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">14459</span>– <span class="NLM_lpage">14464</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.22.14459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1074%2Fjbc.272.22.14459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9162087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFygs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=14459-14464&issue=22&author=D.+B.+Whyteauthor=P.+Kirschmeierauthor=T.+N.+Hockenberryauthor=I.+Nunez-Olivaauthor=L.+Jamesauthor=J.+J.+Catinoauthor=W.+R.+Bishopauthor=J.-K.+Pai&title=K-and+N-Ras+are+geranylgeranylated+in+cells+treated+with+farnesyl+protein+transferase+inhibitors&doi=10.1074%2Fjbc.272.22.14459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors</span></div><div class="casAuthors">Whyte, David B.; Kirschmeier, Paul; Hockenberry, Tish N.; Nunez-Oliva, Irma; James, Linda; Catino, Joseph J.; Bishop, W. Robert; Pai, Jin-Keon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">14459-14464</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The assocn. of mutant forms of Ras protein with a variety of human cancers has stimulated intense interest in therapies based on inhibiting oncogenic Ras signaling.  Attachment of Ras proteins to the plasma membrane is required for effective Ras signaling and is initiated by the enzyme farnesyl protein transferase.  We found that in the presence of potent farnesyl protein transferase inhibitors, Ras proteins in the human colon carcinoma cell line DLD-1 were alternatively prenylated by geranylgeranyl transferase-1.  When H-Ras, N-Ras, K-Ras4A, and K-Ras4B were expressed individually in COS cells, H-Ras prenylation and membrane assocn. were uniquely sensitive to farnesyl transferase inhibitors; N- and K-Ras proteins incorporated the geranylgeranyl isoprene group and remained assocd. with the membrane fraction.  The alternative prenylation of N- and K-Ras has significant implications for our understanding of the mechanism of action of farnesyl protein transferase inhibitors as anti-cancer chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgCoY9uLK4rVg90H21EOLACvtfcHk0liOm5oTNC6Tjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFygs74%253D&md5=50e8f78cabe32449915cf26ae9aa79f6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.22.14459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.22.14459%26sid%3Dliteratum%253Aachs%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DHockenberry%26aufirst%3DT.%2BN.%26aulast%3DNunez-Oliva%26aufirst%3DI.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DCatino%26aufirst%3DJ.%2BJ.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DPai%26aufirst%3DJ.-K.%26atitle%3DK-and%2520N-Ras%2520are%2520geranylgeranylated%2520in%2520cells%2520treated%2520with%2520farnesyl%2520protein%2520transferase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26issue%3D22%26spage%3D14459%26epage%3D14464%26doi%3D10.1074%2Fjbc.272.22.14459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Judd, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slattum, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhoite, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valppu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostanin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery and SAR of methylated tetrahydropyranyl derivatives as inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5031</span>– <span class="NLM_lpage">5047</span>, <span class="refDoi"> DOI: 10.1021/jm200249a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200249a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFShsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5031-5047&issue=14&author=W.+R.+Juddauthor=P.+M.+Slattumauthor=K.+C.+Hoangauthor=L.+Bhoiteauthor=L.+Valppuauthor=G.+Albertsauthor=B.+Brownauthor=B.+Rothauthor=K.+Ostaninauthor=L.+Huang&title=Discovery+and+SAR+of+methylated+tetrahydropyranyl+derivatives+as+inhibitors+of+isoprenylcysteine+carboxyl+methyltransferase+%28ICMT%29&doi=10.1021%2Fjm200249a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)</span></div><div class="casAuthors">Judd, Weston R.; Slattum, Paul M.; Hoang, Khanh C.; Bhoite, Leena; Valppu, Liisa; Alberts, Glen; Brown, Brita; Roth, Bruce; Ostanin, Kirill; Huang, Liwen; Wettstein, Daniel; Richards, Burt; Willardsen, J. Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5031-5047</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydropyranyl (THP) derivs. has been developed as potent inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT) for use as anticancer agents.  Structural modification of the submicromolar hit compd. I led to the potent 3-methoxy substituted analog II [R = H].  Further SAR development around the THP ring resulted in an addnl. 10-fold increase in potency, exemplified by analog II [R = Me] with an IC50 of 1.3 nM.  Active and potent compds. demonstrated a dose-dependent increase in Ras cytosolic protein.  Potent ICMT inhibitors also reduced cell viability in several cancer cell lines with growth inhibition (GI50) values ranging from 0.3 to >100 μM.  However, none of the cellular effects obsd. using ICMT inhibitors were as pronounced as those resulting from a farnesyl-transferase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxtJBz5EBh_LVg90H21EOLACvtfcHk0liOm5oTNC6Tjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFShsrk%253D&md5=70c861a9d4ef4efcde4b94a2e0a88de9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm200249a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200249a%26sid%3Dliteratum%253Aachs%26aulast%3DJudd%26aufirst%3DW.%2BR.%26aulast%3DSlattum%26aufirst%3DP.%2BM.%26aulast%3DHoang%26aufirst%3DK.%2BC.%26aulast%3DBhoite%26aufirst%3DL.%26aulast%3DValppu%26aufirst%3DL.%26aulast%3DAlberts%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DB.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DOstanin%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520methylated%2520tetrahydropyranyl%2520derivatives%2520as%2520inhibitors%2520of%2520isoprenylcysteine%2520carboxyl%2520methyltransferase%2520%2528ICMT%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D14%26spage%3D5031%26epage%3D5047%26doi%3D10.1021%2Fjm200249a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dechert, A.-M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacNamara, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breevoort, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrandt, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembree, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLain, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, T. M.</span></span> <span> </span><span class="NLM_article-title">Modulation of the inhibitor properties of dipeptidyl (acyloxy) methyl ketones toward the CAAX proteases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6230</span>– <span class="NLM_lpage">6237</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.07.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.bmc.2010.07.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=20696584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKgsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=6230-6237&issue=17&author=A.-M.+R.+Dechertauthor=J.+P.+MacNamaraauthor=S.+R.+Breevoortauthor=E.+R.+Hildebrandtauthor=N.+W.+Hembreeauthor=A.+C.+Reaauthor=D.+E.+McLainauthor=S.+B.+Porterauthor=W.+K.+Schmidtauthor=T.+M.+Dore&title=Modulation+of+the+inhibitor+properties+of+dipeptidyl+%28acyloxy%29+methyl+ketones+toward+the+CAAX+proteases&doi=10.1016%2Fj.bmc.2010.07.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the inhibitor properties of dipeptidyl (acyloxy)methyl ketones toward the CaaX proteases</span></div><div class="casAuthors">Dechert, Anne-Marie R.; MacNamara, James P.; Breevoort, Sarah R.; Hildebrandt, Emily R.; Hembree, Ned W.; Rea, Adam C.; McLain, Duncan E.; Porter, Stephen B.; Schmidt, Walter K.; Dore, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6230-6237</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dipeptidyl (acyloxy)methyl ketones (AOMKs) have been identified as mechanism-based inhibitors of certain cysteine proteases.  These compds. are also inhibitors of the integral membrane proteins Rce1p and Ste24p, which are proteases that independently mediate a cleavage step assocd. with the maturation of certain isoprenylated proteins.  The enzymic mechanism of Rce1p is ill-defined, whereas Ste24p is a zinc metalloprotease.  Rce1p is required for the proper processing of the oncoprotein Ras and is viewed as a potential target for cancer therapy.  In this study, we synthesized a small library of dipeptidyl AOMKs to investigate the structural elements that contribute to the inhibitor properties of this class of mols. toward Rce1p and Ste24p.  The compds. were evaluated using a fluorescence-based in vitro proteolysis assay.  The most potent dipeptidyl AOMKs contained an arginine residue and the identity of the benzoate group strongly influenced potency.  A 'warhead' free AOMK inhibited Rce1p and Ste24p.  The data suggest that the dipeptidyl AOMKs are not mechanism-based inhibitors of Rce1p and Ste24p and corroborate the hypothesis that Rce1p is not a cysteine protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwY3YF72cWwLVg90H21EOLACvtfcHk0lhk17CrDDfnmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKgsLnF&md5=06e4477d4f1d267cf6cb6c24b5b8447d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.07.041%26sid%3Dliteratum%253Aachs%26aulast%3DDechert%26aufirst%3DA.-M.%2BR.%26aulast%3DMacNamara%26aufirst%3DJ.%2BP.%26aulast%3DBreevoort%26aufirst%3DS.%2BR.%26aulast%3DHildebrandt%26aufirst%3DE.%2BR.%26aulast%3DHembree%26aufirst%3DN.%2BW.%26aulast%3DRea%26aufirst%3DA.%2BC.%26aulast%3DMcLain%26aufirst%3DD.%2BE.%26aulast%3DPorter%26aufirst%3DS.%2BB.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DDore%26aufirst%3DT.%2BM.%26atitle%3DModulation%2520of%2520the%2520inhibitor%2520properties%2520of%2520dipeptidyl%2520%2528acyloxy%2529%2520methyl%2520ketones%2520toward%2520the%2520CAAX%2520proteases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26issue%3D17%26spage%3D6230%26epage%3D6237%26doi%3D10.1016%2Fj.bmc.2010.07.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita-Yoshigaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshio, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villafranca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaziro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span> <span> </span><span class="NLM_article-title">Mutations that abolish the ability of Ha-Ras to associate with Raf-1</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2153</span>– <span class="NLM_lpage">2157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=8036000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2cXlvFyrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1994&pages=2153-2157&issue=8&author=M.+Shirouzuauthor=H.+Koideauthor=J.+Fujita-Yoshigakiauthor=H.+Oshioauthor=Y.+Toyamaauthor=K.+Yamasakiauthor=S.+A.+Fuhrmanauthor=E.+Villafrancaauthor=Y.+Kaziroauthor=S.+Yokoyama&title=Mutations+that+abolish+the+ability+of+Ha-Ras+to+associate+with+Raf-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations that abolish the ability of Ha-Ras to associate with Raf-1</span></div><div class="casAuthors">Shirouzu, Mikako; Koide, Hiroshi; Fujita-Yoshigaki, Junko; Oshio, Hisayo; Toyama, Youichi; Yamasaki, Kazuhiko; Fuhrman, Shella A.; Villafranca, Ernie; Kaziro, Yoshito; Yokoyama, Shigeyuki</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2153-7</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">Recent studies have revealed that Ras can assoc. phys. with Raf.  In the present study, we tested 34 mutants of Ha-Ras carrying substitution(s) in the region of residues 23-71 for their ability to assoc. with Raf-1.  Mouse Ba/F3 cell lysates were incubated with each mutant Ras protein, in either the guanosine 5'-[γ-thio]triphosphate (GTPγS)- or the guanosine 5'-[β-thio]diphosphate (GDPβS)-bound form, and the anti-Ras antibody Y13-238.  The immunoppts. were analyzed for the presence of Raf-1 by Western blotting with an anti-Raf-1 antibody.  Six mutants of Ras, E31K, P34G, T35S, D38N, D57A and A59T, failed to bind Raf-1.  Mutations N26G, V29A, S39A, Y40W, R41A, V44A, V45E, L56A and T58A partially reduced the ability to bind Raf-1.  All the other mutants could assoc. with Raf-1 with nearly the same efficiency as that of wild-type Ras.  Thus, the Raf-1-binding ability of Ras appears to be affected by mutations in the N-terminal region, and in particular, by those in and neighboring the effector region (residues 32-40) and in the region (residues 56-59) flanking the N-terminal of Switch II.  The abilities to bind Raf-1 and to induce neurite outgrowth of pheochromocytoma (PC) 12 cells correlate to each other for 22 Ras mutants.  However, mutation A59T, which does not reduce the neurite-inducing or transforming activities, abolishes the ability to bind Raf-1.  In contrast, mutations Y32F, K42A and L53A, which impair the neurite-inducing activity of Ras, have no effect on the Ras·Raf-1 assocn.  Partially reduced Raf-1-binding ability was obsd. for mutants V29A, S39A, Y40W, R41A, V44A, L56A and T58A, which exhibit full neurite-inducing activity, and also for mutant V45E, which has no activity of neurite induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_3PtqUfeo2rVg90H21EOLACvtfcHk0lhk17CrDDfnmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlvFyrsro%253D&md5=716bcabbcc087203bb985013c3faab14</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DKoide%26aufirst%3DH.%26aulast%3DFujita-Yoshigaki%26aufirst%3DJ.%26aulast%3DOshio%26aufirst%3DH.%26aulast%3DToyama%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DK.%26aulast%3DFuhrman%26aufirst%3DS.%2BA.%26aulast%3DVillafranca%26aufirst%3DE.%26aulast%3DKaziro%26aufirst%3DY.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DMutations%2520that%2520abolish%2520the%2520ability%2520of%2520Ha-Ras%2520to%2520associate%2520with%2520Raf-1%26jtitle%3DOncogene%26date%3D1994%26volume%3D9%26issue%3D8%26spage%3D2153%26epage%3D2157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moodie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villafranca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirshmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willumsen, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfman, A.</span></span> <span> </span><span class="NLM_article-title">Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">454</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=7630628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2MXnsFyhsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=447-454&issue=3&author=S.+A.+Moodieauthor=M.+Parisauthor=E.+Villafrancaauthor=P.+Kirshmeierauthor=B.+M.+Willumsenauthor=A.+Wolfman&title=Different+structural+requirements+within+the+switch+II+region+of+the+Ras+protein+for+interactions+with+specific+downstream+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets</span></div><div class="casAuthors">Moodie, Shonna A.; Paris, Mark; Villafranca, Ernest; Kirshmeier, Paul; Willumsen, Berthe M.; Wolfman, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">447-54</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Ras proteins function through the formation of specific complexes with Raf-1, B-raf, PI-3 kinase and RalGDS.  These interactions all require Ras-GTP with an intact effector binding domain (Switch I region).  The authors have examd. the requirements of the Switch II region (amino acids 60-72) for the prodn. of stable interactions between Ras and its downstream effectors.  A point mutation at position 65 or 64 combined with addnl. mutations at either position 65 or 71 rendered nucleotide-free Ras protein unable to stably interact with Ras specific guanine nucleotide exchange factors.  Ha-Ras contg. point mutations at positions 65 and 71 possessed a twofold higher affinity for B-raf and consequently MEK1.  The point mutation at 64, in combination with addnl. point mutations at either position 65 or 71, resulted in a protein which failed to interact with either PI-3 kinase or neurofibromin, though these Ras mutants effectively bound both Raf-1 and B-raf.  An activated form of Ras, Q61L-Ras, assocd. with all effector proteins independent of the bound guanine nucleotide.  Q61L-Ras-GDP was almost as effective as wild type Ras-GMPPNP in the in vitro activation of MEK1 and MAP kinase.  Competitive studies with the catalytic domain of neurofibromin, NF1-GRD, demonstrated that its interaction with Ras-GRD, demonstrated that its interaction with Ras-GMPPNP is mutually exclusive with both Raf-1 and B-raf.  These data suggest that rasGAP and neurofibromin are unable to downregulate Ras-GTP complexed to Raf-1 or B-raf.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokId0KQx0MobVg90H21EOLACvtfcHk0lhk17CrDDfnmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnsFyhsbc%253D&md5=ef1c439a9b5244ae5be22150ae566e1c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoodie%26aufirst%3DS.%2BA.%26aulast%3DParis%26aufirst%3DM.%26aulast%3DVillafranca%26aufirst%3DE.%26aulast%3DKirshmeier%26aufirst%3DP.%26aulast%3DWillumsen%26aufirst%3DB.%2BM.%26aulast%3DWolfman%26aufirst%3DA.%26atitle%3DDifferent%2520structural%2520requirements%2520within%2520the%2520switch%2520II%2520region%2520of%2520the%2520Ras%2520protein%2520for%2520interactions%2520with%2520specific%2520downstream%2520targets%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26issue%3D3%26spage%3D447%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, F.</span></span> <span> </span><span class="NLM_article-title">Nucleotide binding affects intrinsic dynamics and structural communication in Ras GTPases</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">4214</span>– <span class="NLM_lpage">4225</span>, <span class="refDoi"> DOI: 10.2174/1381612811319230006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.2174%2F1381612811319230006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23170885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4214-4225&issue=23&author=F.+Fanelliauthor=F.+Raimondi&title=Nucleotide+binding+affects+intrinsic+dynamics+and+structural+communication+in+Ras+GTPases&doi=10.2174%2F1381612811319230006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleotide binding affects intrinsic dynamics and structural communication in Ras GTPases</span></div><div class="casAuthors">Fanelli, Francesca; Raimondi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4214-4225</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Ras superfamily comprises many guanine nucleotide-binding proteins (G proteins) that are essential to intracellular signal transduction.  These proteins act biol. as mol. switches, which, cycling between OFF and ON states, play fundamental role in cell biol.  This review article summarizes the inferences from the widest computational analyses done so far on Ras GTPases aimed at providing a comprehensive structural/dynamic view of the trans-family and family-specific functioning mechanisms.  These variegated comparative analyses could infer the evolutionary and intrinsic flexibilities as well as the structural communication features in the most representative G protein families in different functional states.  In spite of the low sequence similarities, the members of the Ras superfamily share the topol. of the Ras-like domain, including the nucleotide binding site.  GDP and GTP make very similar interactions in all GTPases and differences in their binding modes are localized around the γ-phosphate of GTP.  Remarkably, such subtle local differences result in significant differences in the functional dynamics and structural communication features of the protein.  In Ras GTPases, the nucleotide plays a central and active role in dictating functional dynamics, establishing the major structure network, and mediating the communication paths instrumental in function retention and specialization.  Collectively, the results of these studies support the speculation that an "extended conformational selection model" that embraces a repertoire of selection and adjustment processes is likely more suitable to describe the nucleotide behavior in these important mol. switches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovtaxyGikHf7Vg90H21EOLACvtfcHk0lgIyM9jW2Qqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyrt7s%253D&md5=c1857a83b638a762fd239640a8845b71</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F1381612811319230006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319230006%26sid%3Dliteratum%253Aachs%26aulast%3DFanelli%26aufirst%3DF.%26aulast%3DRaimondi%26aufirst%3DF.%26atitle%3DNucleotide%2520binding%2520affects%2520intrinsic%2520dynamics%2520and%2520structural%2520communication%2520in%2520Ras%2520GTPases%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26issue%3D23%26spage%3D4214%26epage%3D4225%26doi%3D10.2174%2F1381612811319230006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, M. E.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1246</span>, <span class="refDoi"> DOI: 10.1021/jm8008597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&issue=5&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design&doi=10.1021%2Fjm8008597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0lgIyM9jW2Qqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D5%26spage%3D1231%26epage%3D1246%26doi%3D10.1021%2Fjm8008597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1002/anie.201307387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fanie.201307387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvValsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=199-204&issue=1&author=S.+M.+Limauthor=K.+D.+Westoverauthor=S.+B.+Ficarroauthor=R.+A.+Harrisonauthor=H.+G.+Choiauthor=M.+E.+Pacoldauthor=M.+Carrascoauthor=J.+Hunterauthor=N.+D.+Kimauthor=T.+Xie&title=Therapeutic+targeting+of+oncogenic+K-Ras+by+a+covalent+catalytic+site+inhibitor&doi=10.1002%2Fanie.201307387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor</span></div><div class="casAuthors">Lim, Sang Min; Westover, Kenneth D.; Ficarro, Scott B.; Harrison, Rane A.; Choi, Hwan Geun; Pacold, Michael E.; Carrasco, Martin; Hunter, John; Kim, Nam Doo; Xie, Ting; Sim, Taebo; Jaenne, Pasi A.; Meyerson, Matthew; Marto, Jarrod A.; Engen, John R.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">199-204</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We report the synthesis of a GDP analog, SML-8-73-1, and a prodrug deriv., SML-10-70-1, which are selective, direct-acting covalent inhibitors of the K-Ras G12C mutant relative to wild-type Ras.  Biochem. and biophys. measurements suggest that modification of K-Ras with SML-8-73-1 renders the protein in an inactive state.  These first-in-class covalent K-Ras inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfLlkUFFkg-7Vg90H21EOLACvtfcHk0lgIyM9jW2Qqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvValsrbN&md5=f99a8c9603d4139135606c964706a822</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307387%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BM.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DHarrison%26aufirst%3DR.%2BA.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DCarrasco%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DXie%26aufirst%3DT.%26atitle%3DTherapeutic%2520targeting%2520of%2520oncogenic%2520K-Ras%2520by%2520a%2520covalent%2520catalytic%2520site%2520inhibitor%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26issue%3D1%26spage%3D199%26epage%3D204%26doi%3D10.1002%2Fanie.201307387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span> <span> </span><span class="NLM_article-title">In situ selectivity profiling and crystal structure of SML-8–73–1, an active site inhibitor of oncogenic K-Ras G12C</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8895</span>– <span class="NLM_lpage">8900</span>, <span class="refDoi"> DOI: 10.1073/pnas.1404639111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.1404639111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=24889603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlKqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8895-8900&issue=24&author=J.+C.+Hunterauthor=D.+Gurbaniauthor=S.+B.+Ficarroauthor=M.+A.+Carrascoauthor=S.+M.+Limauthor=H.+G.+Choiauthor=T.+Xieauthor=J.+A.+Martoauthor=Z.+Chenauthor=N.+S.+Grayauthor=K.+D.+Westover&title=In+situ+selectivity+profiling+and+crystal+structure+of+SML-8%E2%80%9373%E2%80%931%2C+an+active+site+inhibitor+of+oncogenic+K-Ras+G12C&doi=10.1073%2Fpnas.1404639111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C</span></div><div class="casAuthors">Hunter, John C.; Gurbani, Deepak; Ficarro, Scott B.; Carrasco, Martin A.; Lim, Sang Min; Choi, Hwan Geun; Xie, Ting; Marto, Jarrod A.; Chen, Zhe; Gray, Nathanael S.; Westover, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8895-8900</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Directly targeting oncogenic V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras) with small-mol. inhibitors has historically been considered prohibitively challenging.  Recent reports of compds. that bind directly to the K-Ras G12C mutant suggest avenues to overcome key obstacles that stand in the way of developing such compds.  We aim to target the guanine nucleotide (GN)-binding pocket because the natural contents of this pocket dictate the signaling state of K-Ras.  Here, we characterize the irreversible inhibitor SML-8-73-1 (SML), which targets the GN-binding pocket of K-Ras G12C.  We report a high-resoln. x-ray crystal structure of G12C K-Ras bound to SML, revealing that the compd. binds in a manner similar to GDP, forming a covalent linkage with Cys-12.  The resulting conformation renders K-Ras in the open, inactive conformation, which is not predicted to assoc. productively with or activate downstream effectors.  Conservation anal. of the Ras family GN-binding pocket reveals variability in the side chains surrounding the active site and adjacent regions, esp. in the switch I region.  This variability may enable building specificity into new iterations of Ras and other GTPase inhibitors.  High-resoln. in situ chem. proteomic profiling of SML confirms that SML effectively discriminates between K-Ras G12C and other cellular GTP-binding proteins.  A biochem. assay provides addnl. evidence that SML is able to compete with millimolar concns. of GTP and GDP for the GN-binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphz2MYHd6_n7Vg90H21EOLACvtfcHk0lgIyM9jW2Qqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlKqsrc%253D&md5=e32ec21482b3aef278c23c83470a146c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1404639111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1404639111%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DJ.%2BC.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DCarrasco%26aufirst%3DM.%2BA.%26aulast%3DLim%26aufirst%3DS.%2BM.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26atitle%3DIn%2520situ%2520selectivity%2520profiling%2520and%2520crystal%2520structure%2520of%2520SML-8%25E2%2580%259373%25E2%2580%25931%252C%2520an%2520active%2520site%2520inhibitor%2520of%2520oncogenic%2520K-Ras%2520G12C%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D24%26spage%3D8895%26epage%3D8900%26doi%3D10.1073%2Fpnas.1404639111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taouji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevet, E.</span></span> <span> </span><span class="NLM_article-title">Current screens based on the AlphaScreen technology for deciphering cell signalling pathways</span>. <i>Curr. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.2174/138920209787847041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.2174%2F138920209787847041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=19794881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVCisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=93-101&issue=2&author=S.+Taoujiauthor=S.+Dahanauthor=R.+Boss%C3%A9author=E.+Chevet&title=Current+screens+based+on+the+AlphaScreen+technology+for+deciphering+cell+signalling+pathways&doi=10.2174%2F138920209787847041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Current screens based on the AlphaScreen technology for deciphering cell signalling pathways</span></div><div class="casAuthors">Taouji, Said; Dahan, Sophie; Bosse, Roger; Chevet, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Current Genomics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-101</span>CODEN:
                <span class="NLM_cas:coden">CGUEA8</span>;
        ISSN:<span class="NLM_cas:issn">1389-2029</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Global deciphering of signal transduction pathways represents a new challenge of the postgenomic era.  However, for the majority of these signaling pathways, the role(s), the function(s), and the interaction(s) of the signaling intermediates remain to be characterized in an integrated fashion.  The global mol. study of cell signaling pathways and networks consequently requires sensitive, robust technologies which may allow in addn. multi-parallel and high-throughput applications.  The Alphascreen technol., relying on a bead-based homogenous approach, constitutes a valuable tool to detect and quantify a wide range of signaling events such as enzymic activities or biomol. interactions.  In this article, the authors exhaustively review the literature and report the broad spectrum of Alphascreen-based applications in the study of signal transduction pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJIrb-Muqpz7Vg90H21EOLACvtfcHk0lj-LhES0T-fiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVCisLw%253D&md5=7ddc87469ce10b96f3eb0943cb2de73e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2174%2F138920209787847041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920209787847041%26sid%3Dliteratum%253Aachs%26aulast%3DTaouji%26aufirst%3DS.%26aulast%3DDahan%26aufirst%3DS.%26aulast%3DBoss%25C3%25A9%26aufirst%3DR.%26aulast%3DChevet%26aufirst%3DE.%26atitle%3DCurrent%2520screens%2520based%2520on%2520the%2520AlphaScreen%2520technology%2520for%2520deciphering%2520cell%2520signalling%2520pathways%26jtitle%3DCurr.%2520Genomics%26date%3D2009%26volume%3D10%26issue%3D2%26spage%3D93%26epage%3D101%26doi%3D10.2174%2F138920209787847041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manandhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Covalent guanosine mimetic inhibitors of G12C KRAS.</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyntrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=61-66&issue=1&author=Y.+Xiongauthor=J.+Luauthor=J.+Hunterauthor=L.+Liauthor=D.+Scottauthor=H.+G.+Choiauthor=S.+M.+Limauthor=A.+Manandharauthor=S.+Gondiauthor=T.+Sim&title=Covalent+guanosine+mimetic+inhibitors+of+G12C+KRAS.&doi=10.1021%2Facsmedchemlett.6b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Guanosine Mimetic Inhibitors of G12C KRAS</span></div><div class="casAuthors">Xiong, Yuan; Lu, Jia; Hunter, John; Li, Lianbo; Scott, David; Choi, Hwan Geun; Lim, Sang Min; Manandhar, Anuj; Gondi, Sudershan; Sim, Taebo; Westover, Kenneth D.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-66</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ras proteins are members of a large family of GTPase enzymes that are commonly mutated in cancer where they act as dominant oncogenes.  The authors previously developed an irreversible guanosine-derived inhibitor, SML-8-73-1, of mutant G12C RAS which forms a covalent bond with cysteine 12.  Here the authors report exploration of the structure-activity relationships (SAR) of hydrolytically stable analogs of SML-8-73-1 as covalent G12C KRAS inhibitors.  The authors report the discovery of difluoromethylene bisphosphonate analogs such as compd. I, which despite exhibiting reduced efficiency as covalent G12C KRAS inhibitors, remove the liability of the hydrolytic instability of the diphosphate moiety present in SML-8-73-1 and provide the foundation for development of prodrugs to facilitate cellular uptake.  The SAR and crystallog. results reaffirm the exquisite mol. recognition that exists in the diphosphate-region of RAS for guanosine nucleotides which must be considered in the design of nucleotide-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraZMoq5jUr_rVg90H21EOLACvtfcHk0lj-LhES0T-fiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyntrbF&md5=b36c23e91f8a3c3f30aa9819d931870f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00373%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DScott%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DLim%26aufirst%3DS.%2BM.%26aulast%3DManandhar%26aufirst%3DA.%26aulast%3DGondi%26aufirst%3DS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DCovalent%2520guanosine%2520mimetic%2520inhibitors%2520of%2520G12C%2520KRAS.%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D61%26epage%3D66%26doi%3D10.1021%2Facsmedchemlett.6b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeganathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goody, R. S.</span></span> <span> </span><span class="NLM_article-title">Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3687</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-03973-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41598-017-03973-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=28623374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3687&issue=1&author=M.+P.+M%C3%BCllerauthor=S.+Jeganathanauthor=A.+Heidrichauthor=J.+Camposauthor=R.+S.+Goody&title=Nucleotide+based+covalent+inhibitors+of+KRas+can+only+be+efficient+in+vivo+if+they+bind+reversibly+with+GTP-like+affinity&doi=10.1038%2Fs41598-017-03973-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-03973-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-03973-6%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BP.%26aulast%3DJeganathan%26aufirst%3DS.%26aulast%3DHeidrich%26aufirst%3DA.%26aulast%3DCampos%26aufirst%3DJ.%26aulast%3DGoody%26aufirst%3DR.%2BS.%26atitle%3DNucleotide%2520based%2520covalent%2520inhibitors%2520of%2520KRas%2520can%2520only%2520be%2520efficient%2520in%2520vivo%2520if%2520they%2520bind%2520reversibly%2520with%2520GTP-like%2520affinity%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D3687%26doi%3D10.1038%2Fs41598-017-03973-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>503</i></span> (<span class="NLM_issue">7477</span>),  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nature12796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnature12796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=24256730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2013&pages=548-551&issue=7477&author=J.+M.+Ostremauthor=U.+Petersauthor=M.+L.+Sosauthor=J.+A.+Wellsauthor=K.+M.+Shokat&title=K-Ras+%28G12C%29+inhibitors+allosterically+control+GTP+affinity+and+effector+interactions&doi=10.1038%2Fnature12796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</span></div><div class="casAuthors">Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L.; Wells, James A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">7477</span>),
    <span class="NLM_cas:pages">548-551</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally assocd. with poor response to std. therapies.  Efforts to target this oncogene directly have faced difficulties owing to its picomolar affinity for GTP/GDP and the absence of known allosteric regulatory sites.  Oncogenic mutations result in functional activation of Ras family proteins by impairing GTP hydrolysis.  With diminished regulation by GTPase activity, the nucleotide state of Ras becomes more dependent on relative nucleotide affinity and concn.  This gives GTP an advantage over GDP and increases the proportion of active GTP-bound Ras.  Here we report the development of small mols. that irreversibly bind to a common oncogenic mutant, K-Ras(G12C).  These compds. rely on the mutant cysteine for binding and therefore do not affect the wild-type protein.  Crystallog. studies reveal the formation of a new pocket that is not apparent in previous structures of Ras, beneath the effector binding switch-II region.  Binding of these inhibitors to K-Ras(G12C) disrupts both switch-I and switch-II, subverting the native nucleotide preference to favor GDP over GTP and impairing binding to Raf.  Our data provide structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokkgcVXuBn_rVg90H21EOLACvtfcHk0lg3Xnb-YkU2PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO&md5=27c1e7d8ef6b7e4b2919e9f00a073923</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnature12796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12796%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DK-Ras%2520%2528G12C%2529%2520inhibitors%2520allosterically%2520control%2520GTP%2520affinity%2520and%2520effector%2520interactions%26jtitle%3DNature%26date%3D2013%26volume%3D503%26issue%3D7477%26spage%3D548%26epage%3D551%26doi%3D10.1038%2Fnature12796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braisted, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raphael, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span> <span> </span><span class="NLM_article-title">Site-directed ligand discovery</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">9367</span>– <span class="NLM_lpage">9372</span>, <span class="refDoi"> DOI: 10.1073/pnas.97.17.9367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.97.17.9367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10944209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtVensr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=9367-9372&issue=17&author=D.+A.+Erlansonauthor=A.+C.+Braistedauthor=D.+R.+Raphaelauthor=M.+Randalauthor=R.+M.+Stroudauthor=E.+M.+Gordonauthor=J.+A.+Wells&title=Site-directed+ligand+discovery&doi=10.1073%2Fpnas.97.17.9367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Site-directed ligand discovery</span></div><div class="casAuthors">Erlanson, Daniel A.; Braisted, Andrew C.; Raphael, Darren R.; Randal, Mike; Stroud, Robert M.; Gordon, Eric M.; Wells, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9367-9372</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We report a strategy (called "tethering") to discover low mol. wt. ligands (≈250 Da) that bind weakly to targeted sites on proteins through an intermediary disulfide tether.  A native or engineered cysteine in a protein is allowed to react reversibly with a small library of disulfide-contg. mols. (≈1,200 compds.) at concns. typically used in drug screening (10 to 200 μM).  The cysteine-captured ligands, which are readily identified by MS, are among the most stable complexes, even though in the absence of the covalent tether the ligands may bind very weakly.  This method was applied to generate a potent inhibitor for thymidylate synthase, an essential enzyme in pyrimidine metab. with therapeutic applications in cancer and infectious diseases.  The affinity of the untethered ligand (Ki≈1 mM) was improved 3,000-fold by synthesis of a small set of analogs with the aid of crystallog. structures of the tethered complex.  Such site-directed ligand discovery allows one to nucleate drug design from a spatially targeted lead fragment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4pxPEoDE3FrVg90H21EOLACvtfcHk0lg3Xnb-YkU2PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtVensr8%253D&md5=fef57a0d21af9bc7f6f1f4bf8c023ae5</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.17.9367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.17.9367%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DBraisted%26aufirst%3DA.%2BC.%26aulast%3DRaphael%26aufirst%3DD.%2BR.%26aulast%3DRandal%26aufirst%3DM.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DGordon%26aufirst%3DE.%2BM.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26atitle%3DSite-directed%2520ligand%2520discovery%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26issue%3D17%26spage%3D9367%26epage%3D9372%26doi%3D10.1073%2Fpnas.97.17.9367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F2159-8290.CD-15-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26739882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=316-329&issue=3&author=M.+P.+Patricelliauthor=M.+R.+Janesauthor=L.-S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=L.+V.+Kesslerauthor=Y.+Chenauthor=J.+M.+Kucharskiauthor=J.+Fengauthor=T.+Ely&title=Selective+inhibition+of+oncogenic+KRAS+output+with+small+molecules+targeting+the+inactive+state&doi=10.1158%2F2159-8290.CD-15-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State</span></div><div class="casAuthors">Patricelli, Matthew P.; Janes, Matthew R.; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Kessler, Linda V.; Chen, Yuching; Kucharski, Jeff M.; Feng, Jun; Ely, Tess; Chen, Jeffrey H.; Firdaus, Sarah J.; Babbar, Anjali; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-329</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS gain-of-function mutations occur in approx. 30% of all human cancers.  Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered for cancers with KRAS mutations.  Here, we describe ARS-853, a selective, covalent inhibitor of KRASG12C that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.  Based on the rates of engagement and inhibition obsd. for ARS-853, along with a mutant-specific mass spectrometry-based assay for assessing KRAS activation status, we show that the nucleotide state of KRASG12C is in a state of dynamic flux that can be modulated by upstream signaling factors.  These studies provide convincing evidence that the KRASG12C mutation generates a "hyperexcitable" rather than a "statically active" state and that targeting the inactive, GDP-bound form is a promising approach for generating novel anti-RAS therapeutics.  Significance: A cell-active, mutant-specific, covalent inhibitor of KRASG12C is described that targets the GDP-bound, inactive state and prevents subsequent activation.  Using this novel compd., we demonstrate that KRASG12C oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJJA-9IIHeN7Vg90H21EOLACvtfcHk0lg3Xnb-YkU2PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D&md5=41db2f02006e8f0be7a9bb47354addcd</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1105%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DKessler%26aufirst%3DL.%2BV.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKucharski%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEly%26aufirst%3DT.%26atitle%3DSelective%2520inhibition%2520of%2520oncogenic%2520KRAS%2520output%2520with%2520small%2520molecules%2520targeting%2520the%2520inactive%2520state%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D3%26spage%3D316%26epage%3D329%26doi%3D10.1158%2F2159-8290.CD-15-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">The reactivity-driven biochemical mechanism of covalent KRAS G12C inhibitors</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0061-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41594-018-0061-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29760531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=454-462&issue=6&author=R.+Hansenauthor=U.+Petersauthor=A.+Babbarauthor=Y.+Chenauthor=J.+Fengauthor=M.+R.+Janesauthor=L.-S.+Liauthor=P.+Renauthor=Y.+Liuauthor=P.+P.+Zarrinkar&title=The+reactivity-driven+biochemical+mechanism+of+covalent+KRAS+G12C+inhibitors&doi=10.1038%2Fs41594-018-0061-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors</span></div><div class="casAuthors">Hansen, Rasmus; Peters, Ulf; Babbar, Anjali; Chen, Yuching; Feng, Jun; Janes, Matthew R.; Li, Lian-Sheng; Ren, Pingda; Liu, Yi; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">454-462</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Activating mutations in KRAS are among the most common tumor driver mutations.  Until recently, KRAS had been considered undruggable with small mols.; the discovery of the covalent KRASG12C inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals.  Although the biol. activity of these inhibitors has been described, the biochem. mechanism of how the compds. achieve potent inhibition remained incompletely understood.  We now show that the activity of ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the chem. reaction with Cys12 in human KRASG12C, while the reversible binding affinity is weak, in the hundreds of micromolar or higher range.  The mechanism resolves how an induced, shallow and dynamic pocket not expected to support high-affinity binding of small mols. can nevertheless be targeted with potent inhibitors and may be applicable to other targets conventionally considered undruggable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrya_A4ZYnOu7Vg90H21EOLACvtfcHk0lg3Xnb-YkU2PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7nL&md5=b3f9198f55998306f3b881c256be22a9</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0061-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0061-5%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DThe%2520reactivity-driven%2520biochemical%2520mechanism%2520of%2520covalent%2520KRAS%2520G12C%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D6%26spage%3D454%26epage%3D462%26doi%3D10.1038%2Fs41594-018-0061-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span> (<span class="NLM_issue">6273</span>),  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1126/science.aad6204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1126%2Fscience.aad6204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26841430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=604-608&issue=6273&author=P.+Litoauthor=M.+Solomonauthor=L.-S.+Liauthor=R.+Hansenauthor=N.+Rosen&title=Allele-specific+inhibitors+inactivate+mutant+KRAS+G12C+by+a+trapping+mechanism&doi=10.1126%2Fscience.aad6204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span></div><div class="casAuthors">Lito, Piro; Solomon, Martha; Li, Lian-Sheng; Hansen, Rasmus; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6273</span>),
    <span class="NLM_cas:pages">604-608</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">It is thought that KRAS oncoproteins are constitutively active because their guanosine triphosphatase (GTPase) activity is disabled.  Consequently, drugs targeting the inactive or GDP-bound conformation are not expected to be effective.  We describe a mechanism that enables such drugs to inhibit KRASG12C signaling and cancer cell growth.  Inhibition requires intact GTPase activity and occurs because drug-bound KRASG12C is insusceptible to nucleotide exchange factors and thus trapped in its inactive state.  Indeed, mutants completely lacking GTPase activity and those promoting exchange reduced the potency of the drug.  Suppressing nucleotide exchange activity downstream of various tyrosine kinases enhanced KRASG12C inhibition, whereas its potentiation had the opposite effect.  These findings reveal that KRASG12C undergoes nucleotide cycling in cancer cells and provide a basis for developing effective therapies to treat KRASG12C-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK3AbqEZO6k7Vg90H21EOLACvtfcHk0lj4Ja-T0EgQ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D&md5=22a47908ac0146822ecf19f5d0c952de</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad6204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad6204%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DAllele-specific%2520inhibitors%2520inactivate%2520mutant%2520KRAS%2520G12C%2520by%2520a%2520trapping%2520mechanism%26jtitle%3DScience%26date%3D2016%26volume%3D351%26issue%3D6273%26spage%3D604%26epage%3D608%26doi%3D10.1126%2Fscience.aad6204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdaus, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.cell.2018.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29373830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislyisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=578-589&issue=3&author=M.+R.+Janesauthor=J.+Zhangauthor=L.-S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=X.+Guoauthor=Y.+Chenauthor=A.+Babbarauthor=S.+J.+Firdausauthor=L.+Darjania&title=Targeting+KRAS+mutant+cancers+with+a+covalent+G12C-specific+inhibitor&doi=10.1016%2Fj.cell.2018.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor</span></div><div class="casAuthors">Janes, Matthew R.; Zhang, Jingchuan; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Guo, Xin; Chen, Yuching; Babbar, Anjali; Firdaus, Sarah J.; Darjania, Levan; Feng, Jun; Chen, Jeffrey H.; Li, Shuangwei; Li, Shisheng; Long, Yun O.; Thach, Carol; Liu, Yuan; Zarieh, Ata; Ely, Tess; Kucharski, Jeff M.; Kessler, Linda V.; Wu, Tao; Yu, Ke; Wang, Yi; Yao, Yvonne; Deng, Xiaohu; Zarrinkar, Patrick P.; Brehmer, Dirk; Dhanak, Dashyant; Lorenzi, Matthew V.; Hu-Lowe, Dana; Patricelli, Matthew P.; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">578-589.e17</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">KRASG12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys 12 in vicinity to an inducible allosteric switch II pocket (S-IIP).  Success of this approach requires active cycling of KRASG12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state.  This strategy proved feasible for inhibiting mutant KRAS in vitro; however, it is uncertain whether this approach would translate to in vivo.  Here, the authors describe structure-based design and identification of ARS-1620, a covalent compd. with high potency and selectivity for KRASG12C.  ARS-1620 achieves rapid and sustained in vivo target occupancy to induce tumor regression.  The authors use ARS-1620 to dissect oncogenic KRAS dependency and demonstrate that monolayer culture formats significantly underestimate KRAS dependency in vivo.  This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRASG12C-specific inhibitors with promising therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVmv4KAl4_dLVg90H21EOLACvtfcHk0lj4Ja-T0EgQ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislyisb8%253D&md5=d0883bde981b51e41a794179ffae87be</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DFirdaus%26aufirst%3DS.%2BJ.%26aulast%3DDarjania%26aufirst%3DL.%26atitle%3DTargeting%2520KRAS%2520mutant%2520cancers%2520with%2520a%2520covalent%2520G12C-specific%2520inhibitor%26jtitle%3DCell%26date%3D2018%26volume%3D172%26issue%3D3%26spage%3D578%26epage%3D589%26doi%3D10.1016%2Fj.cell.2018.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <i>Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists</i>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2013</span>; Vol.  <span class="NLM_volume">2</span>, pp  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">282</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2F9781118540398.ch7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=245-282&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery%3A+A+Guide+for+Medicinal+Chemists+and+Pharmacologists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2F9781118540398.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118540398.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery%253A%2520A%2520Guide%2520for%2520Medicinal%2520Chemists%2520and%2520Pharmacologists%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2013%26volume%3D2%26spage%3D245%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feru, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Potent and selective covalent quinazoline inhibitors of KRAS G12C</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1016</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.chembiol.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=28781124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yltr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1005-1016&issue=8&author=M.+Zengauthor=J.+Luauthor=L.+Liauthor=F.+Feruauthor=C.+Quanauthor=T.+W.+Geroauthor=S.+B.+Ficarroauthor=Y.+Xiongauthor=C.+Ambrogioauthor=R.+M.+Paranal&title=Potent+and+selective+covalent+quinazoline+inhibitors+of+KRAS+G12C&doi=10.1016%2Fj.chembiol.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective covalent quinazoline inhibitors of kras g12c</span></div><div class="casAuthors">Zeng, Mei; Lu, Jia; Li, Lianbo; Feru, Frederic; Quan, Chunshan; Gero, Thomas W.; Ficarro, Scott B.; Xiong, Yuan; Ambrogio, Chiara; Paranal, Raymond M.; Catalano, Marco; Shao, Jay; Wong, Kwok-Kin; Marto, Jarrod A.; Fischer, Eric S.; Janne, Pasi A.; Scott, David A.; Westover, Kenneth D.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1005-1016.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Targeted covalent small mols. have shown promise for cancers driven by KRAS G12C.  Allosteric compds. that access an inducible pocket formed by movement of a dynamic structural element in KRAS, switch II, have been reported, but these compds. require further optimization to enable their advancement into clin. development.  We demonstrate that covalent quinazoline-based switch II pocket (SIIP) compds. effectively suppress GTP loading of KRAS G12C, MAPK phosphorylation, and the growth of cancer cells harboring G12C.  Notably we find that adding an amide substituent to the quinazoline scaffold allows addnl. interactions with KRAS G12C, and remarkably increases the labeling efficiency, potency, and selectivity of KRAS G12C inhibitors.  Structural studies using X-ray crystallog. reveal a new conformation of SIIP and key interactions made by substituents located at the quinazoline 2-, 4-, and 7-positions.  Optimized lead compds. in the quinazoline series selectively inhibit KRAS G12C-dependent signaling and cancer cell growth at sub-micromolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxY0-7NkfIeLVg90H21EOLACvtfcHk0lj4Ja-T0EgQ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yltr3N&md5=e793972cb711c5a8c0db46d8288697af</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26atitle%3DPotent%2520and%2520selective%2520covalent%2520quinazoline%2520inhibitors%2520of%2520KRAS%2520G12C%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26issue%3D8%26spage%3D1005%26epage%3D1016%26doi%3D10.1016%2Fj.chembiol.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00382</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00382" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFagurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1230-1234&issue=12&author=J.+B.+Fellauthor=J.+P.+Fischerauthor=B.+R.+Baerauthor=J.+Ballardauthor=J.+F.+Blakeauthor=K.+Bouhanaauthor=B.+J.+Brandhuberauthor=D.+M.+Briereauthor=L.+E.+Burgessauthor=M.+R.+Burkard&title=Discovery+of+tetrahydropyridopyrimidines+as+irreversible+covalent+inhibitors+of+KRAS-G12C+with+in+vivo+activity&doi=10.1021%2Facsmedchemlett.8b00382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity</span></div><div class="casAuthors">Fell, Jay B.; Fischer, John P.; Baer, Brian R.; Ballard, Joshua; Blake, James F.; Bouhana, Karyn; Brandhuber, Barbara J.; Briere, David M.; Burgess, Laurence E.; Burkard, Michael R.; Chiang, Harrah; Chicarelli, Mark J.; Davidson, Kevin; Gaudino, John J.; Hallin, Jill; Hanson, Lauren; Hee, Kenneth; Hicken, Erik J.; Hinklin, Ronald J.; Marx, Matthew A.; Mejia, Macedonio J.; Olson, Peter; Savechenkov, Pavel; Sudhakar, Niranjan; Tang, Tony P.; Vigers, Guy P.; Zecca, Henry; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1230-1234</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly assocd. with poor prognosis and resistance to std. treatment.  The ability to effectively target and block the function of mutated KRAS has remained elusive despite decades of research.  Recent findings have demonstrated that directly targeting KRAS-G12C with electrophilic small mols. that covalently modify the mutated codon 12 cysteine is feasible.  We have discovered a series of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity.  The PK/PD and efficacy of compd. 13 will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGs80kLXd9TbVg90H21EOLACvtfcHk0lgYK28IpH31qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFagurfP&md5=f40ea2037c92c98dd84e907ebdcb4af6</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00382%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DBouhana%26aufirst%3DK.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DBurgess%26aufirst%3DL.%2BE.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520tetrahydropyridopyrimidines%2520as%2520irreversible%2520covalent%2520inhibitors%2520of%2520KRAS-G12C%2520with%2520in%2520vivo%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D12%26spage%3D1230%26epage%3D1234%26doi%3D10.1021%2Facsmedchemlett.8b00382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6679</span>– <span class="NLM_lpage">6693</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02052</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02052" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtlCntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6679-6693&issue=13&author=J.+B.+Fellauthor=J.+P.+Fischerauthor=B.+R.+Baerauthor=J.+F.+Blakeauthor=K.+Bouhanaauthor=D.+M.+Briereauthor=K.+D.+Brownauthor=L.+E.+Burgessauthor=A.+C.+Burnsauthor=M.+R.+Burkard&title=Identification+of+the+clinical+development+candidate+MRTX849%2C+a+covalent+KRASG12C+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Facs.jmedchem.9b02052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Fell, Jay B.; Fischer, John P.; Baer, Brian R.; Blake, James F.; Bouhana, Karyn; Briere, David M.; Brown, Karin D.; Burgess, Laurence E.; Burns, Aaron C.; Burkard, Michael R.; Chiang, Harrah; Chicarelli, Mark J.; Cook, Adam W.; Gaudino, John J.; Hallin, Jill; Hanson, Lauren; Hartley, Dylan P.; Hicken, Erik J.; Hingorani, Gary P.; Hinklin, Ronald J.; Mejia, Macedonio J.; Olson, Peter; Otten, Jennifer N.; Rhodes, Susan P.; Rodriguez, Martha E.; Savechenkov, Pavel; Smith, Darin J.; Sudhakar, Niranjan; Sullivan, Francis X.; Tang, Tony P.; Vigers, Guy P.; Wollenberg, Lance; Christensen, James G.; Marx, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6679-6693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence.  As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12.  Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metab. and excretion screening approach, analogs were synthesized to increase the potency and reduce metabolic liabilities of this series.  The discovery of the clin. development candidate MRTX849(I)as a potent, selective covalent inhibitor of KRASG12C is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqJvp87w62jbVg90H21EOLACvtfcHk0lgYK28IpH31qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtlCntb4%253D&md5=3618280ab3669376227ebd6932d18076</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02052%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DBouhana%26aufirst%3DK.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DBrown%26aufirst%3DK.%2BD.%26aulast%3DBurgess%26aufirst%3DL.%2BE.%26aulast%3DBurns%26aufirst%3DA.%2BC.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26atitle%3DIdentification%2520of%2520the%2520clinical%2520development%2520candidate%2520MRTX849%252C%2520a%2520covalent%2520KRASG12C%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D13%26spage%3D6679%26epage%3D6693%26doi%3D10.1021%2Facs.jmedchem.9b02052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">A Phase 1 Clinical Trial Evaluating the Pharmacokinetics (PK), Safety, and Clinical Activity of MRTX849, a Mutant-Selective Small Molecule KRAS G12C Inhibitor, in Advanced Solid Tumors</span>. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 28, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+A.+J%C3%A4nne&title=A+Phase+1+Clinical+Trial+Evaluating+the+Pharmacokinetics+%28PK%29%2C+Safety%2C+and+Clinical+Activity+of+MRTX849%2C+a+Mutant-Selective+Small+Molecule+KRAS+G12C+Inhibitor%2C+in+Advanced+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DA%2520Phase%25201%2520Clinical%2520Trial%2520Evaluating%2520the%2520Pharmacokinetics%2520%2528PK%2529%252C%2520Safety%252C%2520and%2520Clinical%2520Activity%2520of%2520MRTX849%252C%2520a%2520Mutant-Selective%2520Small%2520Molecule%2520KRAS%2520G12C%2520Inhibitor%252C%2520in%2520Advanced%2520Solid%2520Tumors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span>; <span class="NLM_string-name">Erlanson, D.</span>; <span class="NLM_string-name">Cancilla, M.</span></span> <span> </span><span class="NLM_article-title">Methods of Chemotype Evolution</span>. <span class="NLM_patent">US 10,107,798 B2</span>, October 23, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Hansen&author=D.+Erlanson&author=M.+Cancilla&title=Methods+of+Chemotype+Evolution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DS.%26atitle%3DMethods%2520of%2520Chemotype%2520Evolution%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achanta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvedson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campuzano, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingersoll, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(1-acryloylazetidin-3-yl)-2-(1<i>H</i>-indol-1-yl) acetamides as covalent inhibitors of KRASG12C</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1302</span>– <span class="NLM_lpage">1308</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2qs73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1302-1308&issue=9&author=Y.+Shinauthor=J.+W.+Jeongauthor=R.+P.+Wurzauthor=P.+Achantaauthor=T.+Arvedsonauthor=M.+D.+Bartbergerauthor=I.+D.+Campuzanoauthor=R.+Fuciniauthor=S.+K.+Hansenauthor=J.+Ingersoll&title=Discovery+of+N-%281-acryloylazetidin-3-yl%29-2-%281H-indol-1-yl%29+acetamides+as+covalent+inhibitors+of+KRASG12C&doi=10.1021%2Facsmedchemlett.9b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C</span></div><div class="casAuthors">Shin, Youngsook; Jeong, Joon Won; Wurz, Ryan P.; Achanta, Pragathi; Arvedson, Tara; Bartberger, Michael D.; Campuzano, Iain D. G.; Fucini, Ray; Hansen, Stig K.; Ingersoll, John; Iwig, Jeffrey S.; Lipford, J. Russell; Ma, Vu; Kopecky, David J.; McCarter, John; San Miguel, Tisha; Mohr, Christopher; Sabet, Sudi; Saiki, Anne Y.; Sawayama, Andrew; Sethofer, Steven; Tegley, Christopher M.; Volak, Laurie P.; Yang, Kevin; Lanman, Brian A.; Erlanson, Daniel A.; Cee, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1302-1308</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C.  KRAS regulates many cellular processes including proliferation, survival, and differentiation.  Point mutants of KRAS have long been known to be mol. drivers of cancer.  KRAS p.G12C, which occurs in approx. 14% of lung adenocarcinomas, 3-5% of colorectal cancers, and low levels in other solid tumors, represents an attractive therapeutic target for covalent inhibitors.  Herein, we disclose the discovery of a class of novel, potent, and selective covalent inhibitors of KRASG12C identified through a custom library synthesis and screening platform called Chemotype Evolution and structure-based design.  Identification of a hidden surface groove bordered by H95/Y96/Q99 side chains was key to the optimization of this class of mols.  Best-in-series exemplars exhibit a rapid covalent reaction with cysteine 12 of GDP-KRASG12C with submicromolar inhibition of downstream signaling in a KRASG12C-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSOlO88sogkLVg90H21EOLACvtfcHk0lggPO_hQcLpMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2qs73P&md5=ec097c0fb0e018a2d86f024117f8008f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00258%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DY.%26aulast%3DJeong%26aufirst%3DJ.%2BW.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DAchanta%26aufirst%3DP.%26aulast%3DArvedson%26aufirst%3DT.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCampuzano%26aufirst%3DI.%2BD.%26aulast%3DFucini%26aufirst%3DR.%26aulast%3DHansen%26aufirst%3DS.%2BK.%26aulast%3DIngersoll%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520N-%25281-acryloylazetidin-3-yl%2529-2-%25281H-indol-1-yl%2529%2520acetamides%2520as%2520covalent%2520inhibitors%2520of%2520KRASG12C%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D9%26spage%3D1302%26epage%3D1308%26doi%3D10.1021%2Facsmedchemlett.9b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amegadzie, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01180</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01180" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGitrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=52-65&author=B.+A.+Lanmanauthor=J.+R.+Allenauthor=J.+G.+Allenauthor=A.+K.+Amegadzieauthor=K.+S.+Ashtonauthor=S.+K.+Bookerauthor=J.+J.+Chenauthor=N.+Chenauthor=M.+J.+Frohnauthor=G.+Goodman&title=Discovery+of+a+covalent+inhibitor+of+KRASG12C+%28AMG+510%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.9b01180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Lanman, Brian A.; Allen, Jennifer R.; Allen, John G.; Amegadzie, Albert K.; Ashton, Kate S.; Booker, Shon K.; Chen, Jian Jeffrey; Chen, Ning; Frohn, Michael J.; Goodman, Guy; Kopecky, David J.; Liu, Longbin; Lopez, Patricia; Low, Jonathan D.; Ma, Vu; Minatti, Ana E.; Nguyen, Thomas T.; Nishimura, Nobuko; Pickrell, Alexander J.; Reed, Anthony B.; Shin, Youngsook; Siegmund, Aaron C.; Tamayo, Nuria A.; Tegley, Christopher M.; Walton, Mary C.; Wang, Hui-Ling; Wurz, Ryan P.; Xue, May; Yang, Kevin C.; Achanta, Pragathi; Bartberger, Michael D.; Canon, Jude; Hollis, L. Steven; McCarter, John D.; Mohr, Christopher; Rex, Karen; Saiki, Anne Y.; San Miguel, Tisha; Volak, Laurie P.; Wang, Kevin H.; Whittington, Douglas A.; Zech, Stephan G.; Lipford, J. Russell; Cee, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-65</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRASG12C has emerged as a promising target in the treatment of solid tumors.  Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-"undruggable" target; however clin. viable inhibitors have yet to be identified.  Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRASG12C to identify inhibitors suitable for clin. development.  Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond.  Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRASG12C inhibitor currently in phase I clin. trials (NCT03600883).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGeWqRRXX6lbVg90H21EOLACvtfcHk0lgIz08krGF_vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGitrrK&md5=d973189be70bb913020edb4989f6ba7d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01180%26sid%3Dliteratum%253Aachs%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DAmegadzie%26aufirst%3DA.%2BK.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DFrohn%26aufirst%3DM.%2BJ.%26aulast%3DGoodman%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520covalent%2520inhibitor%2520of%2520KRASG12C%2520%2528AMG%2520510%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D52%26epage%3D65%26doi%3D10.1021%2Facs.jmedchem.9b01180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, P. K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngang, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3003</span>, <span class="refDoi"> DOI: 10.1200/JCO.2019.37.15_suppl.3003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1200%2FJCO.2019.37.15_suppl.3003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=3003&author=M.+Fakihauthor=B.+O%E2%80%99Neilauthor=T.+J.+Priceauthor=G.+S.+Falchookauthor=J.+Desaiauthor=J.+Kuoauthor=R.+Govindanauthor=E.+Rasmussenauthor=P.+K.+H.+Morrowauthor=J.+Ngang&title=Phase+1+study+evaluating+the+safety%2C+tolerability%2C+pharmacokinetics+%28PK%29%2C+and+efficacy+of+AMG+510%2C+a+novel+small+molecule+KRASG12C+inhibitor%2C+in+advanced+solid+tumors&doi=10.1200%2FJCO.2019.37.15_suppl.3003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.3003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.3003%26sid%3Dliteratum%253Aachs%26aulast%3DFakih%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DJ.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DRasmussen%26aufirst%3DE.%26aulast%3DMorrow%26aufirst%3DP.%2BK.%2BH.%26aulast%3DNgang%26aufirst%3DJ.%26atitle%3DPhase%25201%2520study%2520evaluating%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%2520%2528PK%2529%252C%2520and%2520efficacy%2520of%2520AMG%2520510%252C%2520a%2520novel%2520small%2520molecule%2520KRASG12C%2520inhibitor%252C%2520in%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D3003%26doi%3D10.1200%2FJCO.2019.37.15_suppl.3003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekharan, S.</span></span> <span> </span><span class="NLM_article-title">Structure-based macrocycle design in small-molecule drug discovery and simple metrics to identify opportunities for macrocyclization of small-molecule ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6843</span>– <span class="NLM_lpage">6853</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01985</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01985" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks1yktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6843-6853&issue=15&author=M.+D.+Cummingsauthor=S.+Sekharan&title=Structure-based+macrocycle+design+in+small-molecule+drug+discovery+and+simple+metrics+to+identify+opportunities+for+macrocyclization+of+small-molecule+ligands&doi=10.1021%2Facs.jmedchem.8b01985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands</span></div><div class="casAuthors">Cummings, Maxwell D.; Sekharan, Sivakumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6843-6853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Interest is growing in the use of macrocycles in pharmaceutical discovery.  Macrocylization may provide a gateway to an expanded chem. space for small-mol. drug discovery, and this could be beneficial in prosecuting difficult targets, e.g., protein-protein interactions.  Most, but not all, macrocycle drugs are derived from natural products.  Studies on synthetic drug-like small-mol. macrocycles are limited, and our current understanding of macrocycle drugs is similarly limited.  Following some background discussion, we review several examples of the structure-based design of synthetic macrocycles.  Our opinion is that in conformationally suitable systems macrocycles are an analog class worthy of consideration.  We then summarize an approach for the initial evaluation of mols. as candidates for macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCAQg11Q6Hk7Vg90H21EOLACvtfcHk0lgIz08krGF_vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks1yktb4%253D&md5=32ac78d837075171d19c4cea694dce3f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01985%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DSekharan%26aufirst%3DS.%26atitle%3DStructure-based%2520macrocycle%2520design%2520in%2520small-molecule%2520drug%2520discovery%2520and%2520simple%2520metrics%2520to%2520identify%2520opportunities%2520for%2520macrocyclization%2520of%2520small-molecule%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D6843%26epage%3D6853%26doi%3D10.1021%2Facs.jmedchem.8b01985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRASG12C</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4468</span>– <span class="NLM_lpage">4483</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01720</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01720" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitleqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4468-4483&issue=9&author=J.+G.+Kettleauthor=S.+K.+Bagalauthor=S.+Bickertonauthor=M.+S.+Bodnarchukauthor=J.+Breedauthor=R.+J.+Carbajoauthor=D.+J.+Cassarauthor=A.+Chakrabortyauthor=S.+Cosulichauthor=I.+Cumming&title=Structure-based+design+and+pharmacokinetic+optimization+of+covalent+allosteric+inhibitors+of+the+mutant+GTPase+KRASG12C&doi=10.1021%2Facs.jmedchem.9b01720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C</span></div><div class="casAuthors">Kettle, Jason G.; Bagal, Sharan K.; Bickerton, Sue; Bodnarchuk, Michael S.; Breed, Jason; Carbajo, Rodrigo J.; Cassar, Doyle J.; Chakraborty, Atanu; Cosulich, Sabina; Cumming, Iain; Davies, Michael; Eatherton, Andrew; Evans, Laura; Feron, Lyman; Fillery, Shaun; Gleave, Emma S.; Goldberg, Frederick W.; Harlfinger, Stephanie; Hanson, Lyndsey; Howard, Martin; Howells, Rachel; Jackson, Anne; Kemmitt, Paul; Kingston, Jennifer K.; Lamont, Scott; Lewis, Hilary J.; Li, Songlei; Liu, Libin; Ogg, Derek; Phillips, Christopher; Polanski, Radek; Robb, Graeme; Robinson, David; Ross, Sarah; Smith, James M.; Tonge, Michael; Whiteley, Rebecca; Yang, Junsheng; Zhang, Longfei; Zhao, Xiliang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4468-4483</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia.  The KRASG12C mutant represents an "Achilles heel" and has recently yielded to covalent targeting with small mols. that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state.  A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification.  Subsequent introduction of a key Me group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopBW-lAYRSirVg90H21EOLACvtfcHk0lgIz08krGF_vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitleqsbg%253D&md5=510af250cf2bbde4c9f18f9735df9eb1</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01720%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBickerton%26aufirst%3DS.%26aulast%3DBodnarchuk%26aufirst%3DM.%2BS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCassar%26aufirst%3DD.%2BJ.%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DCumming%26aufirst%3DI.%26atitle%3DStructure-based%2520design%2520and%2520pharmacokinetic%2520optimization%2520of%2520covalent%2520allosteric%2520inhibitors%2520of%2520the%2520mutant%2520GTPase%2520KRASG12C%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D9%26spage%3D4468%26epage%3D4483%26doi%3D10.1021%2Facs.jmedchem.9b01720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downward, J.</span></span> <span> </span><span class="NLM_article-title">RAS’s cloak of invincibility slips at last?</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.ccr.2013.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=24434204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=5-6&issue=1&author=J.+Downward&title=RAS%E2%80%99s+cloak+of+invincibility+slips+at+last%3F&doi=10.1016%2Fj.ccr.2013.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">RAS's Cloak of Invincibility Slips at Last?</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-6</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  KRAS is the most frequently activated oncogene in human cancer, but it has, so far, shrugged off all attempts to inhibit its function directly.  However, a recent report provides an entirely new approach to blocking mutant KRAS with small mols. and has the added benefit of sparing the wild-type protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEnsg96oBiOrVg90H21EOLACvtfcHk0lhw33rzVi-21w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSqtbk%253D&md5=96f7bbbd41c48f68bc342ba12eda999a</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DRAS%25E2%2580%2599s%2520cloak%2520of%2520invincibility%2520slips%2520at%2520last%253F%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D25%26issue%3D1%26spage%3D5%26epage%3D6%26doi%3D10.1016%2Fj.ccr.2013.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrenton, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauber, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5299</span>– <span class="NLM_lpage">5304</span>, <span class="refDoi"> DOI: 10.1073/pnas.1116510109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.1116510109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=22431598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=5299-5304&issue=14&author=T.+Maurerauthor=L.+S.+Garrentonauthor=A.+Ohauthor=K.+Pittsauthor=D.+J.+Andersonauthor=N.+J.+Skeltonauthor=B.+P.+Fauberauthor=B.+Panauthor=S.+Malekauthor=D.+Stokoe&title=Small-molecule+ligands+bind+to+a+distinct+pocket+in+Ras+and+inhibit+SOS-mediated+nucleotide+exchange+activity&doi=10.1073%2Fpnas.1116510109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity</span></div><div class="casAuthors">Maurer, Till; Garrenton, Lindsay S.; Oh, Angela; Pitts, Keith; Anderson, Daniel J.; Skelton, Nicholas J.; Fauber, Benjamin P.; Pan, Borlan; Malek, Shiva; Stokoe, David; Ludlam, Mary J. C.; Bowman, Krista K.; Wu, Jiansheng; Giannetti, Anthony M.; Starovasnik, Melissa A.; Mellman, Ira; Jackson, Peter K.; Rudolph, Joachim; Wang, Weiru; Fang, Guowei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5299-5304, S5299/1-S5299/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The Ras gene is frequently mutated in cancer, and mutant Ras drives tumorigenesis.  Although Ras is a central oncogene, small mols. that bind to Ras in a well-defined manner and exert inhibitory effects have not been uncovered to date.  Through an NMR-based fragment screen, we identified a group of small mols. that all bind to a common site on Ras.  High-resoln. cocrystal structures delineated a unique ligand-binding pocket on the Ras protein that is adjacent to the switch I/II regions and can be expanded upon compd. binding.  Structure anal. predicts that compd.-binding interferes with the Ras/SOS interactions.  Indeed, selected compds. inhibit SOS-mediated nucleotide exchange and prevent Ras activation by blocking the formation of intermediates of the exchange reaction.  The discovery of a small-mol. binding pocket on Ras with functional significance provides a new direction in the search of therapeutically effective inhibitors of the Ras oncoprotein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXIzMe7yBqrVg90H21EOLACvtfcHk0lhw33rzVi-21w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOjsrc%253D&md5=a7210cad45154c42eb2a1faeabf88c20</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1116510109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1116510109%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DGarrenton%26aufirst%3DL.%2BS.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DFauber%26aufirst%3DB.%2BP.%26aulast%3DPan%26aufirst%3DB.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DStokoe%26aufirst%3DD.%26atitle%3DSmall-molecule%2520ligands%2520bind%2520to%2520a%2520distinct%2520pocket%2520in%2520Ras%2520and%2520inhibit%2520SOS-mediated%2520nucleotide%2520exchange%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D14%26spage%3D5299%26epage%3D5304%26doi%3D10.1073%2Fpnas.1116510109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bos, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span> <span> </span><span class="NLM_article-title">GEFs and GAPs: Critical elements in the control of small G proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.cell.2007.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=17540168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsl2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=865-877&issue=5&author=J.+L.+Bosauthor=H.+Rehmannauthor=A.+Wittinghofer&title=GEFs+and+GAPs%3A+Critical+elements+in+the+control+of+small+G+proteins&doi=10.1016%2Fj.cell.2007.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">GEFs and GAPs: critical elements in the control of small G proteins</span></div><div class="casAuthors">Bos, Johannes L.; Rehmann, Holger; Wittinghofer, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">865-877</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) regulate the activity of small guanine nucleotide-binding (G) proteins to control cellular functions.  In general, GEFs turn on signaling by catalyzing the exchange from G-protein-bound GDP to GTP, whereas GAPs terminate signaling by inducing GTP hydrolysis.  GEFs and GAPs are multidomain proteins that are regulated by extracellular signals and localized cues that control cellular events in time and space.  Recent evidence suggests that these proteins may be potential therapeutic targets for developing drugs to treat various diseases, including cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob9D00HUjUuLVg90H21EOLACvtfcHk0lhw33rzVi-21w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsl2qsLw%253D&md5=4e65294b82df5f95eb17ebe1d2c3dec1</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DBos%26aufirst%3DJ.%2BL.%26aulast%3DRehmann%26aufirst%3DH.%26aulast%3DWittinghofer%26aufirst%3DA.%26atitle%3DGEFs%2520and%2520GAPs%253A%2520Critical%2520elements%2520in%2520the%2520control%2520of%2520small%2520G%2520proteins%26jtitle%3DCell%26date%3D2007%26volume%3D129%26issue%3D5%26spage%3D865%26epage%3D877%26doi%3D10.1016%2Fj.cell.2007.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boriack-Sjodin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margarit, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">The structural basis of the activation of Ras by Sos</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>394</i></span> (<span class="NLM_issue">6691</span>),  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/28548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2F28548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9690470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK1cXkvFKnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=1998&pages=337-343&issue=6691&author=P.+A.+Boriack-Sjodinauthor=S.+M.+Margaritauthor=D.+Bar-Sagiauthor=J.+Kuriyan&title=The+structural+basis+of+the+activation+of+Ras+by+Sos&doi=10.1038%2F28548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis of the activation of Ras by Sos</span></div><div class="casAuthors">Boriack-Sjodin, P. Ann; Margarit, S. Mariana; Bar-Sagi, Dafna; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">6691</span>),
    <span class="NLM_cas:pages">337-343</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The crystal structure of human H-Ras complexed with the Ras guanine-nucleotide-exchange-factor region of the Son of sevenless (Sos) protein has been detd. at 2.8 Å resoln.  The normally tight interaction of nucleotides with Ras is disrupted by Sos in two ways.  First, the insertion into Ras of an α-helix from Sos results in the displacement of the Switch 1 region of Ras, opening up the nucleotide-binding site.  Second, side chains presented by this helix and by a distorted conformation of the Switch 2 region of Ras alter the chem. environment of the binding site for the phosphate groups of the nucleotide and the assocd. magnesium in, so that their binding is no longer favored.  Sos does not impede the binding sites for the base and the ribose of GTP or GDP, so the Ras-Sos complex adopts a structure that allows nucleotide release and rebinding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZY4Ffb8--JbVg90H21EOLACvtfcHk0li9QQbMK9dT0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvFKnsLs%253D&md5=1b0a7879011c1fc1148e7f870e0ded11</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2F28548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F28548%26sid%3Dliteratum%253Aachs%26aulast%3DBoriack-Sjodin%26aufirst%3DP.%2BA.%26aulast%3DMargarit%26aufirst%3DS.%2BM.%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DThe%2520structural%2520basis%2520of%2520the%2520activation%2520of%2520Ras%2520by%2520Sos%26jtitle%3DNature%26date%3D1998%26volume%3D394%26issue%3D6691%26spage%3D337%26epage%3D343%26doi%3D10.1038%2F28548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olejniczak, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossanese, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">6140</span>– <span class="NLM_lpage">6143</span>, <span class="refDoi"> DOI: 10.1002/anie.201201358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fanie.201201358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1entr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=6140-6143&issue=25&author=Q.+Sunauthor=J.+P.+Burkeauthor=J.+Phanauthor=M.+C.+Burnsauthor=E.+T.+Olejniczakauthor=A.+G.+Watersonauthor=T.+Leeauthor=O.+W.+Rossaneseauthor=S.+W.+Fesik&title=Discovery+of+small+molecules+that+bind+to+K-Ras+and+inhibit+Sos-mediated+activation&doi=10.1002%2Fanie.201201358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation</span></div><div class="casAuthors">Sun, Qi; Burke, Jason P.; Phan, Jason; Burns, Michael C.; Olejniczak, Edward T.; Waterson, Alex G.; Lee, Taekyu; Rossanese, Olivia W.; Fesik, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6140-6143, S6140/1-S6140/17</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">K-Ras inhibition represents an attractive therapeutic strategy for many cancers.  We report on the discovery of novel small mols. that bind directly to K-Ras between switch I and switch II and inhibit Sos-catalyzed K-Ras activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy5Cx7BSO1pLVg90H21EOLACvtfcHk0li9QQbMK9dT0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1entr4%253D&md5=7d579523462aaf7eac1890643f91fab3</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fanie.201201358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201201358%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DBurke%26aufirst%3DJ.%2BP.%26aulast%3DPhan%26aufirst%3DJ.%26aulast%3DBurns%26aufirst%3DM.%2BC.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520small%2520molecules%2520that%2520bind%2520to%2520K-Ras%2520and%2520inhibit%2520Sos-mediated%2520activation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26issue%3D25%26spage%3D6140%26epage%3D6143%26doi%3D10.1002%2Fanie.201201358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmachl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantoulidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Drugging an undruggable pocket on KRAS</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">15823</span>– <span class="NLM_lpage">15829</span>, <span class="refDoi"> DOI: 10.1073/pnas.1904529116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.1904529116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31332011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFChs7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=15823-15829&issue=32&author=D.+Kesslerauthor=M.+Gmachlauthor=A.+Mantoulidisauthor=L.+J.+Martinauthor=A.+Zoephelauthor=M.+Mayerauthor=A.+Gollnerauthor=D.+Coviniauthor=S.+Fischerauthor=T.+Gerstberger&title=Drugging+an+undruggable+pocket+on+KRAS&doi=10.1073%2Fpnas.1904529116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging an undruggable pocket on KRAS</span></div><div class="casAuthors">Kessler, Dirk; Gmachl, Michael; Mantoulidis, Andreas; Martin, Laetitia J.; Zoephel, Andreas; Mayer, Moriz; Gollner, Andreas; Covini, David; Fischer, Silke; Gerstberger, Thomas; Gmaschitz, Teresa; Goodwin, Craig; Greb, Peter; Haring, Daniela; Hela, Wolfgang; Hoffmann, Johann; Karolyi-Oezguer, Jale; Knesl, Petr; Kornigg, Stefan; Koegl, Manfred; Kousek, Roland; Lamarre, Lyne; Moser, Franziska; Munico-Martinez, Silvia; Peinsipp, Christoph; Phan, Jason; Rinnenthal, Jorg; Sai, Jiqing; Salamon, Christian; Scherbantin, Yvonne; Schipany, Katharina; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Siszler, Gabriella; Sun, Qi; Waterson, Alex; Wolkerstorfer, Bernhard; Zeeb, Markus; Pearson, Mark; Fesik, Stephen W.; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">15823-15829</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">(Imidazolylmethylindolylmethylaminomethyl)indolyl hydroxyisoindolone I, an inhibitor of both the active and inactive forms of KRAS, was discovered using fragment-based screening.  I bound to KRAS in a pocket between switches I and II of KRAS, blocking all GEF, GAP, and effector interactions with KRAS and thus inhibiting downstream signaling; I inhibited KRAS mutant cells at low micromolar concns.  Uniformly 15N-labeled KRAS bound to the stable GTP analog GCP was prepd. with yields of 10 mg/L for use in crystallog. of KRAS-inhibitor complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaMeFg74p2-rVg90H21EOLACvtfcHk0li9QQbMK9dT0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFChs7jJ&md5=ebf443050cb2ce6cbeec1e40084129d0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1904529116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1904529116%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DD.%26aulast%3DGmachl%26aufirst%3DM.%26aulast%3DMantoulidis%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DL.%2BJ.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DGollner%26aufirst%3DA.%26aulast%3DCovini%26aufirst%3DD.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DGerstberger%26aufirst%3DT.%26atitle%3DDrugging%2520an%2520undruggable%2520pocket%2520on%2520KRAS%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26issue%3D32%26spage%3D15823%26epage%3D15829%26doi%3D10.1073%2Fpnas.1904529116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fetics, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guterres, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.str.2014.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=25684575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=505-516&issue=3&author=S.+K.+Feticsauthor=H.+Guterresauthor=B.+M.+Kearneyauthor=G.+Buhrmanauthor=B.+Maauthor=R.+Nussinovauthor=C.+Mattos&title=Allosteric+effects+of+the+oncogenic+RasQ61L+mutant+on+Raf-RBD&doi=10.1016%2Fj.str.2014.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Effects of the Oncogenic RasQ61L Mutant on Raf-RBD</span></div><div class="casAuthors">Fetics, Susan K.; Guterres, Hugo; Kearney, Bradley M.; Buhrman, Greg; Ma, Buyong; Nussinov, Ruth; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">505-516</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Ras/Raf/MEK/ERK signal transduction pathway is a major regulator of cell proliferation activated by Ras-guanosine triphosphate (GTP).  The oncogenic mutant RasQ61L is not able to hydrolyze GTP in the presence of Raf and thus is a constitutive activator of this mitogenic pathway.  The Ras/Raf interaction is essential for the activation of the Raf kinase domain through a currently unknown mechanism.  We present the crystal structures of the Ras-GppNHp/Raf-RBD and RasQ61L-GppNHp/Raf-RBD complexes, which, in combination with MD simulations, reveal differences in allosteric interactions leading from the Ras/Raf interface to the Ras calcium-binding site and to the remote Raf-RBD loop L4.  In the presence of Raf, the RasQ61L mutant has a rigid switch II relative to the wild-type and increased flexibility at the interface with switch I, which propagates across Raf-RBD.  We show that in addn. to local perturbations on Ras, RasQ61L has substantial long-range effects on the Ras allosteric lobe and on Raf-RBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_0AG0DEzRLVg90H21EOLACvtfcHk0li9QQbMK9dT0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSjt7c%253D&md5=bcfe99bb008e13f00c7f970d9f86c48b</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DFetics%26aufirst%3DS.%2BK.%26aulast%3DGuterres%26aufirst%3DH.%26aulast%3DKearney%26aufirst%3DB.%2BM.%26aulast%3DBuhrman%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DAllosteric%2520effects%2520of%2520the%2520oncogenic%2520RasQ61L%2520mutant%2520on%2520Raf-RBD%26jtitle%3DStructure%26date%3D2015%26volume%3D23%26issue%3D3%26spage%3D505%26epage%3D516%26doi%3D10.1016%2Fj.str.2014.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheffzek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmüller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lautwein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span> <span> </span><span class="NLM_article-title">The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">5324</span>),  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1126/science.277.5324.333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1126%2Fscience.277.5324.333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9219684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2sXkvVelsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=333-8&issue=5324&author=K.+Scheffzekauthor=M.+R.+Ahmadianauthor=W.+Kabschauthor=L.+Wiesm%C3%BCllerauthor=A.+Lautweinauthor=F.+Schmitzauthor=A.+Wittinghofer&title=The+Ras-RasGAP+complex%3A+structural+basis+for+GTPase+activation+and+its+loss+in+oncogenic+Ras+mutants&doi=10.1126%2Fscience.277.5324.333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants</span></div><div class="casAuthors">Scheffzek, Klaus; Ahmadian, Mohammad Reza; Kabsch, Wolfgang; Wiesmuller, Lisa; Lautwein, Alfred; Schmitz, Frank; Wittinghofer, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5324</span>),
    <span class="NLM_cas:pages">333-338</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120GAP (GAP-334) in the presence of aluminum fluoride was solved at a resoln. of 2.5 angstroms.  The structure shows the partly hydrophilic and partly hydrophobic nature of the communication between the two mols., which explains the sensitivity of the interaction toward both salts and lipids.  An arginine side chain (arginine-789) of GAP-334 is supplied into the active site of Ras to neutralize developing charges in the transition state.  The switch II region of Ras is stabilized by GAP-334, thus allowing glutamine-61 of Ras, mutation of which activates the oncogenic potential, to participate in catalysis.  The structural arrangement in the active site is consistent with a mostly associative mechanism of phosphoryl transfer and provides an explanation for the activation of Ras by glycine-12 and glutamine-61 mutations.  Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of GAP-334 and glutamine-61 of Ras, and even its mutation to alanine would disturb the arrangements of residues in the transition state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnMHwqUOucX7Vg90H21EOLACvtfcHk0ljX_MBDZ2uUZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkvVelsr8%253D&md5=95f61d57ccd837d06afc18636de7f123</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5324.333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5324.333%26sid%3Dliteratum%253Aachs%26aulast%3DScheffzek%26aufirst%3DK.%26aulast%3DAhmadian%26aufirst%3DM.%2BR.%26aulast%3DKabsch%26aufirst%3DW.%26aulast%3DWiesm%25C3%25BCller%26aufirst%3DL.%26aulast%3DLautwein%26aufirst%3DA.%26aulast%3DSchmitz%26aufirst%3DF.%26aulast%3DWittinghofer%26aufirst%3DA.%26atitle%3DThe%2520Ras-RasGAP%2520complex%253A%2520structural%2520basis%2520for%2520GTPase%2520activation%2520and%2520its%2520loss%2520in%2520oncogenic%2520Ras%2520mutants%26jtitle%3DScience%26date%3D1997%26volume%3D277%26issue%3D5324%26spage%3D333%26epage%3D8%26doi%3D10.1126%2Fscience.277.5324.333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quevedo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Migoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bery, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bataille, C. J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulmin, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors of Ras-effector protein interactions derived using an intracellular antibody fragment</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3169</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-05707-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41467-018-05707-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30093669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ms12mtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3169&issue=1&author=C.+E.+Quevedoauthor=A.+Cruz-Migoniauthor=N.+Beryauthor=A.+Millerauthor=T.+Tanakaauthor=D.+Petchauthor=C.+J.+R.+Batailleauthor=L.+Y.+W.+Leeauthor=P.+S.+Fallonauthor=H.+Tulmin&title=Small+molecule+inhibitors+of+Ras-effector+protein+interactions+derived+using+an+intracellular+antibody+fragment&doi=10.1038%2Fs41467-018-05707-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment</span></div><div class="casAuthors">Quevedo Camilo E; Cruz-Migoni Abimael; Bery Nicolas; Miller Ami; Tulmin Hanna; Ehebauer Matthias T; Rabbitts Terence H; Cruz-Migoni Abimael; Fernandez-Fuentes Narcis; Carr Stephen B; Phillips Simon E V; Tanaka Tomoyuki; Petch Donna; Tanaka Tomoyuki; Bataille Carole J R; Russell Angela J; Lee Lydia Y W; Fallon Phillip S; Tulmin Hanna; Ehebauer Matthias T; Fernandez-Fuentes Narcis; Carr Stephen B; Phillips Simon E V</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3169</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered unsuitable for PPI inhibition.  A potential solution to these problems is to select intracellular antibody fragments to block PPIs, use these antibody fragments for target validation in disease models and finally derive small molecules overlapping the antibody-binding site.  Here, we explore this strategy using an anti-mutant RAS antibody fragment as a competitor in a small-molecule library screen for identifying RAS-binding compounds.  The initial hits are optimized by structure-based design, resulting in potent RAS-binding compounds that interact with RAS inside the cells, prevent RAS-effector interactions and inhibit endogenous RAS-dependent signalling.  Our results may aid RAS-dependent cancer drug development and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIUnXfwZaCRvxQvRxYU81tfW6udTcc2eZI7OWwJBHZ77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ms12mtQ%253D%253D&md5=79679120c60be8cd9be9fbbfe0c9fdb6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05707-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05707-2%26sid%3Dliteratum%253Aachs%26aulast%3DQuevedo%26aufirst%3DC.%2BE.%26aulast%3DCruz-Migoni%26aufirst%3DA.%26aulast%3DBery%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DPetch%26aufirst%3DD.%26aulast%3DBataille%26aufirst%3DC.%2BJ.%2BR.%26aulast%3DLee%26aufirst%3DL.%2BY.%2BW.%26aulast%3DFallon%26aufirst%3DP.%2BS.%26aulast%3DTulmin%26aufirst%3DH.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520Ras-effector%2520protein%2520interactions%2520derived%2520using%2520an%2520intracellular%2520antibody%2520fragment%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D3169%26doi%3D10.1038%2Fs41467-018-05707-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Migoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quevedo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bataille, C. J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bery, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, S. E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbitts, T. H.</span></span> <span> </span><span class="NLM_article-title">Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2545</span>– <span class="NLM_lpage">2550</span>, <span class="refDoi"> DOI: 10.1073/pnas.1811360116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.1811360116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30683716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVajsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=2545-2550&issue=7&author=A.+Cruz-Migoniauthor=P.+Canningauthor=C.+E.+Quevedoauthor=C.+J.+R.+Batailleauthor=N.+Beryauthor=A.+Millerauthor=A.+J.+Russellauthor=S.+E.+V.+Phillipsauthor=S.+B.+Carrauthor=T.+H.+Rabbitts&title=Structure-based+development+of+new+RAS-effector+inhibitors+from+a+combination+of+active+and+inactive+RAS-binding+compounds&doi=10.1073%2Fpnas.1811360116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds</span></div><div class="casAuthors">Cruz-Migoni, Abimael; Canning, Peter; Quevedo, Camilo E.; Bataille, Carole J. R.; Bery, Nicolas; Miller, Ami; Russell, Angela J.; Phillips, Simon E. V.; Carr, Stephen B.; Rabbitts, Terence H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2545-2550</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The RAS gene family is frequently mutated in human cancers, and the quest for compds. that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions.  We have refined crystn. conditions for KRAS169Q61H-yielding crystals suitable for soaking with compds. and exploited this to assess new RAS-binding compds. selected by screening a protein-protein interaction-focused compd. library using surface plasmon resonance.  Two compds., referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compds. had been previously developed, including RAS effector protein-protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compds.).  Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compds. were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties.  By fusing the common, anchoring part from the two new compds. with the inhibitory substituents of the Abd series, we have created a set of compds. that inhibit RAS-effector interactions with increased potency.  These fused compds. add to the growing catalog of RAS protein-protein inhibitors and show that building a chem. series by crossing over two chem. series is a strategy to create RAS-binding small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8m8k26dNT_7Vg90H21EOLACvtfcHk0lhXFo418Rot-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVajsbo%253D&md5=163014795c0bf4cb10e751c251a0dda3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1811360116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1811360116%26sid%3Dliteratum%253Aachs%26aulast%3DCruz-Migoni%26aufirst%3DA.%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DQuevedo%26aufirst%3DC.%2BE.%26aulast%3DBataille%26aufirst%3DC.%2BJ.%2BR.%26aulast%3DBery%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DA.%2BJ.%26aulast%3DPhillips%26aufirst%3DS.%2BE.%2BV.%26aulast%3DCarr%26aufirst%3DS.%2BB.%26aulast%3DRabbitts%26aufirst%3DT.%2BH.%26atitle%3DStructure-based%2520development%2520of%2520new%2520RAS-effector%2520inhibitors%2520from%2520a%2520combination%2520of%2520active%2520and%2520inactive%2520RAS-binding%2520compounds%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26issue%3D7%26spage%3D2545%26epage%3D2550%26doi%3D10.1073%2Fpnas.1811360116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badgley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Multivalent small-molecule pan-RAS inhibitors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">878</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.cell.2017.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=28235199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVWrs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=878-889&issue=5&author=M.+E.+Welschauthor=A.+Kaplanauthor=J.+M.+Chambersauthor=M.+E.+Stokesauthor=P.+H.+Bosauthor=A.+Zaskauthor=Y.+Zhangauthor=M.+Sanchez-Martinauthor=M.+A.+Badgleyauthor=C.+S.+Huang&title=Multivalent+small-molecule+pan-RAS+inhibitors&doi=10.1016%2Fj.cell.2017.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent Small-Molecule Pan-RAS Inhibitors</span></div><div class="casAuthors">Welsch, Matthew E.; Kaplan, Anna; Chambers, Jennifer M.; Stokes, Michael E.; Bos, Pieter H.; Zask, Arie; Zhang, Yan; Sanchez-Martin, Marta; Badgley, Michael A.; Huang, Christine S.; Tran, Timothy H.; Akkiraju, Hemanth; Brown, Lewis M.; Nandakumar, Renu; Cremers, Serge; Yang, Wan Seok; Tong, Liang; Olive, Kenneth P.; Ferrando, Adolfo; Stockwell, Brent R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">878-889.e29</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Design of small mols. that disrupt protein-protein interactions, including the interaction of RAS proteins and their effectors, may provide chem. probes and therapeutic agents.  The authors describe here the synthesis and testing of potential small-mol. pan-RAS ligands, which were designed to interact with adjacent sites on the surface of oncogenic KRAS.  One compd., termed 3144, was found to bind to RAS proteins using microscale thermophoresis, NMR spectroscopy, and isothermal titrn. calorimetry and to exhibit lethality in cells partially dependent on expression of RAS proteins.  This compd. was metabolically stable in liver microsomes and displayed anti-tumor activity in xenograft mouse cancer models.  These findings suggest that pan-RAS inhibition may be an effective therapeutic strategy for some cancers and that structure-based design of small mols. targeting multiple adjacent sites to create multivalent inhibitors may be effective for some proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcWYewcTWv8bVg90H21EOLACvtfcHk0lhXFo418Rot-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVWrs7g%253D&md5=a14627b2f9b2475b5ca72f1facf2367e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DWelsch%26aufirst%3DM.%2BE.%26aulast%3DKaplan%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DJ.%2BM.%26aulast%3DStokes%26aufirst%3DM.%2BE.%26aulast%3DBos%26aufirst%3DP.%2BH.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSanchez-Martin%26aufirst%3DM.%26aulast%3DBadgley%26aufirst%3DM.%2BA.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26atitle%3DMultivalent%2520small-molecule%2520pan-RAS%2520inhibitors%26jtitle%3DCell%26date%3D2017%26volume%3D168%26issue%3D5%26spage%3D878%26epage%3D889%26doi%3D10.1016%2Fj.cell.2017.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardeesy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguirre, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hezel, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, U.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5947</span>– <span class="NLM_lpage">5952</span>, <span class="refDoi"> DOI: 10.1073/pnas.0601273103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.0601273103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=16585505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFaitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=5947-5952&issue=15&author=N.+Bardeesyauthor=A.+J.+Aguirreauthor=G.+C.+Chuauthor=K.-h.+Chengauthor=L.+V.+Lopezauthor=A.+F.+Hezelauthor=B.+Fengauthor=C.+Brennanauthor=R.+Weisslederauthor=U.+Mahmood&title=Both+p16%28Ink4a%29+and+the+p19%28Arf%29-p53+pathway+constrain+progression+of+pancreatic+adenocarcinoma+in+the+mouse&doi=10.1073%2Fpnas.0601273103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse</span></div><div class="casAuthors">Bardeesy, Nabeel; Aguirre, Andrew J.; Chu, Gerald C.; Cheng, Kuang-hung; Lopez, Lyle V.; Hezel, Aram F.; Feng, Bin; Brennan, Cameron; Weissleder, Ralph; Mahmood, Umar; Hanahan, Douglas; Redston, Mark S.; Chin, Lynda; DePinho, Ronald A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5947-5952</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activating KRAS mutations and p16Ink4a inactivation are near universal events in human pancreatic ductal adenocarcinoma (PDAC).  In mouse models, KrasG12D initiates formation of premalignant pancreatic ductal lesions, and loss of either Ink4a/Arf (p16Ink4a/p19Arf) or p53 enables their malignant progression.  As recent mouse modeling studies have suggested a less prominent role for p16Ink4a in constraining malignant progression, we sought to assess the pathol. and genomic impact of inactivation of p16Ink4a, p19Arf, and/or p53 in the KrasG12D model.  Rapidly progressive PDAC was obsd. in the setting of homozygous deletion of either p53 or p16Ink4a, the latter with intact germ-line p53 and p19Arf sequences.  Addnl., KrasG12D in the context of heterozygosity either for p53 plus p16Ink4a or for p16Ink4a/p19Arf produced PDAC with longer latency and greater propensity for distant metastases relative to mice with homozygous deletion of p53 or p16Ink4a/p19Arf.  Tumors from the double-heterozygous cohorts showed frequent p16Ink4a inactivation and loss of either p53 or p19Arf.  Different genotypes were assocd. with specific histopathol. characteristics, most notably a trend toward less differentiated features in the homozygous p16Ink4a/p19Arf mutant model.  High-resoln. genomic anal. revealed that the tumor suppressor genotype influenced the specific genomic patterns of these tumors and showed overlap in regional chromosomal alterations between murine and human PDAC.  Collectively, our results establish that disruptions of p16Ink4a and the p19ARF-p53 circuit play crit. and cooperative roles in PDAC progression, with specific tumor suppressor genotypes provocatively influencing the tumor biol. phenotypes and genomic profiles of the resultant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCLwHVjyV20LVg90H21EOLACvtfcHk0lhXFo418Rot-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFaitLY%253D&md5=abbdb46c78d1b972d36fa8915e92a109</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0601273103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0601273103%26sid%3Dliteratum%253Aachs%26aulast%3DBardeesy%26aufirst%3DN.%26aulast%3DAguirre%26aufirst%3DA.%2BJ.%26aulast%3DChu%26aufirst%3DG.%2BC.%26aulast%3DCheng%26aufirst%3DK.-h.%26aulast%3DLopez%26aufirst%3DL.%2BV.%26aulast%3DHezel%26aufirst%3DA.%2BF.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DMahmood%26aufirst%3DU.%26atitle%3DBoth%2520p16%2528Ink4a%2529%2520and%2520the%2520p19%2528Arf%2529-p53%2520pathway%2520constrain%2520progression%2520of%2520pancreatic%2520adenocarcinoma%2520in%2520the%2520mouse%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26issue%3D15%26spage%3D5947%26epage%3D5952%26doi%3D10.1073%2Fpnas.0601273103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Expanding the scope of electrophiles capable of targeting K-Ras oncogenes</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">3178</span>– <span class="NLM_lpage">3183</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGrsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=3178-3183&issue=25&author=L.+M.+McGregorauthor=M.+L.+Jenkinsauthor=C.+Kerwinauthor=J.+E.+Burkeauthor=K.+M.+Shokat&title=Expanding+the+scope+of+electrophiles+capable+of+targeting+K-Ras+oncogenes&doi=10.1021%2Facs.biochem.7b00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes</span></div><div class="casAuthors">McGregor, Lynn M.; Jenkins, Meredith L.; Kerwin, Caitlin; Burke, John E.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3178-3183</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is growing interest in reversible and irreversible covalent inhibitors that target noncatalytic amino acids in target proteins.  With a goal of targeting oncogenic K-Ras variants (e.g., G12D) by expanding the types of amino acids that can be targeted by covalent inhibitors, we survey a set of electrophiles for their ability to label carboxylates.  We functionalized an optimized ligand for the K-Ras switch II pocket with a set of electrophiles previously reported to react with carboxylates and characterized the ability of these compds. to react with model nucleophiles and oncogenic K-Ras proteins.  Here, we report that aziridines and stabilized diazo groups preferentially react with free carboxylates over thiols.  Although we did not identify a warhead that potently labels K-Ras G12D, we were able to study the interactions of many electrophiles with K-Ras, as most of the electrophiles rapidly label K-Ras G12C.  We characterized the resulting complexes by crystallog., hydrogen/deuterium exchange, and differential scanning fluorometry.  Our results both demonstrate the ability of a noncatalytic cysteine to react with a diverse set of electrophiles and emphasize the importance of proper spatial arrangements between a covalent inhibitor and its intended nucleophile.  We hope that these results can expand the range of electrophiles and nucleophiles of use in covalent protein modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcvKWYdfIxw7Vg90H21EOLACvtfcHk0lhJE9rU3vncYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGrsbnI&md5=0b25b65210248a4cad2916efba90ddae</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00271%26sid%3Dliteratum%253Aachs%26aulast%3DMcGregor%26aufirst%3DL.%2BM.%26aulast%3DJenkins%26aufirst%3DM.%2BL.%26aulast%3DKerwin%26aufirst%3DC.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DExpanding%2520the%2520scope%2520of%2520electrophiles%2520capable%2520of%2520targeting%2520K-Ras%2520oncogenes%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26issue%3D25%26spage%3D3178%26epage%3D3183%26doi%3D10.1021%2Facs.biochem.7b00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knelson, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span> <span> </span><span class="NLM_article-title">A Bright future for KRAS inhibitors</span>. <i>Nature Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1038/s43018-019-0016-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs43018-019-0016-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2020&pages=25-27&issue=1&author=D.+Bar-Sagiauthor=E.+H.+Knelsonauthor=L.+V.+Sequist&title=A+Bright+future+for+KRAS+inhibitors&doi=10.1038%2Fs43018-019-0016-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fs43018-019-0016-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs43018-019-0016-8%26sid%3Dliteratum%253Aachs%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DKnelson%26aufirst%3DE.%2BH.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DA%2520Bright%2520future%2520for%2520KRAS%2520inhibitors%26jtitle%3DNature%2520Cancer%26date%3D2020%26volume%3D1%26issue%3D1%26spage%3D25%26epage%3D27%26doi%3D10.1038%2Fs43018-019-0016-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span> <span> </span><span class="NLM_article-title">Kras and tumor immunity: friend or foe?</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">a031849</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a031849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1101%2Fcshperspect.a031849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29229670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCltr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=a031849&issue=9&author=J.+Cullisauthor=S.+Dasauthor=D.+Bar-Sagi&title=Kras+and+tumor+immunity%3A+friend+or+foe%3F&doi=10.1101%2Fcshperspect.a031849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Kras and tumor immunity: friend or foe?</span></div><div class="casAuthors">Cullis, Jane; Das, Shipra; Bar-Sagi, Dafna</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">a031849/1-a031849/22</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">With the recent breakthroughs in immunotherapy as curative treatments in certain tumor types, there has been renewed interest in the relationship between immunity and tumor growth.  Although we are gaining a greater understanding of the complex interplay of immune modulating components in the tumor microenvironment, the specific role that tumor cells play in shaping the immune milieu is still not well characterized.  In this review, we focus on how mutant Kras tumor cells contribute to tumor immunity, with a specific focus on processes induced directly or indirectly by the oncogene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaDNG73BzdfrVg90H21EOLACvtfcHk0lhJE9rU3vncYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCltr3O&md5=e6ecf9d69a16d57f61acb38700b0273e</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a031849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a031849%26sid%3Dliteratum%253Aachs%26aulast%3DCullis%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DBar-Sagi%26aufirst%3DD.%26atitle%3DKras%2520and%2520tumor%2520immunity%253A%2520friend%2520or%2520foe%253F%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2018%26volume%3D8%26issue%3D9%26spage%3Da031849%26doi%3D10.1101%2Fcshperspect.a031849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danoff, S.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1416</span>– <span class="NLM_lpage">1423</span>, <span class="refDoi"> DOI: 10.1016/j.chest.2018.08.1048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.chest.2018.08.1048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30189190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BB3c3mt1Wrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=1416-1423&issue=6&author=K.+Sureshauthor=J.+Naidooauthor=C.+T.+Linauthor=S.+Danoff&title=Immune+checkpoint+immunotherapy+for+non-small+cell+lung+cancer%3A+benefits+and+pulmonary+toxicities&doi=10.1016%2Fj.chest.2018.08.1048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities</span></div><div class="casAuthors">Suresh Karthik; Naidoo Jarushka; Lin Cheng Ting; Danoff Sonye</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1416-1423</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been shown to improve survival in advanced non-small cell lung cancer (NSCLC).  Unlike traditional chemotherapeutic agents, ICIs work by boosting the body's natural tumor killing response.  However, this unique mechanism of action has also led to the recognition of class-specific side effects.  Labeled immune-related adverse events, these toxicities can affect multiple organ systems including the lungs.  Immune-mediated lung injury because of ICI use, termed checkpoint inhibitor pneumonitis (CIP), occurs in about 3% to 5% of patients receiving ICIs; however, the real-world incidence of this entity may be higher, especially now that ICIs are being used in nonclinical trial settings.  In this review, we briefly introduce the biology of ICIs and the indications for ICI use in NSCLC and then discuss the epidemiology and clinical and radiologic manifestations of CIP.  Next, we discuss management strategies for CIP, including the current consensus on management of steroid-refractory CIP.  Given the nascent nature of this field, we highlight areas of uncertainty and emerging research questions in the burgeoning field of checkpoint inhibitor pulmonary toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdAutAFukrJpVVjGoY74BafW6udTcc2ea5Miw54K74NLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3mt1Wrsg%253D%253D&md5=db9e27c4b602501d2adcac00b171067a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.chest.2018.08.1048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chest.2018.08.1048%26sid%3Dliteratum%253Aachs%26aulast%3DSuresh%26aufirst%3DK.%26aulast%3DNaidoo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%2BT.%26aulast%3DDanoff%26aufirst%3DS.%26atitle%3DImmune%2520checkpoint%2520immunotherapy%2520for%2520non-small%2520cell%2520lung%2520cancer%253A%2520benefits%2520and%2520pulmonary%2520toxicities%26jtitle%3DChest%26date%3D2018%26volume%3D154%26issue%3D6%26spage%3D1416%26epage%3D1423%26doi%3D10.1016%2Fj.chest.2018.08.1048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qeriqi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazutis, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Rapid non-uniform adaptation to vonformation-specific KRAS (G12C) inhibition</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>577</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1884-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41586-019-1884-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31915379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsleisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=577&publication_year=2020&pages=421-425&author=J.+Y.+Xueauthor=Y.+Zhaoauthor=J.+Aronowitzauthor=T.+T.+Maiauthor=A.+Videsauthor=B.+Qeriqiauthor=D.+Kimauthor=C.+Liauthor=E.+de+Stanchinaauthor=L.+Mazutis&title=Rapid+non-uniform+adaptation+to+vonformation-specific+KRAS+%28G12C%29+inhibition&doi=10.1038%2Fs41586-019-1884-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition</span></div><div class="casAuthors">Xue, Jenny Y.; Zhao, Yulei; Aronowitz, Jordan; Mai, Trang T.; Vides, Alberto; Qeriqi, Besnik; Kim, Dongsung; Li, Chuanchuan; de Stanchina, Elisa; Mazutis, Linas; Risso, Davide; Lito, Piro</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">577</span>
        (<span class="NLM_cas:issue">7790</span>),
    <span class="NLM_cas:pages">421-425</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS GTPases are activated in one-third of cancers, and KRAS(G12C) is one of the most common activating alterations in lung adenocarcinoma1,2.  KRAS(G12C) inhibitors3,4 are in phase-I clin. trials and early data show partial responses in nearly half of patients with lung cancer.  How cancer cells bypass inhibition to prevent maximal response to therapy is not understood.  Because KRAS(G12C) cycles between an active and inactive conformation4-6, and the inhibitors bind only to the latter, we tested whether isogenic cell populations respond in a non-uniform manner by studying the effect of treatment at a single-cell resoln.  Here we report that, shortly after treatment, some cancer cells are sequestered in a quiescent state with low KRAS activity, whereas others bypass this effect to resume proliferation.  This rapid divergent response occurs because some quiescent cells produce new KRAS(G12C) in response to suppressed mitogen-activated protein kinase output.  New KRAS(G12C) is maintained in its active, drug-insensitive state by epidermal growth factor receptor and aurora kinase signalling.  Cells without these adaptive changes-or cells in which these changes are pharmacol. inhibited-remain sensitive to drug treatment, because new KRAS(G12C) is either not available or exists in its inactive, drug-sensitive state.  The direct targeting of KRAS oncoproteins has been a longstanding objective in precision oncol.  Our study uncovers a flexible non-uniform fitness mechanism that enables groups of cells within a population to rapidly bypass the effect of treatment.  This adaptive process must be overcome if we are to achieve complete and durable responses in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs98vxCKonTbVg90H21EOLACvtfcHk0liUM828aRMHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsleisA%253D%253D&md5=23df9a8dc75959ebb136f3412e40fc36</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1884-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1884-x%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DAronowitz%26aufirst%3DJ.%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DVides%26aufirst%3DA.%26aulast%3DQeriqi%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DMazutis%26aufirst%3DL.%26atitle%3DRapid%2520non-uniform%2520adaptation%2520to%2520vonformation-specific%2520KRAS%2520%2528G12C%2529%2520inhibition%26jtitle%3DNature%26date%3D2020%26volume%3D577%26spage%3D421%26epage%3D425%26doi%3D10.1038%2Fs41586-019-1884-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montero-Conde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Llorente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauf, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghossein, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span> <span> </span><span class="NLM_article-title">Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-Mutant thyroid carcinomas</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">520</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F2159-8290.CD-12-0531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23365119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVOmur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=520-533&issue=5&author=C.+Montero-Condeauthor=S.+Ruiz-Llorenteauthor=J.+M.+Dominguezauthor=J.+A.+Knaufauthor=A.+Vialeauthor=E.+J.+Shermanauthor=M.+Ryderauthor=R.+A.+Ghosseinauthor=N.+Rosenauthor=J.+A.+Fagin&title=Relief+of+feedback+inhibition+of+HER3+transcription+by+RAF+and+MEK+inhibitors+attenuates+their+antitumor+effects+in+BRAF-Mutant+thyroid+carcinomas&doi=10.1158%2F2159-8290.CD-12-0531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas</span></div><div class="casAuthors">Montero-Conde, Cristina; Ruiz-Llorente, Sergio; Dominguez, Jose M.; Knauf, Jeffrey A.; Viale, Agnes; Sherman, Eric J.; Ryder, Mabel; Ghossein, Ronald A.; Rosen, Neal; Fagin, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">520-533</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The RAF inhibitor vemurafenib (PLX40B2) increases survival in patients with BRAF-mutant metastatic melanoma, but has limited efficacy in patients with colorν ectal cancers.  Thyroid cancer cells are also comparatively refractory to RAF inhibitors.  In contrast to melanomas, inhibition of mitogen-activated protein kinase (MAPK) signaling by PLX4032 is transient in thyroid and colorectal cancer cells.  The rebound in extracellular signal-regulated kinase (ERK) in thyroid cells is accompanied by increased HERB signaling caused by induction of ERBB3 (HER3) tranν scription through decreased promoter occupancy by the transcriptional repressors C-terminal binding protein 1 and 2 and by autocrine secretion of neuregulin-1 (NRG1).  The HER kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAP-ERK kinase inhibitors.  This provides a rationale for combining ERK pathway antagonists with inhibitors of feedback- reactivated HER signaling in this disease.  The determinants of primary resistance to MAPK inhibitors vary between cancer types, due to preferential upregulation of specific receptor tyrosine kinases, and the abundance of their resp. ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkFqZRkwGftbVg90H21EOLACvtfcHk0liUM828aRMHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVOmur4%253D&md5=01c1c948c2a5df35f6520875cf122994</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0531%26sid%3Dliteratum%253Aachs%26aulast%3DMontero-Conde%26aufirst%3DC.%26aulast%3DRuiz-Llorente%26aufirst%3DS.%26aulast%3DDominguez%26aufirst%3DJ.%2BM.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DE.%2BJ.%26aulast%3DRyder%26aufirst%3DM.%26aulast%3DGhossein%26aufirst%3DR.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DRelief%2520of%2520feedback%2520inhibition%2520of%2520HER3%2520transcription%2520by%2520RAF%2520and%2520MEK%2520inhibitors%2520attenuates%2520their%2520antitumor%2520effects%2520in%2520BRAF-Mutant%2520thyroid%2520carcinomas%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D5%26spage%3D520%26epage%3D533%26doi%3D10.1158%2F2159-8290.CD-12-0531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span> <span> </span><span class="NLM_article-title">EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">xi41</span>– <span class="NLM_lpage">xi42</span>, <span class="refDoi"> DOI: 10.1016/S0923-7534(20)32033-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2FS0923-7534%2820%2932033-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=xi41-xi42&author=H.+Ebi&title=EGFR-mediated+re-activation+of+MAPK+signaling+contributes+to+insensitivity+of+BRAF+mutant+colorectal+cancers+to+RAF+inhibition&doi=10.1016%2FS0923-7534%2820%2932033-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS0923-7534%2820%2932033-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0923-7534%252820%252932033-0%26sid%3Dliteratum%253Aachs%26aulast%3DEbi%26aufirst%3DH.%26atitle%3DEGFR-mediated%2520re-activation%2520of%2520MAPK%2520signaling%2520contributes%2520to%2520insensitivity%2520of%2520BRAF%2520mutant%2520colorectal%2520cancers%2520to%2520RAF%2520inhibition%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3Dxi41%26epage%3Dxi42%26doi%3D10.1016%2FS0923-7534%2820%2932033-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fece de la Cruz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahzade, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span> <span> </span><span class="NLM_article-title">Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C Inhibition</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1633</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-3523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F1078-0432.CCR-19-3523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31776128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1GnurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=1633-1643&author=M.+B.+Ryanauthor=F.+Fece+de+la+Cruzauthor=S.+Phatauthor=D.+T.+Myersauthor=E.+Wongauthor=H.+A.+Shahzadeauthor=C.+B.+Hongauthor=R.+B.+Corcoran&title=Vertical+pathway+inhibition+overcomes+adaptive+feedback+resistance+to+KRASG12C+Inhibition&doi=10.1158%2F1078-0432.CCR-19-3523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition</span></div><div class="casAuthors">Ryan, Meagan B.; Fece de la Cruz, Ferran; Phat, Sarah; Myers, David T.; Wong, Edmond; Shahzade, Heather A.; Hong, Catriona B.; Corcoran, Ryan B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1633-1643</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although KRAS represents the most commonly mutated oncogene, it has long been considered an "undruggable" target.  Novel covalent inhibitors selective for the KRASG12C mutation offer the unprecedented opportunity to target KRAS directly.  However, prior efforts to target the RAS-MAPK pathway have been hampered by adaptive feedback, which drives pathway reactivation and resistance.  Exptl. Design: A panel of KRASG12C cell lines were treated with the KRASG12C inhibitors ARS-1620 and AMG 510 to assess effects on signaling and viability.  Isoform-specific pulldown of activated GTP-bound RAS was performed to evaluate effects on the activity of specific RAS isoforms over time following treatment.  RTK inhibitors, SHP2 inhibitors, and MEK/ERK inhibitors were assessed in combination with KRASG12C inhibitors in vitro and in vivo as potential strategies to overcome resistance and enhance efficacy.  Results: We obsd. rapid adaptive RAS pathway feedback reactivation following KRASG12C inhibition in the majority of KRASG12C models, driven by RTK-mediated activation of wild-type RAS, which cannot be inhibited by G12C-specific inhibitors.  Importantly, multiple RTKs can mediate feedback, with no single RTK appearing crit. across all KRASG12C models.  However, coinhibition of SHP2, which mediates signaling from multiple RTKs to RAS, abrogated feedback reactivation more universally, and combined KRASG12C/SHP2 inhibition drove sustained RAS pathway suppression and improved efficacy in vitro and in vivo.  Conclusions: These data identify feedback reactivation of wild-type RAS as a key mechanism of adaptive resistance to KRASG12C inhibitors and highlight the potential importance of vertical inhibition strategies to enhance the clin. efficacy of KRASG12C inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobM76MIQz9zLVg90H21EOLACvtfcHk0liUM828aRMHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1GnurjP&md5=ef6ee3796adfcf0747400aee61256fc1</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-3523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-3523%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DM.%2BB.%26aulast%3DFece%2Bde%2Bla%2BCruz%26aufirst%3DF.%26aulast%3DPhat%26aufirst%3DS.%26aulast%3DMyers%26aufirst%3DD.%2BT.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DShahzade%26aufirst%3DH.%2BA.%26aulast%3DHong%26aufirst%3DC.%2BB.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26atitle%3DVertical%2520pathway%2520inhibition%2520overcomes%2520adaptive%2520feedback%2520resistance%2520to%2520KRASG12C%2520Inhibition%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D1633%26epage%3D1643%26doi%3D10.1158%2F1078-0432.CCR-19-3523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lorenz  Herdeis</span>, <span class="hlFld-ContribAuthor ">Daniel  Gerlach</span>, <span class="hlFld-ContribAuthor ">Darryl B.  McConnell</span>, <span class="hlFld-ContribAuthor ">Dirk  Kessler</span>. </span><span class="cited-content_cbyCitation_article-title">Stopping the beating heart of cancer: KRAS reviewed. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Structural Biology</span><span> <strong>2021,</strong> <em>71 </em>, 136-147. <a href="https://doi.org/10.1016/j.sbi.2021.06.013" title="DOI URL">https://doi.org/10.1016/j.sbi.2021.06.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.sbi.2021.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.sbi.2021.06.013%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Structural%2520Biology%26atitle%3DStopping%252Bthe%252Bbeating%252Bheart%252Bof%252Bcancer%25253A%252BKRAS%252Breviewed%26aulast%3DHerdeis%26aufirst%3DLorenz%26date%3D2021%26volume%3D71%26spage%3D136%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Severin  Thompson</span>, <span class="hlFld-ContribAuthor ">Andreas  Buckl</span>, <span class="hlFld-ContribAuthor ">Alexander G.  Dossetter</span>, <span class="hlFld-ContribAuthor ">Ed  Griffen</span>, <span class="hlFld-ContribAuthor ">Adrian  Gill</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1080/13543776.2021.1952984" title="DOI URL">https://doi.org/10.1080/13543776.2021.1952984</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1952984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1952984%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall%252Bmolecule%252BSon%252Bof%252BSevenless%252B1%252B%252528SOS1%252529%252Binhibitors%25253A%252Ba%252Breview%252Bof%252Bthe%252Bpatent%252Bliterature%26aulast%3DThompson%26aufirst%3DSeverin%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Kevin R.  Webster</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting mutant KRAS. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2021,</strong> <em>62 </em>, 101-108. <a href="https://doi.org/10.1016/j.cbpa.2021.02.010" title="DOI URL">https://doi.org/10.1016/j.cbpa.2021.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2021.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2021.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTargeting%252Bmutant%252BKRAS%26aulast%3DErlanson%26aufirst%3DDaniel%2BA.%26date%3D2021%26volume%3D62%26spage%3D101%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuicui  Li</span>, <span class="hlFld-ContribAuthor ">Ni  Zhao</span>, <span class="hlFld-ContribAuthor ">Luyan  An</span>, <span class="hlFld-ContribAuthor ">Zhen  Dai</span>, <span class="hlFld-ContribAuthor ">Xiaoyi  Chen</span>, <span class="hlFld-ContribAuthor ">Fan  Yang</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Bin  Di</span>, <span class="hlFld-ContribAuthor ">Chi  Hu</span>, <span class="hlFld-ContribAuthor ">Lili  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRASG12C. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1016/j.apsb.2021.06.013" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.06.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.06.013%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DApoptosis-inducing%252Bactivity%252Bof%252Bsynthetic%252Bhydrocarbon-stapled%252Bpeptides%252Bin%252BH358%252Bcancer%252Bcells%252Bexpressing%252BKRASG12C%26aulast%3DLi%26aufirst%3DCuicui%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seong Ho  Hong</span>, <span class="hlFld-ContribAuthor ">Daniel Y.  Yoo</span>, <span class="hlFld-ContribAuthor ">Louis  Conway</span>, <span class="hlFld-ContribAuthor ">Khyle C.  Richards-Corke</span>, <span class="hlFld-ContribAuthor ">Christopher G.  Parker</span>, <span class="hlFld-ContribAuthor ">Paramjit S.  Arora</span>. </span><span class="cited-content_cbyCitation_article-title">A Sos proteomimetic as a pan-Ras inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2021,</strong> <em>118 </em>
                                    (18)
                                     , e2101027118. <a href="https://doi.org/10.1073/pnas.2101027118" title="DOI URL">https://doi.org/10.1073/pnas.2101027118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.2101027118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.2101027118%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DA%252BSos%252Bproteomimetic%252Bas%252Ba%252Bpan-Ras%252Binhibitor%26aulast%3DHong%26aufirst%3DSeong%2BHo%26date%3D2021%26date%3D2021%26volume%3D118%26issue%3D18%26spage%3De2101027118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linor  Rubinstein-Achiasaf</span>, <span class="hlFld-ContribAuthor ">Dina  Morein</span>, <span class="hlFld-ContribAuthor ">Hagar  Ben-Yaakov</span>, <span class="hlFld-ContribAuthor ">Yulia  Liubomirski</span>, <span class="hlFld-ContribAuthor ">Tsipi  Meshel</span>, <span class="hlFld-ContribAuthor ">Eti  Elbaz</span>, <span class="hlFld-ContribAuthor ">Orly  Dorot</span>, <span class="hlFld-ContribAuthor ">Edward  Pichinuk</span>, <span class="hlFld-ContribAuthor ">Michael  Gershovits</span>, <span class="hlFld-ContribAuthor ">Miguel  Weil</span>, <span class="hlFld-ContribAuthor ">Adit  Ben-Baruch</span>. </span><span class="cited-content_cbyCitation_article-title">Persistent Inflammatory Stimulation Drives the Conversion of MSCs to Inflammatory CAFs That Promote Pro-Metastatic Characteristics in Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (6)
                                     , 1472. <a href="https://doi.org/10.3390/cancers13061472" title="DOI URL">https://doi.org/10.3390/cancers13061472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13061472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13061472%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DPersistent%252BInflammatory%252BStimulation%252BDrives%252Bthe%252BConversion%252Bof%252BMSCs%252Bto%252BInflammatory%252BCAFs%252BThat%252BPromote%252BPro-Metastatic%252BCharacteristics%252Bin%252BBreast%252BCancer%252BCells%26aulast%3DRubinstein-Achiasaf%26aufirst%3DLinor%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D6%26spage%3D1472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0033.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of GDP-bound KRAS (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OBE">4OBE</a>). The effector lobe, allosteric lobe, and hypervariable region are shown in blue, pink, and cyan, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Comparison of the KRAS GppNHp-bound active conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GOD">6GOD</a>) and the KRAS GDP-bound inactive conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OBE">4OBE</a>). (A) KRAS active conformation. The switch I region, the switch II region, and the P-loop are shown in blue, pink, and yellow, respectively. Hydrogen bonds are shown in dashed yellow lines. Guanosine 5′-[β,γ-imido]triphosphate (GppNHp) is a nonhydrolyzable analogue of GTP where one oxygen atom is replaced by an amine. (B) Alignment of KRAS active and inactive conformations. The major difference lies in the conformation of the switch II region, which moves away from the guanine binding pocket as the γ-phosphate is dissociated (as indicated by the pink arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Profiles of KRAS codon 12 mutations in three types of cancer.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mutated KRAS signaling pathways and current therapeutic strategies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Reported binding pockets for direct KRAS inhibitors. The switch I and switch II regions of KRAS are colored in blue and red ribbons, respectively. The nucleotide-binding pocket is colored in pink (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LDJ">4LDJ</a>). The A59 site is colored in ocher (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DSN">4DSN</a>). The switch I/II pocket is colored in blue (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPY">4EPY</a>). The switch II pocket is colored in green (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F2E">5F2E</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. GDP binding pocket of the KRAS G12C mutant. (A) GDP in complex with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LDJ">4LDJ</a>). The β-phosphate of GDP is proximal to KRAS Cys12. (B) SML-8-73-1 in complex with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NMM">4NMM</a>). A covalent bond has been formed between Cys12 and the 2-chloroacetamide moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0021.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Structural Modifications of the Covalent GDP Mimics as KRAS G12C Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding of <b>6</b> induces a conformational change in KRAS G12C. The switch I region, the switch II region, Gly60, and Cys12 are shown in blue, pink, cyan, and yellow, respectively. (A) KRAS GppNHp-bound active conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P21">5P21</a>). A hydrogen bond is formed between Gly60 and the GppNHp terminal phosphoramidate group. (B) KRAS G12C GDP in complex with <b>6</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LUC">4LUC</a>). Compound <b>6</b> penetrates into the switch II region and pushes Gly60 away from the nucleotide binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0022.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Optimization Process for ARS-853</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Binding mode of ARS-853 with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F2E">5F2E</a>). The key residues are represented as stick structures. Hydrogen bonds are shown as yellow dashes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Rationale for ARS-853 KRAS G12C inhibition. The inhibitor targets the KRAS G12C GDP-bound inactive state to prevent nucleotide exchange. Therefore, the level of the KRAS G12C GTP-bound active form decreases as nucleotide hydrolysis takes place.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0023.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Optimization Process for ARS-1620</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Binding mode of ARS-1620 with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U">5V9U</a>). The key residues are represented as stick structures. Hydrogen bonds are shown as yellow dashes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0024.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Optimization Process for 4-AM</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Binding modes of KRAS G12C with <b>14</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N2J">6N2J</a>) and MRTX849 (<b>19</b>) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UT0">6UT0</a>). The key residues are represented as stick structures. Hydrogen bonds are shown as yellow dashes. The bound water molecule between Gly10 and Thr58 is highlighted in yellow. The cyanomethyl substituent that displaces the bound water is highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0025.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Optimization Process for MRTX849</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0012.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Binding mode of <b>20</b> with KRAS G12C (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6P8Y">6P8Y</a>). (B) Superimposition of the binding modes of ARS-1620 (pink, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U">5V9U</a>) and <b>20</b> (green). Hydrogen bonds are shown as yellow dashes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0026.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Optimization Process for AMG 510</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0013.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Superimposition of the binding modes of AMG 510 (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OIM">6OIM</a>) and ARS-1620 (pink, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U">5V9U</a>). The two molecules have highly similar binding conformations, except for the substituted pyridine moiety of AMG 510, which penetrates into the “cryptic pocket” surrounded by His95, Tyr96, and Gln99.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0027.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Optimization Process for Compound <b>30</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0014.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Superimposition of the binding modes of <b>30</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T5B">6T5B</a>) and a typical quinazoline inhibitor, ARS-1620 (pink, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U">5V9U</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0015.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Binding mode of DCAI with KRAS G12D. (A) Overview of the switch I/II binding pocket. The switch I and II regions of KRAS are shown in blue and pink, respectively. The side chain of Asp54 (shown in cyan, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DSN">4DSN</a>) rotates outward upon ligand binding (shown in light gray, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DST">4DST</a>). (B) Alignment of the KRAS–DCAI complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DST">4DST</a>) with the KRAS–SOS complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BKD">1BKD</a>). The ethylamine side chain of DCAI penetrates into the surface between KRAS and SOS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0016.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Binding modes of (A) <b>32</b> with KRAS (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPV">4EPV</a>) and (B) <b>34</b> with KRAS G12V (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPY">4EPY</a>). The key residues are represented as stick structures. Hydrogen bonds are shown as yellow dashes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0028.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Optimization Process for Compounds <b>33</b> and <b>34</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0029.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Optimization Process for Compound <b>37</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0017.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Binding mode of BI-2852 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GJ7">6GJ7</a>) and alignment of the interaction interfaces between KRAS and its effector proteins SOS, GAP, and RAF (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BKD">1BKD</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0N">4G0N</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1WQ1">1WQ1</a>, respectively).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0018.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Rationale for KRAS inhibition by S-I/IIP inhibitors. The inhibitor targets both the KRAS GDP-bound inactive state and the KRAS GTP-bound active state at the same level by mutually impeding nucleotide exchange and GTP hydrolysis. Although KRAS GTP-bound levels remain unchanged, binding of the inhibitor with the KRAS GTP-bound form disrupts the interaction between KRAS and its effectors to block KRAS signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0019.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Binding modes of Abd-2 (<b>38</b>) and Abd-7 (<b>39</b>) with KRAS Q61H (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OCO">5OCO</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FA4">6FA4</a>, respectively). The key residues are represented as stick structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0030.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Structural Modification of the 1,1′-Biaryl Switch I/II Pocket Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/medium/jm0c01312_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0020.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Proposed binding mode of 3144 (wheat) with KRAS G12D. The switch I region and the switch II region are shown in blue and pink, respectively. The proximal switch I/II binding pocket is indicated by the bound inhibitor DCAI (pink sticks).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01312/20201203/images/large/jm0c01312_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01312&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08052" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08052" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 97 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Ras history</span>. <i>Small GTPases</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.4161/sgtp.1.1.12178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.4161%2Fsgtp.1.1.12178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=21686117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BC2srisVWnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=2-27&issue=1&author=A.+D.+Coxauthor=C.+J.+Der&title=Ras+history&doi=10.4161%2Fsgtp.1.1.12178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Ras history: The saga continues</span></div><div class="casAuthors">Cox Adrienne D; Der Channing J</div><div class="citationInfo"><span class="NLM_cas:title">Small GTPases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although the roots of Ras sprouted from the rich history of retrovirus research, it was the discovery of mutationally activated RAS genes in human cancer in 1982 that stimulated an intensive research effort to understand Ras protein structure, biochemistry and biology.  While the ultimate goal has been developing anti-Ras drugs for cancer treatment, discoveries from Ras have laid the foundation for three broad areas of science.  First, they focused studies on the origins of cancer to the molecular level, with the subsequent discovery of genes mutated in cancer that now number in the thousands.  Second, elucidation of the biochemical mechanisms by which Ras facilitates signal transduction established many of our fundamental concepts of how a normal cell orchestrates responses to extracellular cues.  Third, Ras proteins are also founding members of a large superfamily of small GTPases that regulate all key cellular processes and established the versatile role of small GTP-binding proteins in biology.  We highlight some of the key findings of the last 28 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJN8gMSAebef9pSBfyDvp7fW6udTcc2eZ377B_IBJs9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srisVWnsA%253D%253D&md5=69fba6e1e1203a0f35fad4d1c89258ae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.4161%2Fsgtp.1.1.12178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fsgtp.1.1.12178%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DRas%2520history%26jtitle%3DSmall%2520GTPases%26date%3D2010%26volume%3D1%26issue%3D1%26spage%3D2%26epage%3D27%26doi%3D10.4161%2Fsgtp.1.1.12178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancias, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">KRAS: feeding pancreatic cancer proliferation</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2013.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.tibs.2013.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=24388967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=91-100&issue=2&author=K.+L.+Bryantauthor=J.+D.+Manciasauthor=A.+C.+Kimmelmanauthor=C.+J.+Der&title=KRAS%3A+feeding+pancreatic+cancer+proliferation&doi=10.1016%2Fj.tibs.2013.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS: feeding pancreatic cancer proliferation</span></div><div class="casAuthors">Bryant, Kirsten L.; Mancias, Joseph D.; Kimmelman, Alec C.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Oncogenic KRAS mutation is the signature genetic event in the progression and growth of pancreatic ductal adenocarcinoma (PDAC), an almost universally fatal disease.  Although it has been appreciated for some time that nearly 95% of PDAC harbor mutationally activated KRAS, to date no effective treatments that target this mutant protein have reached the clinic.  A no. of studies have shown that oncogenic KRAS plays a central role in controlling tumor metab. by orchestrating multiple metabolic changes including stimulation of glucose uptake, differential channeling of glucose intermediates, reprogrammed glutamine metab., increased autophagy, and macropinocytosis.  We review these recent findings and address how they may be applied to develop new PDAC treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrziZgcJvGfpbVg90H21EOLACvtfcHk0ljl1OPS_yTU_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVCjug%253D%253D&md5=e027cbe3a26649002154765249cfef93</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2013.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2013.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DK.%2BL.%26aulast%3DMancias%26aufirst%3DJ.%2BD.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DKRAS%253A%2520feeding%2520pancreatic%2520cancer%2520proliferation%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2014%26volume%3D39%26issue%3D2%26spage%3D91%26epage%3D100%26doi%3D10.1016%2Fj.tibs.2013.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pylayeva-Gupta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabocka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span> <span> </span><span class="NLM_article-title">RAS oncogenes: weaving a tumorigenic web</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1038/nrc3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrc3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=21993244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=761-774&issue=11&author=Y.+Pylayeva-Guptaauthor=E.+Grabockaauthor=D.+Bar-Sagi&title=RAS+oncogenes%3A+weaving+a+tumorigenic+web&doi=10.1038%2Fnrc3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">RAS oncogenes: weaving a tumorigenic web</span></div><div class="casAuthors">Pylayeva-Gupta, Yuliya; Grabocka, Elda; Bar-Sagi, Dafna</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">761-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAS proteins are essential components of signalling pathways that emanate from cell surface receptors.  Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer.  A wealth of biochem. and genetic studies indicates that RAS proteins control a complex mol. circuitry that consists of a wide array of interconnecting pathways.  In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdHRt0jsiXtLVg90H21EOLACvtfcHk0ljl1OPS_yTU_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K&md5=d1be47023ab43a30cb81e71cb92bc0aa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3106%26sid%3Dliteratum%253Aachs%26aulast%3DPylayeva-Gupta%26aufirst%3DY.%26aulast%3DGrabocka%26aufirst%3DE.%26aulast%3DBar-Sagi%26aufirst%3DD.%26atitle%3DRAS%2520oncogenes%253A%2520weaving%2520a%2520tumorigenic%2520web%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26issue%3D11%26spage%3D761%26epage%3D774%26doi%3D10.1038%2Fnrc3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prior, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">A comprehensive survey of Ras mutations in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2467</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-2612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F0008-5472.CAN-11-2612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=22589270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2457-2467&issue=10&author=I.+A.+Priorauthor=P.+D.+Lewisauthor=C.+Mattos&title=A+comprehensive+survey+of+Ras+mutations+in+cancer&doi=10.1158%2F0008-5472.CAN-11-2612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Survey of Ras Mutations in Cancer</span></div><div class="casAuthors">Prior, Ian A.; Lewis, Paul D.; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2457-2467</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  All mammalian cells express 3 closely related Ras proteins, termed H-Ras, K-Ras, and N-Ras, that promote oncogenesis when they are mutationally activated at codon 12, 13, or 61.  Although there is a high degree of similarity among the isoforms, K-Ras mutations are far more frequently obsd. in cancer, and each isoform displays preferential coupling to particular cancer types.  We examd. the mutational spectra of Ras isoforms curated from large-scale tumor profiling and found that each isoform exhibits surprisingly distinctive codon mutation and amino-acid substitution biases.  These findings were unexpected given that these mutations occur in regions that share 100% amino-acid sequence identity among the 3 isoforms.  Of importance, many of these mutational biases were not due to differences in exposure to mutagens, because the patterns were still evident when compared within specific cancer types.  We discuss potential genetic and epigenetic mechanisms, as well as isoform-specific differences in protein structure and signaling, that may promote these distinct mutation patterns and differential coupling to specific cancers.  Cancer Res; 72(10); 2457-67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2lqiicosOLVg90H21EOLACvtfcHk0lhPx0SFBkeyLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D&md5=6d1894847015468f77c8b08b57c6d62a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-2612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-2612%26sid%3Dliteratum%253Aachs%26aulast%3DPrior%26aufirst%3DI.%2BA.%26aulast%3DLewis%26aufirst%3DP.%2BD.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DA%2520comprehensive%2520survey%2520of%2520Ras%2520mutations%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3D10%26spage%3D2457%26epage%3D2467%26doi%3D10.1158%2F0008-5472.CAN-11-2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marabese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganzinelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garassino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caiola, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macerelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauricella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floriani, I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">34014</span>– <span class="NLM_lpage">34022</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.18632%2Foncotarget.5607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26416458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BC283ms1eruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=34014-34022&issue=32&author=M.+Marabeseauthor=M.+Ganzinelliauthor=M.+C.+Garassinoauthor=F.+A.+Shepherdauthor=S.+Pivaauthor=E.+Caiolaauthor=M.+Macerelliauthor=A.+Bettiniauthor=C.+Lauricellaauthor=I.+Floriani&title=KRAS+mutations+affect+prognosis+of+non-small-cell+lung+cancer+patients+treated+with+first-line+platinum+containing+chemotherapy&doi=10.18632%2Foncotarget.5607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy</span></div><div class="casAuthors">Marabese Mirko; Caiola Elisa; Floriani Irene; Broggini Massimo; Rulli Eliana; Ganzinelli Monica; Garassino Marina C; Macerelli Marianna; Shepherd Frances A; Piva Sheila; Farina Gabriella; Bettini Anna; Bonomi Lucia; Lauricella Calogero; Veronese Silvio; Longo Flavia; Fabbri M Agnese; Marsoni Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">34014-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  KRAS mutations seem to indicate a poor outcome in Non-Small-Cell Lung Cancer (NSCLC) but such evidence is still debated.  The aim of this planned ancillary study within the TAILOR trial was to assess the prognostic value of KRAS mutations in advanced NSCLC patients treated with platinum-based first-line chemotherapy.  Patients (N = 540), enrolled in the study in 52 Italian hospitals, were centrally genotyped twice in two independent laboratories for EGFR and KRAS mutational status.Of these, 247 patients were eligible and included in the present study.  The primary endpoint was overall survival (OS) according to KRAS mutational status in patients harboring EGFR wild-type.Sixty (24.3%) out of 247 patients harbored KRAS mutations.  Median OS was 14.3 months and 10.6 months in wild-type and mutated KRAS patients, respectively (unadjusted Hazard Ratio [HR]=1.41, 95%Confidence Interval [CI]: 1.03-1.94 P = 0.032; adjusted HR=1.39, 95%CI: 1.00-1.94 P = 0.050).  This study, with all consecutive patients genotyped, indicates that the presence of KRAS mutations has a mild negative impact on OS in advanced NSCLC patient treated with a first-line platinum-containing regimen.  TRIAL REGISTRATION:  clinicaltrials.gov identifierNCT00637910.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyoFn7ddEXhxFwe7cAcrfPfW6udTcc2eZ8sdNN-o9zvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ms1eruw%253D%253D&md5=8405e9fa5762ce0fd27a414662626763</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5607%26sid%3Dliteratum%253Aachs%26aulast%3DMarabese%26aufirst%3DM.%26aulast%3DGanzinelli%26aufirst%3DM.%26aulast%3DGarassino%26aufirst%3DM.%2BC.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DPiva%26aufirst%3DS.%26aulast%3DCaiola%26aufirst%3DE.%26aulast%3DMacerelli%26aufirst%3DM.%26aulast%3DBettini%26aufirst%3DA.%26aulast%3DLauricella%26aufirst%3DC.%26aulast%3DFloriani%26aufirst%3DI.%26atitle%3DKRAS%2520mutations%2520affect%2520prognosis%2520of%2520non-small-cell%2520lung%2520cancer%2520patients%2520treated%2520with%2520first-line%2520platinum%2520containing%2520chemotherapy%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D32%26spage%3D34014%26epage%3D34022%26doi%3D10.18632%2Foncotarget.5607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lohinai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klikovits, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldvay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostoros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalszky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenessey, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aigner, C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39721</span>, <span class="refDoi"> DOI: 10.1038/srep39721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fsrep39721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=28051122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=39721&issue=1&author=Z.+Lohinaiauthor=T.+Klikovitsauthor=J.+Moldvayauthor=G.+Ostorosauthor=E.+Rasoauthor=J.+Timarauthor=K.+Fabianauthor=I.+Kovalszkyauthor=I.+Kenesseyauthor=C.+Aigner&title=KRAS-mutation+incidence+and+prognostic+value+are+metastatic+site-specific+in+lung+adenocarcinoma%3A+poor+prognosis+in+patients+with+KRAS+mutation+and+bone+metastasis&doi=10.1038%2Fsrep39721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis</span></div><div class="casAuthors">Lohinai, Zoltan; Klikovits, Thomas; Moldvay, Judit; Ostoros, Gyula; Raso, Erzsebet; Timar, Jozsef; Fabian, Katalin; Kovalszky, Ilona; Kenessey, Istvan; Aigner, Clemens; Renyi-Vamos, Ferenc; Klepetko, Walter; Dome, Balazs; Hegedus, Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39721</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS mutation in lung adenocarcinoma (LADC).  We investigated the effect of KRAS mutation on overall survival (OS) in this setting.  In our retrospective study, 500 consecutive Caucasian metastatic LADC patients with known KRAS mutational status were analyzed after excluding 32 patients with EGFR mutations.  KRAS mutation incidence was 28.6%.  The most frequent metastatic sites were lung (45.6%), bone (26.2%), adrenal gland (17.4%), brain (16.8%), pleura (15.6%) and liver (11%).  Patients with intrapulmonary metastasis had significantly increased KRAS mutation frequency compared to those with extrapulmonary metastases (35% vs 26.5%, p = 0.0125).  In contrast, pleural dissemination and liver involvement were assocd. with significantly decreased KRAS mutation incidence (vs all other metastatic sites; 17% (p < 0.001) and 16% (p = 0.02) vs 33%, resp.).  Strikingly, we found a significant prognostic effect of KRAS status only in the bone metastatic subcohort (KRAS-wild-type vs KRAS-mutant; median OS 9.7 v 3.7 mo; HR, 0.49; 95% CI, 0.31 to 0.79; p = 0.003).  Our study suggests that KRAS mutation frequency in LADC patients shows a metastatic site dependent variation and, moreover, that the presence of KRAS mutation is assocd. with significantly worse outcome in bone metastatic cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZSgE4MURwRLVg90H21EOLACvtfcHk0lhPx0SFBkeyLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslOjsw%253D%253D&md5=00a2dc3c1d6273f4975bd3c34a008bfb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fsrep39721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep39721%26sid%3Dliteratum%253Aachs%26aulast%3DLohinai%26aufirst%3DZ.%26aulast%3DKlikovits%26aufirst%3DT.%26aulast%3DMoldvay%26aufirst%3DJ.%26aulast%3DOstoros%26aufirst%3DG.%26aulast%3DRaso%26aufirst%3DE.%26aulast%3DTimar%26aufirst%3DJ.%26aulast%3DFabian%26aufirst%3DK.%26aulast%3DKovalszky%26aufirst%3DI.%26aulast%3DKenessey%26aufirst%3DI.%26aulast%3DAigner%26aufirst%3DC.%26atitle%3DKRAS-mutation%2520incidence%2520and%2520prognostic%2520value%2520are%2520metastatic%2520site-specific%2520in%2520lung%2520adenocarcinoma%253A%2520poor%2520prognosis%2520in%2520patients%2520with%2520KRAS%2520mutation%2520and%2520bone%2520metastasis%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D39721%26doi%3D10.1038%2Fsrep39721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gounder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Tine, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhem, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conry, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movva, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Sorafenib for advanced and refractory desmoid tumors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">2417</span>– <span class="NLM_lpage">2428</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1805052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1056%2FNEJMoa1805052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30575484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlt1SjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=2417-2428&issue=25&author=M.+M.+Gounderauthor=M.+R.+Mahoneyauthor=B.+A.+Van+Tineauthor=V.+Raviauthor=S.+Attiaauthor=H.+A.+Deshpandeauthor=A.+A.+Guptaauthor=M.+M.+Milhemauthor=R.+M.+Conryauthor=S.+Movva&title=Sorafenib+for+advanced+and+refractory+desmoid+tumors&doi=10.1056%2FNEJMoa1805052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib for advanced and refractory desmoid tumors</span></div><div class="casAuthors">Gounder, Mrinal M.; Mahoney, Michelle R.; Van Tine, Brian A.; Ravi, Vinod; Attia, Steven; Deshpande, Hari A.; Gupta, Abha A.; Milhem, Mohammed M.; Conry, Robert M.; Movva, Sujana; Pishvaian, Michael J.; Riedel, Richard F.; Sabagh, Tarek; Tap, William D.; Horvat, Natally; Basch, Ethan; Schwartz, Lawrence H.; Maki, Robert G.; Agaram, Narasimhan P.; Lefkowitz, Robert A.; Mazaheri, Yousef; Yamashita, Rikiya; Wright, John J.; Dueck, Amylou C.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2417-2427</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs.  There is no std. of care. methods In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.  Crossover to the sorafenib group was permitted for patients in the placebo group who had disease progression.  The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated. results With a median follow-up of 27.2 mo, the 2-yr progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001).  Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.  The median time to an objective response among patients who had a response was 9.6 mo (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 mo (interquartile range, 11.2 to 31.1) in the placebo group.  The objective responses are ongoing.  Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%). conclusions Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged progression-free survival and induced durable responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1f78z_60ZrVg90H21EOLACvtfcHk0ljkYuQuBfDubA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlt1SjtQ%253D%253D&md5=1ea0d38a8e70ca3552886654a7efc7a2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1805052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1805052%26sid%3Dliteratum%253Aachs%26aulast%3DGounder%26aufirst%3DM.%2BM.%26aulast%3DMahoney%26aufirst%3DM.%2BR.%26aulast%3DVan%2BTine%26aufirst%3DB.%2BA.%26aulast%3DRavi%26aufirst%3DV.%26aulast%3DAttia%26aufirst%3DS.%26aulast%3DDeshpande%26aufirst%3DH.%2BA.%26aulast%3DGupta%26aufirst%3DA.%2BA.%26aulast%3DMilhem%26aufirst%3DM.%2BM.%26aulast%3DConry%26aufirst%3DR.%2BM.%26aulast%3DMovva%26aufirst%3DS.%26atitle%3DSorafenib%2520for%2520advanced%2520and%2520refractory%2520desmoid%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D25%26spage%3D2417%26epage%3D2428%26doi%3D10.1056%2FNEJMoa1805052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.+C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurata&title=Osimertinib+in+untreated+EGFR-mutated+advanced+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0ljkYuQuBfDubA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26atitle%3DOsimertinib%2520in%2520untreated%2520EGFR-mutated%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashiguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iinuma, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer</span>. <i>Int. J. Colorectal Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1007/s00384-019-03344-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1007%2Fs00384-019-03344-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31309326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BB3Mznslejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=1491-1496&issue=8&author=T.+Hayamaauthor=Y.+Hashiguchiauthor=K.+Okamotoauthor=Y.+Okadaauthor=K.+Onoauthor=R.+Shimadaauthor=T.+Ozawaauthor=T.+Toyodaauthor=T.+Tsuchiyaauthor=H.+Iinuma&title=G12V+and+G12C+mutations+in+the+gene+KRAS+are+associated+with+a+poorer+prognosis+in+primary+colorectal+cancer&doi=10.1007%2Fs00384-019-03344-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer</span></div><div class="casAuthors">Hayama Tamuro; Hashiguchi Yojiro; Okada Yuka; Ono Kohei; Shimada Ryu; Ozawa Tsuyoshi; Tsuchiya Takeshi; Iinuma Hisae; Nozawa Keijiro; Matsuda Keiji; Okamoto Koichi; Toyoda Tetsutaka</div><div class="citationInfo"><span class="NLM_cas:title">International journal of colorectal disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1491-1496</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The increased incidence of colorectal cancer (CRC) has necessitated the development of novel prognostic and predictive factors from which new diagnostic tests could evolve.  Evidence suggests the KRAS gene represents such a factor; its mutations are considered to be early indicators of CRC progression.  This study assessed the prognostic impact of specific known KRAS codon 12/13 mutations on survival in patients with CRC.  METHODS:  Formalin-fixed paraffin-embedded tissue blocks or sections from primary were obtained from patients registered between 2014 and 2016 for genomic DNA extraction.  KRAS gene was analyzed by direct sequencing or Luminex assay.  The primary endpoint was the frequency of KRAS gene mutations and the secondary endpoints were differences in KRAS mutation rates by various stratification factors.  Univariate and multivariate analyses were performed to investigate relationships between KRAS mutation rates and patient background factors.  RESULTS:  Sequencing of 200 CRC primary tumor samples demonstrated 74 (37.5%) with KRAS mutations in codons 12 (77%; 57/74) and 13 (23%; 17/74), all of which were TNM stages I-III.  Tumors with KRAS mutations were more frequently located in the right side of the colon.  Multivariate analysis indicated that G12V or G12C mutations were associated with poor prognosis [hazard ratio (HR) = 3.77, 95% confidence interval (CI), 1.54-8.39 and HR = 6.57; 95% CI, 1.90-17.7, respectively] in terms of recurrence-free survival.  CONCLUSION:  KRAS codon 12G-to-V or G-to-C mutations are independent prognostic factors in patients with stage I-III CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRc23_CSyS508ULxIEhxUjPfW6udTcc2eYAhnjN8I4CH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mznslejug%253D%253D&md5=895688f5e8c9e70683851435a9039ea1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00384-019-03344-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00384-019-03344-9%26sid%3Dliteratum%253Aachs%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DHashiguchi%26aufirst%3DY.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DR.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DToyoda%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DT.%26aulast%3DIinuma%26aufirst%3DH.%26atitle%3DG12V%2520and%2520G12C%2520mutations%2520in%2520the%2520gene%2520KRAS%2520are%2520associated%2520with%2520a%2520poorer%2520prognosis%2520in%2520primary%2520colorectal%2520cancer%26jtitle%3DInt.%2520J.%2520Colorectal%2520Dis.%26date%3D2019%26volume%3D34%26issue%3D8%26spage%3D1491%26epage%3D1496%26doi%3D10.1007%2Fs00384-019-03344-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, E. F.</span></span> <span> </span><span class="NLM_article-title">The structure of Ras protein: a model for a universal molecular switch</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1016/0968-0004(91)90156-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2F0968-0004%2891%2990156-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1785141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3MXmslemsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1991&pages=382-387&author=A.+Wittinghoferauthor=E.+F.+Pal&title=The+structure+of+Ras+protein%3A+a+model+for+a+universal+molecular+switch&doi=10.1016%2F0968-0004%2891%2990156-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of Ras protein:  a model for a universal molecular switch</span></div><div class="casAuthors">Wittinghofer, Alfred; Pai, Emil F.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">382-7</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    </div><div class="casAbstract">A review and discussion with 33 refs.  X-ray crystallog. has revealed the mol. architecture of the cellular and oncogenic forms of p21Ha-ras, the protein encoded by the human Ha-ras gene, in both its active (GTP-bound) and in its inactive (GDP-bound) forms.  From comparison of these 2 structures, a mechanism is suggested for the GTPase hydrolysis reaction that triggers the conformational change necessary for signal transduction.  The structures have also allowed identification of the structural consequences of point mutations and the way in which they interfere with the intrinsic GTPase activity of p21ras.  The p21ras structure is similar to that of the G-domain of elongation factor Tu (EF-Tu) from Escherichia coli, suggesting that p21ras can serve as a good model for other guanine nucleotide-binding proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolH9XO3ovsfLVg90H21EOLACvtfcHk0lj3kw4Op4kvDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmslemsb4%253D&md5=85e2227d6ca0c097d3b5efc8fdbb3156</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2F0968-0004%2891%2990156-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0968-0004%252891%252990156-P%26sid%3Dliteratum%253Aachs%26aulast%3DWittinghofer%26aufirst%3DA.%26aulast%3DPal%26aufirst%3DE.%2BF.%26atitle%3DThe%2520structure%2520of%2520Ras%2520protein%253A%2520a%2520model%2520for%2520a%2520universal%2520molecular%2520switch%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1991%26volume%3D16%26spage%3D382%26epage%3D387%26doi%3D10.1016%2F0968-0004%2891%2990156-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downward, J.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrc969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&issue=1&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy&doi=10.1038%2Fnrc969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0lj3kw4Op4kvDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26issue%3D1%26spage%3D11%26epage%3D22%26doi%3D10.1038%2Fnrc969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">The GTPase superfamily: conserved structure and molecular mechanism</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>349</i></span> (<span class="NLM_issue">6305</span>),  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1038/349117a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2F349117a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1898771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3MXlslygsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=1991&pages=117-127&issue=6305&author=H.+R.+Bourneauthor=D.+A.+Sandersauthor=F.+McCormick&title=The+GTPase+superfamily%3A+conserved+structure+and+molecular+mechanism&doi=10.1038%2F349117a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The GTPase superfamily:  conserved structure and molecular mechanism</span></div><div class="casAuthors">Bourne, Henry R.; Sanders, David A.; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">6305</span>),
    <span class="NLM_cas:pages">117-27</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A review with 150 refs.  GTPases are conserved mol. switches, built according to a common structural design.  Rapidly accruing knowledge of individual GTPases, crystal structures, biochem. properties, or results of mol. genetic expts., support and generate hypotheses relating structure to function in other members of the diverse family of GTPases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoitAaJH96dMrVg90H21EOLACvtfcHk0lj3kw4Op4kvDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlslygsA%253D%253D&md5=38aeab01721108f6e6827033830ed6bf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2F349117a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F349117a0%26sid%3Dliteratum%253Aachs%26aulast%3DBourne%26aufirst%3DH.%2BR.%26aulast%3DSanders%26aufirst%3DD.%2BA.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DThe%2520GTPase%2520superfamily%253A%2520conserved%2520structure%2520and%2520molecular%2520mechanism%26jtitle%3DNature%26date%3D1991%26volume%3D349%26issue%3D6305%26spage%3D117%26epage%3D127%26doi%3D10.1038%2F349117a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span> <span> </span><span class="NLM_article-title">Therapeutic strategies to target RAS-mutant cancers</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">720</span>, <span class="refDoi"> DOI: 10.1038/s41571-018-0105-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41571-018-0105-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30275515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVeqs7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=709-720&issue=11&author=M.+B.+Ryanauthor=R.+B.+Corcoran&title=Therapeutic+strategies+to+target+RAS-mutant+cancers&doi=10.1038%2Fs41571-018-0105-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to target RAS-mutant cancers</span></div><div class="casAuthors">Ryan, Meagan B.; Corcoran, Ryan B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">709-720</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive.  A key aspect of this challenge is the fact that direct inhibition of RAS proteins has proved difficult, leading researchers to test numerous alternative strategies aimed at exploiting RAS-related vulnerabilities or targeting RAS effectors.  In the past few years, we have witnessed renewed efforts to target RAS directly, with several promising strategies being tested in clin. trials at different stages of completion.  Important advances have also been made in approaches designed to indirectly target RAS by improving inhibition of RAS effectors, exploiting synthetic lethal interactions or metabolic dependencies, using therapeutic combination strategies or harnessing the immune system.  In this Review, we describe historical and ongoing efforts to target RAS-mutant cancers and outline the current therapeutic landscape in the collective quest to overcome the effects of this crucial oncogene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojQcBt2xwv47Vg90H21EOLACvtfcHk0lj3kw4Op4kvDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVeqs7bM&md5=44839eb1482998d710b74e9362f4e0ea</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41571-018-0105-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41571-018-0105-0%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DM.%2BB.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26atitle%3DTherapeutic%2520strategies%2520to%2520target%2520RAS-mutant%2520cancers%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26issue%3D11%26spage%3D709%26epage%3D720%26doi%3D10.1038%2Fs41571-018-0105-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Drugging the undruggable RAS: mission possible?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">828</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1038/nrd4389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrd4389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=25323927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=828-851&issue=11&author=A.+D.+Coxauthor=S.+W.+Fesikauthor=A.+C.+Kimmelmanauthor=J.+Luoauthor=C.+J.+Der&title=Drugging+the+undruggable+RAS%3A+mission+possible%3F&doi=10.1038%2Fnrd4389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the undruggable RAS: Mission Possible?</span></div><div class="casAuthors">Cox, Adrienne D.; Fesik, Stephen W.; Kimmelman, Alec C.; Luo, Ji; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">828-851</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite more than three decades of intensive effort, no effective pharmacol. inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'.  However, recent data from the lab. and the clinic have renewed our hope for the development of RAS-inhibitory mols.  In this Review, we summarize the progress and the promise of five key approaches.  Firstly, we focus on the prospects of using direct inhibitors of RAS.  Secondly, we address the issue of whether blocking RAS membrane assocn. is a viable approach.  Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favorable current approach.  Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise.  Finally, RAS-mediated changes in cell metab. have recently been described and we discuss whether these changes could be exploited for new therapeutic directions.  We conclude with perspectives on how addnl. complexities, which are not yet fully understood, may affect each of these approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvWzW1JqxN4LVg90H21EOLACvtfcHk0lgkgQccq6KCyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE&md5=6c8645293b079023de7d31011ae1a192</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd4389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4389%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DDrugging%2520the%2520undruggable%2520RAS%253A%2520mission%2520possible%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D11%26spage%3D828%26epage%3D851%26doi%3D10.1038%2Fnrd4389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span> <span> </span><span class="NLM_article-title">Crystal structures at 2.2 A resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP.</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>217</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1016/0022-2836(91)90753-S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2F0022-2836%2891%2990753-S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1899707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3MXhtFOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=1991&pages=503-516&issue=3&author=L.+A.+Tongauthor=A.+M.+de+Vosauthor=M.+V.+Milburnauthor=S.+H.+Kim&title=Crystal+structures+at+2.2+A+resolution+of+the+catalytic+domains+of+normal+ras+protein+and+an+oncogenic+mutant+complexed+with+GDP.&doi=10.1016%2F0022-2836%2891%2990753-S"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures at 2.2 Å resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP</span></div><div class="casAuthors">Tong, Liang; De Vos, Abraham M.; Milburn, Michael V.; Kim, Sung Hou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">503-16</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">The biol. functions of ras proteins are controlled by the bound guanine nucleotides, GDP or GTP.  The GTP-bound conformation was biol. active, and was rapidly deactivated to the GDP-bound conformation through interaction with GAP (GTPase-activating protein).  Most transforming mutants of ras proteins have drastically reduced GTP hydrolysis rates even in the presence of GAP.  The crystal structures of the GDP complexes of ras proteins at 2.2 Å resoln. revealed the detailed interaction between the ras proteins and the GDP mol.  All of the currently known transforming mutation positions are clustered around the bound guanine nucleotide mol.  The presumed effector region and the GAP recognition region are both highly exposed.  No significant structural differences were found between the GDP complexes of normal ras protein and the oncogenic mutant with valine at position 12, except the side-chain of the valine residue.  However, comparison with GTP-analog complexes of ras proteins suggests that the valine side-chain may inhibit GTP hydrolysis in 2 possible ways: (1) interacting directly with the γ-phosphate and altering its orientation or the conformation of protein residues around the phosphates; and/or (2) preventing either the departure of γ-phosphate on GTP hydrolysis or the entrance of a nucleophilic group to attack the γ-phosphate.  The structural similarity between ras protein and bacterial elongation factor Tu suggests that their common structural motif might be conserved for other guanine nucleotide-binding proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6GojCi4jrr7Vg90H21EOLACvtfcHk0lgkgQccq6KCyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtFOhsb8%253D&md5=8995773660b0e6ba4a7982c25fcc19fd</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2F0022-2836%2891%2990753-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-2836%252891%252990753-S%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%2BA.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26atitle%3DCrystal%2520structures%2520at%25202.2%2520A%2520resolution%2520of%2520the%2520catalytic%2520domains%2520of%2520normal%2520ras%2520protein%2520and%2520an%2520oncogenic%2520mutant%2520complexed%2520with%2520GDP.%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1991%26volume%3D217%26issue%3D3%26spage%3D503%26epage%3D516%26doi%3D10.1016%2F0022-2836%2891%2990753-S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hallak, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azmi, A. S.</span></span> <span> </span><span class="NLM_article-title">KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">101974</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2020.101974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.ctrv.2020.101974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=32014824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFKqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2020&pages=101974&author=M.+Nagasakaauthor=Y.+Liauthor=A.+Sukariauthor=S.+I.+Ouauthor=M.+N.+Al-Hallakauthor=A.+S.+Azmi&title=KRAS+G12C+Game+of+Thrones%2C+which+direct+KRAS+inhibitor+will+claim+the+iron+throne%3F&doi=10.1016%2Fj.ctrv.2020.101974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?</span></div><div class="casAuthors">Nagasaka, Misako; Li, Yiwei; Sukari, Ammar; Ou, Sai-Hong Ignatius; Al-Hallak, Mohammed Najeeb; Azmi, Asfar S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101974</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) are among the most common aberrations in cancer, including non-small cell lung cancer (NSCLC).  The lack of an ideal small mol. binding pocket in the KRAS protein and its high affinity towards the abundance of cellular guanosine triphosphate (GTP) renders the design of specific small mol. drugs challenging.  Despite efforts, KRAS remains a challenging therapeutic target.  Among the different known mutations; the KRASG12C (glycine 12 to cysteine) mutation has been considered potentially druggable.  Several novel covalent direct inhibitors targeting KRASG12C with similar covalent binding mechanisms are now in clin. trials.  Both AMG 510 from Amgen and MRTX849 from Mirati Therapeutics covalently binds to KRASG12C at the cysteine at residue 12, keeping KRASG12C in its inactive GDP-bound state and inhibiting KRAS-dependent signaling.  Both inhibitors are being studied as a single agent or as combination with other targets.  In addn., two novel KRAS G12C inhibitors JNJ-74699157 and LY3499446 will have entered phase 1 studies by the end of 2019.  Given the rapid clin. development of 4 direct covalent KRAS G12C inhibitors within a short period of time, understanding the similarities and differences among these will be important to det. the best treatment option based on tumor specific response (NSCLC vs. colorectal carcinoma), potential resistance mechanisms (i.e. anticipated acquired mutation at the cysteine 12 residue) and central nervous system (CNS) activity.  Addnl., further investigation evaluating the efficacy and safety of combination therapies with agents such as immune checkpoint inhibitors will be important next steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW_hHZl2d9TrVg90H21EOLACvtfcHk0lgkgQccq6KCyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFKqur8%253D&md5=94a40ad262868c5ff7185da4aed0bf62</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2020.101974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2020.101974%26sid%3Dliteratum%253Aachs%26aulast%3DNagasaka%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSukari%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DAl-Hallak%26aufirst%3DM.%2BN.%26aulast%3DAzmi%26aufirst%3DA.%2BS.%26atitle%3DKRAS%2520G12C%2520Game%2520of%2520Thrones%252C%2520which%2520direct%2520KRAS%2520inhibitor%2520will%2520claim%2520the%2520iron%2520throne%253F%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2020%26volume%3D84%26spage%3D101974%26doi%3D10.1016%2Fj.ctrv.2020.101974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppada, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span> (<span class="NLM_issue">7781</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1694-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41586-019-1694-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31666701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=217-223&issue=7781&author=J.+Canonauthor=K.+Rexauthor=A.+Y.+Saikiauthor=C.+Mohrauthor=K.+Cookeauthor=D.+Bagalauthor=K.+Gaidaauthor=T.+Holtauthor=C.+G.+Knutsonauthor=N.+Koppada&title=The+clinical+KRAS%28G12C%29+inhibitor+AMG+510+drives+anti-tumour+immunity&doi=10.1038%2Fs41586-019-1694-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span></div><div class="casAuthors">Canon, Jude; Rex, Karen; Saiki, Anne Y.; Mohr, Christopher; Cooke, Keegan; Bagal, Dhanashri; Gaida, Kevin; Holt, Tyler; Knutson, Charles G.; Koppada, Neelima; Lanman, Brian A.; Werner, Jonathan; Rapaport, Aaron S.; San Miguel, Tisha; Ortiz, Roberto; Osgood, Tao; Sun, Ji-Rong; Zhu, Xiaochun; McCarter, John D.; Volak, Laurie P.; Houk, Brett E.; Fakih, Marwan G.; O'Neil, Bert H.; Price, Timothy J.; Falchook, Gerald S.; Desai, Jayesh; Kuo, James; Govindan, Ramaswamy; Hong, David S.; Ouyang, Wenjun; Henary, Haby; Arvedson, Tara; Cee, Victor J.; Lipford, J. Russell</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7781</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumors1,2.  The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclin. activity3-5.  Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity.  Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clin. development.  In preclin. analyses, treatment with AMG 510 led to the regression of KRASG12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents.  In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumor microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors.  Cured mice rejected the growth of isogenic KRASG12D tumors, which suggests adaptive immunity against shared antigens.  Furthermore, in clin. trials, AMG 510 demonstrated anti-tumor activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHdBftQfnhbVg90H21EOLACvtfcHk0lhwtvw8j1ENbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F&md5=3819175980905976ba87ff545b9506e1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1694-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1694-1%26sid%3Dliteratum%253Aachs%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DK.%26aulast%3DBagal%26aufirst%3DD.%26aulast%3DGaida%26aufirst%3DK.%26aulast%3DHolt%26aufirst%3DT.%26aulast%3DKnutson%26aufirst%3DC.%2BG.%26aulast%3DKoppada%26aufirst%3DN.%26atitle%3DThe%2520clinical%2520KRAS%2528G12C%2529%2520inhibitor%2520AMG%2520510%2520drives%2520anti-tumour%2520immunity%26jtitle%3DNature%26date%3D2019%26volume%3D575%26issue%3D7781%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fs41586-019-1694-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calinisan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowcut, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-19-1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F2159-8290.CD-19-1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31658955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtleitbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=54-71&issue=1&author=J.+Hallinauthor=L.+D.+Engstromauthor=L.+Hargisauthor=A.+Calinisanauthor=R.+Arandaauthor=D.+M.+Briereauthor=N.+Sudhakarauthor=V.+Bowcutauthor=B.+R.+Baerauthor=J.+A.+Ballard&title=The+KRASG12C+inhibitor+MRTX849+provides+insight+toward+therapeutic+susceptibility+of+KRAS-mutant+cancers+in+mouse+models+and+patients&doi=10.1158%2F2159-8290.CD-19-1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients</span></div><div class="casAuthors">Hallin, Jill; Engstrom, Lars D.; Hargis, Lauren; Calinisan, Andrew; Aranda, Ruth; Briere, David M.; Sudhakar, Niranjan; Bowcut, Vickie; Baer, Brian R.; Ballard, Joshua A.; Burkard, Michael R.; Fell, Jay B.; Fischer, John P.; Vigers, Guy P.; Xue, Yaohua; Gatto, Sole; Fernandez-Banet, Julio; Pavlicek, Adam; Velastagui, Karen; Chao, Richard C.; Barton, Jeremy; Pierobon, Mariaelena; Baldelli, Elisa; Patricoin, Emanuel F., III; Cassidy, Douglas P.; Marx, Matthew A.; Rybkin, Igor I.; Johnson, Melissa L.; Ou, Sai-Hong Ignatius; Lito, Piro; Papadopoulos, Kyriakos P.; Janne, Pasi A.; Olson, Peter; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-71</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite decades of research, efforts to directly target KRAS have been challenging.  MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits KRAS-dependent signaling.  MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRASG12C-pos. cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been obsd. in patients with KRASG12C-pos. lung and colon adenocarcinomas.  Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant nonclin. models identified mechanisms implicated in limiting antitumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence.  These factors included activation of receptor tyrosine kinases (RTK), bypass of KRAS dependence, and genetic dysregulation of cell cycle.  Combinations of MRTX849 with agents that target RTKs, mTOR, or cell cycle demonstrated enhanced response and marked tumor regression in several tumor models, including MRTX849-refractory models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxAUhi3n75ULVg90H21EOLACvtfcHk0lhwtvw8j1ENbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtleitbfL&md5=48f4c34e757385eed89b47f19cbb10db</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-1167%26sid%3Dliteratum%253Aachs%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHargis%26aufirst%3DL.%26aulast%3DCalinisan%26aufirst%3DA.%26aulast%3DAranda%26aufirst%3DR.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DSudhakar%26aufirst%3DN.%26aulast%3DBowcut%26aufirst%3DV.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520KRASG12C%2520inhibitor%2520MRTX849%2520provides%2520insight%2520toward%2520therapeutic%2520susceptibility%2520of%2520KRAS-mutant%2520cancers%2520in%2520mouse%2520models%2520and%2520patients%26jtitle%3DCancer%2520Discovery%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D54%26epage%3D71%26doi%3D10.1158%2F2159-8290.CD-19-1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassar, N.</span></span> <span> </span><span class="NLM_article-title">The structural basis for the transition from Ras-GTP to Ras-GDP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">12138</span>– <span class="NLM_lpage">12142</span>, <span class="refDoi"> DOI: 10.1073/pnas.192453199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.192453199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=12213964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD38XntlClu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=12138-12142&issue=19&author=B.+E.+Hallauthor=D.+Bar-Sagiauthor=N.+Nassar&title=The+structural+basis+for+the+transition+from+Ras-GTP+to+Ras-GDP&doi=10.1073%2Fpnas.192453199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for the transition from Ras-GTP to Ras-GDP</span></div><div class="casAuthors">Hall, Brian E.; Bar-Sagi, Dafna; Nassar, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12138-12142</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The conformational changes in Ras that accompany the hydrolysis of GTP are crit. to its function as a mol. switch in signaling pathways.  Understanding how GTP is hydrolyzed by revealing the sequence of intermediary structures in the reaction is essential for understanding Ras signaling.  Until now, no structure of an intermediate in GTP hydrolysis has been exptl. detd. for Ras alone.  We have solved the crystal structure of the Ala-59 to Gly mutant of Ras, (RasA59G), bound to guanosine 5'-imidotriphosphate or GDP to 1.7-Å resoln.  In the guanosine 5'-imidotriphosphate-bound form, this mutant adopts a conformation that is intermediate between the GTP- and GDP-bound forms of wild-type Ras and that is similar to what has been predicted by mol. dynamics simulation.  This conformation is stabilized by direct and water-mediated interactions between the switch 1 and switch 2 regions and is characterized by an increase in the binding affinity for GTP.  We propose that the structural changes promoted by the Ala-59 to Gly mutation exhibit a discrete conformational state assumed by wild-type Ras during GTP hydrolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc87uPfQFSWrVg90H21EOLACvtfcHk0lhwtvw8j1ENbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntlClu7o%253D&md5=e50240da002f78dd9db37a61cc211a2e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.192453199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.192453199%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DB.%2BE.%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DNassar%26aufirst%3DN.%26atitle%3DThe%2520structural%2520basis%2520for%2520the%2520transition%2520from%2520Ras-GTP%2520to%2520Ras-GDP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26issue%3D19%26spage%3D12138%26epage%3D12142%26doi%3D10.1073%2Fpnas.192453199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVos, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaizumi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span> <span> </span><span class="NLM_article-title">Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>247</i></span> (<span class="NLM_issue">4945</span>),  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">945</span>, <span class="refDoi"> DOI: 10.1126/science.2406906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1126%2Fscience.2406906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=2406906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3cXhslCgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1990&pages=939-945&issue=4945&author=M.+V.+Milburnauthor=L.+Tongauthor=A.+M.+DeVosauthor=A.+Brungerauthor=Z.+Yamaizumiauthor=S.+Nishimuraauthor=S.-H.+Kim&title=Molecular+switch+for+signal+transduction%3A+structural+differences+between+active+and+inactive+forms+of+protooncogenic+ras+proteins&doi=10.1126%2Fscience.2406906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular switch for signal transduction:  structural differences between active and inactive forms of protooncogenic ras proteins</span></div><div class="casAuthors">Milburn, Michael V.; Tong, Liang; DeVos, Abraham M.; Bruenger, Axel; Yamaizumi, Ziro; Nishimura, Susumu; Kim, Sung Hou</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">4945</span>),
    <span class="NLM_cas:pages">939-45</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Ras proteins participate as a mol. switch in the early steps of the signal transduction pathway that is assocd. with cell growth and differentiation.  When the protein is in its GTP complexed form it is active in signal transduction, whereas it is inactive in its GDP complexed form.  A comparison of 8 3-dimensional structures of ras proteins in 4 different crystal lattices, 5 with a nonhydrolyzable GTP analog and 3 with GDP, reveals that the on and off states of the switch are distinguished by conformational differences that span a length of >40 Å, and are induced by the γ-phosphate.  The most significant differences are localized in 2 regions: residues 30-38 (the switch I region) in the second loop and residues 60-76 (the switch II region) consisting of the fourth loop and the short α-helix that follows the loop.  Both regions are highly exposed and form a continuous strip on the mol. surface most likely to be the recognition sites for the effector and receptor mol. (or mols.).  The conformational differences also provide a structural basis for understanding the biol. and biochem. changes of the proteins due to oncogenic mutations, autophosphorylation, and GTP hydrolysis, and for understanding the interactions with other proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYvBH7oUudMLVg90H21EOLACvtfcHk0lgH32SxtuuGKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslCgtrw%253D&md5=edc58a62f4a5ad734a7f6bcc1c84a333</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.2406906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2406906%26sid%3Dliteratum%253Aachs%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DDeVos%26aufirst%3DA.%2BM.%26aulast%3DBrunger%26aufirst%3DA.%26aulast%3DYamaizumi%26aufirst%3DZ.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.-H.%26atitle%3DMolecular%2520switch%2520for%2520signal%2520transduction%253A%2520structural%2520differences%2520between%2520active%2520and%2520inactive%2520forms%2520of%2520protooncogenic%2520ras%2520proteins%26jtitle%3DScience%26date%3D1990%26volume%3D247%26issue%3D4945%26spage%3D939%26epage%3D945%26doi%3D10.1126%2Fscience.2406906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratcioglu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keskin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Ras conformational ensembles, allostery, and signaling</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6607</span>– <span class="NLM_lpage">6665</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=6607-6665&issue=11&author=S.+Luauthor=H.+Jangauthor=S.+Muratciogluauthor=A.+Gursoyauthor=O.+Keskinauthor=R.+Nussinovauthor=J.+Zhang&title=Ras+conformational+ensembles%2C+allostery%2C+and+signaling&doi=10.1021%2Facs.chemrev.5b00542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ras Conformational Ensembles, Allostery, and Signaling</span></div><div class="casAuthors">Lu, Shaoyong; Jang, Hyunbum; Muratcioglu, Serena; Gursoy, Attila; Keskin, Ozlem; Nussinov, Ruth; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6607-6665</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ras proteins are classical members of small GTPases that function as mol. switches by alternating between inactive GDP-bound and active GTP-bound states.  Ras activation is regulated by guanine nucleotide exchange factors that catalyze the exchange of GDP by GTP, and inactivation is terminated by GTPase-activating proteins that accelerate the intrinsic GTP hydrolysis rate by orders of magnitude.  In this review, we focus on data that have accumulated over the past few years pertaining to the conformational ensembles and the allosteric regulation of Ras proteins and their interpretation from our conformational landscape standpoint.  The Ras ensemble embodies all states, including the ligand-bound conformations, the activated (or inactivated) allosteric modulated states, post-translationally modified states, mutational states, transition states, and nonfunctional states serving as a reservoir for emerging functions.  The ensemble is shifted by distinct mutational events, cofactors, post-translational modifications, and different membrane compns.  A better understanding of Ras biol. can contribute to therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY2oezVaRCvbVg90H21EOLACvtfcHk0lgH32SxtuuGKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyhu74%253D&md5=7600b971015bd3cf635ca1b4299dc7d5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00542%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DMuratcioglu%26aufirst%3DS.%26aulast%3DGursoy%26aufirst%3DA.%26aulast%3DKeskin%26aufirst%3DO.%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DRas%2520conformational%2520ensembles%252C%2520allostery%252C%2520and%2520signaling%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26issue%3D11%26spage%3D6607%26epage%3D6665%26doi%3D10.1021%2Facs.chemrev.5b00542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krengel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span> <span> </span><span class="NLM_article-title">Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>341</i></span> (<span class="NLM_issue">6239</span>),  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/341209a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2F341209a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=2476675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaL1MXmtFSksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1989&pages=209-214&issue=6239&author=E.+F.+Paiauthor=W.+Kabschauthor=U.+Krengelauthor=K.+C.+Holmesauthor=J.+Johnauthor=A.+Wittinghofer&title=Structure+of+the+guanine-nucleotide-binding+domain+of+the+Ha-ras+oncogene+product+p21+in+the+triphosphate+conformation&doi=10.1038%2F341209a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation</span></div><div class="casAuthors">Pai, Emil F.; Kabsch, Wolfgang; Krengel, Ute; Holmes, Kenneth C.; John, Jacob; Wittinghofer, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6239</span>),
    <span class="NLM_cas:pages">209-14</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The crystal structure of the guanine nucleotide-binding domain of p21 (amino acids 1-166) complexed to the GTP analog guanosine-5'-(β,γ-imido)triphosphate (GppNp) has been detd. at a resoln. of 2.6 Å.  The topol. order of secondary structure elements is the same as that of the guanine nucleotide-binding domain of bacterial elongation factor EF-Tu.  Many interactions between nucleotide and protein have been identified.  The effects of point mutations and the conservation of amino acid sequence in the guanine-nucleotide-binding proteins are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphBg5LmSHO07Vg90H21EOLACvtfcHk0lgH32SxtuuGKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtFSksLs%253D&md5=799c6cfbd2561db9c075fdccfebab93a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2F341209a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F341209a0%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DE.%2BF.%26aulast%3DKabsch%26aufirst%3DW.%26aulast%3DKrengel%26aufirst%3DU.%26aulast%3DHolmes%26aufirst%3DK.%2BC.%26aulast%3DJohn%26aufirst%3DJ.%26aulast%3DWittinghofer%26aufirst%3DA.%26atitle%3DStructure%2520of%2520the%2520guanine-nucleotide-binding%2520domain%2520of%2520the%2520Ha-ras%2520oncogene%2520product%2520p21%2520in%2520the%2520triphosphate%2520conformation%26jtitle%3DNature%26date%3D1989%26volume%3D341%26issue%3D6239%26spage%3D209%26epage%3D214%26doi%3D10.1038%2F341209a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spencer-Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Bryan, J. P.</span></span> <span> </span><span class="NLM_article-title">Direct inhibition of RAS: quest for the holy grail?</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2017.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.semcancer.2017.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29248537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWmu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=138-148&author=R.+Spencer-Smithauthor=J.+P.+O%E2%80%99Bryan&title=Direct+inhibition+of+RAS%3A+quest+for+the+holy+grail%3F&doi=10.1016%2Fj.semcancer.2017.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Direct inhibition of RAS: Quest for the Holy Grail?</span></div><div class="casAuthors">Spencer-Smith, Russell; O'Bryan, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-148</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  RAS GTPases (H-, K-, and N-RAS) are the most frequently mutated oncoprotein family in human cancer.  However, the relatively smooth surface architecture of RAS and its picomolar affinity for nucleotide have given rise to the assumption that RAS is an "undruggable" target.  Recent advancements in drug screening, mol. modeling, and a greater understanding of RAS function have led to a resurgence in efforts to pharmacol. target this challenging foe.  This review focuses on the state of the art of RAS inhibition, the approaches taken to achieve this goal, and the challenges of translating these discoveries into viable therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJGavQxEObQ7Vg90H21EOLACvtfcHk0lgH32SxtuuGKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWmu7%252FN&md5=0286efe034301610071e6db9586433f4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2017.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2017.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSpencer-Smith%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Bryan%26aufirst%3DJ.%2BP.%26atitle%3DDirect%2520inhibition%2520of%2520RAS%253A%2520quest%2520for%2520the%2520holy%2520grail%253F%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2019%26volume%3D54%26spage%3D138%26epage%3D148%26doi%3D10.1016%2Fj.semcancer.2017.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">The Ras–membrane interface: isoform-specific differences in the catalytic domain</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-14-0535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F1541-7786.MCR-14-0535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=25566993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlChsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=595-603&issue=4&author=J.+A.+Parkerauthor=C.+Mattos&title=The+Ras%E2%80%93membrane+interface%3A+isoform-specific+differences+in+the+catalytic+domain&doi=10.1158%2F1541-7786.MCR-14-0535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras-Membrane Interface: Isoform-Specific Differences in the Catalytic Domain</span></div><div class="casAuthors">Parker, Jillian A.; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">595-603</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The small GTPase Ras is mutated in about 20% of human cancers, primarily at active site amino acid residues G12, G13, and Q61.  Thus, structural biol. research has focused on the active site, impairment of GTP hydrolysis by oncogenic mutants, and characterization of protein-protein interactions in the effector lobe half of the protein.  The C-terminal hypervariable region has increasingly gained attention due to its importance in H-Ras, N-Ras, and K-Ras differences in membrane assocn.  A high-resoln. mol. view of the Ras-membrane interaction involving the allosteric lobe of the catalytic domain has lagged behind, although evidence suggests that it contributes to isoform specificity.  The allosteric lobe has recently gained interest for harboring potential sites for more selective targeting of this elusive "undruggable" protein.  The present review reveals crit. insight that isoform-specific differences appear prominently at these potentially targetable sites and integrates these differences with knowledge of Ras plasma membrane localization, with the intent to better understand the structure-function relationships needed to design isoform-specific Ras inhibitors.  ©2015 AACR, Mol Cancer Res; 13(4); 595-603.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr68q_rIeYO07Vg90H21EOLACvtfcHk0lhiqDbwmCFUmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlChsb4%253D&md5=728b13cfc149ce878dd2bb7b60d76f35</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-14-0535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-14-0535%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DJ.%2BA.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DThe%2520Ras%25E2%2580%2593membrane%2520interface%253A%2520isoform-specific%2520differences%2520in%2520the%2520catalytic%2520domain%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26issue%3D4%26spage%3D595%26epage%3D603%26doi%3D10.1158%2F1541-7786.MCR-14-0535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahearn, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. R.</span></span> <span> </span><span class="NLM_article-title">Regulating the regulator: post-translational modification of RAS</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nrm3255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrm3255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GksLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=39-51&issue=1&author=I.+M.+Ahearnauthor=K.+Haigisauthor=D.+Bar-Sagiauthor=M.+R.+Philips&title=Regulating+the+regulator%3A+post-translational+modification+of+RAS&doi=10.1038%2Fnrm3255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Regulating the regulator: post-translational modification of RAS</span></div><div class="casAuthors">Ahearn, Ian M.; Haigis, Kevin; Bar-Sagi, Dafna; Philips, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAS proteins are monomeric GTPases that act as binary mol. switches to regulate a wide range of cellular processes.  The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), which regulate the activation state of RAS without covalently modifying it.  By contrast, post-translational modifications (PTMs) of RAS proteins direct them to various cellular membranes and, in some cases, modulate GTP-GDP exchange.  Important RAS PTMs include the constitutive and irreversible remodeling of its C-terminal CAAX motif by farnesylation, proteolysis, and methylation, reversible palmitoylation, and conditional modifications, including phosphorylation, peptidyl-prolyl isomerization, monoubiquitination, diubiquitination, nitrosylation, ADP-ribosylation, and glucosylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlGVFnsduedLVg90H21EOLACvtfcHk0lhiqDbwmCFUmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GksLnP&md5=5983466c8e758dabac8326710a44e64a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrm3255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3255%26sid%3Dliteratum%253Aachs%26aulast%3DAhearn%26aufirst%3DI.%2BM.%26aulast%3DHaigis%26aufirst%3DK.%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DRegulating%2520the%2520regulator%253A%2520post-translational%2520modification%2520of%2520RAS%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D13%26issue%3D1%26spage%3D39%26epage%3D51%26doi%3D10.1038%2Fnrm3255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beare, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">suppl_1</span>),  <span class="NLM_fpage">D945</span>– <span class="NLM_lpage">D950</span>, <span class="refDoi"> DOI: 10.1093/nar/gkq929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1093%2Fnar%2Fgkq929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=20952405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivF2msbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=D945-D950&issue=suppl_1&author=S.+A.+Forbesauthor=N.+Bindalauthor=S.+Bamfordauthor=C.+Coleauthor=C.+Y.+Kokauthor=D.+Beareauthor=M.+Jiaauthor=R.+Shepherdauthor=K.+Leungauthor=A.+Menzies&title=COSMIC%3A+mining+complete+cancer+genomes+in+the+catalogue+of+somatic+mutations+in+cancer&doi=10.1093%2Fnar%2Fgkq929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer</span></div><div class="casAuthors">Forbes, Simon A.; Bindal, Nidhi; Bamford, Sally; Cole, Charlotte; Kok, Chai Yin; Beare, David; Jia, Mingming; Shepherd, Rebecca; Leung, Kenric; Menzies, Andrew; Teague, Jon W.; Campbell, Peter J.; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">D945-D950</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">COSMIC (http://www.sanger.ac.uk/cosmic) curates comprehensive information on somatic mutations in human cancer.  Release v48 (July 2010) describes over 136 000 coding mutations in almost 542 000 tumor samples; of the 18 490 genes documented, 4803 (26%) have one or more mutations.  Full scientific literature curations are available on 83 major cancer genes and 49 fusion gene pairs (19 new cancer genes and 30 new fusion pairs this year) and this no. is continually increasing.  Key amongst these is TP53, now available through a collaboration with the IARC p53 database.  In addn. to data from the Cancer Genome Project (CGP) at the Sanger Institute, UK, and The Cancer Genome Atlas project (TCGA), large systematic screens are also now curated.  Major website upgrades now make these data much more mineable, with many new selection filters and graphics.  A Biomart is now available allowing more automated data mining and integration with other biol. databases.  Annotation of genomic features has become a significant focus; COSMIC has begun curating full-genome resequencing expts., developing new web pages, export formats and graphics styles.  With all genomic information recently updated to GRCh37, COSMIC integrates many diverse types of mutation information and is making much closer links with Ensembl and other data resources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpalgzfv6Y9s7Vg90H21EOLACvtfcHk0lhiqDbwmCFUmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivF2msbo%253D&md5=3456c7ae37b9f81da68a624a09d0d524</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkq929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkq929%26sid%3Dliteratum%253Aachs%26aulast%3DForbes%26aufirst%3DS.%2BA.%26aulast%3DBindal%26aufirst%3DN.%26aulast%3DBamford%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DC.%26aulast%3DKok%26aufirst%3DC.%2BY.%26aulast%3DBeare%26aufirst%3DD.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DShepherd%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DMenzies%26aufirst%3DA.%26atitle%3DCOSMIC%253A%2520mining%2520complete%2520cancer%2520genomes%2520in%2520the%2520catalogue%2520of%2520somatic%2520mutations%2520in%2520cancer%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2011%26volume%3D39%26issue%3Dsuppl_1%26spage%3DD945%26epage%3DD950%26doi%3D10.1093%2Fnar%2Fgkq929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manandhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span> <span> </span><span class="NLM_article-title">Biochemical and structural analysis of common cancer-associated KRAS mutations</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1335</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-15-0203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F1541-7786.MCR-15-0203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26037647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=1325-1335&issue=9&author=J.+C.+Hunterauthor=A.+Manandharauthor=M.+A.+Carrascoauthor=D.+Gurbaniauthor=S.+Gondiauthor=K.+D.+Westover&title=Biochemical+and+structural+analysis+of+common+cancer-associated+KRAS+mutations&doi=10.1158%2F1541-7786.MCR-15-0203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations</span></div><div class="casAuthors">Hunter, John C.; Manandhar, Anuj; Carrasco, Martin A.; Gurbani, Deepak; Gondi, Sudershan; Westover, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1325-1335</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS mutations are the most common genetic abnormalities in cancer, but the distribution of specific mutations across cancers and the differential responses of patients with specific KRAS mutations in therapeutic clin. trials suggest that different KRAS mutations have unique biochem. behaviors.  To further explain these high-level clin. differences and to explore potential therapeutic strategies for specific KRAS isoforms, we characterized the most common KRAS mutants biochem. for substrate binding kinetics, intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activities, and interactions with the RAS effector, RAF kinase.  Of note, KRAS G13D shows rapid nucleotide exchange kinetics compared with other mutants analyzed.  This property can be explained by changes in the electrostatic charge distribution of the active site induced by the G13D mutation as shown by X-ray crystallog.  High-resoln. X-ray structures are also provided for the GDP-bound forms of KRAS G12V, G12R, and Q61L and reveal addnl. insight.  Overall, the structural data and measurements, obtained herein, indicate that measurable biochem. properties provide clues for identifying KRAS-driven tumors that preferentially signal through RAF.  Implications: Biochem. profiling and subclassification of KRAS-driven cancers will enable the rational selection of therapies targeting specific KRAS isoforms or specific RAS effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh7ZuvQswanLVg90H21EOLACvtfcHk0lgd7nBdElt7Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVykt7fK&md5=50c6126a383e79e46f35b4e7677d6543</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-15-0203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-15-0203%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DJ.%2BC.%26aulast%3DManandhar%26aufirst%3DA.%26aulast%3DCarrasco%26aufirst%3DM.%2BA.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DGondi%26aufirst%3DS.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26atitle%3DBiochemical%2520and%2520structural%2520analysis%2520of%2520common%2520cancer-associated%2520KRAS%2520mutations%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26issue%3D9%26spage%3D1325%26epage%3D1335%26doi%3D10.1158%2F1541-7786.MCR-15-0203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnrd.2016.139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=27469033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=771-785&issue=11&author=J.+M.+L.+Ostremauthor=K.+M.+Shokat&title=Direct+small-molecule+inhibitors+of+KRAS%3A+from+structural+insights+to+mechanism-based+design&doi=10.1038%2Fnrd.2016.139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design</span></div><div class="casAuthors">Ostrem, Jonathan M. L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">771-785</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in human cancer.  In addn. to holding this distinction, unsuccessful attempts to target this protein have led to the characterization of RAS as 'undruggable'.  However, recent advances in technol. and novel approaches to drug discovery have renewed hope that a direct KRAS inhibitor may be on the horizon.  In this Review, we provide an in-depth anal. of the structure, dynamics, mutational activation and inactivation, and signalling mechanisms of RAS.  From this perspective, we then consider potential mechanisms of action for effective RAS inhibitors.  Finally, we examine each of the many recent reports of direct RAS inhibitors and discuss promising avenues for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBobrhZLF3V7Vg90H21EOLACvtfcHk0lgd7nBdElt7Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FK&md5=b0832c7ef45cc0555e11c59baccc5abd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.139%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DDirect%2520small-molecule%2520inhibitors%2520of%2520KRAS%253A%2520from%2520structural%2520insights%2520to%2520mechanism-based%2520design%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D771%26epage%3D785%26doi%3D10.1038%2Fnrd.2016.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherfils, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeghouf, M.</span></span> <span> </span><span class="NLM_article-title">Regulation of small gtpases by gefs, gaps, and gdis</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1152/physrev.00003.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1152%2Fphysrev.00003.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23303910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=269-309&issue=1&author=J.+Cherfilsauthor=M.+Zeghouf&title=Regulation+of+small+gtpases+by+gefs%2C+gaps%2C+and+gdis&doi=10.1152%2Fphysrev.00003.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of small GTPases by GEFs, GAPs, and GDIs</span></div><div class="casAuthors">Cherfils, Jacqueline; Zeghouf, Mahel</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">269-309</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Small GTPases use GDP/GTP alternation to actuate a variety of functional switches that are pivotal for cell dynamics.  The GTPase switch is turned on by GEFs, which stimulate dissocn. of the tightly bound GDP, and turned off by GAPs, which accelerate the intrinsically sluggish hydrolysis of GTP.  For Ras, Rho, and Rab GTPases, this switch incorporates a membrane/cytosol alternation regulated by GDIs and GDI-like proteins.  The structures and core mechanisms of representative members of small GTPase regulators from most families have now been elucidated, illuminating their general traits combined with scores of unique features.  Recent studies reveal that small GTPase regulators have themselves unexpectedly sophisticated regulatory mechanisms, by which they process cellular signals and build up specific cell responses.  These mechanisms include multilayered autoinhibition with stepwise release, feedback loops mediated by the activated GTPase, feed-forward signaling flow between regulators and effectors, and a phosphorylation code for RhoGDIs.  The flipside of these highly integrated functions is that they make small GTPase regulators susceptible to biochem. abnormalities that are directly correlated with diseases, notably a striking no. of missense mutations in congenital diseases, and susceptible to bacterial mimics of GEFs, GAPs, and GDIs that take command of small GTPases in infections.  This review presents an overview of the current knowledge of these many facets of small GTPase regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Tzda3wVs6LVg90H21EOLACvtfcHk0lgd7nBdElt7Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKns7s%253D&md5=e718a66f23b7040e1354e4990c8d15d8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00003.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00003.2012%26sid%3Dliteratum%253Aachs%26aulast%3DCherfils%26aufirst%3DJ.%26aulast%3DZeghouf%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520small%2520gtpases%2520by%2520gefs%252C%2520gaps%252C%2520and%2520gdis%26jtitle%3DPhysiol.%2520Rev.%26date%3D2013%26volume%3D93%26issue%3D1%26spage%3D269%26epage%3D309%26doi%3D10.1152%2Fphysrev.00003.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sprang, S. R.</span></span> <span> </span><span class="NLM_article-title">G proteins, effectors and GAPs: structure and mechanism</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.1016/S0959-440X(97)80157-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2FS0959-440X%2897%2980157-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9434906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK1cXjtl2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=849-856&issue=6&author=S.+R.+Sprang&title=G+proteins%2C+effectors+and+GAPs%3A+structure+and+mechanism&doi=10.1016%2FS0959-440X%2897%2980157-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">G proteins, effectors and GAPs: structure and mechanism</span></div><div class="casAuthors">Sprang, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">849-856</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review, with 62 refs.  G proteins form a diverse family of regulatory GTPases which, in the GTP-bound state, bind to and activate downstream effectors.  Structures of Ras homologs bound to effector domains have revealed mechanisms by which G proteins couple GTP binding to effector activation and achieve specificity.  Complexes between structurally unrelated GTPase-activating proteins with complementary G proteins suggest common mechanisms by which GTP hydrolysis is stimulated via direct interactions with conformationally labile switch regions of the G protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_mG_wz29YXrVg90H21EOLACvtfcHk0lgd7nBdElt7Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtl2lsw%253D%253D&md5=46d618e0cce0d01e384dd57c97ab0980</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0959-440X%2897%2980157-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-440X%252897%252980157-1%26sid%3Dliteratum%253Aachs%26aulast%3DSprang%26aufirst%3DS.%2BR.%26atitle%3DG%2520proteins%252C%2520effectors%2520and%2520GAPs%253A%2520structure%2520and%2520mechanism%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D7%26issue%3D6%26spage%3D849%26epage%3D856%26doi%3D10.1016%2FS0959-440X%2897%2980157-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willumsen, B. M.</span></span> <span> </span><span class="NLM_article-title">Function and regulation of ras</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">851</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1146/annurev.bi.62.070193.004223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1146%2Fannurev.bi.62.070193.004223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=8352603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFCjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1993&pages=851-891&issue=1&author=D.+R.+Lowyauthor=B.+M.+Willumsen&title=Function+and+regulation+of+ras&doi=10.1146%2Fannurev.bi.62.070193.004223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Function and regulation of ras</span></div><div class="casAuthors">Lowy, Douglas R.; Willumsen, Berthe M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">851-91</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    </div><div class="casAbstract">A review, with 315 refs., on the structure, regulation, properties and function of ras genes and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX9Nsuu0HOq7Vg90H21EOLACvtfcHk0lijRVGpQZBw5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFCjuro%253D&md5=bc95816f7b6e73c5222b684b240ee87a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.62.070193.004223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.62.070193.004223%26sid%3Dliteratum%253Aachs%26aulast%3DLowy%26aufirst%3DD.%2BR.%26aulast%3DWillumsen%26aufirst%3DB.%2BM.%26atitle%3DFunction%2520and%2520regulation%2520of%2520ras%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1993%26volume%3D62%26issue%3D1%26spage%3D851%26epage%3D891%26doi%3D10.1146%2Fannurev.bi.62.070193.004223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnecki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span> <span> </span><span class="NLM_article-title">Ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1041</span>– <span class="NLM_lpage">1050</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(92)90076-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2F0092-8674%2892%2990076-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1312393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK38XisV2gt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1992&pages=1041-1050&issue=6&author=K.+W.+Woodauthor=C.+Sarneckiauthor=T.+M.+Robertsauthor=J.+Blenis&title=Ras+mediates+nerve+growth+factor+receptor+modulation+of+three+signal-transducing+protein+kinases%3A+MAP+kinase%2C+Raf-1%2C+and+RSK&doi=10.1016%2F0092-8674%2892%2990076-O"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK</span></div><div class="casAuthors">Wood, Kenneth W.; Sarnecki, Charlyn; Roberts, Thomas M.; Blenis, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1041-50</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The authors report that in PC12 cells, expression of a dominant inhibitory mutant of ras, c-Ha-ras(Asn-17), antagonizes growth factor- and phorbol ester-induced activation of the erk-encoded family of mitogen-activated protein (MAP) kinases, the 85-92-kDa RSKs, and the kinase(s) responsible for hyperphosphorylation of the proto-oncogene product Raf-1.  In addn., the authors find that expression of the activated ras oncogene is sufficient to stimulate these events.  These data indicate that ras mediates nerve growth factor receptor and protein kinase C modulation of MAP kinases, RSKs, and Raf-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8yvMuYoOGvrVg90H21EOLACvtfcHk0lijRVGpQZBw5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisV2gt7g%253D&md5=15cdeebc5e970907a0d246e1aaf3527d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2892%2990076-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252892%252990076-O%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DK.%2BW.%26aulast%3DSarnecki%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DRas%2520mediates%2520nerve%2520growth%2520factor%2520receptor%2520modulation%2520of%2520three%2520signal-transducing%2520protein%2520kinases%253A%2520MAP%2520kinase%252C%2520Raf-1%252C%2520and%2520RSK%26jtitle%3DCell%26date%3D1992%26volume%3D68%26issue%3D6%26spage%3D1041%26epage%3D1050%26doi%3D10.1016%2F0092-8674%2892%2990076-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunn, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederrecht, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, J. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5256</span>– <span class="NLM_lpage">5267</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1996.tb00911.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fj.1460-2075.1996.tb00911.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=8895571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK28XmsVeiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=5256-5267&issue=19&author=G.+J.+Brunnauthor=J.+Williamsauthor=C.+Sabersauthor=G.+Wiederrechtauthor=J.+C.+Lawrenceauthor=R.+T.+Abraham&title=Direct+inhibition+of+the+signaling+functions+of+the+mammalian+target+of+rapamycin+by+the+phosphoinositide+3-kinase+inhibitors%2C+wortmannin+and+LY294002&doi=10.1002%2Fj.1460-2075.1996.tb00911.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002</span></div><div class="casAuthors">Brunn, Greogry J.; Williams, Josie; Sabers, Candace; Widerrecht, Gregory; Lawrence, John C., Jr.; Abraham, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5256-5267</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The immunosuppressant, rapamycin, inhibits cell growth by interfering with the function of a novel kinase, termed mammalian target of rapamycin (mTOR).  The putative catalytic domain of mTOR is similar to those of mammalian and yeast phosphatidylinositol (PI) 3-kinases.  This study demonstrates that mTOR is a component of a cytokine-triggered protein kinase cascade leading to the phosphorylation of the eukaryotic initiation factor-4E (eIF-4E)-binding protein, PHAS-1, in activated T lymphocytes.  This event promotes G1 phase progression by stimulating eIF-4E-dependent translation initiation.  A mutant YAC-1 T lymphoma cell line, which was selected for resistance to the growth-inhibitory action of rapamycin, was correspondingly resistant to the suppressive effect of this drug on PHAS-1 phosphorylation.  In contrast, the PI 3-kinase inhibitor, wortmannin, reduced the phosphorylation of PHAS-1 in both rapamycin-sensitive and -resistant T cells.  At similar drug concns. (0.1-1 μM), wortmannin irreversibly inhibited the serine-specific autokinase activity of mTOR.  The autokinase activity of mTOR was also sensitive to the structurally distinct PI 3-kinase inhibitor, LY294002, at concns. (1-30 μM) nearly identical to those required for inhibition of the lipid kinase activity of the mammalian p85-p110 heterodimer.  These studies indicate that the signaling functions of mTOR, and potentially those of other high mol. wt. PI 3-kinase homologs, are directly affected by cellular treatment with wortmannin or LY294002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ntqkdItCzLVg90H21EOLACvtfcHk0lijRVGpQZBw5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVeiu74%253D&md5=792b373486bb634c47ebc3d0d298f4d3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1996.tb00911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1996.tb00911.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrunn%26aufirst%3DG.%2BJ.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DSabers%26aufirst%3DC.%26aulast%3DWiederrecht%26aufirst%3DG.%26aulast%3DLawrence%26aufirst%3DJ.%2BC.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DDirect%2520inhibition%2520of%2520the%2520signaling%2520functions%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520by%2520the%2520phosphoinositide%25203-kinase%2520inhibitors%252C%2520wortmannin%2520and%2520LY294002%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26issue%3D19%26spage%3D5256%26epage%3D5267%26doi%3D10.1002%2Fj.1460-2075.1996.tb00911.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. S.</span></span> <span> </span><span class="NLM_article-title">Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">11089</span>– <span class="NLM_lpage">11093</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.23.11089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.91.23.11089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=7972015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2MXitV2rtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=11089-11093&issue=23&author=F.+Hoferauthor=S.+Fieldsauthor=C.+Schneiderauthor=G.+S.+Martin&title=Activated+Ras+interacts+with+the+Ral+guanine+nucleotide+dissociation+stimulator&doi=10.1073%2Fpnas.91.23.11089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator</span></div><div class="casAuthors">Hofer, Franz; Fields, Stanley; Schneider, Christopher; Martin, G. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11089-93</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The yeast two-hybrid system was used to identify proteins that interact with Ras.  H-Ras protein interacted with a guanine nucleotide dissocn. stimulator (GDS) that has been previously shown to regulate guanine nucleotide exchange on another member of the Ras protein family, Ral.  The interaction is mediated by the C-terminal, noncatalytic segment of the RalGDS and can be detected both in vivo, using the two-hybrid system, and in vitro, with purified recombinant proteins.  The interaction of the RalGDS C-terminal segment with Ras is specific, dependent on activation of Ras by GTP, and blocked by a mutation that affects Ras effector function.  These characteristics are similar to those previously demonstrated for the interaction between Ras and its putative effector, Raf, suggesting that the RalGDS may also be a Ras effector.  Consistent with this idea, the RalGDS inhibited the binding of Raf to Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ZEobZ7aA3bVg90H21EOLACvtfcHk0lixGnEk-KN9BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitV2rtr8%253D&md5=853ec836b570b5f2d423843f2fdf8328</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.23.11089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.23.11089%26sid%3Dliteratum%253Aachs%26aulast%3DHofer%26aufirst%3DF.%26aulast%3DFields%26aufirst%3DS.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DActivated%2520Ras%2520interacts%2520with%2520the%2520Ral%2520guanine%2520nucleotide%2520dissociation%2520stimulator%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26issue%3D23%26spage%3D11089%26epage%3D11093%26doi%3D10.1073%2Fpnas.91.23.11089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamarsheh, S.’a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groß, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiser, R.</span></span> <span> </span><span class="NLM_article-title">Immune modulatory effects of oncogenic KRAS in cancer.</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5439</span>, <span class="refDoi"> DOI: 10.1038/s41467-020-19288-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41467-020-19288-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=33116132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Ojur%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=5439&issue=1&author=S.%E2%80%99a+Hamarshehauthor=O.+Gro%C3%9Fauthor=T.+Brummerauthor=R.+Zeiser&title=Immune+modulatory+effects+of+oncogenic+KRAS+in+cancer.&doi=10.1038%2Fs41467-020-19288-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Immune modulatory effects of oncogenic KRAS in cancer</span></div><div class="casAuthors">Hamarsheh, Shaima'a; Gross, Olaf; Brummer, Tilman; Zeiser, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5439</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most difficult to target.  While sustained proliferation caused by oncogenic KRAS-downstream signalling is a main driver of carcinogenesis, there is increasing evidence that it also mediates autocrine effects and crosstalk with the tumor microenvironment (TME).  Here, we discuss recent reports connecting KRAS mutations with tumor-promoting inflammation and immune modulation caused by KRAS that leads to immune escape in the TME.  We discuss the preclin. work on KRAS-induced inflammation and immune modulation in the context of currently ongoing clin. trials targeting cancer entities that carry KRAS mutations and strategies to overcome the oncogene-induced effects on the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY2OLEfSnyQLVg90H21EOLACvtfcHk0lixGnEk-KN9BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Ojur%252FM&md5=6b3e28bd7b539bffd67471dbd8a63fca</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-19288-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-19288-6%26sid%3Dliteratum%253Aachs%26aulast%3DHamarsheh%26aufirst%3DS.%25E2%2580%2599a%26aulast%3DGro%25C3%259F%26aufirst%3DO.%26aulast%3DBrummer%26aufirst%3DT.%26aulast%3DZeiser%26aufirst%3DR.%26atitle%3DImmune%2520modulatory%2520effects%2520of%2520oncogenic%2520KRAS%2520in%2520cancer.%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D5439%26doi%3D10.1038%2Fs41467-020-19288-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Ras–SOS interactions</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">821</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fcmdc.201500481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26630662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=814-821&issue=8&author=S.+Luauthor=H.+Jangauthor=J.+Zhangauthor=R.+Nussinov&title=Inhibitors+of+Ras%E2%80%93SOS+interactions&doi=10.1002%2Fcmdc.201500481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Ras-SOS Interactions</span></div><div class="casAuthors">Lu, Shaoyong; Jang, Hyunbum; Zhang, Jian; Nussinov, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">814-821</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Activating Ras mutations are found in about 30 % of human cancers.  Ras activation is regulated by guanine nucleotide exchange factors, such as the son of sevenless (SOS), which form protein-protein interactions (PPIs) with Ras and catalyze the exchange of GDP by GTP.  This is the rate-limiting step in Ras activation.  However, Ras surfaces lack any evident suitable pockets where a mol. might bind tightly, rendering Ras proteins still 'undruggable' for over 30 years.  Among the alternative approaches is the design of inhibitors that target the Ras-SOS PPI interface, a strategy that is gaining increasing recognition for treating Ras mutant cancers.  Herein we focus on data that has accumulated over the past few years pertaining to the design of small-mol. modulators or peptide mimetics aimed at the interface of the Ras-SOS PPI.  We emphasize, however, that even if such Ras-SOS therapeutics are potent, drug resistance may emerge.  To counteract this development, we propose "pathway drug cocktails", i.e., drug combinations aimed at parallel (or compensatory) pathways.  A repertoire of classified cancer, cell/tissue, and pathway/protein combinations would be beneficial toward this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFdUllM-dcxLVg90H21EOLACvtfcHk0lixGnEk-KN9BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsrvK&md5=697ec8726368e7b1b89f569c4a079750</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500481%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520Ras%25E2%2580%2593SOS%2520interactions%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D8%26spage%3D814%26epage%3D821%26doi%3D10.1002%2Fcmdc.201500481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span> <span> </span><span class="NLM_article-title">A treatment strategy for KRAS-driven tumors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">902</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0111-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41591-018-0111-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29988139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWjsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=902-904&issue=7&author=T.+T.+Maiauthor=P.+Lito&title=A+treatment+strategy+for+KRAS-driven+tumors&doi=10.1038%2Fs41591-018-0111-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A treatment strategy for KRAS-driven tumors</span></div><div class="casAuthors">Mai, Trang T.; Lito, Piro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">902-904</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgaFi5mnw3KrVg90H21EOLACvtfcHk0liLL0g3R2Yiow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWjsLvK&md5=03c6ec6d34bac76f8826e1f783dac0a7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0111-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0111-x%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DLito%26aufirst%3DP.%26atitle%3DA%2520treatment%2520strategy%2520for%2520KRAS-driven%2520tumors%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D7%26spage%3D902%26epage%3D904%26doi%3D10.1038%2Fs41591-018-0111-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.ejmech.2020.112117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=32061959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112117&author=D.+Shenauthor=W.+Chenauthor=J.+Zhuauthor=G.+Wuauthor=R.+Shenauthor=M.+Xiauthor=H.+Sun&title=Therapeutic+potential+of+targeting+SHP2+in+human+developmental+disorders+and+cancers&doi=10.1016%2Fj.ejmech.2020.112117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting SHP2 in human developmental disorders and cancers</span></div><div class="casAuthors">Shen, Dadong; Chen, Wenxia; Zhu, Jinlin; Wu, Guofeng; Shen, Runpu; Xi, Meiyang; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Src homol. 2 (SH2)-contg. protein tyrosine phosphatase 2 (SHP2), encoded by PTPN11, regulates cell proliferation, differentiation, apoptosis and survival via releasing intramol. autoinhibition and modulating various signaling pathways, such as mitogen-activated protein kinase (MAPK) pathway.  Mutations and aberrant expression of SHP2 are implicated in human developmental disorders, leukemias and several solid tumors.  As an oncoprotein in some cancers, SHP2 represents a rational target for inhibitors to interfere.  Nevertheless, its tumor suppressive effect has also been uncovered, indicating the context-specificity.  Even so, two types of SHP2 inhibitors including targeting catalytic pocket and allosteric sites have been developed assocd. with resolved cocrystal complexes.  Herein, we describe its structure, biol. function, deregulation in human diseases and summarize recent advance in development of SHP2 inhibitors, trying to give an insight into the therapeutic potential in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkb-7jOXJ8DLVg90H21EOLACvtfcHk0liLL0g3R2Yiow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFWgsrk%253D&md5=9f40f6d2a560deac59c2b24616ac9f94</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112117%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DXi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520SHP2%2520in%2520human%2520developmental%2520disorders%2520and%2520cancers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112117%26doi%3D10.1016%2Fj.ejmech.2020.112117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunn, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederrecht, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5256</span>– <span class="NLM_lpage">5267</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1996.tb00911.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fj.1460-2075.1996.tb00911.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=8895571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK28XmsVeiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=5256-5267&issue=19&author=G.+J.+Brunnauthor=J.+Williamsauthor=C.+Sabersauthor=G.+Wiederrechtauthor=J.+Lawrenceauthor=R.+T.+Abraham&title=Direct+inhibition+of+the+signaling+functions+of+the+mammalian+target+of+rapamycin+by+the+phosphoinositide+3-kinase+inhibitors%2C+wortmannin+and+LY294002&doi=10.1002%2Fj.1460-2075.1996.tb00911.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002</span></div><div class="casAuthors">Brunn, Greogry J.; Williams, Josie; Sabers, Candace; Widerrecht, Gregory; Lawrence, John C., Jr.; Abraham, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5256-5267</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The immunosuppressant, rapamycin, inhibits cell growth by interfering with the function of a novel kinase, termed mammalian target of rapamycin (mTOR).  The putative catalytic domain of mTOR is similar to those of mammalian and yeast phosphatidylinositol (PI) 3-kinases.  This study demonstrates that mTOR is a component of a cytokine-triggered protein kinase cascade leading to the phosphorylation of the eukaryotic initiation factor-4E (eIF-4E)-binding protein, PHAS-1, in activated T lymphocytes.  This event promotes G1 phase progression by stimulating eIF-4E-dependent translation initiation.  A mutant YAC-1 T lymphoma cell line, which was selected for resistance to the growth-inhibitory action of rapamycin, was correspondingly resistant to the suppressive effect of this drug on PHAS-1 phosphorylation.  In contrast, the PI 3-kinase inhibitor, wortmannin, reduced the phosphorylation of PHAS-1 in both rapamycin-sensitive and -resistant T cells.  At similar drug concns. (0.1-1 μM), wortmannin irreversibly inhibited the serine-specific autokinase activity of mTOR.  The autokinase activity of mTOR was also sensitive to the structurally distinct PI 3-kinase inhibitor, LY294002, at concns. (1-30 μM) nearly identical to those required for inhibition of the lipid kinase activity of the mammalian p85-p110 heterodimer.  These studies indicate that the signaling functions of mTOR, and potentially those of other high mol. wt. PI 3-kinase homologs, are directly affected by cellular treatment with wortmannin or LY294002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ntqkdItCzLVg90H21EOLACvtfcHk0liLL0g3R2Yiow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVeiu74%253D&md5=792b373486bb634c47ebc3d0d298f4d3</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1996.tb00911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1996.tb00911.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrunn%26aufirst%3DG.%2BJ.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DSabers%26aufirst%3DC.%26aulast%3DWiederrecht%26aufirst%3DG.%26aulast%3DLawrence%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DDirect%2520inhibition%2520of%2520the%2520signaling%2520functions%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520by%2520the%2520phosphoinositide%25203-kinase%2520inhibitors%252C%2520wortmannin%2520and%2520LY294002%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26issue%3D19%26spage%3D5256%26epage%3D5267%26doi%3D10.1002%2Fj.1460-2075.1996.tb00911.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimaraes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1351</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1038/nm.1890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnm.1890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=19029981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1351-1356&issue=12&author=J.+A.+Engelmanauthor=L.+Chenauthor=X.+Tanauthor=K.+Crosbyauthor=A.+R.+Guimaraesauthor=R.+Upadhyayauthor=M.+Mairaauthor=K.+McNamaraauthor=S.+A.+Pereraauthor=Y.+Song&title=Effective+use+of+PI3K+and+MEK+inhibitors+to+treat+mutant+Kras+G12D+and+PIK3CA+H1047R+murine+lung+cancers&doi=10.1038%2Fnm.1890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers</span></div><div class="casAuthors">Engelman, Jeffrey A.; Chen, Liang; Tan, Xiaohong; Crosby, Katherine; Guimaraes, Alexander R.; Upadhyay, Rabi; Maira, Michel; McNamara, Kate; Perera, Samanthi A.; Song, Youngchul; Chirieac, Lucian R.; Kaur, Ramneet; Lightbown, Angela; Simendinger, Jessica; Li, Timothy; Padera, Robert F.; Garcia-Echeverria, Carlos; Weissleder, Ralph; Mahmood, Umar; Cantley, Lewis C.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1351-1356</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations that activate phosphoinositide 3-kinase (P13K) have been identified in the p1 10-x catalytic subunit (encoded by PIK3CA).  They are most frequently obsd. in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R).  Although the pl 10-o mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models.  Furthermore, clin. trials with P13K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies.  In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p-110-c H 1047R.  Treatment of these tumors - with NVP-BEZ235, a dual pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor in clin. development, led to labored breathing and MRI images consistent with lung tumors after marked tumor regression as shown by positron emission imaging and microscopic examn.  In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to CN single-agent NVP-BEZ235.  However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these kras-mutant cancers.  These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmFCNzeJpeErVg90H21EOLACvtfcHk0lhf-LASzb0nNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rI&md5=3d9fd9c11132319c5e22807e15d592f3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnm.1890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1890%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DGuimaraes%26aufirst%3DA.%2BR.%26aulast%3DUpadhyay%26aufirst%3DR.%26aulast%3DMaira%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DSong%26aufirst%3DY.%26atitle%3DEffective%2520use%2520of%2520PI3K%2520and%2520MEK%2520inhibitors%2520to%2520treat%2520mutant%2520Kras%2520G12D%2520and%2520PIK3CA%2520H1047R%2520murine%2520lung%2520cancers%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26issue%3D12%26spage%3D1351%26epage%3D1356%26doi%3D10.1038%2Fnm.1890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C. D.</span></span> <span> </span><span class="NLM_article-title">PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2121-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1007%2Fs00280-013-2121-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23443307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVejsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=1395-1409&issue=6&author=C.+D.+Britten&title=PI3K+and+MEK+inhibitor+combinations%3A+examining+the+evidence+in+selected+tumor+types&doi=10.1007%2Fs00280-013-2121-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types</span></div><div class="casAuthors">Britten, Carolyn D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1395-1409</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most frequently dysregulated kinase cascades in human cancer.  Mol. alterations in these pathways are implicated in tumorigenesis and resistance to anticancer therapies.  The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are known to interact with each other at several nodes, and mounting evidence suggests that dual blockade of both pathways may be required to achieve anticancer effects in certain contexts.  This may include tumor types with a high frequency of RAS/RAF/MEK/ERK pathway activation, or situations in which dual pathway strategies may be required to overcome resistance to current targeted therapies.  Several clin. studies are currently evaluating the combination of PI3K and MEK inhibitors in a variety of different cancers with certain types of mol. alterations.  This review will summarize existing knowledge of the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways, the cross-talk between them, and the current generation of PI3K and MEK inhibitors that target them.  The preclin. rationale for dual pathway inhibition will be discussed within the context of the major tumor types currently being explored in ongoing clin. trials, namely malignant melanoma with BRAF or NRAS mutations, and colorectal, ovarian, pancreatic, and basal-like breast cancers.  The emerging clin. profile of PI3K and MEK inhibitor combinations, as reported in Phase I trials, will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop6Rpu4niStLVg90H21EOLACvtfcHk0lhf-LASzb0nNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVejsLo%253D&md5=c746af8f20c34afa8542c27b1c7d89ce</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2121-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2121-1%26sid%3Dliteratum%253Aachs%26aulast%3DBritten%26aufirst%3DC.%2BD.%26atitle%3DPI3K%2520and%2520MEK%2520inhibitor%2520combinations%253A%2520examining%2520the%2520evidence%2520in%2520selected%2520tumor%2520types%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26issue%3D6%26spage%3D1395%26epage%3D1409%26doi%3D10.1007%2Fs00280-013-2121-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeannin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinsted, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zazulina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70489-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2FS1470-2045%2812%2970489-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23200175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BC3s7otVCnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=38-47&issue=1&author=P.+A.+J%C3%A4nneauthor=A.+T.+Shawauthor=J.+R.+Pereiraauthor=G.+Jeanninauthor=J.+Vansteenkisteauthor=C.+Barriosauthor=F.+A.+Frankeauthor=L.+Grinstedauthor=V.+Zazulinaauthor=P.+Smith&title=Selumetinib+plus+docetaxel+for+KRAS-mutant+advanced+non-small-cell+lung+cancer%3A+a+randomised%2C+multicentre%2C+placebo-controlled%2C+phase+2+study&doi=10.1016%2FS1470-2045%2812%2970489-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study</span></div><div class="casAuthors">Janne Pasi A; Shaw Alice T; Pereira Jose Rodrigues; Jeannin Gaelle; Vansteenkiste Johan; Barrios Carlos; Franke Fabio Andre; Grinsted Lynda; Zazulina Victoria; Smith Paul; Smith Ian; Crino Lucio</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  No targeted therapies are available for KRAS-mutant non-small-cell lung cancer (NSCLC).  Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers.  We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC.  METHODS:  Eligible patients were older than 18 years of age; had histologically or cytologically confirmed stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performance status of 0-1; had not received previous therapy with either a MEK inhibitor or docetaxel; and had adequate bone marrow, renal, and liver function.  Patients were randomly assigned (in a 1:1 ratio) to either oral selumetinib (75 mg twice daily in a 21 day cycle) or placebo; all patients received intravenous docetaxel (75 mg/m(2) on day 1 of a 21 day cycle).  Randomisation was done with an interactive voice response system and investigators, patients, data analysts, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival, analysed for all patients with confirmed KRAS mutations.  This study is registered with ClinicalTrials.gov, number NCT00890825.  FINDINGS:  Between April 20, 2009, and June 30, 2010, we randomly assigned 44 patients to receive selumetinib and docetaxel (selumetinib group) and 43 to receive placebo and docetaxel (placebo group).  Of these, one patient in the selumetinib group and three in the placebo group were excluded from efficacy analyses because their tumours were not confirmed to be KRAS-mutation positive.  Median overall survival was 9·4 months (6·8-13·6) in the selumetinib group and 5·2 months (95% CI 3·8-non-calculable) in the placebo group (hazard ratio [HR] for death 0·80, 80% CI 0·56-1·14; one-sided p=0·21).  Median progression-free survival was 5·3 months (4·6-6·4) in the selumetinib group and 2·1 months (95% CI 1·4-3·7) in the placebo group (HR for progression 0·58, 80% CI 0·42-0·79; one-sided p=0·014). 16 (37%) patients in the selumetinib group and none in the placebo group had an objective response (p<0·0001).  Adverse events of grade 3 or higher occurred in 36 (82%) patients in the selumetinib group and 28 (67%) patients in the placebo group.  The most common grade 3-4 adverse events were neutropenia (29 [67%] of 43 patients in the selumetinib group vs 23 [55%] of 42 patients in the placebo group), febrile neutropenia (eight [18%] of 44 patients in the selumetinib group vs none in the placebo group), dyspnoea (one [2%] of 44 patients in the selumetinib group vs five [12%] of 42 in the placebo group), and asthenia (four [9%] of 44 patients in the selumetinib group vs none in the placebo group).  INTERPRETATION:  Selumetinib plus docetaxel has promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC.  These findings warrant further clinical investigation of selumetinib plus docetaxel in KRAS-mutant NSCLC.  FUNDING:  AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_DnSQjq4ctlm8bhe6roZYfW6udTcc2eYfe-PyCzb0D7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7otVCnug%253D%253D&md5=3987f8d7cb411810eb05c507a0bc9a73</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970489-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970489-8%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DPereira%26aufirst%3DJ.%2BR.%26aulast%3DJeannin%26aufirst%3DG.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%26aulast%3DFranke%26aufirst%3DF.%2BA.%26aulast%3DGrinsted%26aufirst%3DL.%26aulast%3DZazulina%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DP.%26atitle%3DSelumetinib%2520plus%2520docetaxel%2520for%2520KRAS-mutant%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520randomised%252C%2520multicentre%252C%2520placebo-controlled%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26issue%3D1%26spage%3D38%26epage%3D47%26doi%3D10.1016%2FS1470-2045%2812%2970489-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, J.</span></span> <span> </span><span class="NLM_article-title">Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1989.tb03478.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fj.1460-2075.1989.tb03478.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=2663468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaL1MXitVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1989&pages=1093-1098&issue=4&author=L.+Gutierrezauthor=A.+Mageeauthor=C.+Marshallauthor=J.+Hancock&title=Post-translational+processing+of+p21ras+is+two-step+and+involves+carboxyl-methylation+and+carboxy-terminal+proteolysis&doi=10.1002%2Fj.1460-2075.1989.tb03478.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis</span></div><div class="casAuthors">Gutierrez, Lourdes; Magee, Anthony I.; Marshall, Christoper J.; Hancock, John F.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1093-8</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    </div><div class="casAbstract">The post-translational processing of p21ras proteins was studied.  The primary translation product pro-p21 is cytosolic and is rapidly converted to a cytosolic form (c-p21) of higher mobility on SDS-PAGE.  Protein c-p21 is converted in turn to the membrane-bound mature palmitoylated form (m-p21) of slightly higher mobility.  These processing steps are accompanied by increases in isoelec. point and in hydrophobicity as judged by Triton X-114 partitioning.  Although the increases in electrophoretic mobility and hydrophobicity precede acylation, mutation of Cys186, which has been shown to block acylation, also abolishes the pro-p21 to c-p21 conversion.  Thus the Cys186 residue is involved in the processing steps prior to acylation.  Two processing events were identified which contribute to the pro-p21 conversion.  Site-directed mutagenesis to insert tryptophan, which is not present in the wild type, followed by metabolic labeling with [3H]tryptophan made it possible to map a proteolytic processing event which removes the three C-terminal residues.  In addn., both the c-p21 and m-p21 forms are carboxyl-methylated.  Approx. one Me group is incorporated per mol. of p21 at steady state, which can partially account for the increase in isoelec. point.  Unlike palmitate, Me group turnover is not obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCviE0IiktLrVg90H21EOLACvtfcHk0lg85hwj_5KrvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXitVyjtbg%253D&md5=bd186a082edce40c5b00eb45ccd181d2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1989.tb03478.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1989.tb03478.x%26sid%3Dliteratum%253Aachs%26aulast%3DGutierrez%26aufirst%3DL.%26aulast%3DMagee%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DC.%26aulast%3DHancock%26aufirst%3DJ.%26atitle%3DPost-translational%2520processing%2520of%2520p21ras%2520is%2520two-step%2520and%2520involves%2520carboxyl-methylation%2520and%2520carboxy-terminal%2520proteolysis%26jtitle%3DEMBO%2520J.%26date%3D1989%26volume%3D8%26issue%3D4%26spage%3D1093%26epage%3D1098%26doi%3D10.1002%2Fj.1460-2075.1989.tb03478.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. R.</span></span> <span> </span><span class="NLM_article-title">Thematic review series: lipid posttranslational modifications CAAX modification and membrane targeting of Ras</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1194/jlr.R600004-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1194%2Fjlr.R600004-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=16543601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVChurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=883-891&issue=5&author=L.+P.+Wrightauthor=M.+R.+Philips&title=Thematic+review+series%3A+lipid+posttranslational+modifications+CAAX+modification+and+membrane+targeting+of+Ras&doi=10.1194%2Fjlr.R600004-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">CAAX modification and membrane targeting of Ras</span></div><div class="casAuthors">Wright, Latasha P.; Philips, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">883-891</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Proteins that terminate with a consensus sequence known as CAAX undergo a series of posttranslational modifications that include polyisoprenylation, endoproteolysis, and carboxyl methylation.  These modifications render otherwise hydrophilic proteins hydrophobic at their C termini such that they assoc. with membranes.  Whereas prenylation occurs in the cytosol, postprenylation processing is accomplished on the cytoplasmic surface of the endoplasmic reticulum and Golgi app.  Among the numerous CAAX proteins encoded in mammalian genomes are many signaling mols. such as monomeric GTPases, including the Ras proteins that play an important role in cancer.  In the course of their processing, nascent Ras proteins traffic from their site of synthesis in the cytosol to the endomembrane and then out to the plasma membrane (PM) by at least 2 pathways.  Recently, retrograde pathways were discovered that deliver mature Ras from the PM back to the Golgi.  The Golgi was identified as a platform upon which Ras can signal.  Thus, the subcellular trafficking of Ras proteins has the potential to increase the complexity of Ras signaling by adding a spatial dimension.  The complexity of Ras trafficking also affords a wider array of potential targets for the discovery of drugs that might inhibit tumors by interfering with Ras trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLRbofH7NgtrVg90H21EOLACvtfcHk0lg85hwj_5KrvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVChurs%253D&md5=fd6d0d6dd7a5c200e83241bb34229b1e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R600004-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R600004-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DL.%2BP.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DThematic%2520review%2520series%253A%2520lipid%2520posttranslational%2520modifications%2520CAAX%2520modification%2520and%2520membrane%2520targeting%2520of%2520Ras%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2006%26volume%3D47%26issue%3D5%26spage%3D883%26epage%3D891%26doi%3D10.1194%2Fjlr.R600004-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diver, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S. B.</span></span> <span> </span><span class="NLM_article-title">Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>553</i></span> (<span class="NLM_issue">7689</span>),  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">529</span>, <span class="refDoi"> DOI: 10.1038/nature25439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnature25439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29342140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=553&publication_year=2018&pages=526-529&issue=7689&author=M.+M.+Diverauthor=L.+Pediauthor=A.+Koideauthor=S.+Koideauthor=S.+B.+Long&title=Atomic+structure+of+the+eukaryotic+intramembrane+RAS+methyltransferase+ICMT&doi=10.1038%2Fnature25439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT</span></div><div class="casAuthors">Diver, Melinda M.; Pedi, Leanne; Koide, Akiko; Koide, Shohei; Long, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">553</span>
        (<span class="NLM_cas:issue">7689</span>),
    <span class="NLM_cas:pages">526-529</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The maturation of RAS GTPases and approx. 200 other cellular CAAX proteins involves three enzymic steps: addn. of a farnesyl or geranylgeranyl prenyl lipid to the cysteine (C) in the C-terminal CAAX motif, proteolytic cleavage of the AAX residues and methylation of the exposed prenylcysteine residue at its terminal carboxylate.  This final step is catalyzed by isoprenylcysteine carboxyl methyltransferase (ICMT), a eukaryote-specific integral membrane enzyme that resides in the endoplasmic reticulum.  ICMT is the only cellular enzyme that is known to methylate prenylcysteine substrates; methylation is important for the biol. functions of these substrates, such as the membrane localization and subsequent activity of RAS, prelamin A and RAB.  Inhibition of ICMT has potential for combating progeria and cancer.  Here we present an X-ray structure of ICMT, in complex with its cofactor, an ordered lipid mol. and a monobody inhibitor, at 2.3 Å resoln.  The active site spans cytosolic and membrane-exposed regions, indicating distinct entry routes for the cytosolic Me donor, S-adenosyl-L-methionine, and for prenylcysteine substrates, which are assocd. with the endoplasmic reticulum membrane.  The structure suggests how ICMT overcomes the topog. challenge and unfavorable energetics of bringing two reactants that have different cellular localizations together in a membrane environment-a relatively uncharacterized but defining feature of many integral membrane enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXFRW8xr3AZbVg90H21EOLACvtfcHk0lg85hwj_5KrvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOisb4%253D&md5=612327b61ef2d9448552fbf617e8d891</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnature25439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25439%26sid%3Dliteratum%253Aachs%26aulast%3DDiver%26aufirst%3DM.%2BM.%26aulast%3DPedi%26aufirst%3DL.%26aulast%3DKoide%26aufirst%3DA.%26aulast%3DKoide%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DS.%2BB.%26atitle%3DAtomic%2520structure%2520of%2520the%2520eukaryotic%2520intramembrane%2520RAS%2520methyltransferase%2520ICMT%26jtitle%3DNature%26date%3D2018%26volume%3D553%26issue%3D7689%26spage%3D526%26epage%3D529%26doi%3D10.1038%2Fnature25439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, M. R.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS membrane association: back to the future for anti-RAS drug discovery?</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">8127</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F1078-0432.CCR-14-3214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=25878363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2gt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1819-8127&author=A.+D.+Coxauthor=C.+J.+Derauthor=M.+R.+Philips&title=Targeting+RAS+membrane+association%3A+back+to+the+future+for+anti-RAS+drug+discovery%3F&doi=10.1158%2F1078-0432.CCR-14-3214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?</span></div><div class="casAuthors">Cox, Adrienne D.; Der, Channing J.; Philips, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1819-1827</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">RAS proteins require membrane assocn. for their biol. activity, making this assocn. a logical target for anti-RAS therapeutics.  Lipid modification of RAS proteins by a farnesyl isoprenoid is an obligate step in that assocn., and is an enzymic process.  Accordingly, farnesyltransferase inhibitors (FTI) were developed as potential anti-RAS drugs.  The lack of efficacy of FTIs as anticancer drugs was widely seen as indicating that blocking RAS membrane assocn. was a flawed approach to cancer treatment.  However, a deeper understanding of RAS modification and trafficking has revealed that this was an erroneous conclusion.  In the presence of FTIs, KRAS and NRAS, which are the RAS isoforms most frequently mutated in cancer, become substrates for alternative modification, can still assoc. with membranes, and can still function.  Thus, FTIs failed not because blocking RAS membrane assocn. is an ineffective approach, but because FTIs failed to accomplish that task.  Recent findings regarding RAS isoform trafficking and the regulation of RAS subcellular localization have rekindled interest in efforts to target these processes.  In particular, improved understanding of the palmitoylation/depalmitoylation cycle that regulates RAS interaction with the plasma membrane, endomembranes, and cytosol, and of the potential importance of RAS chaperones, have led to new approaches.  Efforts to validate and target other enzymically regulated posttranslational modifications are also ongoing.  In this review, we revisit lessons learned, describe the current state of the art, and highlight challenging but promising directions to achieve the goal of disrupting RAS membrane assocn. and subcellular localization for anti-RAS drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCImUyZbuCKrVg90H21EOLACvtfcHk0lg85hwj_5KrvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2gt74%253D&md5=6f41ac23a7d14b90633755e374b6ffea</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3214%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DTargeting%2520RAS%2520membrane%2520association%253A%2520back%2520to%2520the%2520future%2520for%2520anti-RAS%2520drug%2520discovery%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1819%26epage%3D8127%26doi%3D10.1158%2F1078-0432.CCR-14-3214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marín-Ramos, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Gutiérrez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Rodríguez, M. L.</span></span> <span> </span><span class="NLM_article-title">Blocking Ras inhibition as an antitumor strategy</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2018.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.semcancer.2018.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29409706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=91-100&author=N.+I.+Mar%C3%ADn-Ramosauthor=S.+Ortega-Guti%C3%A9rrezauthor=M.+L.+L%C3%B3pez-Rodr%C3%ADguez&title=Blocking+Ras+inhibition+as+an+antitumor+strategy&doi=10.1016%2Fj.semcancer.2018.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking Ras inhibition as an antitumor strategy</span></div><div class="casAuthors">Marin-Ramos, Nagore I.; Ortega-Gutierrez, Silvia; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ras proteins are among the most frequently mutated drivers in human cancer and remain an elusive pharmaceutical targeting.  Previous studies have improved the understanding of Ras structure, processing, and signaling pathways in cancer cells and have opened new possibilities for inhibiting Ras function.  In this review we discuss the most recent advances towards inhibiting Ras activity with small mols., highlighting the two approaches: (i) compds. that bind directly to Ras protein and (ii) inhibitors of the enzymes involved in the post-translational modifications of Ras.  In the former, we analyze the most recent contributions in each of the main classes of Ras direct binders, including the different types of nucleotide exchange inhibitors, allosteric compds., and mols. that interfere with the interaction between Ras and its effectors.  In the latter, we examine the compds. that inhibit Ras activation by blocking any of its post-translational modifications.  Also, a special focus is made on those mols. that have progressed the farthest from medicinal chem. and drug development points of view.  Finally, the current scene regarding the clin. trials of Ras inhibitors, together with the future promising avenues for further development of the challenging Ras field are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWw2RqFhpnErVg90H21EOLACvtfcHk0ljoaHkWEvZzOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKjs74%253D&md5=721a62e21dddff7fc9d25732ec30040f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2018.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2018.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DMar%25C3%25ADn-Ramos%26aufirst%3DN.%2BI.%26aulast%3DOrtega-Guti%25C3%25A9rrez%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez-Rodr%25C3%25ADguez%26aufirst%3DM.%2BL.%26atitle%3DBlocking%2520Ras%2520inhibition%2520as%2520an%2520antitumor%2520strategy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2019%26volume%3D54%26spage%3D91%26epage%3D100%26doi%3D10.1016%2Fj.semcancer.2018.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowell, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczyk, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. M.</span></span> <span> </span><span class="NLM_article-title">Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">14093</span>– <span class="NLM_lpage">14097</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.22.14093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1074%2Fjbc.272.22.14093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9162034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=14093-14097&issue=22&author=C.+A.+Rowellauthor=J.+J.+Kowalczykauthor=M.+D.+Lewisauthor=A.+M.+Garcia&title=Direct+demonstration+of+geranylgeranylation+and+farnesylation+of+Ki-Ras+in+vivo&doi=10.1074%2Fjbc.272.22.14093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo</span></div><div class="casAuthors">Rowell, Cheryl A.; Kowalczyk, James J.; Lewis, Michael D.; Garcia, Ana Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">14093-14097</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">It has recently been reported that Ki-Ras protein can be modified in vitro by farnesylation or geranylgeranylation.  However, a previous anal. of Ki-Ras prenylation in vivo found only farnesylated Ki-Ras.  In this report it is shown that under normal conditions, Ki-Ras is farnesylated in vivo and when cells are treated with the farnesyl transferase inhibitors B956 or B957, farnesylation is inhibited and Ki-Ras becomes geranylgeranylated in a dose dependent manner.  These results have strong implications in the design of anticancer drugs based on inhibition of prenylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolB-vVx7wo-bVg90H21EOLACvtfcHk0ljoaHkWEvZzOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOjtro%253D&md5=7cee7201fa0062bd1e62fc28de19f829</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.22.14093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.22.14093%26sid%3Dliteratum%253Aachs%26aulast%3DRowell%26aufirst%3DC.%2BA.%26aulast%3DKowalczyk%26aufirst%3DJ.%2BJ.%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DGarcia%26aufirst%3DA.%2BM.%26atitle%3DDirect%2520demonstration%2520of%2520geranylgeranylation%2520and%2520farnesylation%2520of%2520Ki-Ras%2520in%2520vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26issue%3D22%26spage%3D14093%26epage%3D14097%26doi%3D10.1074%2Fjbc.272.22.14093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockenberry, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez-Oliva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catino, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, J.-K.</span></span> <span> </span><span class="NLM_article-title">K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">14459</span>– <span class="NLM_lpage">14464</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.22.14459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1074%2Fjbc.272.22.14459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9162087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFygs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=14459-14464&issue=22&author=D.+B.+Whyteauthor=P.+Kirschmeierauthor=T.+N.+Hockenberryauthor=I.+Nunez-Olivaauthor=L.+Jamesauthor=J.+J.+Catinoauthor=W.+R.+Bishopauthor=J.-K.+Pai&title=K-and+N-Ras+are+geranylgeranylated+in+cells+treated+with+farnesyl+protein+transferase+inhibitors&doi=10.1074%2Fjbc.272.22.14459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors</span></div><div class="casAuthors">Whyte, David B.; Kirschmeier, Paul; Hockenberry, Tish N.; Nunez-Oliva, Irma; James, Linda; Catino, Joseph J.; Bishop, W. Robert; Pai, Jin-Keon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">14459-14464</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The assocn. of mutant forms of Ras protein with a variety of human cancers has stimulated intense interest in therapies based on inhibiting oncogenic Ras signaling.  Attachment of Ras proteins to the plasma membrane is required for effective Ras signaling and is initiated by the enzyme farnesyl protein transferase.  We found that in the presence of potent farnesyl protein transferase inhibitors, Ras proteins in the human colon carcinoma cell line DLD-1 were alternatively prenylated by geranylgeranyl transferase-1.  When H-Ras, N-Ras, K-Ras4A, and K-Ras4B were expressed individually in COS cells, H-Ras prenylation and membrane assocn. were uniquely sensitive to farnesyl transferase inhibitors; N- and K-Ras proteins incorporated the geranylgeranyl isoprene group and remained assocd. with the membrane fraction.  The alternative prenylation of N- and K-Ras has significant implications for our understanding of the mechanism of action of farnesyl protein transferase inhibitors as anti-cancer chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgCoY9uLK4rVg90H21EOLACvtfcHk0ljoaHkWEvZzOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFygs74%253D&md5=50e8f78cabe32449915cf26ae9aa79f6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.22.14459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.22.14459%26sid%3Dliteratum%253Aachs%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DHockenberry%26aufirst%3DT.%2BN.%26aulast%3DNunez-Oliva%26aufirst%3DI.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DCatino%26aufirst%3DJ.%2BJ.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DPai%26aufirst%3DJ.-K.%26atitle%3DK-and%2520N-Ras%2520are%2520geranylgeranylated%2520in%2520cells%2520treated%2520with%2520farnesyl%2520protein%2520transferase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26issue%3D22%26spage%3D14459%26epage%3D14464%26doi%3D10.1074%2Fjbc.272.22.14459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Judd, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slattum, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhoite, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valppu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostanin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery and SAR of methylated tetrahydropyranyl derivatives as inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5031</span>– <span class="NLM_lpage">5047</span>, <span class="refDoi"> DOI: 10.1021/jm200249a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200249a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFShsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5031-5047&issue=14&author=W.+R.+Juddauthor=P.+M.+Slattumauthor=K.+C.+Hoangauthor=L.+Bhoiteauthor=L.+Valppuauthor=G.+Albertsauthor=B.+Brownauthor=B.+Rothauthor=K.+Ostaninauthor=L.+Huang&title=Discovery+and+SAR+of+methylated+tetrahydropyranyl+derivatives+as+inhibitors+of+isoprenylcysteine+carboxyl+methyltransferase+%28ICMT%29&doi=10.1021%2Fjm200249a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)</span></div><div class="casAuthors">Judd, Weston R.; Slattum, Paul M.; Hoang, Khanh C.; Bhoite, Leena; Valppu, Liisa; Alberts, Glen; Brown, Brita; Roth, Bruce; Ostanin, Kirill; Huang, Liwen; Wettstein, Daniel; Richards, Burt; Willardsen, J. Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5031-5047</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydropyranyl (THP) derivs. has been developed as potent inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT) for use as anticancer agents.  Structural modification of the submicromolar hit compd. I led to the potent 3-methoxy substituted analog II [R = H].  Further SAR development around the THP ring resulted in an addnl. 10-fold increase in potency, exemplified by analog II [R = Me] with an IC50 of 1.3 nM.  Active and potent compds. demonstrated a dose-dependent increase in Ras cytosolic protein.  Potent ICMT inhibitors also reduced cell viability in several cancer cell lines with growth inhibition (GI50) values ranging from 0.3 to >100 μM.  However, none of the cellular effects obsd. using ICMT inhibitors were as pronounced as those resulting from a farnesyl-transferase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxtJBz5EBh_LVg90H21EOLACvtfcHk0liLAHM8Dtoi_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFShsrk%253D&md5=70c861a9d4ef4efcde4b94a2e0a88de9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm200249a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200249a%26sid%3Dliteratum%253Aachs%26aulast%3DJudd%26aufirst%3DW.%2BR.%26aulast%3DSlattum%26aufirst%3DP.%2BM.%26aulast%3DHoang%26aufirst%3DK.%2BC.%26aulast%3DBhoite%26aufirst%3DL.%26aulast%3DValppu%26aufirst%3DL.%26aulast%3DAlberts%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DB.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DOstanin%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520methylated%2520tetrahydropyranyl%2520derivatives%2520as%2520inhibitors%2520of%2520isoprenylcysteine%2520carboxyl%2520methyltransferase%2520%2528ICMT%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D14%26spage%3D5031%26epage%3D5047%26doi%3D10.1021%2Fjm200249a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dechert, A.-M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacNamara, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breevoort, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrandt, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembree, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLain, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, T. M.</span></span> <span> </span><span class="NLM_article-title">Modulation of the inhibitor properties of dipeptidyl (acyloxy) methyl ketones toward the CAAX proteases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6230</span>– <span class="NLM_lpage">6237</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.07.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.bmc.2010.07.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=20696584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKgsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=6230-6237&issue=17&author=A.-M.+R.+Dechertauthor=J.+P.+MacNamaraauthor=S.+R.+Breevoortauthor=E.+R.+Hildebrandtauthor=N.+W.+Hembreeauthor=A.+C.+Reaauthor=D.+E.+McLainauthor=S.+B.+Porterauthor=W.+K.+Schmidtauthor=T.+M.+Dore&title=Modulation+of+the+inhibitor+properties+of+dipeptidyl+%28acyloxy%29+methyl+ketones+toward+the+CAAX+proteases&doi=10.1016%2Fj.bmc.2010.07.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the inhibitor properties of dipeptidyl (acyloxy)methyl ketones toward the CaaX proteases</span></div><div class="casAuthors">Dechert, Anne-Marie R.; MacNamara, James P.; Breevoort, Sarah R.; Hildebrandt, Emily R.; Hembree, Ned W.; Rea, Adam C.; McLain, Duncan E.; Porter, Stephen B.; Schmidt, Walter K.; Dore, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6230-6237</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dipeptidyl (acyloxy)methyl ketones (AOMKs) have been identified as mechanism-based inhibitors of certain cysteine proteases.  These compds. are also inhibitors of the integral membrane proteins Rce1p and Ste24p, which are proteases that independently mediate a cleavage step assocd. with the maturation of certain isoprenylated proteins.  The enzymic mechanism of Rce1p is ill-defined, whereas Ste24p is a zinc metalloprotease.  Rce1p is required for the proper processing of the oncoprotein Ras and is viewed as a potential target for cancer therapy.  In this study, we synthesized a small library of dipeptidyl AOMKs to investigate the structural elements that contribute to the inhibitor properties of this class of mols. toward Rce1p and Ste24p.  The compds. were evaluated using a fluorescence-based in vitro proteolysis assay.  The most potent dipeptidyl AOMKs contained an arginine residue and the identity of the benzoate group strongly influenced potency.  A 'warhead' free AOMK inhibited Rce1p and Ste24p.  The data suggest that the dipeptidyl AOMKs are not mechanism-based inhibitors of Rce1p and Ste24p and corroborate the hypothesis that Rce1p is not a cysteine protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwY3YF72cWwLVg90H21EOLACvtfcHk0liLAHM8Dtoi_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKgsLnF&md5=06e4477d4f1d267cf6cb6c24b5b8447d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.07.041%26sid%3Dliteratum%253Aachs%26aulast%3DDechert%26aufirst%3DA.-M.%2BR.%26aulast%3DMacNamara%26aufirst%3DJ.%2BP.%26aulast%3DBreevoort%26aufirst%3DS.%2BR.%26aulast%3DHildebrandt%26aufirst%3DE.%2BR.%26aulast%3DHembree%26aufirst%3DN.%2BW.%26aulast%3DRea%26aufirst%3DA.%2BC.%26aulast%3DMcLain%26aufirst%3DD.%2BE.%26aulast%3DPorter%26aufirst%3DS.%2BB.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DDore%26aufirst%3DT.%2BM.%26atitle%3DModulation%2520of%2520the%2520inhibitor%2520properties%2520of%2520dipeptidyl%2520%2528acyloxy%2529%2520methyl%2520ketones%2520toward%2520the%2520CAAX%2520proteases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26issue%3D17%26spage%3D6230%26epage%3D6237%26doi%3D10.1016%2Fj.bmc.2010.07.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita-Yoshigaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshio, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villafranca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaziro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span> <span> </span><span class="NLM_article-title">Mutations that abolish the ability of Ha-Ras to associate with Raf-1</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2153</span>– <span class="NLM_lpage">2157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=8036000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2cXlvFyrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1994&pages=2153-2157&issue=8&author=M.+Shirouzuauthor=H.+Koideauthor=J.+Fujita-Yoshigakiauthor=H.+Oshioauthor=Y.+Toyamaauthor=K.+Yamasakiauthor=S.+A.+Fuhrmanauthor=E.+Villafrancaauthor=Y.+Kaziroauthor=S.+Yokoyama&title=Mutations+that+abolish+the+ability+of+Ha-Ras+to+associate+with+Raf-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations that abolish the ability of Ha-Ras to associate with Raf-1</span></div><div class="casAuthors">Shirouzu, Mikako; Koide, Hiroshi; Fujita-Yoshigaki, Junko; Oshio, Hisayo; Toyama, Youichi; Yamasaki, Kazuhiko; Fuhrman, Shella A.; Villafranca, Ernie; Kaziro, Yoshito; Yokoyama, Shigeyuki</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2153-7</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">Recent studies have revealed that Ras can assoc. phys. with Raf.  In the present study, we tested 34 mutants of Ha-Ras carrying substitution(s) in the region of residues 23-71 for their ability to assoc. with Raf-1.  Mouse Ba/F3 cell lysates were incubated with each mutant Ras protein, in either the guanosine 5'-[γ-thio]triphosphate (GTPγS)- or the guanosine 5'-[β-thio]diphosphate (GDPβS)-bound form, and the anti-Ras antibody Y13-238.  The immunoppts. were analyzed for the presence of Raf-1 by Western blotting with an anti-Raf-1 antibody.  Six mutants of Ras, E31K, P34G, T35S, D38N, D57A and A59T, failed to bind Raf-1.  Mutations N26G, V29A, S39A, Y40W, R41A, V44A, V45E, L56A and T58A partially reduced the ability to bind Raf-1.  All the other mutants could assoc. with Raf-1 with nearly the same efficiency as that of wild-type Ras.  Thus, the Raf-1-binding ability of Ras appears to be affected by mutations in the N-terminal region, and in particular, by those in and neighboring the effector region (residues 32-40) and in the region (residues 56-59) flanking the N-terminal of Switch II.  The abilities to bind Raf-1 and to induce neurite outgrowth of pheochromocytoma (PC) 12 cells correlate to each other for 22 Ras mutants.  However, mutation A59T, which does not reduce the neurite-inducing or transforming activities, abolishes the ability to bind Raf-1.  In contrast, mutations Y32F, K42A and L53A, which impair the neurite-inducing activity of Ras, have no effect on the Ras·Raf-1 assocn.  Partially reduced Raf-1-binding ability was obsd. for mutants V29A, S39A, Y40W, R41A, V44A, L56A and T58A, which exhibit full neurite-inducing activity, and also for mutant V45E, which has no activity of neurite induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_3PtqUfeo2rVg90H21EOLACvtfcHk0liLAHM8Dtoi_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlvFyrsro%253D&md5=716bcabbcc087203bb985013c3faab14</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DKoide%26aufirst%3DH.%26aulast%3DFujita-Yoshigaki%26aufirst%3DJ.%26aulast%3DOshio%26aufirst%3DH.%26aulast%3DToyama%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DK.%26aulast%3DFuhrman%26aufirst%3DS.%2BA.%26aulast%3DVillafranca%26aufirst%3DE.%26aulast%3DKaziro%26aufirst%3DY.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DMutations%2520that%2520abolish%2520the%2520ability%2520of%2520Ha-Ras%2520to%2520associate%2520with%2520Raf-1%26jtitle%3DOncogene%26date%3D1994%26volume%3D9%26issue%3D8%26spage%3D2153%26epage%3D2157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moodie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villafranca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirshmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willumsen, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfman, A.</span></span> <span> </span><span class="NLM_article-title">Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">454</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=7630628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2MXnsFyhsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=447-454&issue=3&author=S.+A.+Moodieauthor=M.+Parisauthor=E.+Villafrancaauthor=P.+Kirshmeierauthor=B.+M.+Willumsenauthor=A.+Wolfman&title=Different+structural+requirements+within+the+switch+II+region+of+the+Ras+protein+for+interactions+with+specific+downstream+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets</span></div><div class="casAuthors">Moodie, Shonna A.; Paris, Mark; Villafranca, Ernest; Kirshmeier, Paul; Willumsen, Berthe M.; Wolfman, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">447-54</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Ras proteins function through the formation of specific complexes with Raf-1, B-raf, PI-3 kinase and RalGDS.  These interactions all require Ras-GTP with an intact effector binding domain (Switch I region).  The authors have examd. the requirements of the Switch II region (amino acids 60-72) for the prodn. of stable interactions between Ras and its downstream effectors.  A point mutation at position 65 or 64 combined with addnl. mutations at either position 65 or 71 rendered nucleotide-free Ras protein unable to stably interact with Ras specific guanine nucleotide exchange factors.  Ha-Ras contg. point mutations at positions 65 and 71 possessed a twofold higher affinity for B-raf and consequently MEK1.  The point mutation at 64, in combination with addnl. point mutations at either position 65 or 71, resulted in a protein which failed to interact with either PI-3 kinase or neurofibromin, though these Ras mutants effectively bound both Raf-1 and B-raf.  An activated form of Ras, Q61L-Ras, assocd. with all effector proteins independent of the bound guanine nucleotide.  Q61L-Ras-GDP was almost as effective as wild type Ras-GMPPNP in the in vitro activation of MEK1 and MAP kinase.  Competitive studies with the catalytic domain of neurofibromin, NF1-GRD, demonstrated that its interaction with Ras-GRD, demonstrated that its interaction with Ras-GMPPNP is mutually exclusive with both Raf-1 and B-raf.  These data suggest that rasGAP and neurofibromin are unable to downregulate Ras-GTP complexed to Raf-1 or B-raf.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokId0KQx0MobVg90H21EOLACvtfcHk0lgz0yKZ-EyedA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnsFyhsbc%253D&md5=ef1c439a9b5244ae5be22150ae566e1c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoodie%26aufirst%3DS.%2BA.%26aulast%3DParis%26aufirst%3DM.%26aulast%3DVillafranca%26aufirst%3DE.%26aulast%3DKirshmeier%26aufirst%3DP.%26aulast%3DWillumsen%26aufirst%3DB.%2BM.%26aulast%3DWolfman%26aufirst%3DA.%26atitle%3DDifferent%2520structural%2520requirements%2520within%2520the%2520switch%2520II%2520region%2520of%2520the%2520Ras%2520protein%2520for%2520interactions%2520with%2520specific%2520downstream%2520targets%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26issue%3D3%26spage%3D447%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, F.</span></span> <span> </span><span class="NLM_article-title">Nucleotide binding affects intrinsic dynamics and structural communication in Ras GTPases</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">4214</span>– <span class="NLM_lpage">4225</span>, <span class="refDoi"> DOI: 10.2174/1381612811319230006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.2174%2F1381612811319230006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23170885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4214-4225&issue=23&author=F.+Fanelliauthor=F.+Raimondi&title=Nucleotide+binding+affects+intrinsic+dynamics+and+structural+communication+in+Ras+GTPases&doi=10.2174%2F1381612811319230006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleotide binding affects intrinsic dynamics and structural communication in Ras GTPases</span></div><div class="casAuthors">Fanelli, Francesca; Raimondi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4214-4225</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Ras superfamily comprises many guanine nucleotide-binding proteins (G proteins) that are essential to intracellular signal transduction.  These proteins act biol. as mol. switches, which, cycling between OFF and ON states, play fundamental role in cell biol.  This review article summarizes the inferences from the widest computational analyses done so far on Ras GTPases aimed at providing a comprehensive structural/dynamic view of the trans-family and family-specific functioning mechanisms.  These variegated comparative analyses could infer the evolutionary and intrinsic flexibilities as well as the structural communication features in the most representative G protein families in different functional states.  In spite of the low sequence similarities, the members of the Ras superfamily share the topol. of the Ras-like domain, including the nucleotide binding site.  GDP and GTP make very similar interactions in all GTPases and differences in their binding modes are localized around the γ-phosphate of GTP.  Remarkably, such subtle local differences result in significant differences in the functional dynamics and structural communication features of the protein.  In Ras GTPases, the nucleotide plays a central and active role in dictating functional dynamics, establishing the major structure network, and mediating the communication paths instrumental in function retention and specialization.  Collectively, the results of these studies support the speculation that an "extended conformational selection model" that embraces a repertoire of selection and adjustment processes is likely more suitable to describe the nucleotide behavior in these important mol. switches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovtaxyGikHf7Vg90H21EOLACvtfcHk0lgz0yKZ-EyedA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyrt7s%253D&md5=c1857a83b638a762fd239640a8845b71</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F1381612811319230006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319230006%26sid%3Dliteratum%253Aachs%26aulast%3DFanelli%26aufirst%3DF.%26aulast%3DRaimondi%26aufirst%3DF.%26atitle%3DNucleotide%2520binding%2520affects%2520intrinsic%2520dynamics%2520and%2520structural%2520communication%2520in%2520Ras%2520GTPases%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26issue%3D23%26spage%3D4214%26epage%3D4225%26doi%3D10.2174%2F1381612811319230006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, M. E.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1246</span>, <span class="refDoi"> DOI: 10.1021/jm8008597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&issue=5&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design&doi=10.1021%2Fjm8008597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0lgz0yKZ-EyedA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D5%26spage%3D1231%26epage%3D1246%26doi%3D10.1021%2Fjm8008597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1002/anie.201307387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fanie.201307387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvValsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=199-204&issue=1&author=S.+M.+Limauthor=K.+D.+Westoverauthor=S.+B.+Ficarroauthor=R.+A.+Harrisonauthor=H.+G.+Choiauthor=M.+E.+Pacoldauthor=M.+Carrascoauthor=J.+Hunterauthor=N.+D.+Kimauthor=T.+Xie&title=Therapeutic+targeting+of+oncogenic+K-Ras+by+a+covalent+catalytic+site+inhibitor&doi=10.1002%2Fanie.201307387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor</span></div><div class="casAuthors">Lim, Sang Min; Westover, Kenneth D.; Ficarro, Scott B.; Harrison, Rane A.; Choi, Hwan Geun; Pacold, Michael E.; Carrasco, Martin; Hunter, John; Kim, Nam Doo; Xie, Ting; Sim, Taebo; Jaenne, Pasi A.; Meyerson, Matthew; Marto, Jarrod A.; Engen, John R.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">199-204</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We report the synthesis of a GDP analog, SML-8-73-1, and a prodrug deriv., SML-10-70-1, which are selective, direct-acting covalent inhibitors of the K-Ras G12C mutant relative to wild-type Ras.  Biochem. and biophys. measurements suggest that modification of K-Ras with SML-8-73-1 renders the protein in an inactive state.  These first-in-class covalent K-Ras inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfLlkUFFkg-7Vg90H21EOLACvtfcHk0lgz0yKZ-EyedA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvValsrbN&md5=f99a8c9603d4139135606c964706a822</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307387%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BM.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DHarrison%26aufirst%3DR.%2BA.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DCarrasco%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DXie%26aufirst%3DT.%26atitle%3DTherapeutic%2520targeting%2520of%2520oncogenic%2520K-Ras%2520by%2520a%2520covalent%2520catalytic%2520site%2520inhibitor%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26issue%3D1%26spage%3D199%26epage%3D204%26doi%3D10.1002%2Fanie.201307387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span> <span> </span><span class="NLM_article-title">In situ selectivity profiling and crystal structure of SML-8–73–1, an active site inhibitor of oncogenic K-Ras G12C</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8895</span>– <span class="NLM_lpage">8900</span>, <span class="refDoi"> DOI: 10.1073/pnas.1404639111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.1404639111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=24889603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlKqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8895-8900&issue=24&author=J.+C.+Hunterauthor=D.+Gurbaniauthor=S.+B.+Ficarroauthor=M.+A.+Carrascoauthor=S.+M.+Limauthor=H.+G.+Choiauthor=T.+Xieauthor=J.+A.+Martoauthor=Z.+Chenauthor=N.+S.+Grayauthor=K.+D.+Westover&title=In+situ+selectivity+profiling+and+crystal+structure+of+SML-8%E2%80%9373%E2%80%931%2C+an+active+site+inhibitor+of+oncogenic+K-Ras+G12C&doi=10.1073%2Fpnas.1404639111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C</span></div><div class="casAuthors">Hunter, John C.; Gurbani, Deepak; Ficarro, Scott B.; Carrasco, Martin A.; Lim, Sang Min; Choi, Hwan Geun; Xie, Ting; Marto, Jarrod A.; Chen, Zhe; Gray, Nathanael S.; Westover, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8895-8900</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Directly targeting oncogenic V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras) with small-mol. inhibitors has historically been considered prohibitively challenging.  Recent reports of compds. that bind directly to the K-Ras G12C mutant suggest avenues to overcome key obstacles that stand in the way of developing such compds.  We aim to target the guanine nucleotide (GN)-binding pocket because the natural contents of this pocket dictate the signaling state of K-Ras.  Here, we characterize the irreversible inhibitor SML-8-73-1 (SML), which targets the GN-binding pocket of K-Ras G12C.  We report a high-resoln. x-ray crystal structure of G12C K-Ras bound to SML, revealing that the compd. binds in a manner similar to GDP, forming a covalent linkage with Cys-12.  The resulting conformation renders K-Ras in the open, inactive conformation, which is not predicted to assoc. productively with or activate downstream effectors.  Conservation anal. of the Ras family GN-binding pocket reveals variability in the side chains surrounding the active site and adjacent regions, esp. in the switch I region.  This variability may enable building specificity into new iterations of Ras and other GTPase inhibitors.  High-resoln. in situ chem. proteomic profiling of SML confirms that SML effectively discriminates between K-Ras G12C and other cellular GTP-binding proteins.  A biochem. assay provides addnl. evidence that SML is able to compete with millimolar concns. of GTP and GDP for the GN-binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphz2MYHd6_n7Vg90H21EOLACvtfcHk0liOHzPuJLYtqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlKqsrc%253D&md5=e32ec21482b3aef278c23c83470a146c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1404639111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1404639111%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DJ.%2BC.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DCarrasco%26aufirst%3DM.%2BA.%26aulast%3DLim%26aufirst%3DS.%2BM.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26atitle%3DIn%2520situ%2520selectivity%2520profiling%2520and%2520crystal%2520structure%2520of%2520SML-8%25E2%2580%259373%25E2%2580%25931%252C%2520an%2520active%2520site%2520inhibitor%2520of%2520oncogenic%2520K-Ras%2520G12C%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D24%26spage%3D8895%26epage%3D8900%26doi%3D10.1073%2Fpnas.1404639111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taouji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevet, E.</span></span> <span> </span><span class="NLM_article-title">Current screens based on the AlphaScreen technology for deciphering cell signalling pathways</span>. <i>Curr. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.2174/138920209787847041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.2174%2F138920209787847041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=19794881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVCisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=93-101&issue=2&author=S.+Taoujiauthor=S.+Dahanauthor=R.+Boss%C3%A9author=E.+Chevet&title=Current+screens+based+on+the+AlphaScreen+technology+for+deciphering+cell+signalling+pathways&doi=10.2174%2F138920209787847041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Current screens based on the AlphaScreen technology for deciphering cell signalling pathways</span></div><div class="casAuthors">Taouji, Said; Dahan, Sophie; Bosse, Roger; Chevet, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Current Genomics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-101</span>CODEN:
                <span class="NLM_cas:coden">CGUEA8</span>;
        ISSN:<span class="NLM_cas:issn">1389-2029</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Global deciphering of signal transduction pathways represents a new challenge of the postgenomic era.  However, for the majority of these signaling pathways, the role(s), the function(s), and the interaction(s) of the signaling intermediates remain to be characterized in an integrated fashion.  The global mol. study of cell signaling pathways and networks consequently requires sensitive, robust technologies which may allow in addn. multi-parallel and high-throughput applications.  The Alphascreen technol., relying on a bead-based homogenous approach, constitutes a valuable tool to detect and quantify a wide range of signaling events such as enzymic activities or biomol. interactions.  In this article, the authors exhaustively review the literature and report the broad spectrum of Alphascreen-based applications in the study of signal transduction pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJIrb-Muqpz7Vg90H21EOLACvtfcHk0liOHzPuJLYtqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVCisLw%253D&md5=7ddc87469ce10b96f3eb0943cb2de73e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2174%2F138920209787847041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920209787847041%26sid%3Dliteratum%253Aachs%26aulast%3DTaouji%26aufirst%3DS.%26aulast%3DDahan%26aufirst%3DS.%26aulast%3DBoss%25C3%25A9%26aufirst%3DR.%26aulast%3DChevet%26aufirst%3DE.%26atitle%3DCurrent%2520screens%2520based%2520on%2520the%2520AlphaScreen%2520technology%2520for%2520deciphering%2520cell%2520signalling%2520pathways%26jtitle%3DCurr.%2520Genomics%26date%3D2009%26volume%3D10%26issue%3D2%26spage%3D93%26epage%3D101%26doi%3D10.2174%2F138920209787847041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manandhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Covalent guanosine mimetic inhibitors of G12C KRAS.</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyntrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=61-66&issue=1&author=Y.+Xiongauthor=J.+Luauthor=J.+Hunterauthor=L.+Liauthor=D.+Scottauthor=H.+G.+Choiauthor=S.+M.+Limauthor=A.+Manandharauthor=S.+Gondiauthor=T.+Sim&title=Covalent+guanosine+mimetic+inhibitors+of+G12C+KRAS.&doi=10.1021%2Facsmedchemlett.6b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Guanosine Mimetic Inhibitors of G12C KRAS</span></div><div class="casAuthors">Xiong, Yuan; Lu, Jia; Hunter, John; Li, Lianbo; Scott, David; Choi, Hwan Geun; Lim, Sang Min; Manandhar, Anuj; Gondi, Sudershan; Sim, Taebo; Westover, Kenneth D.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-66</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ras proteins are members of a large family of GTPase enzymes that are commonly mutated in cancer where they act as dominant oncogenes.  The authors previously developed an irreversible guanosine-derived inhibitor, SML-8-73-1, of mutant G12C RAS which forms a covalent bond with cysteine 12.  Here the authors report exploration of the structure-activity relationships (SAR) of hydrolytically stable analogs of SML-8-73-1 as covalent G12C KRAS inhibitors.  The authors report the discovery of difluoromethylene bisphosphonate analogs such as compd. I, which despite exhibiting reduced efficiency as covalent G12C KRAS inhibitors, remove the liability of the hydrolytic instability of the diphosphate moiety present in SML-8-73-1 and provide the foundation for development of prodrugs to facilitate cellular uptake.  The SAR and crystallog. results reaffirm the exquisite mol. recognition that exists in the diphosphate-region of RAS for guanosine nucleotides which must be considered in the design of nucleotide-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraZMoq5jUr_rVg90H21EOLACvtfcHk0liOHzPuJLYtqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyntrbF&md5=b36c23e91f8a3c3f30aa9819d931870f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00373%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DScott%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DLim%26aufirst%3DS.%2BM.%26aulast%3DManandhar%26aufirst%3DA.%26aulast%3DGondi%26aufirst%3DS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DCovalent%2520guanosine%2520mimetic%2520inhibitors%2520of%2520G12C%2520KRAS.%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D61%26epage%3D66%26doi%3D10.1021%2Facsmedchemlett.6b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeganathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goody, R. S.</span></span> <span> </span><span class="NLM_article-title">Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3687</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-03973-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41598-017-03973-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=28623374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3687&issue=1&author=M.+P.+M%C3%BCllerauthor=S.+Jeganathanauthor=A.+Heidrichauthor=J.+Camposauthor=R.+S.+Goody&title=Nucleotide+based+covalent+inhibitors+of+KRas+can+only+be+efficient+in+vivo+if+they+bind+reversibly+with+GTP-like+affinity&doi=10.1038%2Fs41598-017-03973-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-03973-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-03973-6%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BP.%26aulast%3DJeganathan%26aufirst%3DS.%26aulast%3DHeidrich%26aufirst%3DA.%26aulast%3DCampos%26aufirst%3DJ.%26aulast%3DGoody%26aufirst%3DR.%2BS.%26atitle%3DNucleotide%2520based%2520covalent%2520inhibitors%2520of%2520KRas%2520can%2520only%2520be%2520efficient%2520in%2520vivo%2520if%2520they%2520bind%2520reversibly%2520with%2520GTP-like%2520affinity%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D3687%26doi%3D10.1038%2Fs41598-017-03973-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>503</i></span> (<span class="NLM_issue">7477</span>),  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nature12796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fnature12796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=24256730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2013&pages=548-551&issue=7477&author=J.+M.+Ostremauthor=U.+Petersauthor=M.+L.+Sosauthor=J.+A.+Wellsauthor=K.+M.+Shokat&title=K-Ras+%28G12C%29+inhibitors+allosterically+control+GTP+affinity+and+effector+interactions&doi=10.1038%2Fnature12796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</span></div><div class="casAuthors">Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L.; Wells, James A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">7477</span>),
    <span class="NLM_cas:pages">548-551</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally assocd. with poor response to std. therapies.  Efforts to target this oncogene directly have faced difficulties owing to its picomolar affinity for GTP/GDP and the absence of known allosteric regulatory sites.  Oncogenic mutations result in functional activation of Ras family proteins by impairing GTP hydrolysis.  With diminished regulation by GTPase activity, the nucleotide state of Ras becomes more dependent on relative nucleotide affinity and concn.  This gives GTP an advantage over GDP and increases the proportion of active GTP-bound Ras.  Here we report the development of small mols. that irreversibly bind to a common oncogenic mutant, K-Ras(G12C).  These compds. rely on the mutant cysteine for binding and therefore do not affect the wild-type protein.  Crystallog. studies reveal the formation of a new pocket that is not apparent in previous structures of Ras, beneath the effector binding switch-II region.  Binding of these inhibitors to K-Ras(G12C) disrupts both switch-I and switch-II, subverting the native nucleotide preference to favor GDP over GTP and impairing binding to Raf.  Our data provide structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokkgcVXuBn_rVg90H21EOLACvtfcHk0lhDLlRfMusoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO&md5=27c1e7d8ef6b7e4b2919e9f00a073923</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnature12796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12796%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DK-Ras%2520%2528G12C%2529%2520inhibitors%2520allosterically%2520control%2520GTP%2520affinity%2520and%2520effector%2520interactions%26jtitle%3DNature%26date%3D2013%26volume%3D503%26issue%3D7477%26spage%3D548%26epage%3D551%26doi%3D10.1038%2Fnature12796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braisted, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raphael, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span> <span> </span><span class="NLM_article-title">Site-directed ligand discovery</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">9367</span>– <span class="NLM_lpage">9372</span>, <span class="refDoi"> DOI: 10.1073/pnas.97.17.9367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.97.17.9367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10944209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtVensr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=9367-9372&issue=17&author=D.+A.+Erlansonauthor=A.+C.+Braistedauthor=D.+R.+Raphaelauthor=M.+Randalauthor=R.+M.+Stroudauthor=E.+M.+Gordonauthor=J.+A.+Wells&title=Site-directed+ligand+discovery&doi=10.1073%2Fpnas.97.17.9367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Site-directed ligand discovery</span></div><div class="casAuthors">Erlanson, Daniel A.; Braisted, Andrew C.; Raphael, Darren R.; Randal, Mike; Stroud, Robert M.; Gordon, Eric M.; Wells, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9367-9372</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We report a strategy (called "tethering") to discover low mol. wt. ligands (≈250 Da) that bind weakly to targeted sites on proteins through an intermediary disulfide tether.  A native or engineered cysteine in a protein is allowed to react reversibly with a small library of disulfide-contg. mols. (≈1,200 compds.) at concns. typically used in drug screening (10 to 200 μM).  The cysteine-captured ligands, which are readily identified by MS, are among the most stable complexes, even though in the absence of the covalent tether the ligands may bind very weakly.  This method was applied to generate a potent inhibitor for thymidylate synthase, an essential enzyme in pyrimidine metab. with therapeutic applications in cancer and infectious diseases.  The affinity of the untethered ligand (Ki≈1 mM) was improved 3,000-fold by synthesis of a small set of analogs with the aid of crystallog. structures of the tethered complex.  Such site-directed ligand discovery allows one to nucleate drug design from a spatially targeted lead fragment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4pxPEoDE3FrVg90H21EOLACvtfcHk0lhDLlRfMusoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtVensr8%253D&md5=fef57a0d21af9bc7f6f1f4bf8c023ae5</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.17.9367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.17.9367%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DBraisted%26aufirst%3DA.%2BC.%26aulast%3DRaphael%26aufirst%3DD.%2BR.%26aulast%3DRandal%26aufirst%3DM.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DGordon%26aufirst%3DE.%2BM.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26atitle%3DSite-directed%2520ligand%2520discovery%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26issue%3D17%26spage%3D9367%26epage%3D9372%26doi%3D10.1073%2Fpnas.97.17.9367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F2159-8290.CD-15-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26739882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=316-329&issue=3&author=M.+P.+Patricelliauthor=M.+R.+Janesauthor=L.-S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=L.+V.+Kesslerauthor=Y.+Chenauthor=J.+M.+Kucharskiauthor=J.+Fengauthor=T.+Ely&title=Selective+inhibition+of+oncogenic+KRAS+output+with+small+molecules+targeting+the+inactive+state&doi=10.1158%2F2159-8290.CD-15-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State</span></div><div class="casAuthors">Patricelli, Matthew P.; Janes, Matthew R.; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Kessler, Linda V.; Chen, Yuching; Kucharski, Jeff M.; Feng, Jun; Ely, Tess; Chen, Jeffrey H.; Firdaus, Sarah J.; Babbar, Anjali; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-329</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS gain-of-function mutations occur in approx. 30% of all human cancers.  Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered for cancers with KRAS mutations.  Here, we describe ARS-853, a selective, covalent inhibitor of KRASG12C that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.  Based on the rates of engagement and inhibition obsd. for ARS-853, along with a mutant-specific mass spectrometry-based assay for assessing KRAS activation status, we show that the nucleotide state of KRASG12C is in a state of dynamic flux that can be modulated by upstream signaling factors.  These studies provide convincing evidence that the KRASG12C mutation generates a "hyperexcitable" rather than a "statically active" state and that targeting the inactive, GDP-bound form is a promising approach for generating novel anti-RAS therapeutics.  Significance: A cell-active, mutant-specific, covalent inhibitor of KRASG12C is described that targets the GDP-bound, inactive state and prevents subsequent activation.  Using this novel compd., we demonstrate that KRASG12C oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJJA-9IIHeN7Vg90H21EOLACvtfcHk0lhDLlRfMusoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D&md5=41db2f02006e8f0be7a9bb47354addcd</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1105%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DKessler%26aufirst%3DL.%2BV.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKucharski%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEly%26aufirst%3DT.%26atitle%3DSelective%2520inhibition%2520of%2520oncogenic%2520KRAS%2520output%2520with%2520small%2520molecules%2520targeting%2520the%2520inactive%2520state%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D3%26spage%3D316%26epage%3D329%26doi%3D10.1158%2F2159-8290.CD-15-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">The reactivity-driven biochemical mechanism of covalent KRAS G12C inhibitors</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0061-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41594-018-0061-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29760531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=454-462&issue=6&author=R.+Hansenauthor=U.+Petersauthor=A.+Babbarauthor=Y.+Chenauthor=J.+Fengauthor=M.+R.+Janesauthor=L.-S.+Liauthor=P.+Renauthor=Y.+Liuauthor=P.+P.+Zarrinkar&title=The+reactivity-driven+biochemical+mechanism+of+covalent+KRAS+G12C+inhibitors&doi=10.1038%2Fs41594-018-0061-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors</span></div><div class="casAuthors">Hansen, Rasmus; Peters, Ulf; Babbar, Anjali; Chen, Yuching; Feng, Jun; Janes, Matthew R.; Li, Lian-Sheng; Ren, Pingda; Liu, Yi; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">454-462</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Activating mutations in KRAS are among the most common tumor driver mutations.  Until recently, KRAS had been considered undruggable with small mols.; the discovery of the covalent KRASG12C inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals.  Although the biol. activity of these inhibitors has been described, the biochem. mechanism of how the compds. achieve potent inhibition remained incompletely understood.  We now show that the activity of ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the chem. reaction with Cys12 in human KRASG12C, while the reversible binding affinity is weak, in the hundreds of micromolar or higher range.  The mechanism resolves how an induced, shallow and dynamic pocket not expected to support high-affinity binding of small mols. can nevertheless be targeted with potent inhibitors and may be applicable to other targets conventionally considered undruggable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrya_A4ZYnOu7Vg90H21EOLACvtfcHk0liWDRVzqir7EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7nL&md5=b3f9198f55998306f3b881c256be22a9</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0061-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0061-5%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DThe%2520reactivity-driven%2520biochemical%2520mechanism%2520of%2520covalent%2520KRAS%2520G12C%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D6%26spage%3D454%26epage%3D462%26doi%3D10.1038%2Fs41594-018-0061-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span> (<span class="NLM_issue">6273</span>),  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1126/science.aad6204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1126%2Fscience.aad6204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=26841430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=604-608&issue=6273&author=P.+Litoauthor=M.+Solomonauthor=L.-S.+Liauthor=R.+Hansenauthor=N.+Rosen&title=Allele-specific+inhibitors+inactivate+mutant+KRAS+G12C+by+a+trapping+mechanism&doi=10.1126%2Fscience.aad6204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span></div><div class="casAuthors">Lito, Piro; Solomon, Martha; Li, Lian-Sheng; Hansen, Rasmus; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6273</span>),
    <span class="NLM_cas:pages">604-608</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">It is thought that KRAS oncoproteins are constitutively active because their guanosine triphosphatase (GTPase) activity is disabled.  Consequently, drugs targeting the inactive or GDP-bound conformation are not expected to be effective.  We describe a mechanism that enables such drugs to inhibit KRASG12C signaling and cancer cell growth.  Inhibition requires intact GTPase activity and occurs because drug-bound KRASG12C is insusceptible to nucleotide exchange factors and thus trapped in its inactive state.  Indeed, mutants completely lacking GTPase activity and those promoting exchange reduced the potency of the drug.  Suppressing nucleotide exchange activity downstream of various tyrosine kinases enhanced KRASG12C inhibition, whereas its potentiation had the opposite effect.  These findings reveal that KRASG12C undergoes nucleotide cycling in cancer cells and provide a basis for developing effective therapies to treat KRASG12C-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK3AbqEZO6k7Vg90H21EOLACvtfcHk0liWDRVzqir7EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D&md5=22a47908ac0146822ecf19f5d0c952de</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad6204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad6204%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DAllele-specific%2520inhibitors%2520inactivate%2520mutant%2520KRAS%2520G12C%2520by%2520a%2520trapping%2520mechanism%26jtitle%3DScience%26date%3D2016%26volume%3D351%26issue%3D6273%26spage%3D604%26epage%3D608%26doi%3D10.1126%2Fscience.aad6204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdaus, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.cell.2018.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29373830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislyisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=578-589&issue=3&author=M.+R.+Janesauthor=J.+Zhangauthor=L.-S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=X.+Guoauthor=Y.+Chenauthor=A.+Babbarauthor=S.+J.+Firdausauthor=L.+Darjania&title=Targeting+KRAS+mutant+cancers+with+a+covalent+G12C-specific+inhibitor&doi=10.1016%2Fj.cell.2018.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor</span></div><div class="casAuthors">Janes, Matthew R.; Zhang, Jingchuan; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Guo, Xin; Chen, Yuching; Babbar, Anjali; Firdaus, Sarah J.; Darjania, Levan; Feng, Jun; Chen, Jeffrey H.; Li, Shuangwei; Li, Shisheng; Long, Yun O.; Thach, Carol; Liu, Yuan; Zarieh, Ata; Ely, Tess; Kucharski, Jeff M.; Kessler, Linda V.; Wu, Tao; Yu, Ke; Wang, Yi; Yao, Yvonne; Deng, Xiaohu; Zarrinkar, Patrick P.; Brehmer, Dirk; Dhanak, Dashyant; Lorenzi, Matthew V.; Hu-Lowe, Dana; Patricelli, Matthew P.; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">578-589.e17</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">KRASG12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys 12 in vicinity to an inducible allosteric switch II pocket (S-IIP).  Success of this approach requires active cycling of KRASG12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state.  This strategy proved feasible for inhibiting mutant KRAS in vitro; however, it is uncertain whether this approach would translate to in vivo.  Here, the authors describe structure-based design and identification of ARS-1620, a covalent compd. with high potency and selectivity for KRASG12C.  ARS-1620 achieves rapid and sustained in vivo target occupancy to induce tumor regression.  The authors use ARS-1620 to dissect oncogenic KRAS dependency and demonstrate that monolayer culture formats significantly underestimate KRAS dependency in vivo.  This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRASG12C-specific inhibitors with promising therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVmv4KAl4_dLVg90H21EOLACvtfcHk0liWDRVzqir7EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislyisb8%253D&md5=d0883bde981b51e41a794179ffae87be</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DFirdaus%26aufirst%3DS.%2BJ.%26aulast%3DDarjania%26aufirst%3DL.%26atitle%3DTargeting%2520KRAS%2520mutant%2520cancers%2520with%2520a%2520covalent%2520G12C-specific%2520inhibitor%26jtitle%3DCell%26date%3D2018%26volume%3D172%26issue%3D3%26spage%3D578%26epage%3D589%26doi%3D10.1016%2Fj.cell.2018.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <i>Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists</i>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2013</span>; Vol.  <span class="NLM_volume">2</span>, pp  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">282</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2F9781118540398.ch7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=245-282&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery%3A+A+Guide+for+Medicinal+Chemists+and+Pharmacologists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2F9781118540398.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118540398.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery%253A%2520A%2520Guide%2520for%2520Medicinal%2520Chemists%2520and%2520Pharmacologists%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2013%26volume%3D2%26spage%3D245%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feru, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Potent and selective covalent quinazoline inhibitors of KRAS G12C</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1016</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.chembiol.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=28781124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yltr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1005-1016&issue=8&author=M.+Zengauthor=J.+Luauthor=L.+Liauthor=F.+Feruauthor=C.+Quanauthor=T.+W.+Geroauthor=S.+B.+Ficarroauthor=Y.+Xiongauthor=C.+Ambrogioauthor=R.+M.+Paranal&title=Potent+and+selective+covalent+quinazoline+inhibitors+of+KRAS+G12C&doi=10.1016%2Fj.chembiol.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective covalent quinazoline inhibitors of kras g12c</span></div><div class="casAuthors">Zeng, Mei; Lu, Jia; Li, Lianbo; Feru, Frederic; Quan, Chunshan; Gero, Thomas W.; Ficarro, Scott B.; Xiong, Yuan; Ambrogio, Chiara; Paranal, Raymond M.; Catalano, Marco; Shao, Jay; Wong, Kwok-Kin; Marto, Jarrod A.; Fischer, Eric S.; Janne, Pasi A.; Scott, David A.; Westover, Kenneth D.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1005-1016.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Targeted covalent small mols. have shown promise for cancers driven by KRAS G12C.  Allosteric compds. that access an inducible pocket formed by movement of a dynamic structural element in KRAS, switch II, have been reported, but these compds. require further optimization to enable their advancement into clin. development.  We demonstrate that covalent quinazoline-based switch II pocket (SIIP) compds. effectively suppress GTP loading of KRAS G12C, MAPK phosphorylation, and the growth of cancer cells harboring G12C.  Notably we find that adding an amide substituent to the quinazoline scaffold allows addnl. interactions with KRAS G12C, and remarkably increases the labeling efficiency, potency, and selectivity of KRAS G12C inhibitors.  Structural studies using X-ray crystallog. reveal a new conformation of SIIP and key interactions made by substituents located at the quinazoline 2-, 4-, and 7-positions.  Optimized lead compds. in the quinazoline series selectively inhibit KRAS G12C-dependent signaling and cancer cell growth at sub-micromolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxY0-7NkfIeLVg90H21EOLACvtfcHk0lidaY_iUUHqjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yltr3N&md5=e793972cb711c5a8c0db46d8288697af</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26atitle%3DPotent%2520and%2520selective%2520covalent%2520quinazoline%2520inhibitors%2520of%2520KRAS%2520G12C%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26issue%3D8%26spage%3D1005%26epage%3D1016%26doi%3D10.1016%2Fj.chembiol.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00382</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00382" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFagurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1230-1234&issue=12&author=J.+B.+Fellauthor=J.+P.+Fischerauthor=B.+R.+Baerauthor=J.+Ballardauthor=J.+F.+Blakeauthor=K.+Bouhanaauthor=B.+J.+Brandhuberauthor=D.+M.+Briereauthor=L.+E.+Burgessauthor=M.+R.+Burkard&title=Discovery+of+tetrahydropyridopyrimidines+as+irreversible+covalent+inhibitors+of+KRAS-G12C+with+in+vivo+activity&doi=10.1021%2Facsmedchemlett.8b00382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity</span></div><div class="casAuthors">Fell, Jay B.; Fischer, John P.; Baer, Brian R.; Ballard, Joshua; Blake, James F.; Bouhana, Karyn; Brandhuber, Barbara J.; Briere, David M.; Burgess, Laurence E.; Burkard, Michael R.; Chiang, Harrah; Chicarelli, Mark J.; Davidson, Kevin; Gaudino, John J.; Hallin, Jill; Hanson, Lauren; Hee, Kenneth; Hicken, Erik J.; Hinklin, Ronald J.; Marx, Matthew A.; Mejia, Macedonio J.; Olson, Peter; Savechenkov, Pavel; Sudhakar, Niranjan; Tang, Tony P.; Vigers, Guy P.; Zecca, Henry; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1230-1234</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly assocd. with poor prognosis and resistance to std. treatment.  The ability to effectively target and block the function of mutated KRAS has remained elusive despite decades of research.  Recent findings have demonstrated that directly targeting KRAS-G12C with electrophilic small mols. that covalently modify the mutated codon 12 cysteine is feasible.  We have discovered a series of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity.  The PK/PD and efficacy of compd. 13 will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGs80kLXd9TbVg90H21EOLACvtfcHk0lidaY_iUUHqjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFagurfP&md5=f40ea2037c92c98dd84e907ebdcb4af6</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00382%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DBouhana%26aufirst%3DK.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DBurgess%26aufirst%3DL.%2BE.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520tetrahydropyridopyrimidines%2520as%2520irreversible%2520covalent%2520inhibitors%2520of%2520KRAS-G12C%2520with%2520in%2520vivo%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D12%26spage%3D1230%26epage%3D1234%26doi%3D10.1021%2Facsmedchemlett.8b00382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6679</span>– <span class="NLM_lpage">6693</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02052</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02052" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtlCntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6679-6693&issue=13&author=J.+B.+Fellauthor=J.+P.+Fischerauthor=B.+R.+Baerauthor=J.+F.+Blakeauthor=K.+Bouhanaauthor=D.+M.+Briereauthor=K.+D.+Brownauthor=L.+E.+Burgessauthor=A.+C.+Burnsauthor=M.+R.+Burkard&title=Identification+of+the+clinical+development+candidate+MRTX849%2C+a+covalent+KRASG12C+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Facs.jmedchem.9b02052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Fell, Jay B.; Fischer, John P.; Baer, Brian R.; Blake, James F.; Bouhana, Karyn; Briere, David M.; Brown, Karin D.; Burgess, Laurence E.; Burns, Aaron C.; Burkard, Michael R.; Chiang, Harrah; Chicarelli, Mark J.; Cook, Adam W.; Gaudino, John J.; Hallin, Jill; Hanson, Lauren; Hartley, Dylan P.; Hicken, Erik J.; Hingorani, Gary P.; Hinklin, Ronald J.; Mejia, Macedonio J.; Olson, Peter; Otten, Jennifer N.; Rhodes, Susan P.; Rodriguez, Martha E.; Savechenkov, Pavel; Smith, Darin J.; Sudhakar, Niranjan; Sullivan, Francis X.; Tang, Tony P.; Vigers, Guy P.; Wollenberg, Lance; Christensen, James G.; Marx, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6679-6693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence.  As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12.  Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metab. and excretion screening approach, analogs were synthesized to increase the potency and reduce metabolic liabilities of this series.  The discovery of the clin. development candidate MRTX849(I)as a potent, selective covalent inhibitor of KRASG12C is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqJvp87w62jbVg90H21EOLACvtfcHk0lidaY_iUUHqjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtlCntb4%253D&md5=3618280ab3669376227ebd6932d18076</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02052%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DBouhana%26aufirst%3DK.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DBrown%26aufirst%3DK.%2BD.%26aulast%3DBurgess%26aufirst%3DL.%2BE.%26aulast%3DBurns%26aufirst%3DA.%2BC.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26atitle%3DIdentification%2520of%2520the%2520clinical%2520development%2520candidate%2520MRTX849%252C%2520a%2520covalent%2520KRASG12C%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D13%26spage%3D6679%26epage%3D6693%26doi%3D10.1021%2Facs.jmedchem.9b02052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">A Phase 1 Clinical Trial Evaluating the Pharmacokinetics (PK), Safety, and Clinical Activity of MRTX849, a Mutant-Selective Small Molecule KRAS G12C Inhibitor, in Advanced Solid Tumors</span>. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 28, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+A.+J%C3%A4nne&title=A+Phase+1+Clinical+Trial+Evaluating+the+Pharmacokinetics+%28PK%29%2C+Safety%2C+and+Clinical+Activity+of+MRTX849%2C+a+Mutant-Selective+Small+Molecule+KRAS+G12C+Inhibitor%2C+in+Advanced+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DA%2520Phase%25201%2520Clinical%2520Trial%2520Evaluating%2520the%2520Pharmacokinetics%2520%2528PK%2529%252C%2520Safety%252C%2520and%2520Clinical%2520Activity%2520of%2520MRTX849%252C%2520a%2520Mutant-Selective%2520Small%2520Molecule%2520KRAS%2520G12C%2520Inhibitor%252C%2520in%2520Advanced%2520Solid%2520Tumors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span>; <span class="NLM_string-name">Erlanson, D.</span>; <span class="NLM_string-name">Cancilla, M.</span></span> <span> </span><span class="NLM_article-title">Methods of Chemotype Evolution</span>. <span class="NLM_patent">US 10,107,798 B2</span>, October 23, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Hansen&author=D.+Erlanson&author=M.+Cancilla&title=Methods+of+Chemotype+Evolution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DS.%26atitle%3DMethods%2520of%2520Chemotype%2520Evolution%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achanta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvedson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campuzano, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingersoll, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(1-acryloylazetidin-3-yl)-2-(1<i>H</i>-indol-1-yl) acetamides as covalent inhibitors of KRASG12C</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1302</span>– <span class="NLM_lpage">1308</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2qs73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1302-1308&issue=9&author=Y.+Shinauthor=J.+W.+Jeongauthor=R.+P.+Wurzauthor=P.+Achantaauthor=T.+Arvedsonauthor=M.+D.+Bartbergerauthor=I.+D.+Campuzanoauthor=R.+Fuciniauthor=S.+K.+Hansenauthor=J.+Ingersoll&title=Discovery+of+N-%281-acryloylazetidin-3-yl%29-2-%281H-indol-1-yl%29+acetamides+as+covalent+inhibitors+of+KRASG12C&doi=10.1021%2Facsmedchemlett.9b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C</span></div><div class="casAuthors">Shin, Youngsook; Jeong, Joon Won; Wurz, Ryan P.; Achanta, Pragathi; Arvedson, Tara; Bartberger, Michael D.; Campuzano, Iain D. G.; Fucini, Ray; Hansen, Stig K.; Ingersoll, John; Iwig, Jeffrey S.; Lipford, J. Russell; Ma, Vu; Kopecky, David J.; McCarter, John; San Miguel, Tisha; Mohr, Christopher; Sabet, Sudi; Saiki, Anne Y.; Sawayama, Andrew; Sethofer, Steven; Tegley, Christopher M.; Volak, Laurie P.; Yang, Kevin; Lanman, Brian A.; Erlanson, Daniel A.; Cee, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1302-1308</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C.  KRAS regulates many cellular processes including proliferation, survival, and differentiation.  Point mutants of KRAS have long been known to be mol. drivers of cancer.  KRAS p.G12C, which occurs in approx. 14% of lung adenocarcinomas, 3-5% of colorectal cancers, and low levels in other solid tumors, represents an attractive therapeutic target for covalent inhibitors.  Herein, we disclose the discovery of a class of novel, potent, and selective covalent inhibitors of KRASG12C identified through a custom library synthesis and screening platform called Chemotype Evolution and structure-based design.  Identification of a hidden surface groove bordered by H95/Y96/Q99 side chains was key to the optimization of this class of mols.  Best-in-series exemplars exhibit a rapid covalent reaction with cysteine 12 of GDP-KRASG12C with submicromolar inhibition of downstream signaling in a KRASG12C-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSOlO88sogkLVg90H21EOLACvtfcHk0li21TQYPoQkWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2qs73P&md5=ec097c0fb0e018a2d86f024117f8008f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00258%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DY.%26aulast%3DJeong%26aufirst%3DJ.%2BW.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DAchanta%26aufirst%3DP.%26aulast%3DArvedson%26aufirst%3DT.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCampuzano%26aufirst%3DI.%2BD.%26aulast%3DFucini%26aufirst%3DR.%26aulast%3DHansen%26aufirst%3DS.%2BK.%26aulast%3DIngersoll%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520N-%25281-acryloylazetidin-3-yl%2529-2-%25281H-indol-1-yl%2529%2520acetamides%2520as%2520covalent%2520inhibitors%2520of%2520KRASG12C%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D9%26spage%3D1302%26epage%3D1308%26doi%3D10.1021%2Facsmedchemlett.9b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amegadzie, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01180</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01180" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGitrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=52-65&author=B.+A.+Lanmanauthor=J.+R.+Allenauthor=J.+G.+Allenauthor=A.+K.+Amegadzieauthor=K.+S.+Ashtonauthor=S.+K.+Bookerauthor=J.+J.+Chenauthor=N.+Chenauthor=M.+J.+Frohnauthor=G.+Goodman&title=Discovery+of+a+covalent+inhibitor+of+KRASG12C+%28AMG+510%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.9b01180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Lanman, Brian A.; Allen, Jennifer R.; Allen, John G.; Amegadzie, Albert K.; Ashton, Kate S.; Booker, Shon K.; Chen, Jian Jeffrey; Chen, Ning; Frohn, Michael J.; Goodman, Guy; Kopecky, David J.; Liu, Longbin; Lopez, Patricia; Low, Jonathan D.; Ma, Vu; Minatti, Ana E.; Nguyen, Thomas T.; Nishimura, Nobuko; Pickrell, Alexander J.; Reed, Anthony B.; Shin, Youngsook; Siegmund, Aaron C.; Tamayo, Nuria A.; Tegley, Christopher M.; Walton, Mary C.; Wang, Hui-Ling; Wurz, Ryan P.; Xue, May; Yang, Kevin C.; Achanta, Pragathi; Bartberger, Michael D.; Canon, Jude; Hollis, L. Steven; McCarter, John D.; Mohr, Christopher; Rex, Karen; Saiki, Anne Y.; San Miguel, Tisha; Volak, Laurie P.; Wang, Kevin H.; Whittington, Douglas A.; Zech, Stephan G.; Lipford, J. Russell; Cee, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-65</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRASG12C has emerged as a promising target in the treatment of solid tumors.  Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-"undruggable" target; however clin. viable inhibitors have yet to be identified.  Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRASG12C to identify inhibitors suitable for clin. development.  Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond.  Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRASG12C inhibitor currently in phase I clin. trials (NCT03600883).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGeWqRRXX6lbVg90H21EOLACvtfcHk0li21TQYPoQkWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGitrrK&md5=d973189be70bb913020edb4989f6ba7d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01180%26sid%3Dliteratum%253Aachs%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DAmegadzie%26aufirst%3DA.%2BK.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DFrohn%26aufirst%3DM.%2BJ.%26aulast%3DGoodman%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520covalent%2520inhibitor%2520of%2520KRASG12C%2520%2528AMG%2520510%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D52%26epage%3D65%26doi%3D10.1021%2Facs.jmedchem.9b01180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, P. K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngang, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3003</span>, <span class="refDoi"> DOI: 10.1200/JCO.2019.37.15_suppl.3003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1200%2FJCO.2019.37.15_suppl.3003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=3003&author=M.+Fakihauthor=B.+O%E2%80%99Neilauthor=T.+J.+Priceauthor=G.+S.+Falchookauthor=J.+Desaiauthor=J.+Kuoauthor=R.+Govindanauthor=E.+Rasmussenauthor=P.+K.+H.+Morrowauthor=J.+Ngang&title=Phase+1+study+evaluating+the+safety%2C+tolerability%2C+pharmacokinetics+%28PK%29%2C+and+efficacy+of+AMG+510%2C+a+novel+small+molecule+KRASG12C+inhibitor%2C+in+advanced+solid+tumors&doi=10.1200%2FJCO.2019.37.15_suppl.3003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.3003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.3003%26sid%3Dliteratum%253Aachs%26aulast%3DFakih%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DJ.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DRasmussen%26aufirst%3DE.%26aulast%3DMorrow%26aufirst%3DP.%2BK.%2BH.%26aulast%3DNgang%26aufirst%3DJ.%26atitle%3DPhase%25201%2520study%2520evaluating%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%2520%2528PK%2529%252C%2520and%2520efficacy%2520of%2520AMG%2520510%252C%2520a%2520novel%2520small%2520molecule%2520KRASG12C%2520inhibitor%252C%2520in%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D3003%26doi%3D10.1200%2FJCO.2019.37.15_suppl.3003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekharan, S.</span></span> <span> </span><span class="NLM_article-title">Structure-based macrocycle design in small-molecule drug discovery and simple metrics to identify opportunities for macrocyclization of small-molecule ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6843</span>– <span class="NLM_lpage">6853</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01985</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01985" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks1yktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6843-6853&issue=15&author=M.+D.+Cummingsauthor=S.+Sekharan&title=Structure-based+macrocycle+design+in+small-molecule+drug+discovery+and+simple+metrics+to+identify+opportunities+for+macrocyclization+of+small-molecule+ligands&doi=10.1021%2Facs.jmedchem.8b01985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands</span></div><div class="casAuthors">Cummings, Maxwell D.; Sekharan, Sivakumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6843-6853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Interest is growing in the use of macrocycles in pharmaceutical discovery.  Macrocylization may provide a gateway to an expanded chem. space for small-mol. drug discovery, and this could be beneficial in prosecuting difficult targets, e.g., protein-protein interactions.  Most, but not all, macrocycle drugs are derived from natural products.  Studies on synthetic drug-like small-mol. macrocycles are limited, and our current understanding of macrocycle drugs is similarly limited.  Following some background discussion, we review several examples of the structure-based design of synthetic macrocycles.  Our opinion is that in conformationally suitable systems macrocycles are an analog class worthy of consideration.  We then summarize an approach for the initial evaluation of mols. as candidates for macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCAQg11Q6Hk7Vg90H21EOLACvtfcHk0lhwcP4MvNK8dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks1yktb4%253D&md5=32ac78d837075171d19c4cea694dce3f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01985%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DSekharan%26aufirst%3DS.%26atitle%3DStructure-based%2520macrocycle%2520design%2520in%2520small-molecule%2520drug%2520discovery%2520and%2520simple%2520metrics%2520to%2520identify%2520opportunities%2520for%2520macrocyclization%2520of%2520small-molecule%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D6843%26epage%3D6853%26doi%3D10.1021%2Facs.jmedchem.8b01985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRASG12C</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4468</span>– <span class="NLM_lpage">4483</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01720</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01720" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitleqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4468-4483&issue=9&author=J.+G.+Kettleauthor=S.+K.+Bagalauthor=S.+Bickertonauthor=M.+S.+Bodnarchukauthor=J.+Breedauthor=R.+J.+Carbajoauthor=D.+J.+Cassarauthor=A.+Chakrabortyauthor=S.+Cosulichauthor=I.+Cumming&title=Structure-based+design+and+pharmacokinetic+optimization+of+covalent+allosteric+inhibitors+of+the+mutant+GTPase+KRASG12C&doi=10.1021%2Facs.jmedchem.9b01720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C</span></div><div class="casAuthors">Kettle, Jason G.; Bagal, Sharan K.; Bickerton, Sue; Bodnarchuk, Michael S.; Breed, Jason; Carbajo, Rodrigo J.; Cassar, Doyle J.; Chakraborty, Atanu; Cosulich, Sabina; Cumming, Iain; Davies, Michael; Eatherton, Andrew; Evans, Laura; Feron, Lyman; Fillery, Shaun; Gleave, Emma S.; Goldberg, Frederick W.; Harlfinger, Stephanie; Hanson, Lyndsey; Howard, Martin; Howells, Rachel; Jackson, Anne; Kemmitt, Paul; Kingston, Jennifer K.; Lamont, Scott; Lewis, Hilary J.; Li, Songlei; Liu, Libin; Ogg, Derek; Phillips, Christopher; Polanski, Radek; Robb, Graeme; Robinson, David; Ross, Sarah; Smith, James M.; Tonge, Michael; Whiteley, Rebecca; Yang, Junsheng; Zhang, Longfei; Zhao, Xiliang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4468-4483</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia.  The KRASG12C mutant represents an "Achilles heel" and has recently yielded to covalent targeting with small mols. that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state.  A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification.  Subsequent introduction of a key Me group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopBW-lAYRSirVg90H21EOLACvtfcHk0lhwcP4MvNK8dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitleqsbg%253D&md5=510af250cf2bbde4c9f18f9735df9eb1</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01720%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBickerton%26aufirst%3DS.%26aulast%3DBodnarchuk%26aufirst%3DM.%2BS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCassar%26aufirst%3DD.%2BJ.%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DCumming%26aufirst%3DI.%26atitle%3DStructure-based%2520design%2520and%2520pharmacokinetic%2520optimization%2520of%2520covalent%2520allosteric%2520inhibitors%2520of%2520the%2520mutant%2520GTPase%2520KRASG12C%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D9%26spage%3D4468%26epage%3D4483%26doi%3D10.1021%2Facs.jmedchem.9b01720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downward, J.</span></span> <span> </span><span class="NLM_article-title">RAS’s cloak of invincibility slips at last?</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.ccr.2013.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=24434204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=5-6&issue=1&author=J.+Downward&title=RAS%E2%80%99s+cloak+of+invincibility+slips+at+last%3F&doi=10.1016%2Fj.ccr.2013.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">RAS's Cloak of Invincibility Slips at Last?</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-6</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  KRAS is the most frequently activated oncogene in human cancer, but it has, so far, shrugged off all attempts to inhibit its function directly.  However, a recent report provides an entirely new approach to blocking mutant KRAS with small mols. and has the added benefit of sparing the wild-type protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEnsg96oBiOrVg90H21EOLACvtfcHk0lhwcP4MvNK8dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSqtbk%253D&md5=96f7bbbd41c48f68bc342ba12eda999a</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DRAS%25E2%2580%2599s%2520cloak%2520of%2520invincibility%2520slips%2520at%2520last%253F%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D25%26issue%3D1%26spage%3D5%26epage%3D6%26doi%3D10.1016%2Fj.ccr.2013.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrenton, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauber, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5299</span>– <span class="NLM_lpage">5304</span>, <span class="refDoi"> DOI: 10.1073/pnas.1116510109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.1116510109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=22431598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=5299-5304&issue=14&author=T.+Maurerauthor=L.+S.+Garrentonauthor=A.+Ohauthor=K.+Pittsauthor=D.+J.+Andersonauthor=N.+J.+Skeltonauthor=B.+P.+Fauberauthor=B.+Panauthor=S.+Malekauthor=D.+Stokoe&title=Small-molecule+ligands+bind+to+a+distinct+pocket+in+Ras+and+inhibit+SOS-mediated+nucleotide+exchange+activity&doi=10.1073%2Fpnas.1116510109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity</span></div><div class="casAuthors">Maurer, Till; Garrenton, Lindsay S.; Oh, Angela; Pitts, Keith; Anderson, Daniel J.; Skelton, Nicholas J.; Fauber, Benjamin P.; Pan, Borlan; Malek, Shiva; Stokoe, David; Ludlam, Mary J. C.; Bowman, Krista K.; Wu, Jiansheng; Giannetti, Anthony M.; Starovasnik, Melissa A.; Mellman, Ira; Jackson, Peter K.; Rudolph, Joachim; Wang, Weiru; Fang, Guowei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5299-5304, S5299/1-S5299/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The Ras gene is frequently mutated in cancer, and mutant Ras drives tumorigenesis.  Although Ras is a central oncogene, small mols. that bind to Ras in a well-defined manner and exert inhibitory effects have not been uncovered to date.  Through an NMR-based fragment screen, we identified a group of small mols. that all bind to a common site on Ras.  High-resoln. cocrystal structures delineated a unique ligand-binding pocket on the Ras protein that is adjacent to the switch I/II regions and can be expanded upon compd. binding.  Structure anal. predicts that compd.-binding interferes with the Ras/SOS interactions.  Indeed, selected compds. inhibit SOS-mediated nucleotide exchange and prevent Ras activation by blocking the formation of intermediates of the exchange reaction.  The discovery of a small-mol. binding pocket on Ras with functional significance provides a new direction in the search of therapeutically effective inhibitors of the Ras oncoprotein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXIzMe7yBqrVg90H21EOLACvtfcHk0liOlH3qx6tutA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOjsrc%253D&md5=a7210cad45154c42eb2a1faeabf88c20</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1116510109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1116510109%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DGarrenton%26aufirst%3DL.%2BS.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DFauber%26aufirst%3DB.%2BP.%26aulast%3DPan%26aufirst%3DB.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DStokoe%26aufirst%3DD.%26atitle%3DSmall-molecule%2520ligands%2520bind%2520to%2520a%2520distinct%2520pocket%2520in%2520Ras%2520and%2520inhibit%2520SOS-mediated%2520nucleotide%2520exchange%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D14%26spage%3D5299%26epage%3D5304%26doi%3D10.1073%2Fpnas.1116510109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bos, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span> <span> </span><span class="NLM_article-title">GEFs and GAPs: Critical elements in the control of small G proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.cell.2007.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=17540168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsl2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=865-877&issue=5&author=J.+L.+Bosauthor=H.+Rehmannauthor=A.+Wittinghofer&title=GEFs+and+GAPs%3A+Critical+elements+in+the+control+of+small+G+proteins&doi=10.1016%2Fj.cell.2007.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">GEFs and GAPs: critical elements in the control of small G proteins</span></div><div class="casAuthors">Bos, Johannes L.; Rehmann, Holger; Wittinghofer, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">865-877</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) regulate the activity of small guanine nucleotide-binding (G) proteins to control cellular functions.  In general, GEFs turn on signaling by catalyzing the exchange from G-protein-bound GDP to GTP, whereas GAPs terminate signaling by inducing GTP hydrolysis.  GEFs and GAPs are multidomain proteins that are regulated by extracellular signals and localized cues that control cellular events in time and space.  Recent evidence suggests that these proteins may be potential therapeutic targets for developing drugs to treat various diseases, including cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob9D00HUjUuLVg90H21EOLACvtfcHk0liOlH3qx6tutA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsl2qsLw%253D&md5=4e65294b82df5f95eb17ebe1d2c3dec1</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DBos%26aufirst%3DJ.%2BL.%26aulast%3DRehmann%26aufirst%3DH.%26aulast%3DWittinghofer%26aufirst%3DA.%26atitle%3DGEFs%2520and%2520GAPs%253A%2520Critical%2520elements%2520in%2520the%2520control%2520of%2520small%2520G%2520proteins%26jtitle%3DCell%26date%3D2007%26volume%3D129%26issue%3D5%26spage%3D865%26epage%3D877%26doi%3D10.1016%2Fj.cell.2007.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boriack-Sjodin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margarit, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">The structural basis of the activation of Ras by Sos</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>394</i></span> (<span class="NLM_issue">6691</span>),  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/28548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2F28548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9690470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK1cXkvFKnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=1998&pages=337-343&issue=6691&author=P.+A.+Boriack-Sjodinauthor=S.+M.+Margaritauthor=D.+Bar-Sagiauthor=J.+Kuriyan&title=The+structural+basis+of+the+activation+of+Ras+by+Sos&doi=10.1038%2F28548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis of the activation of Ras by Sos</span></div><div class="casAuthors">Boriack-Sjodin, P. Ann; Margarit, S. Mariana; Bar-Sagi, Dafna; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">6691</span>),
    <span class="NLM_cas:pages">337-343</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The crystal structure of human H-Ras complexed with the Ras guanine-nucleotide-exchange-factor region of the Son of sevenless (Sos) protein has been detd. at 2.8 Å resoln.  The normally tight interaction of nucleotides with Ras is disrupted by Sos in two ways.  First, the insertion into Ras of an α-helix from Sos results in the displacement of the Switch 1 region of Ras, opening up the nucleotide-binding site.  Second, side chains presented by this helix and by a distorted conformation of the Switch 2 region of Ras alter the chem. environment of the binding site for the phosphate groups of the nucleotide and the assocd. magnesium in, so that their binding is no longer favored.  Sos does not impede the binding sites for the base and the ribose of GTP or GDP, so the Ras-Sos complex adopts a structure that allows nucleotide release and rebinding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZY4Ffb8--JbVg90H21EOLACvtfcHk0liOlH3qx6tutA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvFKnsLs%253D&md5=1b0a7879011c1fc1148e7f870e0ded11</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2F28548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F28548%26sid%3Dliteratum%253Aachs%26aulast%3DBoriack-Sjodin%26aufirst%3DP.%2BA.%26aulast%3DMargarit%26aufirst%3DS.%2BM.%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DThe%2520structural%2520basis%2520of%2520the%2520activation%2520of%2520Ras%2520by%2520Sos%26jtitle%3DNature%26date%3D1998%26volume%3D394%26issue%3D6691%26spage%3D337%26epage%3D343%26doi%3D10.1038%2F28548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olejniczak, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossanese, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">6140</span>– <span class="NLM_lpage">6143</span>, <span class="refDoi"> DOI: 10.1002/anie.201201358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1002%2Fanie.201201358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1entr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=6140-6143&issue=25&author=Q.+Sunauthor=J.+P.+Burkeauthor=J.+Phanauthor=M.+C.+Burnsauthor=E.+T.+Olejniczakauthor=A.+G.+Watersonauthor=T.+Leeauthor=O.+W.+Rossaneseauthor=S.+W.+Fesik&title=Discovery+of+small+molecules+that+bind+to+K-Ras+and+inhibit+Sos-mediated+activation&doi=10.1002%2Fanie.201201358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation</span></div><div class="casAuthors">Sun, Qi; Burke, Jason P.; Phan, Jason; Burns, Michael C.; Olejniczak, Edward T.; Waterson, Alex G.; Lee, Taekyu; Rossanese, Olivia W.; Fesik, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6140-6143, S6140/1-S6140/17</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">K-Ras inhibition represents an attractive therapeutic strategy for many cancers.  We report on the discovery of novel small mols. that bind directly to K-Ras between switch I and switch II and inhibit Sos-catalyzed K-Ras activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy5Cx7BSO1pLVg90H21EOLACvtfcHk0lguhNk6ctWdQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1entr4%253D&md5=7d579523462aaf7eac1890643f91fab3</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fanie.201201358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201201358%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DBurke%26aufirst%3DJ.%2BP.%26aulast%3DPhan%26aufirst%3DJ.%26aulast%3DBurns%26aufirst%3DM.%2BC.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520small%2520molecules%2520that%2520bind%2520to%2520K-Ras%2520and%2520inhibit%2520Sos-mediated%2520activation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26issue%3D25%26spage%3D6140%26epage%3D6143%26doi%3D10.1002%2Fanie.201201358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmachl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantoulidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Drugging an undruggable pocket on KRAS</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">15823</span>– <span class="NLM_lpage">15829</span>, <span class="refDoi"> DOI: 10.1073/pnas.1904529116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.1904529116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31332011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFChs7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=15823-15829&issue=32&author=D.+Kesslerauthor=M.+Gmachlauthor=A.+Mantoulidisauthor=L.+J.+Martinauthor=A.+Zoephelauthor=M.+Mayerauthor=A.+Gollnerauthor=D.+Coviniauthor=S.+Fischerauthor=T.+Gerstberger&title=Drugging+an+undruggable+pocket+on+KRAS&doi=10.1073%2Fpnas.1904529116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging an undruggable pocket on KRAS</span></div><div class="casAuthors">Kessler, Dirk; Gmachl, Michael; Mantoulidis, Andreas; Martin, Laetitia J.; Zoephel, Andreas; Mayer, Moriz; Gollner, Andreas; Covini, David; Fischer, Silke; Gerstberger, Thomas; Gmaschitz, Teresa; Goodwin, Craig; Greb, Peter; Haring, Daniela; Hela, Wolfgang; Hoffmann, Johann; Karolyi-Oezguer, Jale; Knesl, Petr; Kornigg, Stefan; Koegl, Manfred; Kousek, Roland; Lamarre, Lyne; Moser, Franziska; Munico-Martinez, Silvia; Peinsipp, Christoph; Phan, Jason; Rinnenthal, Jorg; Sai, Jiqing; Salamon, Christian; Scherbantin, Yvonne; Schipany, Katharina; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Siszler, Gabriella; Sun, Qi; Waterson, Alex; Wolkerstorfer, Bernhard; Zeeb, Markus; Pearson, Mark; Fesik, Stephen W.; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">15823-15829</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">(Imidazolylmethylindolylmethylaminomethyl)indolyl hydroxyisoindolone I, an inhibitor of both the active and inactive forms of KRAS, was discovered using fragment-based screening.  I bound to KRAS in a pocket between switches I and II of KRAS, blocking all GEF, GAP, and effector interactions with KRAS and thus inhibiting downstream signaling; I inhibited KRAS mutant cells at low micromolar concns.  Uniformly 15N-labeled KRAS bound to the stable GTP analog GCP was prepd. with yields of 10 mg/L for use in crystallog. of KRAS-inhibitor complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaMeFg74p2-rVg90H21EOLACvtfcHk0lguhNk6ctWdQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFChs7jJ&md5=ebf443050cb2ce6cbeec1e40084129d0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1904529116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1904529116%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DD.%26aulast%3DGmachl%26aufirst%3DM.%26aulast%3DMantoulidis%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DL.%2BJ.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DGollner%26aufirst%3DA.%26aulast%3DCovini%26aufirst%3DD.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DGerstberger%26aufirst%3DT.%26atitle%3DDrugging%2520an%2520undruggable%2520pocket%2520on%2520KRAS%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26issue%3D32%26spage%3D15823%26epage%3D15829%26doi%3D10.1073%2Fpnas.1904529116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fetics, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guterres, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.str.2014.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=25684575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=505-516&issue=3&author=S.+K.+Feticsauthor=H.+Guterresauthor=B.+M.+Kearneyauthor=G.+Buhrmanauthor=B.+Maauthor=R.+Nussinovauthor=C.+Mattos&title=Allosteric+effects+of+the+oncogenic+RasQ61L+mutant+on+Raf-RBD&doi=10.1016%2Fj.str.2014.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Effects of the Oncogenic RasQ61L Mutant on Raf-RBD</span></div><div class="casAuthors">Fetics, Susan K.; Guterres, Hugo; Kearney, Bradley M.; Buhrman, Greg; Ma, Buyong; Nussinov, Ruth; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">505-516</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Ras/Raf/MEK/ERK signal transduction pathway is a major regulator of cell proliferation activated by Ras-guanosine triphosphate (GTP).  The oncogenic mutant RasQ61L is not able to hydrolyze GTP in the presence of Raf and thus is a constitutive activator of this mitogenic pathway.  The Ras/Raf interaction is essential for the activation of the Raf kinase domain through a currently unknown mechanism.  We present the crystal structures of the Ras-GppNHp/Raf-RBD and RasQ61L-GppNHp/Raf-RBD complexes, which, in combination with MD simulations, reveal differences in allosteric interactions leading from the Ras/Raf interface to the Ras calcium-binding site and to the remote Raf-RBD loop L4.  In the presence of Raf, the RasQ61L mutant has a rigid switch II relative to the wild-type and increased flexibility at the interface with switch I, which propagates across Raf-RBD.  We show that in addn. to local perturbations on Ras, RasQ61L has substantial long-range effects on the Ras allosteric lobe and on Raf-RBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_0AG0DEzRLVg90H21EOLACvtfcHk0lguhNk6ctWdQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSjt7c%253D&md5=bcfe99bb008e13f00c7f970d9f86c48b</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DFetics%26aufirst%3DS.%2BK.%26aulast%3DGuterres%26aufirst%3DH.%26aulast%3DKearney%26aufirst%3DB.%2BM.%26aulast%3DBuhrman%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DAllosteric%2520effects%2520of%2520the%2520oncogenic%2520RasQ61L%2520mutant%2520on%2520Raf-RBD%26jtitle%3DStructure%26date%3D2015%26volume%3D23%26issue%3D3%26spage%3D505%26epage%3D516%26doi%3D10.1016%2Fj.str.2014.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheffzek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmüller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lautwein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span> <span> </span><span class="NLM_article-title">The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">5324</span>),  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1126/science.277.5324.333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1126%2Fscience.277.5324.333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=9219684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADyaK2sXkvVelsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=333-8&issue=5324&author=K.+Scheffzekauthor=M.+R.+Ahmadianauthor=W.+Kabschauthor=L.+Wiesm%C3%BCllerauthor=A.+Lautweinauthor=F.+Schmitzauthor=A.+Wittinghofer&title=The+Ras-RasGAP+complex%3A+structural+basis+for+GTPase+activation+and+its+loss+in+oncogenic+Ras+mutants&doi=10.1126%2Fscience.277.5324.333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants</span></div><div class="casAuthors">Scheffzek, Klaus; Ahmadian, Mohammad Reza; Kabsch, Wolfgang; Wiesmuller, Lisa; Lautwein, Alfred; Schmitz, Frank; Wittinghofer, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5324</span>),
    <span class="NLM_cas:pages">333-338</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120GAP (GAP-334) in the presence of aluminum fluoride was solved at a resoln. of 2.5 angstroms.  The structure shows the partly hydrophilic and partly hydrophobic nature of the communication between the two mols., which explains the sensitivity of the interaction toward both salts and lipids.  An arginine side chain (arginine-789) of GAP-334 is supplied into the active site of Ras to neutralize developing charges in the transition state.  The switch II region of Ras is stabilized by GAP-334, thus allowing glutamine-61 of Ras, mutation of which activates the oncogenic potential, to participate in catalysis.  The structural arrangement in the active site is consistent with a mostly associative mechanism of phosphoryl transfer and provides an explanation for the activation of Ras by glycine-12 and glutamine-61 mutations.  Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of GAP-334 and glutamine-61 of Ras, and even its mutation to alanine would disturb the arrangements of residues in the transition state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnMHwqUOucX7Vg90H21EOLACvtfcHk0lgSsyjeVoBhyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkvVelsr8%253D&md5=95f61d57ccd837d06afc18636de7f123</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5324.333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5324.333%26sid%3Dliteratum%253Aachs%26aulast%3DScheffzek%26aufirst%3DK.%26aulast%3DAhmadian%26aufirst%3DM.%2BR.%26aulast%3DKabsch%26aufirst%3DW.%26aulast%3DWiesm%25C3%25BCller%26aufirst%3DL.%26aulast%3DLautwein%26aufirst%3DA.%26aulast%3DSchmitz%26aufirst%3DF.%26aulast%3DWittinghofer%26aufirst%3DA.%26atitle%3DThe%2520Ras-RasGAP%2520complex%253A%2520structural%2520basis%2520for%2520GTPase%2520activation%2520and%2520its%2520loss%2520in%2520oncogenic%2520Ras%2520mutants%26jtitle%3DScience%26date%3D1997%26volume%3D277%26issue%3D5324%26spage%3D333%26epage%3D8%26doi%3D10.1126%2Fscience.277.5324.333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quevedo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Migoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bery, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bataille, C. J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulmin, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors of Ras-effector protein interactions derived using an intracellular antibody fragment</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3169</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-05707-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41467-018-05707-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30093669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ms12mtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3169&issue=1&author=C.+E.+Quevedoauthor=A.+Cruz-Migoniauthor=N.+Beryauthor=A.+Millerauthor=T.+Tanakaauthor=D.+Petchauthor=C.+J.+R.+Batailleauthor=L.+Y.+W.+Leeauthor=P.+S.+Fallonauthor=H.+Tulmin&title=Small+molecule+inhibitors+of+Ras-effector+protein+interactions+derived+using+an+intracellular+antibody+fragment&doi=10.1038%2Fs41467-018-05707-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment</span></div><div class="casAuthors">Quevedo Camilo E; Cruz-Migoni Abimael; Bery Nicolas; Miller Ami; Tulmin Hanna; Ehebauer Matthias T; Rabbitts Terence H; Cruz-Migoni Abimael; Fernandez-Fuentes Narcis; Carr Stephen B; Phillips Simon E V; Tanaka Tomoyuki; Petch Donna; Tanaka Tomoyuki; Bataille Carole J R; Russell Angela J; Lee Lydia Y W; Fallon Phillip S; Tulmin Hanna; Ehebauer Matthias T; Fernandez-Fuentes Narcis; Carr Stephen B; Phillips Simon E V</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3169</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered unsuitable for PPI inhibition.  A potential solution to these problems is to select intracellular antibody fragments to block PPIs, use these antibody fragments for target validation in disease models and finally derive small molecules overlapping the antibody-binding site.  Here, we explore this strategy using an anti-mutant RAS antibody fragment as a competitor in a small-molecule library screen for identifying RAS-binding compounds.  The initial hits are optimized by structure-based design, resulting in potent RAS-binding compounds that interact with RAS inside the cells, prevent RAS-effector interactions and inhibit endogenous RAS-dependent signalling.  Our results may aid RAS-dependent cancer drug development and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIUnXfwZaCRvxQvRxYU81tfW6udTcc2ea8H5Y6WuIWmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ms12mtQ%253D%253D&md5=79679120c60be8cd9be9fbbfe0c9fdb6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05707-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05707-2%26sid%3Dliteratum%253Aachs%26aulast%3DQuevedo%26aufirst%3DC.%2BE.%26aulast%3DCruz-Migoni%26aufirst%3DA.%26aulast%3DBery%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DPetch%26aufirst%3DD.%26aulast%3DBataille%26aufirst%3DC.%2BJ.%2BR.%26aulast%3DLee%26aufirst%3DL.%2BY.%2BW.%26aulast%3DFallon%26aufirst%3DP.%2BS.%26aulast%3DTulmin%26aufirst%3DH.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520Ras-effector%2520protein%2520interactions%2520derived%2520using%2520an%2520intracellular%2520antibody%2520fragment%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D3169%26doi%3D10.1038%2Fs41467-018-05707-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Migoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quevedo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bataille, C. J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bery, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, S. E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbitts, T. H.</span></span> <span> </span><span class="NLM_article-title">Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2545</span>– <span class="NLM_lpage">2550</span>, <span class="refDoi"> DOI: 10.1073/pnas.1811360116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.1811360116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30683716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVajsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=2545-2550&issue=7&author=A.+Cruz-Migoniauthor=P.+Canningauthor=C.+E.+Quevedoauthor=C.+J.+R.+Batailleauthor=N.+Beryauthor=A.+Millerauthor=A.+J.+Russellauthor=S.+E.+V.+Phillipsauthor=S.+B.+Carrauthor=T.+H.+Rabbitts&title=Structure-based+development+of+new+RAS-effector+inhibitors+from+a+combination+of+active+and+inactive+RAS-binding+compounds&doi=10.1073%2Fpnas.1811360116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds</span></div><div class="casAuthors">Cruz-Migoni, Abimael; Canning, Peter; Quevedo, Camilo E.; Bataille, Carole J. R.; Bery, Nicolas; Miller, Ami; Russell, Angela J.; Phillips, Simon E. V.; Carr, Stephen B.; Rabbitts, Terence H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2545-2550</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The RAS gene family is frequently mutated in human cancers, and the quest for compds. that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions.  We have refined crystn. conditions for KRAS169Q61H-yielding crystals suitable for soaking with compds. and exploited this to assess new RAS-binding compds. selected by screening a protein-protein interaction-focused compd. library using surface plasmon resonance.  Two compds., referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compds. had been previously developed, including RAS effector protein-protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compds.).  Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compds. were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties.  By fusing the common, anchoring part from the two new compds. with the inhibitory substituents of the Abd series, we have created a set of compds. that inhibit RAS-effector interactions with increased potency.  These fused compds. add to the growing catalog of RAS protein-protein inhibitors and show that building a chem. series by crossing over two chem. series is a strategy to create RAS-binding small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8m8k26dNT_7Vg90H21EOLACvtfcHk0lgSsyjeVoBhyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVajsbo%253D&md5=163014795c0bf4cb10e751c251a0dda3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1811360116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1811360116%26sid%3Dliteratum%253Aachs%26aulast%3DCruz-Migoni%26aufirst%3DA.%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DQuevedo%26aufirst%3DC.%2BE.%26aulast%3DBataille%26aufirst%3DC.%2BJ.%2BR.%26aulast%3DBery%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DA.%2BJ.%26aulast%3DPhillips%26aufirst%3DS.%2BE.%2BV.%26aulast%3DCarr%26aufirst%3DS.%2BB.%26aulast%3DRabbitts%26aufirst%3DT.%2BH.%26atitle%3DStructure-based%2520development%2520of%2520new%2520RAS-effector%2520inhibitors%2520from%2520a%2520combination%2520of%2520active%2520and%2520inactive%2520RAS-binding%2520compounds%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26issue%3D7%26spage%3D2545%26epage%3D2550%26doi%3D10.1073%2Fpnas.1811360116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badgley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Multivalent small-molecule pan-RAS inhibitors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">878</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.cell.2017.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=28235199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVWrs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=878-889&issue=5&author=M.+E.+Welschauthor=A.+Kaplanauthor=J.+M.+Chambersauthor=M.+E.+Stokesauthor=P.+H.+Bosauthor=A.+Zaskauthor=Y.+Zhangauthor=M.+Sanchez-Martinauthor=M.+A.+Badgleyauthor=C.+S.+Huang&title=Multivalent+small-molecule+pan-RAS+inhibitors&doi=10.1016%2Fj.cell.2017.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent Small-Molecule Pan-RAS Inhibitors</span></div><div class="casAuthors">Welsch, Matthew E.; Kaplan, Anna; Chambers, Jennifer M.; Stokes, Michael E.; Bos, Pieter H.; Zask, Arie; Zhang, Yan; Sanchez-Martin, Marta; Badgley, Michael A.; Huang, Christine S.; Tran, Timothy H.; Akkiraju, Hemanth; Brown, Lewis M.; Nandakumar, Renu; Cremers, Serge; Yang, Wan Seok; Tong, Liang; Olive, Kenneth P.; Ferrando, Adolfo; Stockwell, Brent R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">878-889.e29</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Design of small mols. that disrupt protein-protein interactions, including the interaction of RAS proteins and their effectors, may provide chem. probes and therapeutic agents.  The authors describe here the synthesis and testing of potential small-mol. pan-RAS ligands, which were designed to interact with adjacent sites on the surface of oncogenic KRAS.  One compd., termed 3144, was found to bind to RAS proteins using microscale thermophoresis, NMR spectroscopy, and isothermal titrn. calorimetry and to exhibit lethality in cells partially dependent on expression of RAS proteins.  This compd. was metabolically stable in liver microsomes and displayed anti-tumor activity in xenograft mouse cancer models.  These findings suggest that pan-RAS inhibition may be an effective therapeutic strategy for some cancers and that structure-based design of small mols. targeting multiple adjacent sites to create multivalent inhibitors may be effective for some proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcWYewcTWv8bVg90H21EOLACvtfcHk0lg46duWKj1b1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVWrs7g%253D&md5=a14627b2f9b2475b5ca72f1facf2367e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DWelsch%26aufirst%3DM.%2BE.%26aulast%3DKaplan%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DJ.%2BM.%26aulast%3DStokes%26aufirst%3DM.%2BE.%26aulast%3DBos%26aufirst%3DP.%2BH.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSanchez-Martin%26aufirst%3DM.%26aulast%3DBadgley%26aufirst%3DM.%2BA.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26atitle%3DMultivalent%2520small-molecule%2520pan-RAS%2520inhibitors%26jtitle%3DCell%26date%3D2017%26volume%3D168%26issue%3D5%26spage%3D878%26epage%3D889%26doi%3D10.1016%2Fj.cell.2017.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardeesy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguirre, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hezel, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, U.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5947</span>– <span class="NLM_lpage">5952</span>, <span class="refDoi"> DOI: 10.1073/pnas.0601273103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1073%2Fpnas.0601273103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=16585505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFaitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=5947-5952&issue=15&author=N.+Bardeesyauthor=A.+J.+Aguirreauthor=G.+C.+Chuauthor=K.-h.+Chengauthor=L.+V.+Lopezauthor=A.+F.+Hezelauthor=B.+Fengauthor=C.+Brennanauthor=R.+Weisslederauthor=U.+Mahmood&title=Both+p16%28Ink4a%29+and+the+p19%28Arf%29-p53+pathway+constrain+progression+of+pancreatic+adenocarcinoma+in+the+mouse&doi=10.1073%2Fpnas.0601273103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse</span></div><div class="casAuthors">Bardeesy, Nabeel; Aguirre, Andrew J.; Chu, Gerald C.; Cheng, Kuang-hung; Lopez, Lyle V.; Hezel, Aram F.; Feng, Bin; Brennan, Cameron; Weissleder, Ralph; Mahmood, Umar; Hanahan, Douglas; Redston, Mark S.; Chin, Lynda; DePinho, Ronald A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5947-5952</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activating KRAS mutations and p16Ink4a inactivation are near universal events in human pancreatic ductal adenocarcinoma (PDAC).  In mouse models, KrasG12D initiates formation of premalignant pancreatic ductal lesions, and loss of either Ink4a/Arf (p16Ink4a/p19Arf) or p53 enables their malignant progression.  As recent mouse modeling studies have suggested a less prominent role for p16Ink4a in constraining malignant progression, we sought to assess the pathol. and genomic impact of inactivation of p16Ink4a, p19Arf, and/or p53 in the KrasG12D model.  Rapidly progressive PDAC was obsd. in the setting of homozygous deletion of either p53 or p16Ink4a, the latter with intact germ-line p53 and p19Arf sequences.  Addnl., KrasG12D in the context of heterozygosity either for p53 plus p16Ink4a or for p16Ink4a/p19Arf produced PDAC with longer latency and greater propensity for distant metastases relative to mice with homozygous deletion of p53 or p16Ink4a/p19Arf.  Tumors from the double-heterozygous cohorts showed frequent p16Ink4a inactivation and loss of either p53 or p19Arf.  Different genotypes were assocd. with specific histopathol. characteristics, most notably a trend toward less differentiated features in the homozygous p16Ink4a/p19Arf mutant model.  High-resoln. genomic anal. revealed that the tumor suppressor genotype influenced the specific genomic patterns of these tumors and showed overlap in regional chromosomal alterations between murine and human PDAC.  Collectively, our results establish that disruptions of p16Ink4a and the p19ARF-p53 circuit play crit. and cooperative roles in PDAC progression, with specific tumor suppressor genotypes provocatively influencing the tumor biol. phenotypes and genomic profiles of the resultant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCLwHVjyV20LVg90H21EOLACvtfcHk0lg46duWKj1b1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFaitLY%253D&md5=abbdb46c78d1b972d36fa8915e92a109</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0601273103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0601273103%26sid%3Dliteratum%253Aachs%26aulast%3DBardeesy%26aufirst%3DN.%26aulast%3DAguirre%26aufirst%3DA.%2BJ.%26aulast%3DChu%26aufirst%3DG.%2BC.%26aulast%3DCheng%26aufirst%3DK.-h.%26aulast%3DLopez%26aufirst%3DL.%2BV.%26aulast%3DHezel%26aufirst%3DA.%2BF.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DMahmood%26aufirst%3DU.%26atitle%3DBoth%2520p16%2528Ink4a%2529%2520and%2520the%2520p19%2528Arf%2529-p53%2520pathway%2520constrain%2520progression%2520of%2520pancreatic%2520adenocarcinoma%2520in%2520the%2520mouse%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26issue%3D15%26spage%3D5947%26epage%3D5952%26doi%3D10.1073%2Fpnas.0601273103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Expanding the scope of electrophiles capable of targeting K-Ras oncogenes</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">3178</span>– <span class="NLM_lpage">3183</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGrsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=3178-3183&issue=25&author=L.+M.+McGregorauthor=M.+L.+Jenkinsauthor=C.+Kerwinauthor=J.+E.+Burkeauthor=K.+M.+Shokat&title=Expanding+the+scope+of+electrophiles+capable+of+targeting+K-Ras+oncogenes&doi=10.1021%2Facs.biochem.7b00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes</span></div><div class="casAuthors">McGregor, Lynn M.; Jenkins, Meredith L.; Kerwin, Caitlin; Burke, John E.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3178-3183</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is growing interest in reversible and irreversible covalent inhibitors that target noncatalytic amino acids in target proteins.  With a goal of targeting oncogenic K-Ras variants (e.g., G12D) by expanding the types of amino acids that can be targeted by covalent inhibitors, we survey a set of electrophiles for their ability to label carboxylates.  We functionalized an optimized ligand for the K-Ras switch II pocket with a set of electrophiles previously reported to react with carboxylates and characterized the ability of these compds. to react with model nucleophiles and oncogenic K-Ras proteins.  Here, we report that aziridines and stabilized diazo groups preferentially react with free carboxylates over thiols.  Although we did not identify a warhead that potently labels K-Ras G12D, we were able to study the interactions of many electrophiles with K-Ras, as most of the electrophiles rapidly label K-Ras G12C.  We characterized the resulting complexes by crystallog., hydrogen/deuterium exchange, and differential scanning fluorometry.  Our results both demonstrate the ability of a noncatalytic cysteine to react with a diverse set of electrophiles and emphasize the importance of proper spatial arrangements between a covalent inhibitor and its intended nucleophile.  We hope that these results can expand the range of electrophiles and nucleophiles of use in covalent protein modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcvKWYdfIxw7Vg90H21EOLACvtfcHk0lg46duWKj1b1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGrsbnI&md5=0b25b65210248a4cad2916efba90ddae</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00271%26sid%3Dliteratum%253Aachs%26aulast%3DMcGregor%26aufirst%3DL.%2BM.%26aulast%3DJenkins%26aufirst%3DM.%2BL.%26aulast%3DKerwin%26aufirst%3DC.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DExpanding%2520the%2520scope%2520of%2520electrophiles%2520capable%2520of%2520targeting%2520K-Ras%2520oncogenes%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26issue%3D25%26spage%3D3178%26epage%3D3183%26doi%3D10.1021%2Facs.biochem.7b00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knelson, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span> <span> </span><span class="NLM_article-title">A Bright future for KRAS inhibitors</span>. <i>Nature Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1038/s43018-019-0016-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs43018-019-0016-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2020&pages=25-27&issue=1&author=D.+Bar-Sagiauthor=E.+H.+Knelsonauthor=L.+V.+Sequist&title=A+Bright+future+for+KRAS+inhibitors&doi=10.1038%2Fs43018-019-0016-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fs43018-019-0016-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs43018-019-0016-8%26sid%3Dliteratum%253Aachs%26aulast%3DBar-Sagi%26aufirst%3DD.%26aulast%3DKnelson%26aufirst%3DE.%2BH.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DA%2520Bright%2520future%2520for%2520KRAS%2520inhibitors%26jtitle%3DNature%2520Cancer%26date%3D2020%26volume%3D1%26issue%3D1%26spage%3D25%26epage%3D27%26doi%3D10.1038%2Fs43018-019-0016-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Sagi, D.</span></span> <span> </span><span class="NLM_article-title">Kras and tumor immunity: friend or foe?</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">a031849</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a031849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1101%2Fcshperspect.a031849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=29229670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCltr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=a031849&issue=9&author=J.+Cullisauthor=S.+Dasauthor=D.+Bar-Sagi&title=Kras+and+tumor+immunity%3A+friend+or+foe%3F&doi=10.1101%2Fcshperspect.a031849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Kras and tumor immunity: friend or foe?</span></div><div class="casAuthors">Cullis, Jane; Das, Shipra; Bar-Sagi, Dafna</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">a031849/1-a031849/22</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">With the recent breakthroughs in immunotherapy as curative treatments in certain tumor types, there has been renewed interest in the relationship between immunity and tumor growth.  Although we are gaining a greater understanding of the complex interplay of immune modulating components in the tumor microenvironment, the specific role that tumor cells play in shaping the immune milieu is still not well characterized.  In this review, we focus on how mutant Kras tumor cells contribute to tumor immunity, with a specific focus on processes induced directly or indirectly by the oncogene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaDNG73BzdfrVg90H21EOLACvtfcHk0liKCfg9C1IzPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCltr3O&md5=e6ecf9d69a16d57f61acb38700b0273e</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a031849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a031849%26sid%3Dliteratum%253Aachs%26aulast%3DCullis%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DBar-Sagi%26aufirst%3DD.%26atitle%3DKras%2520and%2520tumor%2520immunity%253A%2520friend%2520or%2520foe%253F%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2018%26volume%3D8%26issue%3D9%26spage%3Da031849%26doi%3D10.1101%2Fcshperspect.a031849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danoff, S.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1416</span>– <span class="NLM_lpage">1423</span>, <span class="refDoi"> DOI: 10.1016/j.chest.2018.08.1048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2Fj.chest.2018.08.1048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=30189190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A280%3ADC%252BB3c3mt1Wrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=1416-1423&issue=6&author=K.+Sureshauthor=J.+Naidooauthor=C.+T.+Linauthor=S.+Danoff&title=Immune+checkpoint+immunotherapy+for+non-small+cell+lung+cancer%3A+benefits+and+pulmonary+toxicities&doi=10.1016%2Fj.chest.2018.08.1048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities</span></div><div class="casAuthors">Suresh Karthik; Naidoo Jarushka; Lin Cheng Ting; Danoff Sonye</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1416-1423</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been shown to improve survival in advanced non-small cell lung cancer (NSCLC).  Unlike traditional chemotherapeutic agents, ICIs work by boosting the body's natural tumor killing response.  However, this unique mechanism of action has also led to the recognition of class-specific side effects.  Labeled immune-related adverse events, these toxicities can affect multiple organ systems including the lungs.  Immune-mediated lung injury because of ICI use, termed checkpoint inhibitor pneumonitis (CIP), occurs in about 3% to 5% of patients receiving ICIs; however, the real-world incidence of this entity may be higher, especially now that ICIs are being used in nonclinical trial settings.  In this review, we briefly introduce the biology of ICIs and the indications for ICI use in NSCLC and then discuss the epidemiology and clinical and radiologic manifestations of CIP.  Next, we discuss management strategies for CIP, including the current consensus on management of steroid-refractory CIP.  Given the nascent nature of this field, we highlight areas of uncertainty and emerging research questions in the burgeoning field of checkpoint inhibitor pulmonary toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdAutAFukrJpVVjGoY74BafW6udTcc2ea77dkd7O7hfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3mt1Wrsg%253D%253D&md5=db9e27c4b602501d2adcac00b171067a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.chest.2018.08.1048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chest.2018.08.1048%26sid%3Dliteratum%253Aachs%26aulast%3DSuresh%26aufirst%3DK.%26aulast%3DNaidoo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%2BT.%26aulast%3DDanoff%26aufirst%3DS.%26atitle%3DImmune%2520checkpoint%2520immunotherapy%2520for%2520non-small%2520cell%2520lung%2520cancer%253A%2520benefits%2520and%2520pulmonary%2520toxicities%26jtitle%3DChest%26date%3D2018%26volume%3D154%26issue%3D6%26spage%3D1416%26epage%3D1423%26doi%3D10.1016%2Fj.chest.2018.08.1048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qeriqi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazutis, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Rapid non-uniform adaptation to vonformation-specific KRAS (G12C) inhibition</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>577</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1884-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1038%2Fs41586-019-1884-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31915379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsleisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=577&publication_year=2020&pages=421-425&author=J.+Y.+Xueauthor=Y.+Zhaoauthor=J.+Aronowitzauthor=T.+T.+Maiauthor=A.+Videsauthor=B.+Qeriqiauthor=D.+Kimauthor=C.+Liauthor=E.+de+Stanchinaauthor=L.+Mazutis&title=Rapid+non-uniform+adaptation+to+vonformation-specific+KRAS+%28G12C%29+inhibition&doi=10.1038%2Fs41586-019-1884-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition</span></div><div class="casAuthors">Xue, Jenny Y.; Zhao, Yulei; Aronowitz, Jordan; Mai, Trang T.; Vides, Alberto; Qeriqi, Besnik; Kim, Dongsung; Li, Chuanchuan; de Stanchina, Elisa; Mazutis, Linas; Risso, Davide; Lito, Piro</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">577</span>
        (<span class="NLM_cas:issue">7790</span>),
    <span class="NLM_cas:pages">421-425</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS GTPases are activated in one-third of cancers, and KRAS(G12C) is one of the most common activating alterations in lung adenocarcinoma1,2.  KRAS(G12C) inhibitors3,4 are in phase-I clin. trials and early data show partial responses in nearly half of patients with lung cancer.  How cancer cells bypass inhibition to prevent maximal response to therapy is not understood.  Because KRAS(G12C) cycles between an active and inactive conformation4-6, and the inhibitors bind only to the latter, we tested whether isogenic cell populations respond in a non-uniform manner by studying the effect of treatment at a single-cell resoln.  Here we report that, shortly after treatment, some cancer cells are sequestered in a quiescent state with low KRAS activity, whereas others bypass this effect to resume proliferation.  This rapid divergent response occurs because some quiescent cells produce new KRAS(G12C) in response to suppressed mitogen-activated protein kinase output.  New KRAS(G12C) is maintained in its active, drug-insensitive state by epidermal growth factor receptor and aurora kinase signalling.  Cells without these adaptive changes-or cells in which these changes are pharmacol. inhibited-remain sensitive to drug treatment, because new KRAS(G12C) is either not available or exists in its inactive, drug-sensitive state.  The direct targeting of KRAS oncoproteins has been a longstanding objective in precision oncol.  Our study uncovers a flexible non-uniform fitness mechanism that enables groups of cells within a population to rapidly bypass the effect of treatment.  This adaptive process must be overcome if we are to achieve complete and durable responses in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs98vxCKonTbVg90H21EOLACvtfcHk0liKCfg9C1IzPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsleisA%253D%253D&md5=23df9a8dc75959ebb136f3412e40fc36</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1884-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1884-x%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DAronowitz%26aufirst%3DJ.%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DVides%26aufirst%3DA.%26aulast%3DQeriqi%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DMazutis%26aufirst%3DL.%26atitle%3DRapid%2520non-uniform%2520adaptation%2520to%2520vonformation-specific%2520KRAS%2520%2528G12C%2529%2520inhibition%26jtitle%3DNature%26date%3D2020%26volume%3D577%26spage%3D421%26epage%3D425%26doi%3D10.1038%2Fs41586-019-1884-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montero-Conde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Llorente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauf, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghossein, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span> <span> </span><span class="NLM_article-title">Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-Mutant thyroid carcinomas</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">520</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F2159-8290.CD-12-0531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=23365119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVOmur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=520-533&issue=5&author=C.+Montero-Condeauthor=S.+Ruiz-Llorenteauthor=J.+M.+Dominguezauthor=J.+A.+Knaufauthor=A.+Vialeauthor=E.+J.+Shermanauthor=M.+Ryderauthor=R.+A.+Ghosseinauthor=N.+Rosenauthor=J.+A.+Fagin&title=Relief+of+feedback+inhibition+of+HER3+transcription+by+RAF+and+MEK+inhibitors+attenuates+their+antitumor+effects+in+BRAF-Mutant+thyroid+carcinomas&doi=10.1158%2F2159-8290.CD-12-0531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas</span></div><div class="casAuthors">Montero-Conde, Cristina; Ruiz-Llorente, Sergio; Dominguez, Jose M.; Knauf, Jeffrey A.; Viale, Agnes; Sherman, Eric J.; Ryder, Mabel; Ghossein, Ronald A.; Rosen, Neal; Fagin, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">520-533</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The RAF inhibitor vemurafenib (PLX40B2) increases survival in patients with BRAF-mutant metastatic melanoma, but has limited efficacy in patients with colorν ectal cancers.  Thyroid cancer cells are also comparatively refractory to RAF inhibitors.  In contrast to melanomas, inhibition of mitogen-activated protein kinase (MAPK) signaling by PLX4032 is transient in thyroid and colorectal cancer cells.  The rebound in extracellular signal-regulated kinase (ERK) in thyroid cells is accompanied by increased HERB signaling caused by induction of ERBB3 (HER3) tranν scription through decreased promoter occupancy by the transcriptional repressors C-terminal binding protein 1 and 2 and by autocrine secretion of neuregulin-1 (NRG1).  The HER kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAP-ERK kinase inhibitors.  This provides a rationale for combining ERK pathway antagonists with inhibitors of feedback- reactivated HER signaling in this disease.  The determinants of primary resistance to MAPK inhibitors vary between cancer types, due to preferential upregulation of specific receptor tyrosine kinases, and the abundance of their resp. ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkFqZRkwGftbVg90H21EOLACvtfcHk0li58g5BGLhlVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVOmur4%253D&md5=01c1c948c2a5df35f6520875cf122994</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0531%26sid%3Dliteratum%253Aachs%26aulast%3DMontero-Conde%26aufirst%3DC.%26aulast%3DRuiz-Llorente%26aufirst%3DS.%26aulast%3DDominguez%26aufirst%3DJ.%2BM.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DE.%2BJ.%26aulast%3DRyder%26aufirst%3DM.%26aulast%3DGhossein%26aufirst%3DR.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DRelief%2520of%2520feedback%2520inhibition%2520of%2520HER3%2520transcription%2520by%2520RAF%2520and%2520MEK%2520inhibitors%2520attenuates%2520their%2520antitumor%2520effects%2520in%2520BRAF-Mutant%2520thyroid%2520carcinomas%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D5%26spage%3D520%26epage%3D533%26doi%3D10.1158%2F2159-8290.CD-12-0531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span> <span> </span><span class="NLM_article-title">EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">xi41</span>– <span class="NLM_lpage">xi42</span>, <span class="refDoi"> DOI: 10.1016/S0923-7534(20)32033-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1016%2FS0923-7534%2820%2932033-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=xi41-xi42&author=H.+Ebi&title=EGFR-mediated+re-activation+of+MAPK+signaling+contributes+to+insensitivity+of+BRAF+mutant+colorectal+cancers+to+RAF+inhibition&doi=10.1016%2FS0923-7534%2820%2932033-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS0923-7534%2820%2932033-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0923-7534%252820%252932033-0%26sid%3Dliteratum%253Aachs%26aulast%3DEbi%26aufirst%3DH.%26atitle%3DEGFR-mediated%2520re-activation%2520of%2520MAPK%2520signaling%2520contributes%2520to%2520insensitivity%2520of%2520BRAF%2520mutant%2520colorectal%2520cancers%2520to%2520RAF%2520inhibition%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3Dxi41%26epage%3Dxi42%26doi%3D10.1016%2FS0923-7534%2820%2932033-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fece de la Cruz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahzade, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span> <span> </span><span class="NLM_article-title">Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C Inhibition</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1633</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-3523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=10.1158%2F1078-0432.CCR-19-3523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=31776128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1GnurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=1633-1643&author=M.+B.+Ryanauthor=F.+Fece+de+la+Cruzauthor=S.+Phatauthor=D.+T.+Myersauthor=E.+Wongauthor=H.+A.+Shahzadeauthor=C.+B.+Hongauthor=R.+B.+Corcoran&title=Vertical+pathway+inhibition+overcomes+adaptive+feedback+resistance+to+KRASG12C+Inhibition&doi=10.1158%2F1078-0432.CCR-19-3523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition</span></div><div class="casAuthors">Ryan, Meagan B.; Fece de la Cruz, Ferran; Phat, Sarah; Myers, David T.; Wong, Edmond; Shahzade, Heather A.; Hong, Catriona B.; Corcoran, Ryan B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1633-1643</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although KRAS represents the most commonly mutated oncogene, it has long been considered an "undruggable" target.  Novel covalent inhibitors selective for the KRASG12C mutation offer the unprecedented opportunity to target KRAS directly.  However, prior efforts to target the RAS-MAPK pathway have been hampered by adaptive feedback, which drives pathway reactivation and resistance.  Exptl. Design: A panel of KRASG12C cell lines were treated with the KRASG12C inhibitors ARS-1620 and AMG 510 to assess effects on signaling and viability.  Isoform-specific pulldown of activated GTP-bound RAS was performed to evaluate effects on the activity of specific RAS isoforms over time following treatment.  RTK inhibitors, SHP2 inhibitors, and MEK/ERK inhibitors were assessed in combination with KRASG12C inhibitors in vitro and in vivo as potential strategies to overcome resistance and enhance efficacy.  Results: We obsd. rapid adaptive RAS pathway feedback reactivation following KRASG12C inhibition in the majority of KRASG12C models, driven by RTK-mediated activation of wild-type RAS, which cannot be inhibited by G12C-specific inhibitors.  Importantly, multiple RTKs can mediate feedback, with no single RTK appearing crit. across all KRASG12C models.  However, coinhibition of SHP2, which mediates signaling from multiple RTKs to RAS, abrogated feedback reactivation more universally, and combined KRASG12C/SHP2 inhibition drove sustained RAS pathway suppression and improved efficacy in vitro and in vivo.  Conclusions: These data identify feedback reactivation of wild-type RAS as a key mechanism of adaptive resistance to KRASG12C inhibitors and highlight the potential importance of vertical inhibition strategies to enhance the clin. efficacy of KRASG12C inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobM76MIQz9zLVg90H21EOLACvtfcHk0li58g5BGLhlVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1GnurjP&md5=ef6ee3796adfcf0747400aee61256fc1</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-3523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-3523%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DM.%2BB.%26aulast%3DFece%2Bde%2Bla%2BCruz%26aufirst%3DF.%26aulast%3DPhat%26aufirst%3DS.%26aulast%3DMyers%26aufirst%3DD.%2BT.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DShahzade%26aufirst%3DH.%2BA.%26aulast%3DHong%26aufirst%3DC.%2BB.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26atitle%3DVertical%2520pathway%2520inhibition%2520overcomes%2520adaptive%2520feedback%2520resistance%2520to%2520KRASG12C%2520Inhibition%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D1633%26epage%3D1643%26doi%3D10.1158%2F1078-0432.CCR-19-3523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OBE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OBE','PDB','4OBE'); return false;">PDB: 4OBE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GOD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GOD','PDB','6GOD'); return false;">PDB: 6GOD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LDJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LDJ','PDB','4LDJ'); return false;">PDB: 4LDJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DSN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DSN','PDB','4DSN'); return false;">PDB: 4DSN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPY','PDB','4EPY'); return false;">PDB: 4EPY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F2E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F2E','PDB','5F2E'); return false;">PDB: 5F2E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NMM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NMM','PDB','4NMM'); return false;">PDB: 4NMM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P21" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P21','PDB','5P21'); return false;">PDB: 5P21</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LUC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LUC','PDB','4LUC'); return false;">PDB: 4LUC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V9U','PDB','5V9U'); return false;">PDB: 5V9U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N2J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N2J','PDB','6N2J'); return false;">PDB: 6N2J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UT0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UT0','PDB','6UT0'); return false;">PDB: 6UT0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6P8Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6P8Y','PDB','6P8Y'); return false;">PDB: 6P8Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OIM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OIM','PDB','6OIM'); return false;">PDB: 6OIM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T5B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T5B','PDB','6T5B'); return false;">PDB: 6T5B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DST" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DST','PDB','4DST'); return false;">PDB: 4DST</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BKD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BKD','PDB','1BKD'); return false;">PDB: 1BKD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EPV','PDB','4EPV'); return false;">PDB: 4EPV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GJ7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GJ7','PDB','6GJ7'); return false;">PDB: 6GJ7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0N" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0N','PDB','4G0N'); return false;">PDB: 4G0N</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1WQ1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1WQ1','PDB','1WQ1'); return false;">PDB: 1WQ1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OCO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OCO','PDB','5OCO'); return false;">PDB: 5OCO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FA4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FA4','PDB','6FA4'); return false;">PDB: 6FA4</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01312&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01312%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01312" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                11MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a7e02daa9d94a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
